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ABSTRACT 
STACIE B. DUSETZINA: Diagnosis and Treatment of Pediatric Bipolar Disorder in a 
Commercially Insured Population  
(Under the direction of Richard A. Hansen, PhD) 
 
Recent reports indicate that bipolar disorder diagnosis is increasing in U.S. children. 
Increased diagnoses are concerning as diagnostic criteria are unclear and most medications 
prescribed to treat bipolar disorder have not been tested or approved for children.  No studies 
have been conducted to assess the use of clinical treatment guidelines in children with bipolar 
disorder. This is troubling as current prescribing guidelines should dictate treatment in this 
population. The objectives of this dissertation are to examine the medication use patterns for 
privately insured children with bipolar spectrum disorders, and to assess the consistency of 
prescribing patterns with treatment guidelines.  
 MarketScan Commercial Claims and Encounters data (2005-2007) were used to 
identify children with diagnoses of bipolar disorder. Patient demographic and treatment 
characteristics were summarized for the cohort. Additionally, two measures were constructed 
to assess the quality of care received among children with bipolar I disorder. These measures, 
receipt of (1) appropriate first-line treatment, and (2) adequate duration of initial medication 
treatment, were used to determine whether a patient received guideline-recommended care. 
Generalized linear models were used to determine factors associated with receiving 
guideline-recommended care. 
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 We found an average annual prevalence of any bipolar spectrum disorder was 0.25% 
among privately insured children. Most children received pharmacotherapy, and treatments 
were similar across all bipolar subtypes. Anticonvulsants, atypical antipsychotics, 
antidepressants, and stimulants were prescribed commonly. Approximately 40% of the 
population received polypharmacy. 
Among children with bipolar I disorder, 84% received potentially inappropriate first 
line treatment. A majority of these children received either no medication or antidepressant 
medications without mood stabilizers. Several factors were associated with the receipt of 
recommended first line treatment, including bipolar episode type, having comorbid major 
depressive disorder diagnoses, and receiving care from a psychiatrist. Regarding early 
treatment regimen changes, 41% of children had initial treatment trials shorter than 6 weeks. 
However, none of the factors tested were consistently related to early regimen changes.  
These results highlight the high prevalence of bipolar diagnoses and deficiencies in 
the diagnosis and treatment of bipolar spectrum disorders among children by identifying 
trends in prescribing and gaps in the quality of care received by children.   
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CHAPTER ONE: INTRODUCTION 
  
1.1 Overview  
Over the past decade the diagnosis of bipolar disorder has increased in U.S. children at an 
alarming rate. Some studies indicate that there has been a 40-fold increase in this diagnosis 
among children under the age of 19 during the period 1992 – 2002.1  Pediatric bipolar 
disorder is associated with significant risk for suicidality, psychiatric hospitalizations and 
externalizing disorders. 2-8 Additionally, children with bipolar disorder frequently have 
difficulty in both academic and social settings4 and are often plagued by comorbid 
psychiatric conditions such as attention deficit hyperactivity disorder, oppositional defiant 
disorder, conduct disorder, anxiety disorders and substance use disorders. 3, 9-12  
Unfortunately, the evidence base that clinicians have available to inform treatment 
decisions has not been developed in a manner to support this drastic increase in prescribing 
among children.13 For example, pharmacologic agents are commonly used for the treatment 
of pediatric bipolar disorder;1, 14-16 however, most of the medications that are commonly 
prescribed to treat bipolar disorder in this age group have not been tested or approved for use 
in the pediatric population.10, 17, 18 
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In addition to the lack of formal regulatory approval for the use of these products in 
children, there are concerns regarding the use of inappropriate first-line therapies. For 
example, current guidelines recommend the treatment of bipolar I to be a single mood 
stabilizer or atypical antipsychotic agent;17, 19 however, it is unknown the extent to which 
treatment varies from this recommendation. Findings from studies of drug class use among 
patients with bipolar disorder suggest that monotherapy is rare and that use of treatments 
such as antidepressants and stimulants is common.1  
Similarly, regarding the adherence to recommendations, time on treatment prior to 
switching medication has not been studied in the pediatric population. While medication 
switching is common in the treatment and management of bipolar disorder, experts 
recommend that an adequate treatment period be maintained prior to making treatment 
regimen changes. Therefore, it is important to consider the factors that are associated with 
early medication switching (prior to a recommended 4-6 week drug treatment trial) in this 
population since this has important implications for clinical practice.17, 19-21  
1.2 Specific Aims 
Assessing the epidemiology of bipolar disorder, along with medication use and 
treatment patterns in a pediatric population is a necessary step for understanding how 
treatment patterns differ from current consensus guidelines, and can guide future 
interventions.  These issues will be addressed by the following research questions:  
Aim 1: To describe the treatment patterns and the demographic characteristics of a 
cohort of children who are diagnosed with bipolar disorder.  Descriptive information 
regarding the medication classes and class combinations that are used to treat pediatric 
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bipolar disorder will be summarized. This information will be reported as frequencies of use 
for commonly prescribed medication classes and combinations of medication classes. In 
addition to medication summaries, characteristics of children with bipolar disorder will also 
be summarized for the selected cohort. These characteristics will include age at the time of 
diagnosis, sex, and number and type of co-morbidities. 
Additionally, changes in diagnosis, treatment and co-morbid conditions will be 
assessed for the entire cohort and separately by age categories. There is currently a lack of 
information regarding the differences in treatment strategies and diagnosis of children who 
are under the age of 10 years.22 This age group is particularly important because current 
recommendations are to conduct medication trials of only 10 to 17 year old children.20 It is 
important to identify if younger children are receiving similar diagnoses and treatments as 
older children.23 This information can then be used to inform medication trial designs that 
currently suggest excluding this group from analysis. Changes in the prevalence and type of 
diagnosis (separately and combined) will be analyzed using the one-year diagnostic 
prevalence for each year during the study period (2005, 2006 and 2007). The use of drug 
classes, drug class combinations and the presence of co-morbid diagnosis will be analyzed 
similarly over the study period.  
Aim 2: Determine the factors associated with receiving a single mood stabilizer  
or atypical antipsychotic as first line treatment, compared to receiving any other 
bipolar treatment. Guidelines that have been developed regarding the treatment of pediatric 
bipolar disorder emphasize the importance of starting a child on a single mood stabilizer or 
atypical antipsychotic as first-line treatment of bipolar I disorder.17, 19 It is further suggested 
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that children who receive medication for pre-morbid or co-morbid mental health disorders be 
taken off of those medications for a stabilization period.17 Little is known about the extent to 
which these recommendations are followed in clinical practice.  
To address this aim, pharmacologic treatment patterns within the dataset will be used 
to identify children with newly-diagnosed bipolar I disorder who received a guideline-
recommended first-line treatment (versus those that received any other treatment or treatment 
combination). This information will then be used to assess differences in the characteristics 
of children who receive guideline concordant treatment versus those that receive non-
concordant treatment. Generalized linear models will be used to assess the relationship 
between selected patient and provider characteristics and the probability of receiving 
guideline recommended first-line treatments.   
Aim 3: Determine the factors associated with early treatment regimen changes, 
compared with no early regimen changes. In addition to recommendations regarding the 
use of appropriate first-line therapies, guidelines also recommend that medications be 
monitored for a minimum of 6-8 weeks in order to determine treatment effectiveness.21 This 
is considered to be an adequate period of clinical exposure to a medication.20 While 
switching medications is common and often appropriate for second-line treatment (because 
of side effects or a lack of efficacy), it is not recommended for first line treatments.24 
Because of this, early switching can be viewed as a proxy for guideline deviation (although 
switching is permitted if a patient cannot tolerate the medication). It is unclear to what extent 
early medication switching occurs in children with bipolar disorder and if there are factors 
that would predict early medication switching.  
  
5
To address this aim, time from first medication fill will be used to identify children 
with newly-diagnosed bipolar I disorder who had adequate medication treatment trials versus 
those that switched early. This information will then be used to assess differences in the 
characteristics of children who receive adequate or inadequate medication treatment trials. 
Generalized linear models will be used to assess the relationship between selected patient and 
provider characteristics and the probability of having an early medication switch.   
1.3 Importance of Proposed Research Plan 
Child and adolescent psychiatric disorders have been called one of the "final 
frontiers" of epidemiology and experts have noted that an important task of epidemiology 
during the next decade is to monitor the trends in treatment rates, prevalence, and the burden 
of child and adolescent mental illness.25 Currently there is a lack of information concerning 
national trends in the diagnosis of bipolar disorder and treatments that are received.1 Few 
epidemiological studies have been conducted in the area of bipolar disorder in children and 
adolescents. Most of the evidence has been derived from patient samples. While these 
samples provide insight into the disorder, their limited size make it difficult to detect 
diagnostic and treatment patterns that may exist in the population.26 On the other hand, 
epidemiologic samples are able to detect conditions on the bipolar spectrum that are 
underrepresented in clinical samples (such as bipolar II and bipolar NOS). Epidemiological 
studies are needed to provide accurate estimates of the prevalence and clinical characteristics 
of bipolar disorder in youth.26 
The proposed project will add to the literature in several important ways. First, this 
study will provide necessary epidemiologic information on the potential risk factors for 
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bipolar disorder in the selected cohort. Trends in diagnosis and treatment for bipolar disorder 
were increasing at an alarming pace from 1994 to 20031 and there was no evidence of the 
trend leveling off in this previous analysis. This indicates that updated information regarding 
the current level of diagnosing, along with characteristics of the children who are diagnosed 
with bipolar disorder would add to our current knowledge regarding the etiology of pediatric 
bipolar disorder.  
No studies as of yet have assessed the extent to which pediatric bipolar guidelines are 
followed. Other research in this area has been confined to the assessment of adult bipolar 
disorder and these studies have found variation in the use of practice guidelines and 
potentially deleterious effects on patient health outcomes.27 Additionally, limited information 
exists regarding the safety and efficacy of available pharmacologic treatments for use in the 
pediatric population. In these instances, guidelines from expert panels should be used to 
dictate treatment.28 The reliance on these published guidelines as the primary source for 
diagnostic and treatment information for pediatric patients who are suspected to have bipolar 
disorder confers the importance of assessing the extent to which guidelines are followed in 
this population. Finally, identifying modifiable factors that are associated with nonadherence 
to guidelines will provide targets for quality improvement efforts in the population.  
CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
2.1 Epidemiology and Disease Burden  
2.1.1 Prevalence 
Bipolar disorder, once considered rare in children, has now become one of the most 
common diagnoses among child and adolescent inpatients. Recent studies have indicated a 
sharp increase in the number of diagnoses of bipolar disorder in both inpatient and outpatient 
settings. 1, 29-32 Prior to 1998, few studies of bipolar prevalence existed26, 33 but the data that 
were available suggested that the prevalence of bipolar disorder in youth was increasing 
faster than would typically be expected.34  
There is significant variation in the reported prevalence estimates due to a lack of 
consensus of bipolar definitions and differences in reporting (for example, reporting any 
spectrum disorder versus reporting a single disorder on the spectrum). To date, most of the 
data used to describe the prevalence of pediatric bipolar disorder has been extrapolated from 
studies of the adult bipolar population. These estimates have ranged from less than 1% to 
nearly 9%, depending on how prevalence was defined.13, 26, 35-44  
As of 2005, no data existed on the prevalence of pre-adolescent bipolar disorder.45 
However, community surveys and histories of adults with bipolar disorder indicate that 
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childhood and adolescent bipolar disorder is more common than previously considered.26, 46, 
47
  For example, one community study showed a lifetime prevalence of any bipolar spectrum 
disorder was about 1% in youths aged 14-18. Most of the children in this sample, however, 
had bipolar-II or cyclothymia and another 5.7% had sub-syndromal bipolar symptoms instead 
of bipolar I disorder (see section 2.2.1 for a detailed description of bipolar spectrum 
disorders).26 Additionally, data from retrospective studies indicate that as many as 60% of 
adults report early-onset bipolar disorder (prior to age 20) and 10-20% report childhood onset 
(prior to age 10).46, 48-50 
Since few studies possess adequate samples of the population to estimate 
prevalence,51 several retrospective studies have been conducted to try to estimate the 
prevalence of bipolar disorder among children. In such studies, prevalence is assessed using 
administrative claims data or national inpatient and outpatient surveys. While these estimates 
vary, they all point to an increase in the diagnostic prevalence of the disorder in the pediatric 
population. Perhaps the best examples of these noted increases are provided by studies 
conducted recently by Blader, Harpaz-Rotem and Moreno.1, 29, 52-54  
In 2007, Blader and Carlson used a national hospital discharge database to detect 
trends in diagnoses of children and adolescents who were admitted to inpatient psychiatric 
care from 1996 to 2004. In 1996, bipolar disorder was one of the least frequent diagnoses 
recorded among child inpatients, but by 2004 it had become the most common diagnosis 
among this group. Similarly, among adolescents, there were twice as many discharges with a 
major depressive disorder as with bipolar disorder in 1996, but nearly the same number of 
discharges between the two groups by 2004.29 As a proportion of total psychiatrically related 
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discharges, children diagnosed with bipolar disorder constituted 10% in 1996 and 34% by 
2004.29 
In 2004 and 2005, Harpaz-Rotem and colleagues used children's mental health 
insurance claims data to assess the proportion of youth with a diagnosis of bipolar disorder 
who received inpatient or outpatient mental heath services. They compared use in 1995 to 
use in 2000 and found that the proportion of youth that received outpatient treatment for 
bipolar disorder increased by 67%54 and the proportion who received inpatient treatment 
increased by 74%.53 Additionally, over the study period, the proportion of hospitalized 
children who were treated for bipolar disorder doubled, with increases in bipolar diagnoses 
among both adolescents and school-aged children.53 
In 2007, Moreno and colleagues used the National Ambulatory Medical Care Survey 
(NAMCS) to detect trends in the diagnosis of bipolar disorder and the treatments received. 
They compared the annual number of office-based visits that included a diagnosis of bipolar 
disorder in 1994-1995 to those recorded in 2002-2003. They found that the annual number of 
office-based visits in the US that included a diagnosis of bipolar disorder increased in youth 
from 25 per 100,000 in 1994-1995 to 1,003 per 100,000 in 2002-2003. This represented a 40-
fold increase in bipolar-related office visits for youth over the study period.1  
While the true prevalence of pediatric bipolar disorder remains unknown, researchers 
now believe that bipolar disorder is more common in children than had previously been 
acknowledged.55 In fact, the incidence of bipolar disorder in children is approaching that in 
adults.56 It is important to note that increases in diagnosis of bipolar disorder may stem from 
several causes. They could be a reflection of a true increase in prevalence, a rectification of 
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previous under-recognition, changes in the definition or conceptualization of the disorder, or 
inappropriate application of the diagnosis to children who have other illnesses.57  
2.1.2 Differences by Gender and Race  
Consistent with studies of the adult bipolar population, there are few differences in 
bipolar incidence by gender, indicating that the prevalence, age of onset, phenomenology and 
course of bipolar disorder in adolescents is similar for males and females.58 26 Other studies 
in youth show similar results with rates of bipolar spectrum disorders or bipolar subtypes 
remaining constant in males and females.59, 60 Similarly, studies of symptoms, symptom 
expression, and of treatment type have shown no variation by gender.59, 61 There are, 
however, several key areas where gender differences emerge in pediatric bipolar disorder. In 
particular, early-onset cases (prior to age 13) are more frequently male,19 and gender 
differences are found in the presentation of co-morbid conditions, the age at first treatment 
and in rates of symptomatic recovery.59, 62  
Regarding racial and ethnic differences, there are no reports of differential incidence 
of Bipolar I Disorder based on race or ethnicity in the adult bipolar literature.58 In the 
pediatric bipolar literature, however, studies of hospital discharge data have shown changes 
in bipolar diagnoses by both race and gender. For example, prior to 2001, white girls had few 
occurrences of bipolar diagnoses but since that time, rates have reached that of white boys.29 
Similarly, in more recent years (2003 - 2004), discharges for black boys and girls exceeded 
the rate among whites.29, 62 
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2.1.3 Disease Burden 
Bipolar disorder is a devastating disease that results in substantial impairments across 
psychosocial domains. For patients with bipolar disorder there are high risks for the 
following events: suicide, psychosis, familial aggregation and a protracted illness course in 
which the cycles of the disorder appear to be more chronic than episodic.14, 26, 63-69 According 
to the World Health Organization (WHO), bipolar disorder is ranked sixth among all medical 
disorders in years of lost life due to death or disability.70 Additionally, bipolar disorder has 
been consistently rated among the top causes of disability adjusted life years (DALYs) for 
15-44 year olds in developed countries.71 
One of the most disabling features of bipolar disorder is its chronicity, as evidenced 
by the similarities between the 12 month and lifetime rates of bipolar disorder in both adults 
and in children.72 Individuals with bipolar disorder generally experience a chronic, recurrent 
course of illness that increases their risk of lifelong disability and greatly impacts their lives 
and the lives of their families.51, 73  
Children with bipolar disorder have significantly higher rates of morbidity and 
mortality than children without the disorder,67, 74, 75 including psychosocial morbidity, 
impaired academic performance, impaired social and familial support, increased levels of 
substance abuse, weight problems, legal difficulties, and hospitalizations.2-8 For example, one 
author reported that youth in her sample had poor social skills, reported having no friends 
and being teased by other children.76 Even among asymptomatic adolescents with bipolar 
disorder there were significant interpersonal deficits as compared to healthy adolescents.77 
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Researchers have also shown that onset of bipolar disorder prior to age 18 is 
associated with suicidal ideation and suicide attempts.78, 79 In fact, adolescents with bipolar 
disorder have a higher suicide risk than adolescents with any other psychiatric disorder, 34, 80-
82
 and more than 25% of pre-pubertal children or adolescents with bipolar disorder develop a 
suicide plan.34 In the largest community-based study of bipolar disorder, researchers found 
that adolescents with bipolar disorder had a much higher percent of suicide attempts (44.4%) 
than adolescents who were not mentally ill (1.2%), and even compared to those with major 
depressive disorder (22.2%).26 Given the chronic course of the disease, it is important to note 
that research has shown that between 25 and 50% of adults with bipolar disorder attempt 
suicide at least once in their lifetime and between 8 and 19% of them will die from suicide.83   
 The economic impact of bipolar disorder is extremely high, particularly when 
accounting for the opportunity costs of living with a mental illness.84 In fact, a 2003 study 
found that bipolar disorder was the most expensive behavioral health care diagnosis for both 
patients and their insurance plans.85 Since over 90% of patients with bipolar disorder 
experience recurrence and many experience progressive deterioration in functioning,86 it is 
important to consider the impact of this disease from a societal perspective. This cost was 
estimated to be as high as $45 billion per year in the US in 1991.87  In a 2003 study, the 
average lifetime cost per patient with bipolar disorder was estimated to range from $11,720 
for persons with a single manic episode to $624,785 for persons with chronic episodes.88 
Regarding costs of treatment incurred by patients, one study estimated average charges and 
reimbursements per patient-year to be $12,797 and $6,581, respectively. Of these costs, 33% 
was directly attributable to bipolar disorder, and 67% was attributed to comorbidities.89 
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Given the very high rate of co-morbid conditions in children with bipolar disorder, this 
estimate is likely to be low. 
2.2 Description of Pediatric Bipolar Disorder 
2.2.1 DSM-IV-TR Definition 
There are four disorders that make up the bipolar spectrum, as defined by the 
Diagnostic and Statistics Manual for Mental Illness. These are Bipolar I Disorder, Bipolar II 
Disorder, Cyclothymic Disorder and Bipolar, Not Otherwise Specified (Bipolar-NOS). 
Differentiation among the disorders on the spectrum is based on the severity and duration of 
manic and depressive episodes. Definitions of episode symptoms based on the DSM-IV-TR 
definitions are presented in Table 2.1. It is important to note that Cyclothymic Disorder is 
considered to be a milder form of bipolar illness and is clinically very different from the 
other three spectrum disorders.  
Individuals with bipolar disorder generally meet criteria for major depressive 
episodes and/or manic episodes. Major depressive episodes are defined by having five or 
more depressive symptoms, along with one of the cardinal symptoms (either depressed mood 
or loss of interest or pleasure). These symptoms must be present during the same 2-week 
period and represent a change from previous functioning. For manic episodes, individuals 
must experience a distinct period of abnormally and persistently elevated, irritable or 
expansive mood, lasting at least 1 week (unless hospitalized, in which case duration can be 
any length). They must experience at least three manic symptoms during the mood 
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disturbance (four or more if the mood is only irritable) and these symptoms must be present 
to a significant degree.58 
 
1Table 2.1 - Manic and Depressive Episode Symptom Definitions (APA, 2000) 
Depressive Symptoms Manic Symptoms 
• Depressed mood most of the day, nearly every day, 
as indicated by either subjective report or 
observation made by others. In children and 
adolescents, can be irritable mood. 
• Markedly diminished interest or pleasure in all, or 
almost all, activities most of the day, nearly every 
day. 
• Significant weight loss when not dieting or weight 
gain ( > 5% change of body weight in a month), or 
decrease or increase in appetite nearly every day. 
In children, failure to make expected weight gains. 
• Insomnia or hypersomnia nearly every day. 
• Psychomotor agitation or retardation nearly every 
day. 
• Fatigue or loss of energy nearly every day. 
• Feelings of worthlessness or excessive or 
inappropriate guilt nearly every day. 
• Diminished ability to think or concentrate, or 
indecisiveness, nearly every day 
• Recurrent thoughts of death, recurrent suicidal 
ideation without a specific plan, or a suicide 
attempt or a specific plan for committing suicide 
• Inflated self-esteem or grandiosity. 
• Decreased need for sleep (e.g., feels 
rested after only 3 hours of sleep). 
• More talkative than usual or pressure 
to keep talking. 
• Flight of ideas or subjective experience 
that thoughts are racing. 
• Distractibility. 
• Increase in goal-directed activity or 
psychomotor agitation. 
• Excessive involvement in pleasurable 
activities that have a high potential for 
painful consequences. 
 
Hypomanic episodes may be diagnosed in individuals who experience persistently 
elevated, expansive or irritable moods that last at least 4 days and that represent marked 
changes from the patient's usual non-depressed mood. Those with hypomanic episodes 
experience three or more of the manic symptoms to a significant degree (or four or more 
symptoms if presenting with irritability alone).  
In order to be diagnosed with a major depressive or manic episode, symptoms cannot 
meet criteria for mixed episodes. Mixed episodes are those in which criteria (with the 
exception of duration) for both major depressive episodes and manic episodes are met for 
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most days during a 1-week period. In addition to meeting the symptom and duration criteria 
defined above, for major depressive, manic and mixed episodes, symptoms must cause 
clinically significant distress or impairment in functioning and they must not be due to 
substance abuse or other general medical conditions.58 Table 2.2 provides a summary of each 
of the bipolar spectrum disorders and conditions that must be met for diagnosis. 
 
2Table 2.2 - Bipolar Spectrum Disorders (APA, 2000) 
Spectrum Disorder Criteria for Diagnosis 
 
2.2.2 Differences in Pediatric Bipolar Disorder from Classical Presentation 
Uncomplicated classical mania is very uncommon in prepubertal children.90  As 
compared to this classic presentation seen in most adults, there are several features agreed 
upon as being unique to pediatric bipolar disorder. These are (1) chronic course and long 
episode duration; (2) predominance of mixed episodes or rapid cycling; (3) irritability as a 
prominent feature and (4) high rates of co-morbidities.6, 13, 34, 63, 66, 68, 91-93.  
While adults generally experience periods of normal mood between discrete episodes 
of illness, children often experience chronic presentations of illness with no distinct periods 
of recovery.94-96 This form of symptom presentation is reported in about 20% of adults, most 
of whom have treatment-resistant bipolar disorder.83, 97 Early-onset bipolar disorder appears 
Bipolar I Disorder One or more Manic or Mixed Episodes, usually accompanied by a Major 
Depressive Episode. 
 
Bipolar II Disorder One or more Major Depressive Episodes accompanied by at least one 
Hypomanic Episode. 
 
Cyclothymic Disorder Two years of numerous hypomanic and depressive periods which do not meet 
full criteria for either Manic episodes or Major Depressive Episodes. 
 
Bipolar Not Otherwise 
Specified 
Bipolar features that do not meet criteria for a defined bipolar disorder (either 
due to inadequate duration or contradictory information).  
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to increase the severity and lead to worse long-term outcomes than later-onset bipolar 
disorder as evidenced by its chronicity, resistance to mood stabilizers and high rate of 
psychotic symptoms.13, 86, 91, 95, 96, 98-102 Current literature shows that pediatric bipolar disorder 
follows a course where 70 to 100% of children will recover from their index episode but up 
to 80% will relapse, despite ongoing treatment for the disorder.62 Additionally, some studies 
suggest that in these children, syndromal or subsyndromal symptoms are present for up to 
70% of follow-up time.68, 103, 104 During an 8-year follow up study of children with bipolar I 
disorder, the mean number of manic or mixed episodes was two, with significantly shorter 
second and third episodes.103 In this study, subjects under 18 years of age were ill with mood 
episodes 65.5% of the time, while those over 18 were ill for about 49% of the time. 103 
Rapid cycling is also common in pediatric bipolar disorder. This term is used 
differently in adult and pediatric bipolar literature. In adults, rapid cycling represents four or 
more discrete episodes of illness within a year (with periods of normal mood between 
episodes).61 In children, rapid cycling often represents daily or weekly mood changes. In 
studies of rapid cycling in pediatric bipolar patients, daily cycling was the most common 
form of cycling, with no patients experiencing the traditional rapid cycling seen in adults.61, 
105, 106
  
2.2.3 Diagnosing Bipolar Disorder 
The National Institutes of Mental Health (NIMH) has recommended using the adult 
criteria for bipolar disorder to diagnose children, however this is complicated because the 
symptom presentations differs between children and adults.9 There are no clinical markers 
that can be used to assess bipolar disorder in children, therefore assessment of mental illness 
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in child and adolescent psychiatry often consists of structured interviews, questionnaires and 
screening instruments.25 Many of the scales that are used to diagnose bipolar disorder in 
children are adapted from those originally designed for adults. This is problematic because 
(1) the presentation of the disorder may be different at younger ages; (2) symptoms that are 
measured may be inappropriate at younger developmental stages.20 
Among the diagnostic instruments available, the Child Behavior Checklist (CBCL), 
the Parent Mood Disorder Questionnaire (P-MDQ), the Child Mania Rating Scale (CMRS), 
and the Parent General Behavior Inventory (PGBI-SF10) are most frequently used. 57 
Currently there is no agreement among experts regarding the best instrument for diagnosing 
bipolar disorder in youth, making the physicians' clinical assessment key in the diagnostic 
process.  
To further complicate matters, researchers in the field also disagree regarding the 
symptom presentation for pediatric bipolar disorder. Major disagreements in the field focus 
on the key symptoms for diagnosing bipolar disorder in children. In particular, the symptom 
of elated mood (euphoria / grandiosity) is the primary source of disagreement among 
clinicians and researchers. Many feel that this symptom must be observed in order to fully 
meet criteria for bipolar disorder,76, 107 while others suggest that extreme irritability is the 
marker for such a disorder.98, 108, 109 Current research of familial aggregation patterns and 
clinical correlates support the use of elated mood as a cardinal symptom of pediatric bipolar 
disorder,104 but it is unknown to what extent this criterion is used in practice.  
Differentiating among the bipolar spectrum disorders in children also poses unique 
problems. For example, researchers have found that initial presentations of bipolar I disorder 
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in children are generally depressive symptoms or full depressive episodes.110 Further, 
children with bipolar II often receive diagnoses of major depressive disorder,111 since they 
generally seek medical care during major depressive episodes. It is only through detailed 
accounting of a patient's history that clinicians are able to accurately distinguish between 
these disorders.17 A large number of children also fail to meet the required DSM-IV duration 
criteria for hypomania or mania and are subsequently diagnosed as bipolar disorder not 
otherwise specified (NOS).69  
Due to the atypical presentation of pediatric bipolar disorder, the diagnosis is often 
missed, leading to delays in appropriate treatment.91 In fact, one study revealed that the delay 
from initial onset of bipolar symptoms to first treatment was, on average, 16.8 years for 
childhood onset and 11.5 years for adolescent onset.91 Overlapping symptoms make 
differentiating bipolar disorder from other mental health conditions difficult, specifically 
with attention-deficit hyperactivity disorder (ADHD), conduct disorder (CD) and anxiety 
disorders.34, 105, 112, 113 Several medical disorders also mimic symptoms of mania, including 
temporal lobe epilepsy, multiple sclerosis, hyperthyroidism, closed or open head injury and 
systemic lupus erythematosus.17 In addition to this, several drug classes often increase mood 
cycling including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), 
corticosteroids, serotonin and norepinephrine reuptake inhibitors (SNRIs), aminophylline and 
antibiotics such as clarithromycin, amoxicillin and erythromycin.114 Developmental issues 
can also complicate the diagnosis as children often face difficulties in verbalizing their 
emotions. 115 These complexities provide compelling evidence for involving well-trained 
experts in mental health in the initial diagnosis and treatment of childhood bipolar disorder.20  
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2.2.4 Co-morbid and Pre-morbid Conditions 
Children with bipolar disorder often meet DSM-IV criteria for other mental health 
disorders such as oppositional defiant disorder, conduct disorder, anxiety, and depression. 9, 
10, 116, 117
 Pediatric bipolar disorder is rarely seen without other serious co-morbid 
psychopathology. 90 In one study, 97.9% of children had one or more comorbid conditions 
and 20.4% had four or more comorbid conditions.118 This makes differentiating between a 
person with bipolar disorder and one with an exacerbation of another disorder very difficult.  
Understanding the extent to which co-morbid conditions exist for children with 
bipolar disorder is important in determining next steps for treatment development. For 
example, Frank (2002) found that alternative treatment plans were needed for adults with co-
occurring bipolar disorder and panic disorder (as compared to those with bipolar alone).119 
Understanding the prevalence of co-occurring disorders is important for improving 
treatments in this area.120  
There are varying estimates for the rates of specific comorbidities in children with 
pediatric bipolar disorder. Rates tend to differ by age, assessment method, sample (clinical 
versus community), and by the diagnostic classification system that is used (DSM-III versus 
DSM-IV).120 Due to these variations, there is little to no consensus among researchers 
regarding the rates of diagnostic comorbidity.120 Because of this and the symptom overlap 
between pediatric bipolar disorder and other mental illnesses, it is important to determine if 
symptoms of potential co-morbid conditions are present during episode-free phases (when 
the patient is not manic, hypomanic or depressed). 57  
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Among pediatric bipolar samples, the most commonly comorbid condition is 
attention deficit hyperactivity disorder (ADHD). This condition often pre-dates the 
occurrence of pediatric bipolar disorder100, 118, 121 and occurs most frequently in younger aged 
children.7 Studies that have looked at age differences in the co-occurrence of these disorders 
have found higher rates of ADHD comorbidity among younger children than adolescents. 100 
Estimates of the co-occurrence of these disorders are approximately 90% in prepubertal 
children and between 30 and 40% in adolecents.7, 13, 114, 122, 123 Emerging evidence suggests 
that children with co-occurring BPD and ADHD have distinct illness from those with either 
bipolar disorder or ADHD alone. It is also possible that ADHD symptoms represent early 
illness manifestation for children who will go on to be diagnosed with bipolar disorder. 124 
 Other commonly found comorbid or premorbid conditions are depression, 72, 106, 123 
anxiety disorders, 3, 26, 123, 125, 126 oppositional defiant disorder, 123, 127 conduct disorder66, 106, 
123, 128
 and pervasive developmental disorders.6, 129 Estimates of the co-occurrence of these 
disorders with pediatric bipolar disorder differ by age and developmental stage. In general, 
adolescents appear to be more likely to have substance abuse, panic disorders and conduct 
disorders and children are more likely to have ADHD. Anxiety disorders, on the other hand, 
tend to be equally likely among young children and adolescents.120  
2.2.5 Pharmacologic Treatments for Pediatric Bipolar Disorder  
No currently available treatment is able to manage all phases of bipolar illness and to 
protect against recurrence of manic, mixed, manic-depressive, major depressive or other mild 
depressive states.130, 131 The only drugs approved by the US Food and Drug Administration 
for use in treating acute mania in youth are lithium (for children aged 12 and older), and 
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risperidone, or aripiprazole (for children aged 10 and older, respectively). 10 Additionally, as 
of June of 2009, an FDA advisory panel recommended the inclusion of three additional drugs 
for use in children with bipolar disorder. These were Quetiapine, or Olanzapine (for children 
aged 13 - 17, respectively), and Ziprasidone (for children aged 10 - 17).132 Evidence is 
emerging regarding the use of  pharmacologic treatments for pediatric bipolar disorder, but a 
majority of the trials focus on the treatment of mania alone.10 Additionally, the evidence-base 
for decision making relies heavily on efficacy and safety data from trials conducted in adult 
patients.10 As we have learned from the failure of tricyclic antidepressants in pediatric 
depression, it is important to realize that we cannot assume that drugs that are effective at 
treating adults are similarly effective in treating children.133, 134  Table 2.3 summarizes 
medications that are commonly used for treating bipolar disorder (both the generic name and 
Brand names as applicable). 
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3Table 2.3 - Medications Used to Treat Bipolar Disorder 
 
Medication Category Generic Name (Brand Names) 
Mood Stabilizers 
 
          Lithium lithium (Eskalith, Lithobid) 
        
          Anticonvulsants 
 
divalproex sodium (Depakote, Depakote ER, Depakote Sprinkles); 
carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR); lamotrigine 
(Lamictal); topiramate (Topamax); gabapentin (Neurontin); oxcarbazepine 
(Trileptal);  levetiracetam (Kreppa, Kreppa XR); tiagabine (Gabitril)  
 
         Second Generation     
         Antipsychotics 
 
clozapine (Clozaril, FazaClo ODT); risperidone (Risperidal, Risperidal 
Consta, Risperidal M-Tab); olanzapine (Zyprexa, Zyprexa Zydis); quetiapine 
(Seroquel, Seroquel XR); ziprasidone (Geodon); aripiprazole (Abilify, Abilify 
Discmelt) paliperidone (Invega) 
 
         First Generation  
         Antipsychotics 
 
haloperidol (Haldol Decanoate, Haldol Lactate); loxapine (Loxitane); 
thiothixene (Navane); pimozide (Orap); fluphenazine (Prolixin); 
trifluoperazine (Stelazine); chlorpromazine (Thorazine); perphenazine 
(Trilafon) 
 
Antidepressants  
          
         Tricyclics 
 
amitriptyline (Elavil); clomipramine (Anafranil); doxepin; imipramine 
(Tofranil, Tofranil-PM); trimipramine (Surmontil); desipramine (Norpramin); 
nortriptyline (Pamelor); protriptyline (Vivactil) 
          
         Tetracyclics amoxapine; maprotiline 
          
         Selective Serotonin        
         Reuptake Inhibitors   
         (SSRIs) 
 
fluoxetine (Prozac, Prozac Weekly, Sarafem); sertraline (Zoloft); citalopram 
(Celexa); escitalopram (Lexapro); fluvoxamine (Luvox, Luvox CR); 
paroxetine (Paxil, Paxil CR, Pexeva);  
         
        
        Other Antidepressants 
 
 
         
venlafaxine (Effexor, Effexor XR, Venlafaxine ER Tablets); trazodone; 
nefazodone; mirtazapine (Remeron, Remeron SolTabs); duloxetine 
(Cymbalta);  Bupropion HCl (Budeprion SR, Budeprion XL, Buproban, 
Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban) 
          
         Monoamine oxidase  
         inhibitors (MAOIs)   
 
 
isocarboxazid (Marplan); phenelzine (Nardil); tranylcypromine (Parnate) 
 
         Stimulants 
 
methylphenidate (Concerta, Metadate CD, Metadate ER, Methylin, Methylin 
ER, Ritalin, Ritalin LA, Ritalin SR); methylphenidate transdermal 
(Daytrana); dextroamphetamines (Dexedrine, ProCentra); amphetamine salt 
comb (Adderall, Adderall XR); dexmethylphenidate (Focalin, Focalin XR); 
lisdexamphetamine (Vyvanse) 
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2.2.5.1 Treatments for Bipolar Mania 
 
Psychotropic medication use for treatment of bipolar disorder in children has 
increased dramatically in recent years. Several drug classes are commonly used to treat 
bipolar disorder. These are mood stabilizers, including both lithium and anticonvulsants, and 
antipsychotics (both typical and atypical). Standard therapy in adults generally includes 
lithium, divalproex and atypical antipsychotics.17 Each of these classes, and the evidence for 
their use, are described below.  
Lithium and Anticonvulsants 
Of the treatment options available, lithium is the oldest and most researched 
medication. Lithium has been studied in adults and adolescents and has been found to be 
effective at treating acute mania135 and in improving global functioning scores.136 However, 
many studies of lithium (and most of the other mood stabilizers) have not controlled for 
adjunctive psychotropic medication use, making true estimates of a monotherapy's 
effectiveness difficult to determine. Additionally, there are several safety concerns regarding 
the use of Lithium. Lithium has been associated with weight gain and acne, 137, 138 which may 
be considered unacceptable side effects for children in their adolescent years. Lithium-
induced hypothyroidism is also common, with some studies estimating an occurrence in 24% 
of children and adolescents taking lithium and divalproex.139 Major safety concerns regarding 
long term use of lithium generally include lithium toxicity and decreased renal 
functioning.140, 141 
  
24
 In addition to lithium, other commonly used mood stabilizers are divalproex and 
carbamazepine. One study of these three agents suggested that all three drugs had similar 
response rates; however, response was achieved in less than half of the patients on any of 
these individual drugs.142 Of those that did not respond to monotherapy in this study, 80% 
responded to combination mood stabilizer therapy during a 6-month continuation phase of 
the trial.143 Others have also found significant improvement from baseline in outcome 
measures (depression, mania and global rating scales) for adolescents who are prescribed 
combination therapy of lithium and divalproex.144 Accumulated evidence currently suggests 
that lithium and divalproex are equally efficacious in the acute and maintenance treatment of 
pediatric bipolar disorder.145 
 Evidence for divalproex and carbamazepine are mostly limited to open-label trials, 
case reports and retrospective chart reviews.15, 146-150 In these studies, the rates of response 
have ranged from 60 to 100%.10 However, similar to trials of lithium, it is unclear to what 
extent combination therapy may have led to these large response rates as  adjunctive 
treatments were taken by as many as 43% of patients in these studies.10  
Randomized trial evidence of these agents has proven less promising in this 
population. For example, a recent double-blind, placebo-controlled trial of divalproex ER 
showed no benefit over placebo for the treatment of youth with bipolar I manic or mixed 
episodes.151 Additionally, a randomized trial of lithium, divalproex and placebo resulted in 
response rates of 41%, 56% and 30%, respectively.142 Although responses were higher for 
lithium and divalproex than for placebo, the very high rate of response in the placebo group 
is cause for concern. These findings highlight the need for conducting placebo-controlled 
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trials in this population to determine the true benefit of mood stabilizing agents in the 
pediatric bipolar population. 
 Aside from divalproex and carbamazepine, the remaining antiepileptic agents have 
limited efficacy and safety data available. Two open studies of topiramate suggest that it may 
be a useful adjunctive treatment in bipolar youth.152, 153 Unfortunately, there is no evidence of 
topiramate's usefulness as a monotherapy as a large controlled trial of topiramate 
monotherapy was discontinued early due to the drug's failure in adult trials.154 Supportive 
evidence for oxcarbazepine is limited to case reports;155, 156 however, one double-blind, 
placebo-controlled trial of this drug showed no difference in mania rating scale scores as 
compared to placebo.157 Similarly, gabapentin has shown promise in two case reports,158, 159 
but has failed in adult placebo-controlled trials.160, 161  
In addition to concerns regarding the lack of placebo-controlled trial data for these 
medications, medication safety has not been extensively studied for these drugs within the 
pediatric bipolar population. Commonly reported adverse effects of divalproex generally 
include gastrointestinal upsets, neurological symptoms (headache and dizziness).141 
However, several less common effects such as hepatotoxicity, teratogenicity, polycystic 
ovary syndrome, carcinogenesis and pancreatitis have been reported.141, 162  
Regarding the use of Carbamazepine, there are several serious side effects that must 
be considered. The most common serious side effects of this drug include hematological, 
dermatological and hepatic manifestations. There is a black box warning regarding 
agranulocytosis and aplastic anemia.141 Other side effects include nausea, psychosis, mania, 
worsening of seizures, development of seizures, ataxia, behavioral toxicity, diplopia, 
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sleepiness, and vertigo.163 Fortunately, it appears that Carbamazepine does not alter 
metabolism or cause obesity, but due to its mechanism of action it interacts with many other 
medications so its use should be carefully considered.164, 165 
Atypical Antipsychotics 
 Use of atypical antipsychotic agents for the treatment of pediatric bipolar disorder is 
increasing, as is the evidence for their use in this population. Two of these drugs, risperidone 
and aripiprazole are currently approved by the FDA for the treatment of mania in bipolar 
youth (10 years and older).10 Approval for risperidone was based on a multicenter, 
randomized, double-blind, placebo-controlled trial. In this trial, the risperidone group had 
significantly more responders than the placebo group after 3 weeks of treatment.166 Others 
have shown benefits of augmenting mood stabilizer therapy (lithium or divalproex) with 
risperidone.167, 168  
 For aripiprazole, efficacy was established in a 4-week double-blind, placebo-
controlled trial conducted in 2007. In this trial, aripiprazole was found to be more efficacious 
than placebo for treating bipolar mania in youth aged 10 to 17 years.169 Several other studies 
(one open label study and two retrospective chart reviews) also found that aripiprazole was 
effective and well tolerated in children and adolescents with bipolar mania.170-172  Other 
medications in this class for which some evidence of efficacy as either monotherapies or 
adjunctive treatments has been accumulated are quetiapine,173-175 olanzapine, 176, 177 
ziprasidone, 178, 179 and clozapine.180  
 Regarding safety concerns for atypical antipsychotics, the most common side effects 
are hyperprolactinaemia, weight gain, sedation and extrapyramidal symptoms.141 There is 
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also some concern that these drugs may lead to diabetes and hyperglycemia in some patients, 
but this has not been rigorously studied.141 In particular, Olanzapine has been associated with 
the highest risk of weight gain (as compared to other antipsychotic medications),181, 182 as 
well as a risks of hyperglycemia, hyperlipidemia, glucose dysregulation or diabetes 
mellitus.182 Risperidone also is associated with weight gain due to increased appetite, and 
when used in combination with valproic acid, it may increase the risk for diabetes.183 
Risperidone has also been associated with extrapyramidal symptoms (e.g., dystonias, 
parkinsonism, tardive dyskinesias, tremors), although most of these were reversible with 
anticholinergic therapy or discontinuation of drug.141 
 Quetiapine has been associated with a greater frequency and severity of sedation, and 
the development of tachycardia (without QT prolongation), however, weight gain is not as 
prevalent with Quetiapine as with risperidone or olanzapine.184, 185 Ziprasidone, the least 
studied of the atypical antipsychotics at this time, appears to be well tolerated (with the 
exception of sedation). Rare side effects are EPS and hyperprolactinemia.184 
Clozapine is the antipsychotic that is considered for use in cases where multiple other 
treatments have failed. This is primarily because it requires intensive monitoring due to the 
risk of agranulocytosis. The major benefit of this medication is that it is not associated with 
extrapyramidal symptoms and tardive dyskinesia.141 As with other antipsychotics, weight 
gain and sedation are common. Cardiovascular effects may also be of concern as one study 
indicated that 47 of 78 patients experienced tachycardia and another 20 of 70 patients 
experienced orthostatic hypotension.186, 187 Less common, but serious, reported events are 
neutropenia, granulocytopenia, seizure risk, hyperlipidemmia and hyperglycemia.188-190  
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2.2.5.2 Treatments for Bipolar Depression 
Treatments for bipolar depression are less commonly studied than for bipolar mania, 
although suicide risk is highest in those presenting with bipolar depression.10 A delicate 
balance must be maintained in treating bipolar depression as to not induce bipolar mania. 
Available evidence for bipolar depressed children is almost exclusively based on evidence in 
the adult bipolar population. These studies have shown support for use of lithium, divalproex, 
lamotrigine, quetiapine, olanzapine and a combination of olanzapine and fluoxetine in adults 
with bipolar depression.10 Of these treatments, only lithium and lamotrigine have been 
assessed in the pediatric population.   
A single open-label study assessed the efficacy of lithium in treating adolescents with 
bipolar depression. In this study, lithium appeared to be well tolerated and efficacious for the 
treatment of acute depressive episodes.191 Based on current evidence, lamotrigine appears to 
be effective for treatment-refractory bipolar disorder in adult patients, and recent studies in 
the pediatric population are promising.192-195 However, lamotrigine has also received a black 
box warning for use in those under the age of 16 due to increased incidence of Steven-
Johnson's rash.28  
2.2.5.3 Maintenance Treatment for Pediatric Bipolar Disorder 
 Treatment of bipolar disorder generally focuses on the control of episodes (either 
manic or depressive). Very few studies exist regarding the use of maintenance treatments 
after episode-related symptoms are controlled. Recurrence is a common problem in pediatric 
bipolar disorder, particularly after discontinuation of maintenance treatments.10 Maintenance 
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studies of lithium in adolescents have also provided mixed evidence. In one study, 
adolescents who responded to lithium treatment were randomly assigned to either lithium or 
placebo during a 2-week, double-blind follow-up maintenance period.196 In this study, there 
was no difference between placebo and lithium. Additionally, symptom exacerbation was a 
problem for both groups and over half of the lithium-treated group relapsed during the 
discontinuation phase.196 A second study of lithium and divalproex was conducted to test 
whether efficacy differed between these two agents for maintenance therapy. In this study, 
patients were randomized to receive either lithium or divalproex as maintenance treatment 
after being stabilized on a combination regimen of both medications.197 Results indicated that 
both drugs were equally effective as maintenance treatments for bipolar youth who had 
syndromal remission when using the combination treatment.197  
2.2.6 Guideline Recommendations for Treatment 
Currently, there are two main sources for expert-based treatment recommendations 
for pediatric bipolar disorder. These are reports from the Child and Adolescent Bipolar 
Foundation  (CABF) guidelines (March, 2005),17 and the American Academy of Child and 
Adolescent Psychiatry (AACAP) practice parameters (January, 2007).19 These guidelines 
focus on the treatment of bipolar mania (bipolar I) as the lack of evidence for treatment of 
bipolar depression (bipolar II) and bipolar NOS do not support the creation of guidelines for 
these spectrum disorders at this time. 17 While the published parameters are not intended to 
dictate standard of care or include all of the proper methods of care, they are suggested 
strategies for patient management. 
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2.2.6.1 Child and Adolescent Bipolar Foundation Guidelines 
Child and Adolescent Bipolar Foundation (CABF) guidelines target the treatment of 
bipolar I, manic or mixed episodes for children ages 6 to 17 years. There are separate 
treatment guidelines based on the presence or absence of psychosis at initial presentation.  
Initial Treatment of Pediatric Bipolar I Disorder without Psychosis 
In brief, the recommended first line treatment for pediatric bipolar disorder without 
psychosis is monotherapy with a traditional mood stabilizer (lithium, divalproex, 
carbamazepine) or monotherapy with an atypical antipsychotic agent for which ample 
evidence exists (olanzapine, quetiapine, risperidone). Although the panel fell short of 
reaching agreement on which agent would be preferred from those recommended, a majority 
of the panel recommended lithium or divalproex due to the available studies of these agents.  
 When children did not respond to initial monotherapy, it was suggested to switch to 
an alternative monotherapy up to three times before initiating combination therapies. In cases 
of partial response to monotherapy, combination therapies were recommended as next steps. 
After three trials of monotherapy with no response, combination therapies were 
recommended. After two trials of monotherapy and one trial of combination therapy (with 
partial or no response), combinations of two mood stabilizers and one atypical antipsychotic 
agent were recommended.  
 If none of the monotherapies or combinations above were successful, alternate 
monotherapies such as oxcarbazepine, aripiprazole or ziprasidone were recommended (given 
the limited evidence of their effectiveness). In cases where no response was obtained for any 
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of the medication trials, final stages of treatment were clozapine and ECT (for adolescents 
only).  
Initial Treatment of Pediatric Bipolar I Disorder with Psychosis 
For patients with bipolar disorder with psychosis, initial treatment should be a 
combination of a traditional mood stabilizer (lithium, divalproex or carbamazepine) and an 
atypical antipsychotic agent. Similar to the guidelines for those who do not have psychosis, 
up to three medication trials of these combinations should be tested in cases with no 
response. If partial response is obtained during any of these stages, or if a patient has failed 
three stages, two mood stabilizers and one atypical agent should be used. If a patient does not 
respond to any of these trials, a combination of a mood stabilizer and oxcarbazepine, 
ziprasidone or aripiprazole is recommended. As before, final treatment stage 
recommendations are clozapine and ECT (for adolescents only).  
2.2.6.2 American Academy of Child and Adolescent Psychiatry Practice Parameters 
 There is significant overlap between the recommendations made by the expert panels 
for the Child and Adolescent Bipolar Foundation (CABF) and the American Academy of 
Child and Adolescent Psychiatry (AACAP). However, the AACAP practice parameter was 
published two years after the CABF guideline and additional evidence was available for 
some antipsychotic agents at that time.  
Regarding pharmacotherapy, recommendations were that first-line treatments consist 
only of agents that have been approved for use in adults with bipolar disorder (or approved in 
children if evidence became available). In this case, lithium, aripiprazole, divalproex, 
olanzapine, risperidone, quetiapine, and ziprasidone were noted as agents approved for the 
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treatment of acute mania in adults. The key changes from the previous recommendations 
were the addition of aripiprazole and ziprasidone as recommended first-line atypical 
antipsychotic agents.   
2.2.6.3 Summary of Current Recommendations 
Figure 2.1 provides an updated summary of the treatment recommendations for 
pediatric bipolar I disorder (mixed or manic episodes, without psychosis). This figure 
incorporates the recommendations made by both the CABF and the AACAP regarding 
appropriate pharmacologic treatment strategies. In order to assess response, both consensus 
panels recommended that each medication trial last a minimum of 4 to 6 weeks at an 
adequate dose (lithium may need up to 8 weeks) prior to switching or augmenting 
therapies.17 Overall, the literature suggests that the acute phase treatment for bipolar I 
disorder is considered to be during the first 8 weeks of treatment.143 Again, recommendations 
are for children ages 6 - 17 years. No recommendations are currently available for children 
under the age of 6 years.  
The CABF guidelines discussed treatment of comorbid disorders at length. They 
indicated that prior to treating comorbid disorders, symptoms of bipolar disorder should first 
be stabilized and the need for treatment should be reviewed after that time. If it is determined 
that the comorbid condition exists in episode-free periods (i.e., once the bipolar symptoms 
have been adequately treated), treatments for co-morbid disorders should be added 
sequentially to identify the benefits and side effects of each agent. This recommendation is of 
great importance as comorbid conditions are highly prevalent and they often worsen the 
prognosis of pediatric bipolar disorder. 
  
33
Both consensus panels stressed the importance of using comprehensive treatment 
approaches that combine psychopharmacology and adjunctive psychosocial therapies. The 
authors assert that medications tend to help with core symptoms, but they do not address the 
associated functional and developmental impairments and the need for skills building and 
support.  
2.2.6.4 Treatment Algorithm Synthesis 
Figure 2.1 presents a summary of the current treatment recommendations for children 
ages 6 - 17 who are diagnosed with bipolar I disorder without psychosis. Recommended first 
step treatment is use of a single traditional mood stabilizer (lithium, divalproex, or 
carbamazepine) or a single atypical antipsychotic agent (olanzapine, quetiapine, risperidone, 
ziprasidone, or aripiprazole). Patients move through the different treatment steps based on a 
sequence of decisions regarding a patients' response (either none, partial, or full). If a patient 
has no response at each of the steps, they would continue to move through the treatment 
algorithm following the solid lines until they end at Step 6 (clozapine or electroconvulsive 
therapy). If, however, a patient experiences partial response at any of the steps, they would 
move through the treatment algorithm following the dashed lines from their previous step for 
treatment augmentation. As an example, if a patient experiences partial response of 
symptoms in Step 1, the next course of action would be for the initial monotherapy to be 
augmented with a second medication. Finally, if a patient fully responds within a step, their 
treatment is not changed further (essentially, they stay within that step). 
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FOOTNOTE: Dashed lines represent recommendations when a partial response is achieved. 
SOURCE: Adapted from CABF and AACAPGuidelines.17, 19  
Li = lithium; VAL = valproate; CBZ = carbamazepine; OLZ = olanzapine; RISP = risperidone; QUE = 
quetiapine; OXC = oxcarbazepine; ARI = aripiprazole ZIP = ziprazodone. 
 
Step 1: Initial Treatment  
Monotherapy with Mood Stabilizer or Atypical 
Antipsychotic Agent 
(Li, VAL, CBZ, OLZ, QUE, RISP, ZIP, ARI) 
Augmentation 
Li + (VAL, OLZ, QUE, RISP, ZIP, or ARI) 
VAL +(OLZ, QUE, RISP, ZIP or ARI) 
CBZ + (OLZ, QUE, RISP, ZIP, or ARI) 
 
Step 2 
Switch Monotherapy with Mood Stabilizer or 
Atypical Antipsychotic Not Previously Tried 
(Li, VAL, CBZ, OLZ, QUE, RISP, ZIP, ARI) 
Step 3 
Switch Monotherapy with Mood Stabilizer or 
Atypical Antipsychotic Not Previously Tried 
(Li, VAL, CBZ, OLZ, QUE, RISP, ZIP, ARI) 
Step 4 
Combination Treatment 
Li + (VAL, OLZ, QUE, RISP, ZIP, or ARI) 
VAL +(OLZ, QUE, RISP, ZIP or ARI) 
CBZ + (OLZ, QUE, RISP, ZIP, or ARI) 
Augmentation 
Combination Treatment 
Li + VAL + OLZ 
Li + VAL + QUE 
Li + VAL + RISP 
Li + VAL + ZIP 
Li + VAL + ARI 
Li + CBZ + OLZ 
Li + CBZ + QUE 
Li + CBZ + RISP 
Li + CBZ + ZIP 
Li + CBZ + ARI 
Step 5 
Alternate Monotherapy 
OXC 
Step 6 
Clozapine OR Electroconvulsive Therapy* 
*Adolescents Only 
Augmentation 
Li + (VAL, OLZ, QUE, RISP, ZIP, or 
ARI) 
VAL +(OLZ, QUE, RISP, ZIP or ARI) 
1Figure 2.1 - Summary of Current MedicationGuideline Recommendations for the Treatment of 
Bipolar I Disorder without Psychosis in children ages 6 to 17 
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2.2.7 Actual Prescribing Practices and Management 
 While current guidelines emphasize the importance of avoiding polypharmacy, and 
no controlled-trial data support combining medication classes in youth with non-psychotic 
bipolar disorder,1 in practice it appears that a majority of children receive treatment with 
several psychotropic medications simultaneously.143 Even more notable, some of the 
combinations that are being prescribed are explicitly noted as being guideline discordant 
treatment combinations. For example, use of antidepressants (particularly SSRIs) and 
stimulants in this population are highly controversial,18, 76, 115, 198-204 but they are often 
prescribed with or without mood stabilizers. This practice is unacceptable based on current 
practice standards for adults, let alone children.52 
Studies of prescribing behavior have revealed high levels of combination therapy use in 
youth and adults with bipolar disorder. Although pharmacoepidemiologic studies are limited 
in this area, those that have been conducted have provided some interesting information 
regarding medication prescribing in children with bipolar disorder. One study of the National 
Ambulatory Medical Care Survey (NAMCS) was particularly useful for outlining the 
practice patterns for outpatient treatment of pediatric bipolar disorder.1 In this study, Moreno 
and colleagues noted that for youth with a diagnosis of bipolar disorder: 90% of office visits 
resulted in a prescription of one or more psychotropic medications; mood stabilizers were 
prescribed in approximately 2/3 of the visits; antidepressants were prescribed without mood 
stabilizers for 34% of the sample; stimulants were prescribed without mood stabilizers for 
36% of the sample; antipsychotics were prescribed in over 47% of the sample; combination 
  
36
treatment occurred in approximately 63% of the sample; and psychotherapy occurred in 
approximately 42% of the sample.  
Two other studies that utilized the National Ambulatory Medical Care Survey (NAMCS) 
found similar medication use patterns for children with bipolar disorder. First, a study by 
Aparasu and colleagues, outpatient visits for which 11 typical and 6 atypical antipsychotic 
agents were prescribed were selected and characteristics of children and adolescents that 
received these drugs from 2003-2004 were described.205 They found that 40% of the visits in 
which these medications were prescribed were for children with bipolar disorder diagnoses, 
and that specialists prescribed 82% of these drugs. They also noted that children who were 
10-14 and 15-19 were significantly more likely to get an antipsychotic than those under the 
age of 10 years. 205  
A separate study looked at the treatment of bipolar disorder and how treatment has 
changed from 1992-1995 as compared to 1996-1999. While this study focused mainly on the 
treatment of adults, they did not exclude those under the age of 18. What they found was that 
nearly a third of patients with a bipolar diagnosis did not receive any mood stabilizer and 
over 45% of the visits resulted in a prescription for an antidepressant (generally SSRIs).206 
Over the study period, the use of lithium decreased by 40%, while the use of valproate 
increased by 250% and the use of anticonvulsants nearly doubled. The use of antidepressants, 
particularly without a mood stabilizer is concerning because of potential for drug-induced 
mania in this population. However, one antidepressant was shown to have lower manicogenic 
properties but this particular drug, bupropion, only represented 8% of the antidepressant 
prescriptions in this group.206  
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Bhangoo and colleagues also explored the use of a variety of psychotropic medications 
among children and adolescents with bipolar disorder using a sample of 111 patients who 
were receiving treatment for bipolar disorder through a psychiatrist.207 They found that a 
variety of agents were used in practice, including mood stabilizers, antipsychotics, 
stimulants, SSRIs and tricyclic antidepressants, and that polypharmacy was common. In fact, 
the mean number of current psychotropic agents among the sample was 3.4 agents. 
Approximately 18% of the children were taking five or more medications and only 30% were 
taking 2 or fewer medications. Children had, on average, over 6 past medication trials; over 
20% had 10 or more medication trials and 25% had 3 or fewer trials.207 In the sample, 98% 
had received a trial of a mood stabilizer (79% received valproate, 51% lithium, 29% 
gabapentin). However, 15% of the sample received treatment with gabapentin, topiramate or 
lamotrigine without having received a trial of lithium.207 These drugs currently have the 
weakest evidence for use in children, indicating that their use should only be considered after 
a lithium trial has failed. A trial of lithium, depakote, and/or possibly carbamazepine would 
be indicated prior to use of a newer anticonvulsant.207 Additionally, 77% of the children 
received an antipsychotic medication (58% received risperidone, 35% olanzapine, 26% 
quetiapine, 12% a neuroleptic, 4% ziprasidone and 1% clozapine).207  
 Use of medications has also been studied using the National Comorbidity Survey 
Replication (NCS-R).41 Although this study focused on adult populations, the use of a 
nationally representative survey and the 9,282 patients made it particularly useful for 
studying patterns of medication use for patients with bipolar disorder. In this study, 
medication use was classified as "appropriate" or "inappropriate." Medications were 
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"appropriate" if they were mood stabilizers, anticonvulsants or antipsychotics; and 
"inappropriate" if they were antidepressants or other psychotropic medications used without 
an antimanic agent. At the 12 month treatment mark, appropriate medication use was higher 
among patients receiving psychiatric care (45%) versus those receiving general medical care 
(9%). Inappropriate treatment was received by 73.1% of patients treated by a general medical 
professional and by 43.4% of those treated by a psychiatrist.41 
2.3 Quality of Care in Pediatric Bipolar Disorder  
2.3.1 Quality of Care in the U.S. Pediatric Population 
In 1999, the Institute of Medicine published a report on the quality of health care 
services in the U.S. and since that time, much attention has been given to assessment and 
improvement of health care quality.208 The Institute of Medicine defines quality of care as 
"the degree to which health services for individuals and populations increase the likelihood 
of desired health outcomes and are consistent with current professional knowledge."209 
Unfortunately this effort has been focused primarily on the quality of health care services for 
the adult or elderly populations and studies related to quality of health care services for 
pediatric populations are limited.210  
In October of 2007, a landmark paper by Mangione-Smith and colleagues in the New 
England Journal of Medicine, provided evidence of the disparities between recommended 
and received care for children in the United States.210 This study found that pediatric 
outpatients received only 46.5% of indicated care overall (with deficits in acute, chronic and 
preventative care) and that these deficiencies were similar in magnitude to those reported for 
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adults.210 Because of these deficiencies, it is important that our focus on quality improvement 
is not limited only to adults and the elderly, but children as well. Children's health and health 
care deserve particular attention because (1) childhood is a developmentally unique stage of 
life, (2) the child health care system is distinctive, (3) child health is connected with adult 
health, and (4) children are more likely than adults to be socially and economically 
disadvantaged.110, 211, 212  
2.3.2 Quality of Mental Health Care in the U.S.  
In 2005, the Institute of Medicine (IOM) published a report that focused on 
improving the quality of health care for patients with mental illness.208  Since this time, 
efforts have been made to quantify the extent to which patients with mental illness receive 
appropriate care. As was the case with quality of care efforts for other disease areas, the 
focus has been heavily shifted towards the adult population. Even prior to the report by the 
IOM, changes were seen in the use of mental health services in the US. For example, national 
trends in the treatment of mental health disorders revealed that annual visits to mental health 
specialists between 1992 and 2000 increased by 50%.213 Additionally, the number of people 
receiving treatment for depression tripled between 1987 and 1997214 and the number of 
people who were treated by a specialist for a serious mental illness increased by 20% 
between 1997 and 2001.215 As of 2000, the proportion of discharges who were diagnosed 
with bipolar disorder rose dramatically, from 2.9% to 15.1% from 1990 to 2000.31 This 
increase in diagnosis has been seen in both children and adults with bipolar disorder;1 
however, management of the disease has changed significantly over this time as well. For 
example, in a study by Case and colleagues, the length of hospital stays for children and 
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adolescents with bipolar disorder were dramatically reduced from 1990 to 2000 with a 
reduction in length of stay of 72%.31  
Increases in use of mental health services do not necessarily equate to receipt of 
appropriate care, improvement in the quality of mental health care, or even adequate levels of 
disease detection and treatment in the population. For example, over a decade ago, the 
epidemiologic catchment area study indicated that in a given year nearly 40% of individuals 
with bipolar disorder were not receiving treatment.216 Similarly, in a notable study by Kessler 
and colleagues, they estimated that treatment for emotional disorders increased from 12.2% 
between 1990 and 1992 to 20.1% between 2001 and 2003.39 Although there was a significant 
increase in the treatment of disorders during this timeframe (with more than 150% increase in 
the rate of treatment), only 40.5% of respondents who had a serious mental illness between 
2001 and 2003 received treatment for their illness. Further, they found that many patients 
who received treatment in this sector did not complete clinical assessments or receive 
treatment with appropriate ongoing monitoring.39  
Other studies have indicated that, similar to adults, many children who need mental 
health services are not receiving them.217-220 One estimate suggested that approximately 1 in 
10 children have a major mental illness or functional impairment and that only about 1/5th of 
the children who were impaired received treatment for their illnesses.25, 221 More recent 
estimates suggest that as many as 20% of children have a diagnosable mental health 
disorder.222-225  
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2.3.3 Quality of Care for Bipolar Disorder  
There are several key areas of concern regarding quality of health care for patients 
with bipolar disorder. For example, diagnosis of bipolar disorder, (including misdiagnosis, 
overdiagnosis, and delays in diagnosing) 46, 47, 107, 123, 226, 227 shortages of available health care 
professionals who are trained to identify and treat bipolar disorder,228, 229 inappropriate use of 
medications (including use of unapproved medications, overuse or underuse of medications, 
and polypharmacy),19, 227 and lack of adherence to guidelines for treatment and management 
of the disease.230 
2.3.4 Evaluating Quality of Care for Bipolar Disorder Using Published Guidelines  
It has been well documented that physicians do not always adhere to published 
evidence-based guidelines for the treatment of chronic conditions.231 The reasons for this 
vary by condition and by physician type but often include lack of awareness or familiarity, 
disagreement, discomfort, low outcome expectancy or low self efficacy and practice inertia 
related to guidelines.231  Guideline non-adherence has previously been reported as a factor 
that influences patient health outcomes in the area of mental health. For example, guidelines 
for the treatment of major depression have been available since 1993 yet there are numerous 
studies that reveal that inadequate dosing schedules or treatment periods are still routinely 
used by medical care providers.232 Similar studies have been conducted in the areas of 
ADHD233 and bipolar disorder234-236 and these reveal that physician adherence to guidelines 
is inconsistent in these areas as well.  
For example, Alisa Busch and colleagues published a report that detailed changes in 
the quality of care for commercially insured adults with bipolar disorder from 1991-1999.237 
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When comparing results from 1994 to 1999, they found that there were some improvements 
in the quality of care based on appropriate use of antimanic agents (increase from 64% to 
77%), and a reduction in use of antidepressants in the absence of antimanic agents (decrease 
from 23% to 14%). However, they also found that psychotherapy use declined during the 
period (from 89% to 69%).237 Similarly, when looking at quality of care for adults with 
bipolar disorder who receive Medicaid, only one-third of enrollees were noted to have 
received guideline-recommended treatments and nearly one-fifth of patients received 
guideline-discouraged treatments. In this case, the quality measures were receipt of 
recommended care (an antimanic agent plus psychotherapy) or receipt of discouraged care 
(antidepressants without an antimanic agent).235   
In 2001, Lim and colleagues conducted a study to assess the prescribing patterns for 
patients who were diagnosed with Bipolar I disorder to determine how well these patterns fit 
with guideline recommendations.236 They discovered that only one in three patients with 
psychotic features was discharged on medications recommended as preferred treatments. 
Additionally, they found that for patients with bipolar disorder and no psychosis, this 
dropped to only one in six receiving recommended treatments.236 This study indicated that 
there was variation in prescribing patterns and that few patients actually received guideline 
recommended treatment, however, there was no information regarding how these differences 
impacted the patient’s health outcomes.   
There have been several studies, however, that have tied guideline adherence back to 
patient outcomes in the area of bipolar disorder. The Texas Medication Algorithm Projects, 
for example, utilized prescribing algorithms for severe mental illness (including bipolar 
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disorder) and assessed the extent to which adherence to these algorithms impacted patient 
health and economic outcomes.27 Additionally, a recent study of inpatients with acute mania 
was conducted to determine how well current prescribing patterns reflected the published 
clinical guidelines and the overall impact of short-term clinical outcomes. The researchers 
found generally good concordance with treatment guidelines and a statistically significant 
relationship between early medication initiation and reduced time to hospital discharge.230 
Although these study samples were restricted to adults with bipolar disorder, they provide 
evidence that treatment patterns are useful tools for assessing the quality of care and patient 
outcomes in bipolar disorder. 
As described above, specific efforts aimed at evaluating the quality of care for 
patients with bipolar disorder have been made. However, these have been limited to adults 
and have used older data sources (with most recent quality assessments limited to data from 
2000 and earlier). Up-to-date evidence is specifically needed for the use of guideline-
recommended care for children with bipolar disorder.  
2.4 Framework for Guideline Assessment 
2.4.1 Conceptual Framework 
In order to assess the relationship between patient and provider characteristics and the 
receipt of guideline recommended treatment, a conceptual framework is needed. Figure 2.2 
represents the proposed conceptual framework for this study. This model is based on two 
theoretical frameworks - Donabedian’s framework of structure, process and outcome, 
238(Figure 2.3) and Andersen's Behavioral Model of Health Care (Figure 2.4).239 First, the 
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framework proposed by Donabedian consisted of these three elements: structure, process and 
outcomes. The underlying assumption for this particular model is that good structure 
increases the likelihood of good process and that, in turn, increases the likelihood of a good 
outcome.238 Next, Andersen's model suggests that people's use of health services is a function 
of their predisposition to use services, factors that enable the use of services and the need for 
those services.239 In order to detail the influence of patient characteristics, the Andersen 
framework will be combined with the structure-process-outcome framework by Donabedian. 
The factors contributed by each of these frameworks are detailed below.  
 
2Figure 2.2 - Conceptual Framework for the Association between Guideline Concordant Treatment and 
Patient and Physician Characteristics 
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2.4.1.1 Structure, Process and Outcome Variables 
 
3Figure 2.3 - Donabedian's Structure, Process and Outcomes Model 
 
 
Structure is defined as the attributes of the settings in which care occurs. These 
characteristics were described by Donabedian as including the number, mix, and 
qualifications of the staff, the organization and governance of the staff, and features such as 
the physical space.240 When measuring quality of health care, however, structural elements 
can be adapted to include characteristics of physicians and their practice settings.241 The 
attributes in the proposed model that encompass structure include two such provider 
characteristics. Specifically, physician specialty type (primary care or specialist) and 
metropolitan statistical area (MSA) of the practice are considered. These two characteristics 
were selected to identify if there are differences in guideline adherence based on the 
physician type or if there is notable variation in guideline adherence by metropolitan service 
area status.  
Process is defined as what is done in giving and receiving care, or more specifically, 
whether or not guidelines were followed. This will be assessed by comparing the treatment 
that was received (as evidenced in the patient’s medical and pharmacy claims files) and how 
well these treatment patterns conform to the recommended course of treatments per the 
published guidelines.  
Structure Process Outcome 
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Outcome is defined as the effects of care on the health status of patients and 
populations. This component will not be assessed in the proposed research plan. As discussed 
previously, evidence suggests that health and economic outcomes would improve if 
guideline-based treatment were used.27 The focus of the current research plan is on 
establishing the patient and provider factors that are associated with receipt of guideline non-
concordant care.   
2.4.1.2 Predisposing, Enabling and Need Variables 
 
4Figure 2.4 - Andersen's Behavioral Model of Health Services Use 
 
 
 
 
 
 
 
Predisposing characteristics are considered biological and social imperatives that 
suggest the likelihood of needing health services.242 In this case, factors such as the child's 
age at diagnosis, their sex and their geographic region are considered predisposing 
characteristics.  
Enabling resources are factors that promote or inhibit service use. In this case, patient 
insurance type (fee for service or health maintenance organization) will be used as an 
enabling factor, as will the generosity of the patients' outpatient prescription drug benefits. 
Although all patients in the data source are privately insured, there may be differences in the 
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use of health services by plan structure (fee for service or health maintenance organization, 
for example or by the generosity of the insurance plan's prescription drug benefit).243   
 Need factors represent the perceived and evaluated need for health services. 
Although perceived need will not be measured, evaluated need will be considered to be a 
diagnosis of bipolar disorder. Additionally, need variables will include the presence of other 
co-morbid conditions and disease severity indicators.  
2.4.1.3 Rationale for Proposed Conceptual Framework 
The proposed conceptual framework will allow us to evaluate the influence of both 
physician-level and patient-level characteristics on the use of guideline-recommended 
treatment. This is important as process measures have recently become the focus of quality 
measurement efforts. These measures can provide actionable information regarding the 
extent to which clinical practice varies from guideline recommendations.244 If process 
measures identify substantial nonadherence to recommendations, physician-level and patient-
level factors can be explored to identify targets for process-related improvements. 
Establishing these associations is key to improving the quality of health care services 
delivered to children with bipolar disorder.
CHAPTER THREE: METHODS 
 
3.1 Data Source and Aims 
Data for this project originated from the MarketScan Commercial Claims and 
Encounters database. This data source contains de-identified information on clinical 
utilization and expenditures for inpatient, outpatient and pharmacy services.  The data 
represented approximately 100 payers within the United States. From the first quarter of 
2005 through the last quarter of 2007 the average annual population of enrolled children was 
6,048,159. These data were used to answer the following aims.  
Aim 1: To describe the treatment patterns and the demographic characteristics of a 
cohort of children who are diagnosed with bipolar disorder.  
 
Aim 2: To determine the factors associated with receiving a single mood stabilizer or 
atypical antipsychotic as first line treatment, compared with receiving any other bipolar 
treatment.  
 
Aim 3: To determine the factors associated with early treatment regimen changes, 
compared with no early regimen changes. 
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Each of the aims described above are further detailed and explicit methods for their 
analysis are provided in section 3.6.  
3.2 Study Sample 
In order to address the multiple aims of this research project, four samples were 
constructed. These samples were constructed using inclusion and exclusion criteria based on 
studies previously conducted in the pediatric bipolar literature, as well as expert-consensus 
recommendations regarding the design of clinical trials for pediatric bipolar disorder.  Details 
of the study sample inclusion and exclusion criteria are provided below.  
The overall study sample included patients in the MarketScan Commercial Claims 
and Encounters database from January 1, 2005 through December 31, 2007. Patients were 
included if they were under the age of 18 years at the time of their first recorded bipolar 
diagnosis and had either one inpatient or two or more outpatient insurance claims with 
unique service dates for a bipolar spectrum disorder (ICD-9 codes noted in Table 3.1). DSM-
IV codes were mapped to the respective ICD-9 codes to provide conservative estimates of the 
diagnostic prevalence of the spectrum disorders. This mapping was consistent with previous 
literature in this area.235, 245, 246  
Overlapping claims for both inpatient and outpatient services on the same date were 
counted as inpatient claims.  Additionally, because several medical disorders mimic 
symptoms of mania, children with any of the following medical disorders were excluded: 
temporal lobe epilepsy (ICD-9 code 345.4), multiple sclerosis (ICD-9 code 340), 
hyperthyroidism (ICD-9 code 242.9), closed or open head injury (ICD-9 codes 800.x - 801.x 
and 850.x - 854.x) and systemic lupus erythematosus (ICD-9 code 710.0) or if they were 
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pregnant (ICD-9 code V22 - V24 and V27 - V29).3, 247 Patients meeting the criteria noted 
above were included in the initial study sample. Further inclusion and exclusion criteria were 
added to refine the initial study sample for each aim. These modifications are listed below by 
aim with corresponding sample flow diagrams provided in Chapter 4.  
 
 
4Table 3.1 - International Disease Classification, Ninth Edition (ICD-9) and Diagnostic and Statistics 
Manual for Mental Illness, Text Revision (DSM-IV-TR) 
 
Aim 1 was analyzed in two ways (labeled hereafter as aim 1a and aim 1b to 
differentiate the study designs). Aim 1a utilized a repeated cross-sectional study design to 
identify the diagnostic prevalence of bipolar spectrum disorders, along with the treatments 
and demographic characteristics of children with bipolar disorder. This analytic strategy 
allowed us to determine the prevalence of diagnosed bipolar disorder by using annual cross-
sections. Aim 1b: Restricted the patient population to newly diagnosed patients by including 
only those patients who had no previous diagnosis or treatment for a bipolar spectrum 
disorder (an antipsychotic, anticonvulsant or lithium). Using this strategy, patients were 
ICD-9 Code ICD-9 Description DSM-IV-TR Code DSM-IV Description 
296.0x Manic disorder, single 
episode 296 Bipolar disorders 
296.1x Manic disorder, recurrent 
episode 296 Bipolar disorders 
296.4x Bipolar affective disorder, 
manic 296.4x 
Bipolar I disorder, most recent 
episode hypomanic 
296.5x Bipolar affective disorder, depressed 296.5x 
Bipolar I disorder, most recent 
episode depressed 
296.6x Bipolar affective disorder, 
mixed 296.6x 
Bipolar I disorder, most recent 
episode mixed 
296.7x Bipolar affective disorder, 
unspecified 296.7x 
Bipolar I disorder, most recent 
episode unspecified 
296.80 Manic-depressive psychosis, 
unspecified 296.80 Bipolar disorder NOS 
296.89 Other 296.89 Bipolar II disorder 
301.13 Cyclothymic Disorder 301.13 Cyclothymic Disorder 
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followed forward in time to determine if there were changes in their diagnoses or treatments. 
Using this sample, patient characteristics and physician characteristics were summarized by 
the child's index bipolar diagnosis subtype. 
3.2.1 Aim1a: Repeated cross-sectional design, prevalence study 
 For aim 1a patients were classified by the bipolar diagnosis code received at their last 
bipolar-related visit. Because the original study sample required only that patients be under 
the age of 18 years at the time of their first recorded diagnosis, there may have been patients 
in the aim 1a sample who were over the age of 17 years by their last bipolar-related visit. 
Therefore, the age under 18 age limit was re-applied to the aim 1a sample. This sample was 
used for the prevalence and demographic analyses related to aim 1a.  
3.2.2 Aim1a: Repeated cross-sectional design, medication use study 
 Further criteria were applied to accurately identify the prescription drug eligible 
sample. In order to identify medication us in the 30 days following the patient's most recent 
diagnosis, the index diagnosis was modified from the initial sample and above by only 
considering diagnoses that took place prior to December 1st in each study year. Again, the 
age  less than 18 restriction was applied to this study sample. Only patients who had drug 
data reported by their insurance provider to MarketScan were included. These patients were 
identified within the MarketScan claims data as having medication drug information 
available (yes/no). This restriction only required that drug records be available, not that 
patients had a prescription drug claim. Patients were also required to be enrolled in their 
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insurance plan at the time of their diagnosis and up to 30 days after their diagnosis in order to 
correctly classify their use or non-use of medications.    
3.2.3 Aim1b: Incident Diagnosis Study Design 
  Next, additional exclusionary criteria were applied to address Aim 1b.  In order to 
identify patients who were newly diagnosed and to accurately identify their treatments 
received over time, the initial sample was reduced by restricting the sample to patients whose 
first diagnosis occurred between July 1, 2005 and December 31, 2006. Patients also were 
required to have had continuous enrollment over the 18 month study period, and no previous 
evidence of a bipolar diagnosis or treatment (antipsychotic, anticonvulsant or lithium) for 6 
months prior to their index diagnosis.  The index diagnosis was the first recorded diagnosis 
date among patients who met these criteria.248  Similar inclusion criteria have been used 
previously when analyzing prescription claims data for patients with bipolar disorder.235, 248  
Patients were excluded from this cohort if they had a diagnosis of schizophrenia 
(ICD-9 code 295.x),20, 235, 249, 250 a pervasive developmental disorder (i.e., autism or autism 
spectrum disorder, ICD-9 code 299.x),20, 250 mental retardation (ICD-9 codes 317 - 319),  or a 
substance abuse disorder (ICD-9 codes 303 - 304)20 in the 6 months prior to their bipolar 
diagnosis. These criteria are consistent with requirements for clinical trials and with other 
studies in the area of pediatric bipolar disorder.20 Patients who were identified as substance 
users (ICD-9 code 305) were not excluded from the current study.  
In addition to these criteria, patients whose insurance plans did not provide 
information on medication use were excluded so that we could differentiate between non-use 
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of medications and non-reporting of medications. Characteristics of children in the aim 1b 
sample were reported for only those children who had medication information available.   
3.2.4 Aims 2 and 3 Study Sample 
Finally, in order to address Aims 2 and 3 of the research plan, the sample was further 
reduced by excluding patients who had a bipolar spectrum disorder other than bipolar I 
disorder (i.e., excluded those with bipolar unspecified, bipolar II and cyclothymic disorder), 
and children under the age of 6 years at the time of their diagnosis. These exclusions were 
made because the treatment guidelines were specifically designed for patients with bipolar I 
disorder and for children ages 6 - 17 years.17 Patients with bipolar I disorder, depressed 
subtype were included in the analysis but indicator variables were used to identify this 
subtype since the guidelines were designed specifically for manic or mixed subtypes of the 
disorder.  
Because medication use during hospitalization could not be detected in insurance 
claims data, children with hospitalizations 60 days prior to or 45 days post initial bipolar 
diagnosis were excluded. After these exclusions were made, the index treatment date was 
identified as the date at which the first dispensing of bipolar medications was made post 
initial diagnosis.  
3.3 Sample Size 
Sample size calculations were based on the most narrowly defined cohort of patients 
with Bipolar I disorder (the subset of patients needed for aims 2 and 3). Using a conservative 
estimate of the published prevalence of Bipolar I disorder, we assumed that 0.05% of the 
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children in our sample would have this diagnosis. In 2002, there were 944,502 children in the 
MarketScan database.251 We assumed that half of 1% of these would have a bipolar 
diagnosis, so we expected 4,722 children to be eligible for our cohort prior to applying 
inclusion and exclusion criteria. Using Cohen's criteria for assessing power, with an alpha 
level of 0.05 for a two-sided test of significance, and a minimum power of 80%, we should 
have been able to detect small differences in means or proportions.252  
3.4 Study Design 
A retrospective cohort was constructed using MarketScan Commercial Claims and 
Encounters database from January 1, 2005 to December 31, 2007. Inclusion and exclusion 
criteria were defined previously and are provided in Figures 4.1 - 4.5.  To address Aim 1, two 
samples were created. The first sample (aim 1a) was used to assess the diagnostic prevalence 
of bipolar spectrum disorders and treatments for the disorders by using a repeated cross-
sectional study design. In this design, information regarding the demographic and treatment 
characteristics of children who were diagnosed with any bipolar spectrum disorder were 
assessed using frequency information for each variable of interest (e.g., age, gender, co-
morbid conditions, treatment received). Cross-sections were extracted from January 1st to 
December 31st) for each year (2005 - 2007).   
The second sample for aim 1 (aim 1b) included only those patients who were newly 
diagnosed with a bipolar spectrum disorder. This was achieved by requiring that patients 
have a 6 month "clean" period (no evidence of bipolar diagnosis or treatment) prior to their 
initial diagnosis, followed by a 12 month period of continuous enrollment. Constructing the 
sample in this way allowed us to follow patients forward in time to determine if there were 
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changes in their diagnoses or treatments. This sample was also utilized in aims 2 and 3 after 
applying additional inclusion and exclusion criteria; however, the focus of aims 2 and 3 were 
on the date that medication was received and not the date of the diagnosis. For these aims, 
guideline concordant care was assessed by identifying care received among those who were 
new bipolar treatment initiators.  Patients who did not initiate treatment within 90 days of 
diagnosis were categorized as guideline discordant. Descriptive information on patient and 
provider characteristics by type of care (guideline concordant versus non-concordant) was 
assessed for this sample.  
3.5 Measures 
Variables for the analysis and coding specifications are noted in tables 3.2 - 3.3 and 
described below.  
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5Table 3.2 - Variable Descriptions and Coding Strategies for Patient and Physician Characteristics 
Patient Characteristics Variable Coding Variable Definition 
Predisposing Characteristics   
Age at Diagnosis Continuous, Years Age in years at time of service. 
Sex 1 = Male, 2 = Female Patient sex from enrollment file. 
Geographic Region Northeast, North central, West, South 
Geographic region of employee 
residence. 
Enabling Resources   
Insurance Type Comprehensive, HMO, POS, PPO, Other, and Unknown 
Insurance type reported at the time of 
service. 
Generosity of Benefits None/Poor, Fair, Good 
Ratio of patient out of pocket 
payments to total payments for 
prescription drugs. 
Cost of Medical Care Continuous, Dollars Annual cost for Inpatient, Outpatient 
and Pharmacy services per patient. 
Need Characteristics   
Diagnostic Category   
Bipolar I 0 = Absent, 1 = Present Diagnosis code: 296.0x, 296.1x, 296.4x, 296.5x, 296.6x 
Bipolar II 0 = Absent, 1 = Present Diagnosis code: 296.89 
Bipolar NOS 0 = Absent, 1 = Present Diagnosis code: 296.7x, 296.8x (except 296.89) 
Cyclothymic Disorder 0 = Absent, 1 = Present Diagnosis code: 301.13 
Co-Morbid Diagnosis   
Attention Deficit  
Hyperactivity Disorder  0 = Absent, 1 = Present Diagnosis code: 314.00, 314.01 
Conduct Disorder 0 = Absent, 1 = Present Diagnosis code: 312.x 
Oppositional Defiant Disorder 0 = Absent, 1 = Present Diagnosis code: 313.81 
Separation Anxiety Disorder 0 = Absent, 1 = Present Diagnosis code: 309.21 
Post Traumatic Stress Disorder 0 = Absent, 1 = Present Diagnosis code: 309.81 
Obsessive Compulsive 
Disorder 0 = Absent, 1 = Present Diagnosis code: 300.3 
Generalized Anxiety Disorder 0 = Absent, 1 = Present Diagnosis code: 300.02 
Social Phobia 0 = Absent, 1 = Present Diagnosis code: 300.23 
Major Depressive Disorder 0 = Absent, 1 = Present Diagnosis code: 296.2x, 296.3x 
Dysthymic Disorder 0 = Absent, 1 = Present Diagnosis code: 300.4 
Tourette's or Tic Disorders 0 = Absent, 1 = Present Diagnosis code: 307.23, 307.2x,  
Disease Severity   
Number of Diagnoses Continuous, Number of Diagnoses 
Count of total unique diagnoses in 
the year (mental health and other) 
Any Inpatient  
Mental Health Days 0 = No Days , 1 = Any Days 
Any inpatient mental health days 
(Diagnosis codes: 290.00 - 319.99) 
Physician Characteristics   
Structural Characteristics   
Provider Specialty 
0 = Unclassified, 1 = Other 
Medical Specialist, 2 = Other 
Mental Health, 3 = Primary 
Care, 4 = Psychiatry 
Psychiatry, Primary Care, Other 
Mental Health Provider, Other 
Medical Specialist, and Unclassified 
Metropolitan Statistical Area 0 = Non-MSA, 1 = MSA Metropolitan Statistical Area of the primary beneficiary. 
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6Table 3.3 - Variable Descriptions and Coding Strategies for Treatment Characteristics 
Treatment Characteristics Variable Type Variable Range 
Medications Prescribed   
Mood Stabilizers Categorical 1 = Present, 0 = Absent 
       Lithium Categorical 1 = Present, 0 = Absent 
       Anticonvulsants Categorical 1 = Present, 0 = Absent 
Antipsychotic Categorical 1 = Present, 0 = Absent 
Antidepressant Categorical 1 = Present, 0 = Absent 
Stimulant Categorical 1 = Present, 0 = Absent 
Polypharmacy   
2+ Mood Stabilizers Categorical 1 = Present, 0 = Absent 
2+ Antipsychotics Categorical 1 = Present, 0 = Absent 
Mood Stabilizer + Antipsychotic Categorical 1 = Present, 0 = Absent 
Mood Stabilizer + Antidepressant Categorical 1 = Present, 0 = Absent 
Mood Stabilizer + Psychostimulant Categorical 1 = Present, 0 = Absent 
Antipsychotic + Antidepressant Categorical 1 = Present, 0 = Absent 
Antipsychotic + Psychostimulant Categorical 1 = Present, 0 = Absent 
Psychotherapy   
Any Use Categorical 1 = Present, 0 = Absent 
Frequency of Use Continuous Number of Visits per Year 
Other Treatment   
Use Pharmacotherapy Categorical 1 = Yes, 0 = No 
Use Electroconvulsive Therapy Categorical 1 = Yes, 0 = No 
 
3.5.1 Patient Characteristics  
3.5.1.1 Predisposing Characteristics 
Specific predisposing characteristics of interest were age, sex, and geographic region. 
These variables are available within the MarketScan dataset and were coded as follows: Age 
at Onset was calculated as the age at the time of initial bipolar diagnosis (for aims 1b, 2 and 
3), age at the last bipolar-related visit for the study year for aim 1a demographic analyses, 
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and age at the last bipolar-related visit prior to December 1st in the study year for the aim 1a 
medication related analyses. Sex was coded as "male" or "female." Geographic Region was 
based on the "Region" variable in the MarketScan database. This variable is coded as 
Northeast, North Central, West and South and is based on the Geographic Region of 
employee residence. Northeast was used as the reference category. 
3.5.1.2 Enabling Resources 
Enabling resources were assessed based on available information within the 
MarketScan dataset. Included variables were insurance type and generosity of insurance 
benefits. These variables were coded as follows: Insurance type was based on the "Plan 
Indicator" variable in the MarketScan database. This variable was coded as follows: 
Comprehensive, Health Maintenance Organization (HMO), Non-Capitated Point-of-Service 
(POS), Preferred Provider Organization (PPO), Other (Basic/Major Medical, Exclusive 
Provider Organization, Capitated or Partially-Capitated Point-of-Service and Consumer-
Driven Health Plans), and Unknown.  
The generosity of benefits was assessed using a ratio described previously by Artz 
and colleagues.243 This variable is based on a sum of patients' coinsurance, copayments and 
deductible payments for prescription drugs divided by the total net prescription drug 
payments (from all payment sources, minus discounts). This ratio was categorized into four 
levels: None (ratio > 0.99), Poor (ratio > 0.80 and ≤ 0.99), Fair (ratio > 0.20 and ≤ 0.80), and 
Good (ratio ≥ 0 and ≤ 0.20). Only a small number of patients were categorized as either 
"None" or "Poor," therefore these two categories were combined into one category (None / 
Poor). Finally, cost of medical care was summarized for inpatient, outpatient and pharmacy 
  
59
claims for each patient. These cost estimates were used in aim 1b to identify the mean annual 
expenditures for patients with newly diagnosed bipolar disorder.  
3.5.1.3 Need Characteristics 
Need characteristics included both the type of bipolar spectrum disorder (Bipolar I, 
Bipolar II, Bipolar-NOS or Cyclothymic Disorder), as well as co-morbid conditions and 
disease severity. These variables were coded as follows: Bipolar Spectrum Disorder Type 
was coded as Bipolar I, Bipolar II, Bipolar Unspecified (NOS), and Cyclothymic Disorder. 
These were based on diagnostic claims information and ICD-9 codes in the MarketScan 
database and provided in table 3.2. Indicators for diagnosis are "Present" or "Absent" for 
each person in the database. It was anticipated that individuals would have more than one 
diagnosis over time as bipolar diagnosis is unstable in children. For analysis for aim 1a 
(prevalence study), the diagnosis was recorded as the current bipolar diagnosis as of 
December 31st of each year. For analysis for aim 1b (newly diagnosed sample), the diagnosis 
was recorded as the first diagnosis of bipolar disorder following a 6-month clean period.  
Comorbid mental health diagnoses were of primary interest and were summarized for 
the following conditions: attention deficit hyperactivity disorder, other disruptive disorders 
(conduct disorder and oppositional defiant disorder), anxiety disorders (separation anxiety 
disorder, post traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety 
disorder, social phobia, panic disorder), depressive disorders (major depressive disorder, 
dysthymic disorder), and tic disorders (Tourette's, chronic motor or vocal tic disorder, 
transient tic disorder). All comorbid conditions were identified using the appropriate ICD-9 
codes to identify patterns of comorbidities within the children in the cohort (see table 3.2 for 
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specific codes). Conditions were identified as present or absent and also categorized within 
diagnostic classes. Additionally, the presence or absence of Schizophrenia, Pervasive 
Developmental Disorders, Substance Abuse Disorders and Mental Retardation were 
summarized for Aim 1a of the proposal. In addition to summarizing the presence of any 
comorbid mental health condition, summaries for aim 1b also include identification of 
conditions that occurred prior to the index diagnosis (pre-morbid) and those that occurred 
post index diagnosis (post-morbid).  
Disease severity measures were also used. Although ICD-9 severity indicators were 
available within the dataset, these indicators have long been considered to be unreliable. 
Therefore, several variables that have been shown to be associated with severity were 
included and ICD-9 severity indicators were not used. Previous studies have operationalized 
illness severity in a number of ways. For example, the number of comorbid Axis I 
disorders,253 the presence of psychosis,2 age at disease onset,254 and previous 
hospitalizations255 have all been suggested as indicators of illness severity. One insurance 
claims analysis used three indicators for illness severity: number of different diagnoses (all 
diagnoses, not just mental health) in the year, if the child had a dual diagnosis (mental illness 
and substance abuse) and if the child had any inpatient mental health days during the year 
(identified using ICD-9 codes from 290.00 - 319.99).32 This study utilized two of the 
measures identified in the study conducted by Martin and Leslie - the number of different 
diagnoses and the presence of any inpatient mental health days. The measure associated with 
dual diagnosis was not used as patients with substance abuse diagnoses were excluded from 
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the cohort. Finally, aims 2 and 3 utilized an indicator variable for the presence or absence of 
psychosis. This variable was based on the fifth digit of the ICD-9 code, where available.  
3.5.1.4 Treatment Characteristics 
Medications were identified by coding individual drugs as present or absent and then 
grouping them by drug categories. Coding in the MarketScan dataset follows that of the 
American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification 
system.(AHFS, 2008) Medication use was grouped into four major categories: mood 
stabilizers (lithium and anticonvulsants - codes 28.28 and 28.12.92), antipsychotics (code 
28.16.08), antidepressants (code 28.16.04), and stimulants (code 28.20.04).  
These categories were further subdivided as follows: Mood stabilizers included 
lithium, divalproex and other anticonvulsants (carbamazepine, lamotrigine, topiramate, 
gabapentin, oxcarbazepine, levetiracetam, and tiagabine). Consistent with other studies, 
lithium use was summarized separately from other mood stabilizers, unless otherwise 
indicated.1, 76, 206 Antipsychotics included clozapine, other second generation agents 
(risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole), and other first generation 
agents. First generation antipsychotics use was summarized separately from second 
generation antipsychotics, unless otherwise indicated. Antidepressants included tricyclics and 
tetracyclics, selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, 
escitalopram, fluvoxamine, and paroxetine), other antidepressants (venlafaxine, trazodone, 
nefazodone, mirtazapine, duloxetine, and bupropion) and monoamine oxidase inhibitors. 
Stimulants included methylphenidate, methylphenidate transdermal, dextroamphetamines, 
amphetamine salt combinations, dexmethylphenidate, and lisdexamphetamine. 
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Medication use patterns were structured to not only identify drug class use, but use of 
drug class combinations (polypharmacy). This was categorized as use of concurrent drugs 
(two or more mood stabilizers or two or more antipsychotics) as well as combinations of 
drug classes (such as mood stabilizers and antipsychotics; mood stabilizers and 
antidepressants, etc.). Specifically, polypharmacy was captured by looking at concurrent use 
of multiple medications and medication classes.  
Finally, use of psychotherapy or counseling was captured (as any use and then by 
number of visits per year), as was use of electroconvulsive therapy (ECT) and non-use of 
medications. These services were identified in the MarketScan database using Current 
Procedural Terminology, 4th Edition (CPT-4) codes, ICD-9 codes or Healthcare Common 
Procedure Coding System (HCPCS) codes. Electroconvulsive therapy was identified using 
the following procedure codes: 90870, 90871 or 9427. Psychotherapy was defined by the 
presence of any of the following procedure codes: 90804 - 90819, 90821 - 90824, 90826 - 
90829, 90841 - 90844, 90846 - 90849, 90853, 90855, 90857, 90862, 90875, or 90876 in any 
procedure code field (inpatient, outpatient or facility). For those who had any psychotherapy 
use, the total number of visits was calculated to determine the frequency of use.  
Use of either psychotherapy or ECT was calculated among patients who had mental 
health / substance abuse coverage indicators in the MarketScan database. This allowed for 
accurate capture of use, or non-use, as patients without this indicator may have received 
services from a carve-out vendor that were not captured in the MarketScan claims.  
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3.5.2 Structural Measures 
3.5.2.1 Physician Characteristics 
Physician characteristics were also assessed based on available information within the 
MarketScan dataset. Variables that were included in this analysis were provider specialty 
type and Metropolitan Statistical Area classification of the physician's practice.40, 205, 248 
These variables were coded as follows: Provider Specialty was defined using provider 
indicators in the MarketScan database. Providers were classified into one of five categories: 
Psychiatry, Primary Care, Other Mental Health Provider, Other Medical Specialist, and 
Unclassified. Specialty was identified for aim 1a as the provider at the last bipolar-related 
visit. For aim 1b, the provider was categorized using the first bipolar related claim for newly 
diagnosed patients. Aims 2 and 3 used the provider who was seen at the visit that was closest 
to the prescription fill date (on or before the fill date). Additionally, provider type was 
classified so that in cases where multiple providers were seen on the same date, the most 
specific provider would be selected (ordered from most to least specific as: Psychiatry, 
Primary Care, Other Mental Health Provider, Other Medical Specialist, and Unclassified). 
Metropolitan Statistical Area was categorized as MSA or Non-MSA based on the 
MarketScan variables. This variable was based on the MSA of the primary beneficiaries' zip 
code.  
3.5.3 Process Measures  
3.5.3.1 Use of Recommended First-Line Treatment 
 The process measure evaluated by aim 2 of this proposal evaluated whether or not 
patients received the appropriate first-line treatment upon diagnosis with bipolar I disorder. 
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Appropriate treatment is specified by the expert-consensus treatment guidelines produced in 
2005 and 2007.17, 19 These guidelines indicate that initial treatment for patients with Bipolar I 
disorder without psychosis be a mood stabilizer or antipsychotic monotherapy. Therefore, 
individuals were classified as receiving appropriate first-line treatment if they received any 
one of the following drugs: Lithium, divalproex, carbamazepine, olanzapine, quetiapine, 
risperidone, ziprasidone or aripiprazole. Any other drug or combination of drugs would be 
specifically contraindicated by the guidelines, and therefore were classified as inappropriate 
first-line treatment. Additionally, children who did not receive a medication for bipolar 
disorder within 90 days of their initial bipolar diagnosis were considered to have received 
guideline discordant treatment as guidelines recommend pharmacotherapy as a "minimal 
standard" (i.e., expected to apply at least 95% of the time) for children with bipolar I 
disorder.19  
3.5.3.2 Receipt of a 6-8 week medication treatment trial prior to treatment regimen 
changes. 
 The process measure evaluated by aim 3 of this proposal used the number of weeks 
that initial medication trials lasted prior to switching or augmenting treatment to identify 
early medication regimen changes. Studies suggest that medication trials last a minimum of 
six to eight weeks at adequate doses prior to making drug regimen changes. This allows for 
sufficient time to assess medication response.17, 20 It is unclear to what extent this 
recommendation is followed in clinical practice. It is also clear that polypharmacy and 
multiple drug regimen changes are common in this field (which may be appropriate), but it is 
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important that drug trials be sufficiently long to assess effectiveness prior to making these 
changes.  
 Individuals were then classified as receiving early medication regimen changes if 
they had initial medication trials that were shorter than the guideline recommended time 
(conservatively, six weeks was used as the recommended time).20 Only initial medication 
therapy was analyzed using this criteria, as evidence from the Treatment of Early Age Mania 
study indicated that, in the context of second medication trials, there is no longer consensus 
that eight weeks is a sufficient medication trial.24  
3.6 Data Analysis by Aim 
3.6.1 Aim 1: Describe the treatment patterns and the demographic characteristics of 
children who are diagnosed with bipolar disorder.  
Information regarding diagnostic and treatment patterns among children with bipolar 
disorder were summarized in this aim. To achieve this, two study designs were used - a 
prevalence design (aim 1a) and an incident diagnosis design (aim 1b).  
For Aim 1a, repeated cross-sections of data were used to identify the diagnostic 
prevalence of bipolar spectrum disorders and treatments for the disorders among a cohort of 
children under the age of 18 years.  A retrospective cohort was constructed using MarketScan 
Commercial Claims and Encounters database from January 1, 2005 to December 31, 2007. 
Information regarding the demographic and treatment characteristics of children who were 
diagnosed with any bipolar spectrum disorder was assessed using frequency information for 
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each variable of interest (e.g., age, gender, co-morbid conditions, treatment received). Cross-
sections were extracted from January 1st to December 31st for each year (2005 - 2007).   
The annual diagnostic prevalence of bipolar spectrum disorders used the total number 
of children with a specific bipolar diagnosis over each one-year study period (January 1 - 
December 31) divided by the total number of children in the dataset at the mid-point of the 
study period.  Although this method did not allow us to account for the impact of non-
continuous enrollment, it has been used previously in claims based annual-prevalence 
studies.256 A patients' bipolar type (Bipolar I, II, Unspecified, or Cyclothymia) was classified 
according to the bipolar diagnosis code received at their last bipolar-related visit during the 
study year.  In addition to the diagnostic prevalence, patient characteristics (e.g., age, gender, 
co-morbid conditions and disease severity), and physician specialty information were 
summarized by study year for this sample.  
Descriptive information regarding the medication classes and class combinations that 
were used to treat pediatric bipolar disorder were also summarized by year for the medication 
use sample. For this analysis, patients' bipolar type was classified according to the bipolar 
diagnosis code received at the last bipolar-related visit prior to December 1st in each calendar 
year. This was done to ensure that, for all included patients, their medication use could be 
observed for 30 days after their last diagnosis. Summaries included drug-level and class-level 
use, as well as a count variable that indicated the number of drugs taken by each child during 
the 30-days after their last diagnosis.  
In addition to the summaries proposed above, changes in diagnosis, treatment and co-
morbid conditions were also assessed by age categories for aim 1a. There is currently a lack 
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of information regarding the differences in treatment strategies and diagnosis of children who 
are under the age of 10 years.22 This age group is particularly important because current 
recommendations are to conduct medication trials of only 10 to 17 year old children.20 
Therefore, age categories were constructed to assess diagnosis, treatment and comorbidities 
for children under the age of 10 and those ages 10-17 separately. Each summary described 
above was replicated separately for those ages less than 10 years and those ages 10-17 years 
inclusive. 
For Aim 1b, a sample of newly-diagnosed patients was constructed. This was 
achieved by requiring that patients have a 6 month "clean" period (no evidence of bipolar 
diagnosis or treatment) prior to their initial (first identified) diagnosis, followed by a 12 
month period of continuous enrollment. Using this sample, patients were followed forward in 
time to determine if there were changes in their diagnoses or treatments (Figure 3.1). To be 
included in the aim 1b cohort, patients must have had their first diagnosis of bipolar disorder 
between July 1, 2005 and December 31, 2006. Patient characteristics were captured within 
the 6 month pre-diagnosis period and medication use was summarized within the 12 month 
follow-up period for each patient.  
 
5Figure 3.1 Timeline for Assessments 
 
Minimum 
 6 Month 
Pre-Diagnosis 
First Diagnosis between July 1, 2005 
and December 31, 2006 
Minimum 
12 Month 
Follow Up Period 
2005 2007 
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Patient characteristics (age at diagnosis, gender, geographic region, insurance type, 
generosity of benefits, co-morbid conditions and disease severity), and physician 
characteristics (specialty, metropolitan location), were summarized by the child's index 
bipolar diagnosis subtype. In addition to these descriptive summaries, changes in patients' 
bipolar diagnoses were tracked over the one year follow-up period. This allowed us to 
identify the extent to which initial bipolar diagnoses were stable in this population. Finally, 
we were able to summarize comorbid mental health conditions as occurring prior to initial 
diagnosis (pre-morbid) or occurring post initial diagnosis (post-morbid).  
Drug classes were summarized in several ways using this study design. Because we 
were able to identify new users, initially prescribed therapies were summarized at the drug 
class level and by specific drug within each class for each disorder subtype. Initially 
prescribed therapies were defined in two ways: (1) medications used within 30 days of 
diagnosis, and (2) medications used within 90 days of diagnosis. Polypharmacy was assessed 
by identifying the number of drugs used over the selected timeframe. Specific drug use was 
captured as the number of prescriptions for each specific agent within a class over the 
selected timeframes. For this analysis, fills were standardized to a 30 day supply to allow for 
comparisons of use across agents.  
Drug class use within the year following index diagnosis was also summarized. This 
is presented as the number of agents used in the first year from index diagnosis (count of 
medications) as well as the frequency of use for each drug class. Use of psychotherapy and 
electroconvulsive therapy was also assessed for each bipolar subtype by identifying any use, 
and the frequency of use among users. Finally, payments made for treatment were 
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summarized for both patients alone, and patients and insurers combined. These summaries 
included estimates of the median and mean payments for medical care among all patients and 
then separately among users of services.   
3.6.2 Aim 2: Determine the factors associated with receiving a single mood stabilizer or 
atypical antipsychotic as first line treatment. 
The sample for this proposed analysis consisted of children ages 6 - 17 years who 
were newly diagnosed with Bipolar I disorder. The sample from aim 1b was used as a 
starting point, but restricted to only children ages 6 - 17 as the published guidelines were not 
intended for children under the age of 6 years. Additionally, those with an initial diagnosis 
other than Bipolar I disorder  (bipolar unspecified, bipolar II or Cyclothymic disorder) were 
excluded. Although guidelines are specifically targeted towards children with bipolar I 
disorder, manic or mixed subtype,17 the sample included  children with bipolar I disorder, 
depressed episode. An indicator variable was created to identify children with this particular 
form of bipolar I disorder.  Finally, because medication use during hospitalization could not 
be detected in insurance claims data, children with hospitalizations 60 days prior to or 45 
days post index diagnosis were also excluded. 
Pharmacologic treatment patterns within the dataset were used to identify children 
who received a guideline-recommended first-line treatment (versus those that received any 
other treatment or treatment combination). Appropriate treatment was defined as a mood 
stabilizer or atypical antipsychotic monotherapy. Therefore, individuals were classified as 
receiving appropriate first-line treatment if they received any one of the following drugs: 
Lithium, divalproex, carbamazepine, olanzapine, quetiapine, risperidone, ziprasidone or 
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aripiprazole. Any other drug or combination of drugs were specifically not recommended by 
the guidelines, and therefore were classified as inappropriate first-line treatment. This 
variable was dichotomized as receipt of guideline appropriate first line therapy or not. 
Patients who did not fill a medication within 90 days of their first diagnosis were classified as 
receiving guideline discordant care, as guidelines recommend pharmacotherapy as a 
"minimal standard" (i.e., expected to apply at least 95% of the time) for children with bipolar 
I disorder.19  
The proposed generalized linear model will include each of the predictors noted 
below, along with control variables for geographic region, patient insurance type and year of 
diagnosis.  Details of the rationale for inclusion of these variables and initially proposed 
hypotheses for the relationships are provided below. 
 
HYPOTHESIS: Compared with patients with bipolar I disorder who are prescribed 
guideline recommended first line treatment, those who do not receive the recommended 
treatments are more likely to: 
 
Predisposing Characteristics 
• have a younger age of diagnosis (H02a) 
• be male (H02b) 
Enabling Resources 
• have more generous insurance benefits (H02c) 
Need Characteristics 
• have co-morbid mental health conditions (H02d) 
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• have higher levels of disease severity (H02e) 
• have an initial diagnosis of bipolar I depressed episode (H02f) 
• have treatment plans that exclude psychotherapy or counseling (H02g) 
Physician Characteristics 
• have received their diagnosis from a primary care provider (H02h) 
• reside in a non-Metropolitan Statistical Area (H02i) 
 
Initially Proposed Model for Aim 2 
Risk of Recommended Drug Use = α + β1 (Age) + β2 (Sex) + β3 (Insurance Generosity) + β4 
(ADHD)+ β5 (Depressive Disorders) + β6 (Tic Disorders) + β7 (Anxiety Disorders) + β8 
(Other Disruptive Disorders) + β9 (Disease Severity, Number of Diagnoses) + β10 (Disease 
Severity, Any Inpatient Days) + β11 (Disease Severity, Psychosis) + β12 (Bipolar I Depressed 
Episode) + β13 (Psychotherapy or Counseling) + β14  (Primary Care) + β15 (Metropolitan 
Statistical Area Classification)
 
+ β16 (Region) + β17 (Insurance Type) + β18 (Year Diagnosed) 
 
Previous research suggests that children who were over the age of 10 were 
significantly more likely to get an antipsychotic than those under the age of 10 years.205 This 
suggests that older age may be associated with a higher likelihood of receiving mood 
stabilizers as first line therapy. Additionally, young age is often associated with the presence 
of comorbid attention deficit hyperactivity disorder.63 This comorbid condition may lead to 
treatment combinations, (such as mood stabilizers and stimulants) or reluctance to 
discontinue current ADHD treatment upon diagnosis with bipolar disorder. Similarly, male 
  
72
sex is associated with ADHD diagnosis,59 higher rates of comorbidity,61 and early onset 
bipolar disorder.61 Therefore, it is likely that male sex would be associated with receiving 
guideline discordant treatment.   
Regarding enabling factors, generosity of insurance benefits are associated with 
increased prescription drug use, even when controlling for drug use and insurance selection 
factors.243 It is possible that generosity of benefits may lead to receiving more than one 
medication (initial combination therapy) as patient out of pocket spending would be reduced.  
Regarding need characteristics, comorbid conditions are likely to complicate the 
treatment of bipolar disorder and to lead to a lower likelihood of receiving a monotherapy 
that is recommended by guidelines. Guidelines support the discontinuation of treatments for 
comorbid mental health disorders until a patient is stabilized on the treatment for bipolar 
disorder.17 It is unclear, however, if this recommendation is adhered to in clinical practice. 
Comorbid conditions were modeled individually and then combined as appropriate to 
improve the efficiency of the statistical model. For example, conduct disorder and 
oppositional defiant disorder have been identified as having significant overlap for the 
pediatric bipolar population. These disorders have been previously combined into a single 
"disruptive behavior disorder" category without influencing the outcome.257 Others have 
suggested that the combination of ADHD and conduct disorder may represent one disorder 
and thus their collinearity was assessed.12 Finally, some have suggested that comorbid 
conditions may synergistically influence the primary disorder.3, 11 Therefore, interaction 
terms were added to test if effect measure modification is present for combinations of 
comorbid conditions.    
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Disease severity is also hypothesized to be associated with receipt of guideline 
discordant treatment. This measure utilizes information regarding the number of total 
diagnoses that a child has received, the presence of any inpatient days, and psychosis. 
Treating children who have severe disease may lead to more complex treatment strategies 
that are not specifically recommended by guidelines. Guideline recommendations that are 
being evaluated for this aim are specifically related to patients with bipolar I disorder, manic 
or mixed subtypes without psychosis.17 Given this, psychosis should be a predictor for 
guideline discordant treatment in this sample, as should initial diagnosis of bipolar I, 
depressive subtype. Additionally, use of psychotherapy or counseling is likely to be 
associated with receiving guideline recommended therapy as combined therapy (counseling 
and medication) are recommended by guidelines. 
Overall, the literature supports that specialists would be more likely to have adequate 
training to diagnose and treat bipolar disorder in children, and they would likely be more 
familiar with expert-consensus guidelines from the field as compared with primary care 
physicians.20 Because of this, referral to a mental health specialist is strongly recommended 
for the diagnosis and management of this disorder.21 This suggests that specialists may be 
more informed regarding the appropriate treatment for children with bipolar disorder, and 
therefore more likely to adhere to guideline recommendations. Additionally, metropolitan 
statistical area classifications of the physician's practice or of the patient have previously 
been associated with guideline use (where urban location was associated with the receipt of 
guideline recommended treatment) in several studies of the treatment of depression.258, 259  
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Three control variables (insurance type, geographic region, and year of diagnosis) 
will be used in the proposed analysis. Hypotheses regarding the association between 
guideline use and insurance plan type, as well as geographic region will not be tested. 
Instead, these will be used as control variables in the primary analysis and later explored to 
identify if any relationships exist. Private insurance has previously been associated with a 
lower likelihood of receiving antipsychotic medications, as compared to public insurance;205 
however it is unclear if these relationships exist when comparing insurance plan types within 
private insurance. Additionally, geographic variation in practice guideline adoption and 
attitudes towards service use should be controlled for in this population.205 Finally, year of 
diagnosis will be included in the model to account for time-dependent changes in guideline 
adoption or drug approval changes over the study period. 
3.6.2.1 Aim 2: Statistical Analysis, Variable Selection and Modeling 
 Each of the variables in the initially proposed model was reviewed to determine the 
extent of missing data for covariates of interest. When including all of the variables from the 
proposed model above, 73% of patients had no missing values and 25% had only 1 missing 
value. Upon further inspection, it was determined that a majority of the missing values were 
due to the Metropolitan Statistical Area variable. There were 176 missing values for this 
variable. In addition to high levels of missing values, there was little variation in the response 
to this variable. In fact, over 98% of patients were categorized as "MSA" (compared with 
Non-MSA). This extreme lack of variation is likely due to the sampling strategy within the 
MarketScan dataset. Because MarketScan data is comprised of insurance information from 
large employers, nearly all patients are in MSA regions. Because of these two reasons, MSA 
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Status was excluded from the analysis. This resulted in complete information for 95% of 
patients (no missing values).  
 In order to assess the extent to which missing values were related to the outcome, 
generalized linear models were used to compare the number of missing values among 
patients with and without guideline recommended care. The model indicated that missing 
data was not related to the outcome (p = 0.15) for the relationship between missing values 
and the type of care received. Based on this assessment, the remaining missing values were 
considered to be missing at random.  
 Next, each variable in the initially proposed model was assessed to determine the 
appropriate coding. Categorical and continuous variables were modeled in several ways to 
determine which cut-points represented the true relationship between the exposure and 
outcome. Age was assed as a three-level categorical variable (ages 6 - 11, 12 - 14, and 15-
17). These categories were selected due to the low sample sizes for children under the age of 
11. Additionally, age was modeled as a continuous variable (ages 6 - 17) which assumes that 
the risk of the outcome increases or decreases incrementally by each one year change. After 
modeling the relationship using both coding schemes, it was determined that the dose-
response relationship was relatively flat (slight negative slope) and that there were no 
differences between the categorical and continuous age variable for the relationship with the 
outcome. This led us to use the continuous coding for age in years as it was the more 
statistically efficient variable.   
 Next, insurance generosity was reviewed to determine the most appropriate coding. 
This variable is based on a sum of patients' coinsurance, copayments and deductible 
  
76
payments for prescription drugs divided by the total net prescription drug payments (from all 
payment sources, minus discounts). This ratio was originally categorized into three levels: 
None/Poor (ratio > 0.80), Fair (ratio > 0.20 and ≤ 0.80), and Good (ratio ≥ 0 and ≤ 0.20). Due 
to the low number of patients who had none / poor insurance generosity (n = 26), this 
category was set to missing for the analysis as re-categorizing these patients as "fair 
insurance generosity" may have introduced more bias than removing them from the analysis.  
However, there was a significant problem with this variable that had to be addressed. As a 
limitation of the data, we are unable to calculate benefit generosity measures for patients who 
had no medication use during the study period (we calculate this from filled prescriptions, 
not specific information about their benefit designs). This resulted in 81 patients who had 
"unknown" benefit generosity, all of which would have been categorized as "guideline 
discordant" (as they never received medications). Including this measure for analyses that 
included patients with no medications would have provided biased estimates. Therefore, it 
was determined that the resulting variable should be classified as 0 = fair, 1 = good, and used 
only in the analysis restricted to medication users.  
 The distribution of each comorbid condition was considered next. Sample sizes were 
small for a majority of the comorbidities measured. Therefore, comorbidities were grouped 
as disruptive disorders (attention deficit hyperactivity disorder, conduct disorder, and 
oppositional defiant disorder), anxiety disorders (separation anxiety, post-traumatic stress 
disorder, obsessive compulsive disorder, generalized anxiety disorder, Social phobia, and 
panic disorder), and depressive disorders (major depressive disorder, and dysthymic 
disorder). First, disruptive disorders were assessed. There appeared to be no relationship 
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between the occurrence of disruptive disorders and receipt of recommended care (p = 0.89). 
To ensure that combining the three disorders into one category did not influence the result, 
ADHD, conduct disorder and oppositional defiant disorder were tested separately. While 
none of the relationships were statistically significant, the risk estimates differed in that 
ADHD was negatively associated with receipt of recommended care and conduct / 
oppositional defiant disorder were positively associated with receipt of recommended care. 
This suggests that these variables should not be combined. Therefore, this information was 
included in the final model as ADHD (yes/no) and Other Disruptive Disorder (Yes / No).  
 Similarly, tests of the influence of anxiety disorders revealed a non-significant impact 
on the outcome (p = 0.80). Because only 6.2% of the total sample had pre-existing anxiety 
disorders, this category was excluded from the final model.  
Occurrences of depressive disorders appeared to be related to the outcome with both 
major depressive disorder and dysthymic disorder increasing the risk of receiving non-
recommended care. Therefore, this variable was included in the model as depressive 
disorders (yes/no) with dysthymic disorder and major depressive disorder combined.  
Disease severity measures were also assessed. These measures included the number 
of diagnoses received on or prior to the date of bipolar diagnosis, the occurrence of mental 
health hospitalizations prior to diagnosis, and psychosis. Number of diagnoses was based on 
unique diagnoses received during the 6-month pre-diagnosis period. After modeling this 
variable in multiple ways, it was determined that the relationship between the number of 
diagnoses and the outcome had no discernable pattern. Instead, the relationship indicated that 
the risk varied widely based on the number of diagnoses (plotting this risk estimate resulted 
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in a zig-zag shaped line). Given the random distribution of risk and the non-significant 
relationship between this variable and the outcome (no matter how the variable was coded), 
the decision was made to include this predictor as a continuous variable.   
Next, the number of prior inpatient hospitalizations was analyzed. First, only 
hospitalizations prior to initial diagnosis were considered. In this case, very few patients had 
prior mental health hospitalizations. This was likely due to the exclusion of those with 
hospitalizations surrounding their diagnosis date. As a sensitivity analysis, this definition was 
expanded to include hospitalizations any time during the study period. This resulted in a 
higher number of patients within the category. Although the relationship between inpatient 
hospitalizations and the receipt of guideline appropriate care was non-significant, there was a 
trend that indicated that patients with inpatient hospitalizations were more likely to receive 
guideline recommended care. Because of the small sample size when including only 
information for prior hospitalizations, the inpatient mental health visit indicator was 
constructed using any inpatient visit over the study period. While treatment decisions would 
have been made without knowledge of future hospitalizations, these events may be relevant 
as children who are hospitalized later may have a more severe presentation of their illness.  
Presence of psychotherapy or counseling was assessed by considering the occurrence 
of prior psychotherapy or counseling, or that which was received within 30 days of the date 
of treatment initiation. This was defined by searching for counseling or psychotherapy CPT 
codes in the 90 days prior to and 30 days following initial bipolar diagnosis among patients 
who had mental health / substance abuse coverage information. Of the 730 patients, 606 had 
coverage information available. Patients without mental health / substance abuse coverage 
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were categorized as "unknown" as their use of counseling or psychotherapy could not be 
determined. This variable was coded using three disjoint indicators for the receipt of 
psychotherapy: Psychotherapy Received (yes/no), Psychotherapy Not Received (yes/no), and 
Psychotherapy Unknown (yes/no). Physician variables were originally defined in five 
categories: Psychiatry, Primary Care, Other Mental Health (non-Physician), Other Medical 
Specialist, and Unclassified. However, the provider type variable in the MarketScan dataset 
is considered to be somewhat unreliable as coding standards differ by each data contributor 
(MarketScan User Guide). Given this, and the small number of patients in each of the Other 
Medical Specialists and Unclassified provider categories, the final provider variable was 
coded as: Psychiatry, Primary Care, Other Mental Health (non-Physician), and 
Other/Unclassified. Psychiatry was used as the reference category for the statistical models.    
In addition to these variables, several categorical variables were also added to the 
model based on their relevance noted in the literature: the presence of psychosis, sex, and 
current bipolar I episode type.  While the initial model only included an indicator for bipolar 
I depressive episode type, it was determined that each episode type should be considered. 
Therefore, episode types were coded as: Mania, Depressive, Mixed, or Generic (non-specific 
coding of disorder). Generic type was used as the reference category. The revised model 
consisted of the following: 
 
Revised General Model for Aim 2 
Risk of Recommended Drug Use = α + β1 (Age) + β2 (Sex) + β3 (Insurance Generosity) + β4 
(ADHD)+ β5 (Other Disruptive Behavioral Disorder) + β6 (Depressive Disorders) + β7 
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(Disease Severity, Number of Diagnoses) + β8 (Disease Severity, Any Inpatient Days) + β9 
(Disease Severity, Psychosis) + β10 (Bipolar I Episode Type) + β11 (Psychotherapy or 
Counseling) + β12  (Provider Type) + β13 (Region) + β14 (Insurance Type) + β15 (Year 
Diagnosed) 
 
 Unadjusted estimates of the risk of receipt of guideline recommended care were first 
generated using PROC GENMOD in SAS 9.1. Categorical variables were assessed using a 
log link and a binomial distribution within the GENMOD procedure. Continuous variables 
were assessed using an identity link and a binomial distribution. Within the GENMOD 
procedure, the link describes the functional relation between the dependent variable and the 
linear combination of covariates, while the distribution is related to the distribution of the 
dependent variable. Using an identity link provides estimates of the linear risk, while using a 
log link provides estimates of the log risk.  
Each variable was tested separately to determine the bivariate relationship between 
each predictor and the outcome, without controlling for other variables. After these 
relationships were evaluated, the proposed control variables, insurance type and region, were 
evaluated to determine if they should be added to the model. Neither variable was related to 
the outcome of guideline recommended care in the bivariate assessment. Additionally, they 
were not identified as being necessary components to the model based on a review of the 
literature in the area of quality of care in bipolar disorder. It was therefore determined that 
they did not add to the explanatory capability of the model, but only decreased the model 
efficiency. Because of these reasons, these two variables were excluded from the final model.   
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 Finally, a series of interaction terms were added to the model to determine if there 
was variation based on clinically plausible relationships. For example, age and sex variables 
were used in interactions with comorbid mental health disorders, type of bipolar episode, and 
inpatient mental health hospitalizations to determine if there was variation in the influence of 
these predictors based on a patients' age, sex or both. Such examinations would be able to 
detect differential use of guidelines for young versus old children with ADHD comorbidity, 
or males or females with ADHD, for example. After examining interaction terms for the 
model, it was determined that there was no effect measure modification (interactions were 
not significant), and thus they added no additional explanatory power to the statistical model. 
The final model was specified as noted below and hypotheses were restated based on the 
revised model: 
 
Final Model for Aim 2 
Risk of Recommended Drug Use = α + β1 (Age) + β2 (Sex) + β3 (Insurance Generosity) + β4 
(ADHD)+ β5 (Other Disruptive Behavioral Disorder) + β6 (Depressive Disorders) + β7 
(Disease Severity, Number of Diagnoses) + β8 (Disease Severity, Any Inpatient Days) + β9 
(Disease Severity, Psychosis) + β10 (Bipolar I Depressed Episode) + β11 (Psychotherapy or 
Counseling) + β12  (Provider Type) + β13 (Year Diagnosed) 
 
HYPOTHESIS: Compared with patients with bipolar I disorder who are prescribed 
guideline recommended first line treatment, those who do not receive the recommended 
treatments are more likely to: 
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Predisposing Characteristics 
• have a younger age of diagnosis (H02a) 
• be male (H02b) 
Enabling Resources 
• have more generous insurance benefits (H02c) (only considered for medication users 
analysis) 
Need Characteristics 
• have co-morbid mental health conditions (H02d) 
• have higher levels of disease severity (H02e) 
• have an initial diagnosis of bipolar I depressed episode (H02f) 
• have treatment plans that exclude psychotherapy or counseling (H02g) 
Physician Characteristics 
• have received their diagnosis from a provider other than a psychiatrist (H02h) 
 
Once the final model was established, a log binomial model was used to determine the 
effect of each predictor on the likelihood of receiving guideline recommended care, while 
controlling for the effect of each of the other variables in the model. The log binomial model 
was selected because it allows for direct estimation of adjusted risk ratios (which are 
preferred to using odds ratios when outcomes are not rare).260,261  This model is implemented 
in PROC GENMOD by using a log link and a binomial distribution to assess the relationship 
between the predictors and the outcome.  
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This process was used for three separate definitions of the outcome: (1) explicit 
definition of guideline recommended care and non-recommended - only medications 
specifically recommended by guidelines, appropriate pharmacotherapy received; (2) 
expanded definition of guideline recommended care and non-recommended - any 
anticonvulsant or antipsychotic monotherapy considered appropriate; (3) guideline 
recommended and non-recommended, among only patients who received medication - 
explicit definition for recommended care, exclusion of patients who did not use medications 
(comparison of appropriate and inappropriate care among medications users).  
3.6.3 Aim 3: Determine the factors associated with early treatment regimen changes.  
The sample for this proposed analysis will consist of the same sub-cohort as used in 
aim 2 (described in section 3.6.2). This process measure will use the time from first 
medication fill (in weeks) to identify children with newly-diagnosed bipolar I disorder who 
had adequate medication treatment trials versus those that switched or augmented treatment 
early.  Individuals will then be classified as receiving early medication regimen changes if 
they have initial medication trials that are shorter than the guideline recommended time 
(between 4 and 8 weeks, depending on the agent used).17 To reflect recommendations for 
clinical trial design in the area of pediatric bipolar disorder, the primary analysis will use a 
six week timeframe to identify early switching. 20 Additionally, a sensitivity analysis will be 
conducted using the shorter timeframe recommended by guidelines (4 weeks) to determine 
what degree of switching occurs in the first month.  
 This aim will utilize two strategies to account for the influence of medication 
discontinuation. First, analyses will be conducted among only patients who have evidence of 
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ongoing therapy. In other words, patients who discontinue early (within the first 6 weeks) 
will be excluded from this analysis. Patients must have at least two claims or a 60 day supply 
of medications during their first 6 weeks of treatment to be included in this initial analysis. 
Patients who have early switching or augmenting of treatment will be considered to have 
received guideline discordant treatment. Those who do not experience early switching or 
augmenting then are considered to have received guideline concordant treatment.  A second 
analysis will be conducted in which patients who discontinue therapy within the first 6 weeks 
will be considered to have received guideline discordant treatment. Characteristics of patients 
in this group (early treatment discontinuers) will be compared to patients who did not 
discontinue therapy (treatment continuers) and these characteristics will be summarized. 
In order to account for medication switches that are made due to problems with 
tolerability of the medication, switches made during the first three weeks could be considered 
to be potentially appropriate medication changes.20, 24 The primary analysis categorized all 
switches made within the first 6 weeks to be inappropriate switches. Again, only initial 
medication therapy will be analyzed using this criteria, as evidence from the Treatment of 
Early Age Mania study indicated that, in the context of second medication trials, there is no 
longer consensus that eight weeks is a sufficient medication trial.24 Sensitivity analyses were 
planned to determine the impact of drug switching over the first three weeks to determine the 
impact of outcome misclassification on statistically important risk ratio estimates. However, 
adjusted risk ratio estimates resulted in non-significant effects for all variables, negating the 
need for this sensitivity analysis.  
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Patient level and physician level factors that predict guideline recommended 
treatment trials were then explored. Characteristics of children who receive guideline 
concordant treatment versus those that receive non-concordant treatment were assessed using 
a log binomial regression model.  Specific variables of interest and their hypothesized 
relationships are stated below.  
 
HYPOTHESIS: Compared with patients with bipolar I disorder who receive a guideline 
recommended period of exposure ( ≥ 6 weeks) before switching drug classes or augmenting 
treatment, those who do not receive the guideline recommended period of exposure are more 
likely to: 
Predisposing Characteristics 
• have a younger age of diagnosis (H03a) 
• be male (H03b) 
Enabling Resources 
• have less generous insurance benefits (H03c) 
Need Characteristics 
• have co-morbid mental health conditions (H03d) 
• have higher levels of disease severity (H03e) 
• have an initial diagnosis of bipolar I depressed episode (H02f) 
• have treatment plans that exclude psychotherapy or counseling (H02g) 
Physician Characteristics 
• have received their diagnosis from a primary care provider (H03h) 
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• reside in a Metropolitan Statistical Area (H03i) 
Treatment Characteristics 
• be initially prescribed an antidepressant (H03j) 
• use combination treatments(H03k) 
 
The proposed generalized linear model will include each of the predictors noted 
above, along with control variables for geographic region, patient insurance type, and year of 
diagnosis.   
 
Initially Proposed Model for Aim 3:  
Risk of Early Treatment Regimen Changes  = α + β1 (Age) + β2 (Sex) + β3 (Insurance 
Generosity) + β4 (ADHD)+ β5 (Depressive Disorders) + β6 (Tic Disorders) + β7 (Anxiety 
Disorders) + β8 (Other Disruptive Disorders) + β9 (Disease Severity, Number of Diagnoses) + 
β10 (Disease Severity, Any Inpatient Days) + β11 (Disease Severity, Psychosis) + β12 (Bipolar 
I Depressed Episode) + β13 (Psychotherapy or Counseling) + β14  (Primary Care) + β15 
(Provider Metropolitan Statistical Area Classification)
 
+ β16 (Antidepressant Use) + β17 (Use 
of Combination Treatments) + β18 (Region) + β19 (Insurance Type) + β20 (Year Diagnosed) 
  
 
In addition to these specific hypotheses that will be tested, the relationship between 
drug class prescribed and early regimen changes will be explored, as will the relationship 
between receiving recommended first line therapy and early treatment regimen changes. 
These analyses will be exploratory in nature and will focus on hypothesis generation, rather 
than hypothesis testing.   
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As mentioned previously, treatment guidelines are not tailored for younger children, 
thus their treatment may be managed differently than for older children. This may lead to 
more short-term medication trial periods in younger children since evidence in this group is 
lacking. Additionally, male sex may also contribute to switching treatments early due to the 
higher rates of comorbidities and earlier age at onset. Insurance generosity may also be 
related to switching. For example, if patients are unable to afford their prescription due to 
benefits that are less generous, they may request a different medication that has better 
coverage, or a generic of a covered brand.  
Comorbid conditions are also likely to complicate the treatment of bipolar disorder 
and to lead to a lower likelihood of receiving a treatment exposure period that is 
recommended by guidelines, as treatments for comorbid mental health disorders may be re-
introduced prior to the recommended 6-week stabilization period.17 The presence of 
psychosis is also associated with worse illness severity and thus is believed to increase the 
likelihood of early medication changes. Therefore, illness severity is likely to be positively 
associated with early medication switching. Additionally, initial diagnosis of bipolar I 
depressive subtype is likely to lead to less stable treatments as this may be an indicator of 
diagnostic uncertainty since guidelines do not address this particular manifestation of bipolar 
spectrum disorder. Use of psychotherapy or counseling is also hypothesized to be associated 
with receipt of adequate initial medication trials as it may be an indicator of increased 
adherence to published guidelines.  
Similar to aim 2, specialists are thought to be more likely to have adequate training to 
diagnose and treat bipolar disorder in children, and they would likely be more familiar with 
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expert-consensus guidelines from the field as compared with primary care physicians.20  
Also, as mentioned previously, metropolitan statistical area classifications of the physician's 
practice or of the patient have previously been associated with guideline use.258, 259 However, 
it is also possible that patients in non-MSA regions may have fewer visits to their physicians. 
This may contribute to non-MSA areas being related to lower switching rates. 
Finally, two specific treatment characteristics will be considered in this analysis. 
These are the use of antidepressants and the use of multiple drug classes from initial 
treatment. Antidepressant use is believed to lead to drug-induced mania so patients who are 
prescribed these agents will likely experience medication changes earlier than those who do 
not receive them. Additionally, the use of multiple drug classes may influence drug regimen 
changes as there would likely be more potential for drug interactions or side effects.  
Three additional factors (insurance type, geographic region, and year of diagnosis) 
will be used as control variables in the proposed analysis. Hypotheses regarding the 
association between guideline use and insurance plan type, as well as geographic region will 
not be tested. Instead, these will be explored to identify if any relationships exist.  
3.6.3.1 Aim 3: Statistical Analysis, Variable Selection and Modeling 
 Similar to aim 2, each of the variables in the initially proposed model was reviewed to 
determine the extent of missing data for covariates of interest. When including all of the 
variables from the proposed model above, 96.3% of patients had no missing values after the 
exclusion of the variable for Metropolitan Statistical Area. After assessing the extent to 
which missing values were related to the outcome, it was determined that missing data was 
not related to the outcome (p = 0.15) for the relationship between missing values and the type 
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of care received. Based on this assessment, the remaining missing values were considered to 
be missing at random.  
 Variables were tested to determine the appropriate coding for the risk relationship 
with the outcome of receiving an early medication change.  Age was assessed in several ways 
to determine the true relationship with early medication changes. After modeling the 
relationship using one year age categories, it was determined that there was an increased risk 
of early medication changes in the youngest aged children (6-7 year olds) but this estimate 
was unstable because of the very small number of children within this group (n = 18). It also 
appeared that the risk went down between the ages of 8 and 11 and increased after that time.  
After assessing several coding schemes, it was determined that the coding that best reflected 
the true relationship between age and the outcome was a three-level classification of age 
(ages 6-9, 10-13, 14-17).   
 As with aim 2, patients with none/poor insurance generosity were recoded as missing 
for the analysis, with the resulting variable classified as 0 = fair, 1 = good. The cutoffs were 
fair (ratio > 0.20 and ≤ 0.80), and good (ratio ≥ 0 and ≤ 0.20), representing the proportion of 
the total drug costs that were paid by the patient.  
 Similar to aim 2, comorbidities were grouped as ADHD, other disruptive disorders 
(conduct disorder, and oppositional defiant disorder), anxiety disorders (separation anxiety, 
post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, 
Social phobia, and panic disorder), and depressive disorders (major depressive disorder, and 
dysthymic disorder). There appeared to be no relationship between the occurrence of anxiety 
disorders and the receipt of recommended care (p = 0.65). Because of the lack of relationship 
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with the outcome and the small sample sizes for these comorbidities (only 8% had pre-
existing anxiety disorders), this category was excluded from the final model. Consistent with 
Aim 2, both Attention Deficit Hyperactivity Disorder and other disruptive behavioral 
disorders were included in the final model.  
Depressive disorders were common (nearly 26% of patients had a depressive disorder 
on or before the date of bipolar diagnosis) and appeared to be associated with an increased 
risk of receiving non-recommended care. This variable was included in the model as 
depressive disorders (yes/no) with dysthymic disorder and major depressive disorder 
combined.  
Disease severity measures were also assessed. These measures included the number 
of diagnoses received on or prior to the date of bipolar diagnosis, the occurrence of mental 
health hospitalizations prior to diagnosis, and psychosis. Number of diagnoses was based on 
unique diagnoses received during the 6-month pre-diagnosis period. After modeling this 
variable in multiple ways, it was determined that the relationship between the number of 
diagnoses and the outcome was flat, no matter how it was modeled (the risk of early 
medication changes did not vary based on the number of diagnoses). The decision was made 
to include this variable as a continuous predictor in the final model.   
Similar to aim 2, the number inpatient hospitalizations included hospitalizations any 
time during the study period. Because of the small sample size when including only 
information for prior hospitalizations, the inpatient mental health visit indicator was 
constructed using any inpatient visit over the study period. As with aim 2, treatment 
decisions would have been made without knowledge of future hospitalizations, but these 
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events may be relevant as children who are hospitalized later may have a more severe 
presentation of their illness or more difficult treatment courses.  
Presence of psychotherapy or counseling was assessed by considering the occurrence 
of prior psychotherapy or counseling, or that which was received within 30 days of the date 
of treatment initiation. This was defined by searching for counseling or psychotherapy CPT 
codes in the 90 days prior to and 30 days following initial bipolar diagnosis among patients 
who had mental health / substance abuse coverage information. Of the 375 patients included 
in the primary analysis, 322 had coverage information available. Patients without mental 
health / substance abuse coverage were categorized as "unknown" as their use of counseling 
or psychotherapy could not be determined. This variable was coded using three disjoint 
indicators for the receipt of psychotherapy: Psychotherapy Received (yes/no), Psychotherapy 
Not Received (yes/no), and Psychotherapy Unknown (yes/no).  
Physician variables were originally defined in five categories: Psychiatry, Primary 
Care, Other Mental Health (non-Physician), Other Medical Specialist, and Unclassified. 
However, the provider type variable in the MarketScan dataset is considered to be somewhat 
unreliable as coding standards differ by each data contributor (MarketScan User Guide). 
Given this, and the small number of patients in each of the Other Medical Specialists and 
Unclassified provider categories, the final provider variable was coded as: Psychiatry, 
Primary Care, Other Mental Health (non-Physician), and Other/Unclassified. Psychiatry was 
used as the reference category for the statistical models.    
There were two variables that were unique to the aim 3 analysis (not used in aim 2). 
These were (1) an initial treatment regimen that included an antidepressant (yes/no), and 
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initial treatment plans that included combination therapy (yes/no). These variables were 
included in the final model, and an interaction term was tested to determine if there was risk 
ratio modification when a patient received both an antidepressant at treatment initiation, and 
combination therapy. 
In addition to these variables, several categorical variables were also added to the 
model based on their relevance noted in the literature: the presence of psychosis, sex, and 
current bipolar I episode type.  While the initial model only included an indicator for bipolar 
I depressive episode type, it was determined that each episode type should be considered. 
Therefore, episode types were coded as: Mania, Depressive, Mixed, or Generic (non-specific 
coding of disorder). Generic type was used as the reference category. The revised model 
consisted of the following: 
 
Revised Model for Aim 3:  
Risk of Early Treatment Regimen Changes  = α + β1 (Age - Young, Middle, Old) + β2 (Sex) + 
β3 (Insurance Generosity) + β4 (ADHD) + β5 (Other Disruptive Disorders) + β6 (Depressive 
Disorders) + β7 (Disease Severity, Number of Diagnoses) + β8 (Disease Severity, Any 
Inpatient Days) + β9 (Disease Severity, Psychosis) + β10 (Bipolar I Episode Type) + β11 
(Psychotherapy or Counseling) + β12  (Provider Type) + β13 (Antidepressant Use) + β14 (Use 
of Combination Treatments) + β15 (Region) + β16 (Insurance Type) + β17 (Year Diagnosed) 
 
 Unadjusted estimates of the risk of receipt of guideline recommended care were first 
generated using PROC GENMOD in SAS 9.1. As with aim 2, categorical variables were 
assessed using a log link and a binomial distribution within the GENMOD procedure. 
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Continuous variables were assessed using an identity link and a binomial distribution. Each 
variable was tested separately to determine the bivariate relationship between the each 
predictor and the outcome, without controlling for other variables.  
After these relationships were evaluated, the proposed control variables, insurance 
type and region, were evaluated to determine if they should be added to the model. Neither 
variable was related to the outcome of guideline recommended care in the bivariate 
assessment. Additionally, they were not identified as being necessary components to the 
model based on a review of the literature in the area of quality of care in bipolar disorder. It 
was therefore determined that they did not add to the explanatory capability of the model, but 
only decreased the model efficiency. Because of these reasons, these two variables were 
excluded from the final model.   
 Finally, a series of interaction terms were added to the model to determine if there 
was variation based on clinically plausible relationships. For example, age and sex variables 
were used in interactions with comorbid mental health disorders, type of bipolar episode, and 
inpatient mental health hospitalizations to determine if there was variation in the influence of 
these predictors based on a patients' age, sex or both. After examining interaction terms for 
the model, only one interaction term was statistically significant - this was the interaction 
between patient sex and bipolar subtype (specifically, girls with bipolar I manic type). After 
further inspection, it was determined that this interaction would not be included due to the 
small number of children within this category (n = 16).  Finally, the interaction term between 
the use of antidepressants at treatment initiation and the use of combination therapies at 
  
94
initiation was tested. This resulted in a statistically non-significant interaction term (p = 0.46) 
and was therefore not included in the final model.  
After each variable was assessed, a final model was tested using the coding strategy 
identified above. Coding as noted above resulted in a model that did not meet the Hessian 
Convergence criteria. Therefore, variables were further scrutinized to determine which were 
unnecessary for the final model or those that could be recoded to allow for model 
convergence. First, year was removed from the model (p = 0.65 in bivariate assessment), as 
was the total number of diagnoses (p = 0.34). Age was included in the final model, but was 
included as a continuous variable since the model indicated that the three-level categorical 
variable was problematic. Finally, physician type was re-classified as "mental health 
professional" (Psychiatrist or other mental health professional) or "non-mental health 
professional" in order to allow for model convergence. The final model was specified as 
noted below and hypotheses were restated based on the revised model: 
 
Final Model for Aim 3 
Risk of Early Treatment Regimen Changes  = α + β1 (Age) + β2 (Sex) + β3 (Insurance 
Generosity) + β4 (ADHD) + β5 (Other Disruptive Disorders) + β6 (Depressive Disorders) + β7 
(Disease Severity, Number of Diagnoses) + β8 (Disease Severity, Any Inpatient Days) + β9 
(Disease Severity, Psychosis) + β10 (Bipolar I Episode Type) + β11 (Psychotherapy or 
Counseling) + β12  (Provider Type) + β13 (Antidepressant Use) + β14 (Use of Combination 
Treatments)  
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HYPOTHESIS: Compared with patients with bipolar I disorder who receive a guideline 
recommended period of exposure ( ≥ 6 weeks) before switching drug classes or augmenting 
treatment, those who do not receive the guideline recommended period of exposure are more 
likely to: 
Predisposing Characteristics 
• have a younger age of diagnosis (H03a) 
• be male (H03b) 
Enabling Resources 
• have less generous insurance benefits (H03c) 
Need Characteristics 
• have co-morbid mental health conditions (H03d) 
• have higher levels of disease severity (H03e) 
• have an initial diagnosis of bipolar I depressed episode (H02f) 
• have treatment plans that exclude psychotherapy or counseling (H02g) 
Physician Characteristics 
• have received their diagnosis from a non-mental health provider (H03h) 
Treatment Characteristics 
• be initially prescribed an antidepressant (H03j) 
• use combination treatments(H03k) 
 
Once the final model was established, a log binomial model was used to determine the 
effect of each predictor on the likelihood of receiving guideline recommended care, while 
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controlling for the effect of each of the other variables in the model. Again, the log binomial 
model was selected because it allows for direct estimation of adjusted risk ratios (which are 
preferred to using odds ratios when outcomes are not rare).260,261  This model is implemented 
in PROC GENMOD by using a log link and a binomial distribution to assess the relationship 
between the predictors and the outcome.  
This process was used for three separately defined populations: (1) those with 
changes in the first 6 weeks, among patients with continuous therapy; (2) those with changes 
in the first 6 weeks, with early discontinuers considered to have received non-recommended 
care; (3) those with changes in the first 4 weeks, among patients with continuous therapy.  
CHAPTER FOUR: RESULTS 
 
 Using the MarketScan database from January 1, 2005 to December 31, 2007, there 
were 35,526 patients who were eligible for inclusion in the initial study sample. Patients were 
included if they had one inpatient or two unique outpatient claims for a bipolar spectrum 
disorder, and if they were under 18 years of age at the time of their first diagnosis. Patients 
with conditions that mimic mania or that complicated the treatment of bipolar disorder were 
excluded (details regarding specific exclusionary conditions are provided in Figure 4.1 and in 
Chapter 3).   
 
6Figure 4.1 - Inclusion and Exclusion Criteria - Initial Study Sample 
 
 Exclude patients with temporal lobe 
epilepsy (345.4), multiple sclerosis (340), 
hyperthyroidism (242.9), closed or open 
head injury (800.x-801.x and 850.x-854.x) 
and systemic lupus erythematosus (710.0) 
or patients who are pregnant (V22 - V24  
and V27 - V29) 
N=1,821 
 
 
N= 37,347 
 Include insurance claims data provided by 
MarketScan Commercial Claims and Encounters 
from January 1, 2005 - December 31, 2007 
 Include patients with one inpatient or two unique 
outpatient ICD-9-CM claims with a diagnosis code 
for a bipolar spectrum disorder (296.0x, 296.1x, 
296.4x, 296.5x, 296.6x, 296.7x, 296.8x or 301.13)   
 Include patients ages under 18 years at the time of 
their diagnosis 
 
N= 35,526 
Initial 
Sample 
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4.1 Aim 1a Results 
 
4.1.1 Aim 1a: Repeated Cross Sectional Design, Prevalence Study  
 The initial study sample was used as the basis for the repeated cross-sectional 
prevalence study. For aim 1a patients were classified by the bipolar diagnosis code received 
at their last bipolar-related visit. Because the original study sample required only that patients 
be under the age of 18 years at the time of their first recorded diagnosis, there may have been 
patients in the aim 1a sample who were over the age of 17 years by their last bipolar-related 
visit. Therefore, the age under 18 age limit was re-applied to the aim 1a sample. This sample 
was used for the prevalence and demographic analyses related to aim 1a (Figure 4.2).  
 
7Figure 4.2 - Inclusion and Exclusion Criteria: Aim 1a Prevalence Study 
 
  
It is important to note that the study design used in aim 1a allowed patients from the 
initial sample to be included in multiple years. For example, if a patient had insurance claims 
 
N= 35,526* 
2005 
N= 13,788 
2006 
N= 18,467 
2007 
N= 19,205 
Under 18 
N= 13,017 
Under 18 
N= 16,821 
Under 18 
N= 16,641 
Annual 
Prevalence 
Sample 
* Sample sizes across years do not equal the total sample size as patients may  
   contribute to more than one calendar year in the prevalence study. 
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for 2005, 2006, and 2007, they would be counted in each sample. This design then results in 
three non-independent samples. Therefore, all comparisons for the cross-sectional study 
design will be made across bipolar subtypes, within each year. Formal comparisons 
(statistical tests) will not be used to compare across years as this approach would be invalid. 
Instead, trends over time will be described, but interpreted cautiously.  
The annual diagnostic prevalence of any bipolar spectrum disorder was 0.24% in 
2005 and increased to 0.26% by 2006. The prevalence remained unchanged from 2006 to 
2007. In 2007, there were 16,641 children with at least two outpatient or one inpatient visit 
for a bipolar spectrum disorder out of the 6.3 million children enrolled in the MarketScan 
database (Table 4.1). Of patients with a bipolar spectrum disorder, a majority had bipolar 
disorder unspecified type in each year (49.0%, 2005; 49.9%, 2006; 51.9%, 2007), followed 
by bipolar I disorder (37.1%, 2005; 36.8%, 2006; 35.3%, 2007), and bipolar II disorder 
(11%, 2005; 11.4%, 2006; 10.6%, 2007). Cyclothymic disorder was rare in the sample, 
representing 2.8% or less of the bipolar spectrum disorders in each study year. 
  
7Table 4.1 - Annual Treated Prevalence of Bipolar Spectrum Disorders by Year 
  2005 2006 2007 
  N = 5,462,802 N = 6,372,448 N = 6,309,227 
  n (%) n (%) n (%) 
Prevalence of Any Bipolar Spectrum Disorder 13,017 (0.24) 16,821 (0.26) 16,641 (0.26) 
Disorder Subtype at Most Recent Visit       
Bipolar I 4,834 (37.1) 6,194 (36.8) 5,870 (35.3) 
Bipolar II 1,446 (11.1) 1,909 (11.4) 1,769 (10.6) 
Bipolar Unspecified 6,379 (49.0) 8,388 (49.9) 8,644 (51.9) 
Cyclothymic Disorder 358 (2.8) 330 (2.0) 358 (2.2) 
N = Total number of children from January 1 - December 31 of each year who are under the age of 18  
as of December 31. 
n = Total number of children with the specified diagnosis during the period January 1 - December 31  
of each year who had at least 1 inpatient or 2 outpatient claims for a bipolar spectrum disorder. 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
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Patient characteristics and provider characteristics were measured for each study year and 
are summarized by the patients' bipolar subtype at their last visit (Tables 4.2 - 4.4). Year-to-
year changes were small and are noted where statistically important. When comparing within 
years, patients with bipolar unspecified type were slightly younger, with proportionally more 
children in younger age groups (both ages 0-6 and ages 7-12) than patients with other bipolar 
subtypes. Patients with bipolar II disorder were slightly older than those with other disorder 
subtypes, across all study years. Bipolar I and bipolar unspecified were more common among 
males, while bipolar II and Cyclothymic disorder were slightly more likely to occur among 
females (with the exception of 2006, where boys and girls were equally likely to receive a 
diagnosis of Cyclothymic disorder). 
Inpatient mental health days were more common among patients with bipolar I or bipolar 
unspecified type (approximately 28% experiencing inpatient mental health stays in each 
group, in each year). Total number of unique diagnoses during the year were highest among 
patients with bipolar I or bipolar unspecified, in each year, as were the number of comorbid 
mental health conditions.  
 Patients with bipolar unspecified type were less likely than patients with other 
subtypes to have seen a psychiatrist or other mental health professional, and more likely to 
have seen a primary care physician at their last bipolar-related visit. Patients with bipolar 
unspecified type were also more likely to be categorized as having received care by an 
"unclassified" provider. This classification was used when only facility information was 
available (the actual provider information was not provided). For example, if the provider 
type was "Acute Care Hospital" or another type of facility, it was impossible to distinguish 
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the training of the provider who treated the child. Psychiatrists were the predominant 
provider across all bipolar spectrum disorders and years.  
 
8Table 4.2 - Patient and Physician Characteristics by Bipolar Subtype:  Aim 1a - Study Year 2005 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  
N = 4,834 N = 1,446  N = 6,379  N = 358  
Patient Characteristics         
Age - Mean (SD) 13.8 (3.0) 14.1 (2.9) 13.4 (3.2) 13.8 (2.8) 
0 - 6 Years 125 (2.6) 27 (1.9) 220 (3.5) 7 (2.0) 
7 - 12 Years 1,193 (24.7) 318 (22.0) 1,916 (30.0) 88 (24.6) 
13 - 17 Years 3,516 (72.7) 1,101 (76.1) 4,243 (66.5) 263 (73.5) 
Sex - N (%) Female 2,182 (45.1) 742 (51.3) 2,672 (41.9) 189 (52.8) 
Comorbid Mental Health Conditions  1.3 (1.3) 1.2 (1.2) 1.3 (1.3) 1.2 (1.2) 
Total Number of Unique Diagnoses 
in Year 9.8 (7.0) 9.5 (6.8) 9.9 (7.0) 8.7 (5.9) 
Any Inpatient Mental Health Visits  1,383 (28.6) 344 (23.8) 1,778 (27.9) 61 (17.0) 
Physician Characteristics         
Psychiatrist 1,989 (41.1) 581 (40.2) 2,134 (33.5) 143 (39.9) 
Other Mental Health Professional 960 (19.9) 335 (23.2) 799 (12.5) 85 (23.7) 
Primary Care Physician / M.D. 655 (13.5) 152 (10.5) 1,199 (18.8) 36 (10.1) 
Other Medical Specialist 123 (2.5) 37 (2.6) 217 (3.4) 7 (2.0) 
Unclassified 779 (16.1) 246 (17.0) 1,635 (25.6) 57 (15.9) 
Missing 328 (6.8) 95 (6.6) 395 (6.2) 30 (8.4) 
MSA Status 3,620 (97.4) 1,131 (98.4) 4,331 (95.8) 274 (98.6) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
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9Table 4.3 - Patient and Physician Characteristics by Bipolar Subtype:  Aim 1a - Study Year 2006 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  
N = 6,194 N = 1,909  N = 8,388  N = 330  
Patient Characteristics         
Age - Mean (SD) 13.8 (3.0) 14.4 (2.7) 13.4 (3.2) 13.8 (2.9) 
0 - 6 Years 148 (2.4) 25 (1.3) 306 (3.7) 8 (2.4) 
7 - 12 Years 1,536 (24.8) 378 (19.8) 2,480 (29.6) 86 (26.1) 
13 - 17 Years 4,510 (72.8) 1,506 (78.9) 5,602 (66.8) 236 (71.5) 
Sex - N (%) Female 2,766 (44.7) 1,004 (52.6) 3,456 (41.2) 173 (52.4) 
Comorbid Mental Health Conditions 1.3 (1.3) 1.2 (1.2) 1.4 (1.3) 1.1 (1.2) 
Total Number of Unique Diagnoses 
in Year 10.0 (7.4) 9.8 (7.2) 10.1 (7.1) 8.8 (6.3) 
Any Inpatient Mental Health Visits  1,808 (29.2) 420 (22.0) 2,379 (28.4) 50 (15.2) 
Physician Characteristics     
Psychiatrist 2,531 (40.9) 737 (38.6) 2,771 (33.0) 143 (43.3) 
Other Mental Health Professional 1,051 (17.0) 444 (23.3) 976 (11.6) 70 (21.2) 
Primary Care Physician / M.D. 1,104 (17.8) 264 (13.8) 1,748 (20.8) 47 (14.2) 
Other Medical Specialist 100 (1.6) 26 (1.4) 269 (3.2) 6 (1.8) 
Unclassified 895 (14.4) 281 (14.7) 1,663 (19.8) 40 (12.1) 
Missing 513 (8.3) 157 (8.2) 961 (11.5) 24 (7.3) 
MSA Status 4,606 (97.1) 1,513 (98.1) 5,821 (94.6) 270 (98.5) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
 
 
10Table 4.4 - Patient and Physician Characteristics by Bipolar Subtype:  Aim 1a - Study Year 2007 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 5,870 N = 1,769  N = 8,644  N = 358  
Patient Characteristics         
Age - Mean (SD) 13.9 (2.9) 14.3 (2.8) 13.6 (3.1) 13.9 (3.0) 
0 - 6 Years 135 (2.3) 32 (1.8) 242 (2.8) 8 (2.2) 
7 - 12 Years 1,404 (23.9) 338 (19.1) 2,451 (28.4) 86 (24.0) 
13 - 17 Years 4,331 (73.8) 1,399 (79.1) 5,951 (68.9) 265 (73.7) 
Sex - N (%) Female 2,649 (45.1) 918 (51.9) 3,711 (42.9) 173 (48.3) 
Comorbid Mental Health Conditions 1.4 (1.3) 1.2 (1.3) 1.5 (1.4) 1.3 (1.3) 
Total Number of Unique Diagnoses 
in Year 10.6 (7.8) 10.4 (7.8) 11.0 (8.1) 9.7 (6.7) 
Any Inpatient Mental Health Visits  1,692 (28.8) 375 (21.2) 2,554 (29.6) 82 (22.9) 
Physician Characteristics     
Psychiatrist 2,416 (41.2) 646 (36.6) 2,791 (32.3) 150 (41.9) 
Other Mental Health Professional 1,052 (17.9) 423 (23.9) 1,015 (11.7) 75 (20.9) 
Primary Care Physician / M.D. 1,053 (17.9) 271 (15.3) 1,952 (22.6) 44 (12.3) 
Other Medical Specialist 106 (1.8) 28 (1.6) 251 (2.9) 4 (1.1) 
Unclassified 741 (12.6) 259 (14.6) 1,591 (18.4) 38 (10.6) 
Missing 502 (8.6) 142 (8.0) 1,044 (12.1) 47 (13.1) 
MSA Status 4,468 (97.4) 1,385 (98.4) 5,842 (94.3) 279 (98.6) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
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Comorbid mental health conditions were common across all bipolar spectrum 
disorders and all years (Tables 4.5 - 4.7). Approximately 30% of children with each bipolar 
subtype also had co-morbid diagnoses of attention deficit hyperactivity disorder (ADHD) 
during the year. Children with bipolar unspecified type were more likely to have comorbid 
ADHD as compared with children with bipolar I disorder. Over the three years, co-morbidity 
with ADHD appeared to increase in children with bipolar unspecified (33.5% comorbidity in 
2005; 37.3% in 2006; 39.3% in 2007). Conduct disorder and Oppositional Defiant disorder 
were also present in approximately 8 - 14% of children, depending on bipolar subtype and 
year. Conduct disorder was most common among children with bipolar unspecified and least 
common among children with bipolar II diagnoses.    
 Anxiety disorders were uncommon, as were tic disorders, schizophrenia and 
pervasive developmental disorders. Depressive disorders, however, were common and 
occurred in at least 20% of patients, regardless of bipolar subtype or year. Major depressive 
disorder was present in approximately 25% of patients with bipolar I diagnoses in each study 
year. Major depressive disorder comorbidity was least common among patients with bipolar 
unspecified, although comorbidity was still high (19.7% - 21.1%, depending on the year 
studied).  
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11Table 4.5 - Comorbid Mental Health Conditions by Bipolar Subtype: Aim 1a - Study Year 2005 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 4,834 N = 1,446 N = 6,379 N = 358 
Mental Health Diagnosis     
Disruptive Behavior Disorders      
Attention Deficit  
Hyperactivity Disorder 1,411 (29.2) 436 (30.2) 2,137 (33.5) 100 (27.9) 
Conduct Disorder 506 (10.5) 121 (8.4) 796 (12.5) 35 (9.8) 
Oppositional Defiant Disorder 442 (9.1) 129 (8.9) 750 (11.8) 28 (7.8) 
Anxiety Disorders     
Separation Anxiety Disorder 21 (0.43) 2 (0.14) 30 (0.47) 0 (0.0) 
Post-Traumatic Stress Disorder 163 (3.4) 46 (3.2) 257 (4.0) 15 (4.2) 
Obsessive Compulsive Disorder 109 (2.3) 44 (3.0) 149 (2.3) 11 (3.1) 
Generalized Anxiety Disorder 156 (3.2) 48 (3.3) 177 (2.8) 15 (4.2) 
Social Phobia 19 (0.39) 7 (0.48) 16 (0.25) 2 (0.56) 
Panic Disorder 44 (0.91) 18 (1.2) 52 (0.82) 3 (0.84) 
Depressive Disorders     
Major Depressive Disorder 1,289 (26.7) 364 (25.2) 1,343 (21.1) 81 (22.6) 
Dysthymic Disorder 258 (5.3) 95 (6.6) 312 (4.9) 28 (7.8) 
Tic Disorders     
Tourette's Syndrome  
or Other Tic Disorder 26 (0.54) 11 (0.76) 65 (1.0) 1 (0.28) 
Other Mental Health Disorders     
Schizophrenia 139 (2.9) 23 (1.6) 137 (2.2) 3 (0.84) 
Autism or Other Pervasive  
Developmental Disorder 175 (3.6) 39 (2.7) 264 (4.1) 5 (1.4) 
Mental Retardation 21 (0.43)  5 (0.35) 43 (0.67) 2 (0.56) 
Other Mood Disorders 716 (14.8) 186 (12.9) 1,133 (17.8) 39 (10.9) 
Substance Abuse / Use     
Alcohol Dependence 57 (1.2) 14 (0.97) 68 (1.1) 9 (2.5) 
Drug Dependence 177 (3.7) 50 (3.5) 240 (3.8) 14 (3.9) 
Drug or Alcohol Use 399 (8.3) 119 (8.2) 523 (8.2) 25 (7.0) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
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12Table 4.6 - Comorbid Mental Health Conditions by Bipolar Subtype: Aim 1a - Study Year 2006 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 6,194 N = 1,909 N = 8,388 N = 330 
Mental Health Diagnosis     
Disruptive Behavior Disorders      
Attention Deficit  
Hyperactivity Disorder 1,935 (31.2) 567 (29.7) 3,127 (37.3) 100 (30.3) 
Conduct Disorder 653 (10.5) 142 (7.4) 1,075 (12.8) 25 (7.6) 
Oppositional Defiant Disorder 678 (10.9) 165 (8.6) 1,070 (12.8) 37 (11.2) 
Anxiety Disorders     
Separation Anxiety Disorder 22 (0.36) 7 (0.37) 47 (0.56) 2 (0.61) 
Post-Traumatic Stress Disorder 232 (3.8) 53 (2.8) 316 (3.8) 11 (3.3) 
Obsessive Compulsive Disorder 152 (2.5) 53 (2.8) 216 (2.6) 9 (2.7) 
Generalized Anxiety Disorder 221 (3.6) 86 (4.5) 296 (3.5) 14 (4.2) 
Social Phobia 35 (0.57) 12 (0.63) 34 (0.41) 3 (0.91) 
Panic Disorder 68 (1.1) 28 (1.5) 87 (1.0) 5 (1.5) 
Depressive Disorders     
Major Depressive Disorder 1,563 (25.2) 470 (24.6) 1,649 (19.7) 65 (19.7) 
Dysthymic Disorder 295 (4.8) 111 (5.8) 332 (4.0) 19 (5.8) 
Tic Disorders     
Tourette's Syndrome or Other Tic 
Disorder 54 (0.87) 6 (0.31) 79 (0.93) 3 (0.91) 
Other Mental Health Disorders     
Schizophrenia 177 (2.9) 23 (1.2) 163 (1.9) 1 (0.30) 
Autism or Other Pervasive  
Developmental Disorder 227 (3.7) 57 (3.0) 365 (4.4) 6 (1.8) 
Mental Retardation 28 (0.45) 8 (0.42) 53 (0.63) 0 (0.0) 
Other Mood Disorders 961 (15.5) 312 (16.3) 1,665 (19.9) 38 (11.5) 
Substance Abuse / Use     
Alcohol Dependence 59 (0.95) 17 (0.89) 88 (1.1) 3 (0.91) 
Drug Dependence 224 (3.6) 59 (3.1) 307 (3.7) 8 (2.4) 
Drug or Alcohol Use 528 (8.5) 132 (6.9) 706 (8.4) 16 (4.9) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
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13Table 4.7 - Comorbid Mental Health Conditions by Bipolar Subtype: Aim 1a - Study Year 2007 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 5,870 N = 1,769 N = 8,644 N = 358 
Mental Health Diagnosis     
Disruptive Behavior Disorders      
Attention Deficit  
Hyperactivity Disorder 1,978 (33.7) 527 (29.8) 3,394 (39.3) 104 (29.1) 
Conduct Disorder 647 (11.0) 141 (8.0) 1,114 (12.9) 31 (8.7) 
Oppositional Defiant Disorder 641 (10.9) 178 (10.1) 1,198 (13.9) 48 (13.4) 
Anxiety Disorders     
Separation Anxiety Disorder 15 (0.26) 4 (0.23) 29 (0.34) 2 (0.56) 
Post-Traumatic Stress Disorder 214 (3.7) 75 (4.2) 397 (4.6) 15 (4.2) 
Obsessive Compulsive Disorder 156 (2.7) 59 (3.3) 246 (2.9) 17 (4.8) 
Generalized Anxiety Disorder 249 (4.2) 83 (4.7) 354 (4.1) 22 (6.2) 
Social Phobia 30 (0.51) 15 (0.85) 45 (0.52) 4 (1.1) 
Panic Disorder 73 (1.2) 20 (1.1) 114 (1.3) 3 (0.84) 
Depressive Disorders     
Major Depressive Disorder 1,438 (24.5) 384 (21.7) 1,711 (19.8) 71 (19.8) 
Dysthymic Disorder 263 (4.5) 86 (4.9) 380 (4.4) 20 (5.6) 
Tic Disorders     
Tourette's Syndrome  
or Other Tic Disorder 56 (0.95) 18 (1.0) 103 (1.2) 6 (1.7) 
Other Mental Health Disorders     
Schizophrenia 147 (2.5) 26 (1.5) 192 (2.2) 1 (0.28) 
Autism or Other Pervasive  
Developmental Disorder 256 (4.4) 57 (3.2) 486 (5.6) 9 (2.5) 
Mental Retardation 34 (0.58) 9 (0.51) 55 (0.64) 0 (0.0) 
Other Mood Disorders 1,036 (17.7) 284 (16.1) 1,881 (21.8) 59 (16.5) 
Substance Abuse / Use     
Alcohol Dependence 57 (0.97) 21 (1.2) 109 (1.3) 4 (1.1) 
Drug Dependence 217 (3.7) 62 (3.5) 362 (4.2) 9 (2.5) 
Drug or Alcohol Use 516 (8.8) 143 (8.1) 893 (10.3) 25 (7.0) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
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4.1.2 Aim1a: Repeated cross-sectional design, medication use study 
 The prevalence study samples for each year were used as the starting point for the 
medication use study for aim 1a, with additional criteria applied to accurately identify the 
prescription drug eligible sample (Figure 4.3). In order to identify medication us in the 30 
days following the patient's most recent diagnosis, the index diagnosis was modified by only 
considering diagnoses that took place prior to December 1st in each study year. Again, the 
age less than 18 restriction was applied to this study sample. Additionally, only patients who 
had drug data reported by their insurance provider to MarketScan were included. This did not 
require that patients have medication use, but ensured that if they did use medications they 
would be recorded in the dataset. Patients were also required to be enrolled in their insurance 
plan at the time of their diagnosis and up to 30 days after their diagnosis in order to correctly 
classify their use or non-use of medications. As with the prevalence study sample, patients in 
the overall sample could contribute to multiple years. Again, this does not allow for 
comparisons across years, rather comparisons within years and across subtypes will be made. 
Year-to-year changes are assessed by describing trends, but not via statistical testing. 
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8Figure 4.3 - Inclusion and Exclusion Criteria: Aim 1a Medication Use Study                                                      
.                                                                                   
 
 
When comparing patients who were included in the medication use cohort to those in 
the overall cohort, there were few differences in patient characteristics over the study period. 
Patients in the medication use population (Table 4.8) were slightly more likely to have an 
inpatient mental health visit during the year (OR: 1.05, 95% CI: 1.01, 1.09) and slightly less 
likely to have comorbid mental health conditions (OR: 0.97, 95% CI: 0.96, 0.99) than those 
in the prevalence study sample, although differences were small.  
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 14Table 4.8 - Patient and Physician Characteristics by Bipolar Subtype, Study Years 2005 - 2007: Aim 1a 
Medication Use Population 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  Study Year 2005 
Patient  Characteristics N = 3,983 N = 1,193 N = 5,106 N = 283 
Age - Mean (SD) 13.8 (3.0) 14.1 (2.9) 13.3 (3.2) 13.8 (2.8) 
Sex - N (%) Female 1,792 (45.0) 596 (50.0) 2,113 (41.4) 154 (54.4) 
Comorbid Mental Health Conditions 1.3 (1.3) 1.2 (1.2) 1.3 (1.3) 1.2 (1.2) 
Number of Unique Diagnoses in Year 9.8 (7.0) 9.4 (6.5) 9.8 (6.8) 8.6 (5.9) 
Any Inpatient Mental Health Visits  1,151 (28.9) 285 (23.9) 1,431 (28.0) 51 (18.0) 
Physician Specialty         
Psychiatrist 1,681 (42.2) 494 (41.4) 1,782 (34.9) 121 (42.8) 
Other Mental Health Professional 799 (20.1) 268 (22.5) 683 (13.4) 69 (24.4) 
Primary Care Physician / M.D. 538 (13.5) 132 (11.1) 918 (18.0) 28 (9.9) 
Other Medical Specialist 104 (2.6) 27 (2.3) 171 (3.3) 4 (1.4) 
Unclassified 654 (16.4) 210 (17.6) 1,305 (25.6) 44 (15.5) 
Missing 207 (5.2) 62 (5.2) 247 (4.8) 17 (6.0) 
  Study Year 2006 
Patient Characteristics N = 4,132 N = 1,339 N = 5,362 N = 243 
Age - Mean (SD) 13.9 (2.9) 14.3 (2.8) 13.4 (3.2) 13.9 (2.9) 
Sex - N (%) Female 1,845 (44.7) 672 (50.2) 2,237 (41.7) 133 (54.7) 
Comorbid Mental Health Conditions 1.2 (1.3) 1.1 (1.1) 1.3 (1.3) 1.1 (1.1) 
Number of Unique Diagnoses  in Year 9.6 (6.6) 9.4 (6.7) 9.7 (6.6) 8.6 (5.8) 
Any Inpatient Mental Health Visits  1,198 (29.0) 273 (20.4) 1,485 (27.7) 40 (16.5) 
Physician Specialty         
Psychiatrist 1,876 (45.4) 606 (45.3) 2,046 (38.2) 120 (49.4) 
Other Mental Health  818 (19.8) 331 (24.7) 730 (13.6) 57 (23.5) 
Primary Care / M.D. 589 (14.3) 133 (9.9) 1,002 (18.7) 28 (11.5) 
Other Medical Specialist 70 (1.7) 11 (0.80) 151 (2.8) 3 (1.2) 
Unclassified 676 (16.4) 216 (16.1) 1,268 (23.6) 31 (12.8) 
Missing 103 (2.5) 42 (3.1) 165 (3.1) 4 (1.6) 
  Study Year 2007 
Patient Characteristics N = 4,035 N = 1,261 N = 5,665 N = 258 
Age - Mean (SD) 13.9 (2.9) 14.4 (2.8) 13.6 (3.1) 13.8 (2.9) 
Sex - N (%) Female 1,847 (45.8) 673 (53.4) 2,460 (43.4) 119 (46.1) 
Comorbid Mental Health Conditions 1.3 (1.3) 1.2 (1.2) 1.4 (1.4) 1.2 (1.3) 
Number of Unique Diagnoses in Year 10.3 (7.5) 9.9 (7.1) 10.4 (7.4) 9.6 (6.5) 
Any Inpatient Mental Health  1,163 (28.8) 265 (21.0) 1,608 (28.4) 63 (24.4) 
Physician Specialty 
        
Psychiatrist 1,859 (46.1) 531 (42.1) 2,133 (37.7) 119 (46.1) 
Other Mental Health  813 (20.1) 346 (27.4) 786 (13.9) 62 (24.0) 
Primary Care / M.D. 612 (15.2) 130 (10.3) 1,182 (20.9) 32 (12.4) 
Other Medical Specialist 66 (1.6) 17 (1.3) 137 (2.4) 1 (0.40) 
Unclassified 589 (14.6) 211 (16.7) 1,266 (22.3) 35 (13.6) 
Missing 96 (2.4) 26 (2.1) 161 (2.8) 9 (3.5) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.  
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 Information regarding drug class use within the 30 days following a patients' last 
bipolar diagnosis is provided in Table 4.9. In each year, approximately 35% of patients did 
not use any psychotropic medications in the 30 day period following their last diagnosis. 
Twenty-five percent used one psychotropic medication, 23% used two medications and 
nearly 16% used 3 or more medications. Antipsychotic monotherapy increased over each 
study year by approximately 2% (from 11.2% in 2005 to 14.1% in 2007). Mood stabilizer 
(either lithium or anticonvulsants) and antipsychotic combination therapy was common, with 
over 12% of patients in each year using combinations of these two classes. Additionally, 
these classes were paired with antidepressants in over 6% of patients and with stimulants for 
nearly 5% of patients.  
  When looking at the number of prescriptions filled (Table 4.10), atypical 
antipsychotic medications were the most commonly filled drug class, followed by 
anticonvulsants, antidepressants, stimulants, lithium, and typical antipsychotics. Among the 
anticonvulsant medications filled, divalproex was the most frequently used, representing over 
35% of the anticonvulsant medications filled in each year. Lamotrigine use increased over 
the study period (from 21.8% in 2005 to 33.2% in 2007), while oxcarbazepine use decreased 
(from 25.2% in 2005 to 17.2% in 2007). Three agents dominated use in the atypical 
antipsychotic class - aripiprazole, risperidone and quetiapine. Each agent represented over 
25% of the antipsychotic medications filled in each year.  
Antidepressants represented over 20% of the prescribed psychotropic medications in 
each study year. Tricyclics, tetracyclics, and MAOIs were rarely used. Selective serotonin 
reuptake inhibitors (SSRIs) were the most heavily prescribed type of antidepressants 
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(representing nearly 60% of total antidepressant use in each year). Of the SSRIs, 
escitalopram, fluoxetine and sertraline were the most commonly filled medications, with 
fluoxetine and sertraline each contributing over 27% of SSRI use in each year. Among the 
category of other antidepressants, bupropion was prescribed nearly twice as often as any 
other agent in the category.   
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15Table 4.9 - Annual Drug Class Use Among Medication Users within 30 Days of Most Recent  
Bipolar Diagnosis: Aim 1a, 2005 - 2007 
 Year of Diagnosis  
 2005 2006 2007 
 N = 10,565 N = 11,076 N = 11,219 
Total Number of Psychotropic  
Medications Used in 30 Days  
Following the Last Diagnosis 
None 3,751 (35.5) 3,852 (34.8) 4,154 (37.0) 
1 2,633 (24.9) 2,870 (25.9) 2,905 (25.9) 
2 2,443 (23.1) 2,589 (23.4) 2,473 (22.0) 
3 1,252 (11.9) 1,313 (11.9) 1,267 (11.3) 
4 + 486 (4.6) 452 (4.1) 420 (3.7) 
Medication Use Among Users N = 6,814 N = 7,224 N = 7,056 
Single Class Use    
Lithium 178 (2.6) 163 (2.3) 149 (2.1) 
> 1 Lithium Fill - n (%) 0 (0.0) 0 (0.0) 0 (0.0) 
Anticonvulsants 802 (11.8) 775 (10.7) 777 (11.0) 
> 1 Anticonvulsant Fill - n (%) 36 (4.5) 40 (5.2) 38 (4.9) 
Antipsychotics 760 (11.2) 914 (12.7) 997 (14.1) 
> 1 Antipsychotic Fill - n (%) 42 (5.5) 61 (6.7) 58 (5.8) 
Antidepressants 601 (8.8) 642 (8.9) 598 (8.5) 
> 1 Antidepressant Fill - n (%) 62 (10.3) 48 (7.5) 66 (11.0) 
Stimulants 438 (6.4) 535 (7.4) 550 (7.8) 
> 1 Stimulant Fill - n (%) 6 (1.4) 10 (1.9) 4 (7.3) 
Combination Therapy    
Two Classes    
Lithium + Anticonvulsant 56 (0.80) 52 (0.70) 39 (0.60) 
Mood Stabilizer and Antipsychotic 855 (12.5) 871 (12.1) 880 (12.5) 
Mood Stabilizer and Antidepressant 577 (8.5) 552 (7.6) 468 (6.6) 
Mood Stabilizer and Stimulant 362 (5.3) 385 (5.3) 327 (4.6) 
Antipsychotic and Antidepressant 444 (6.5) 478 (6.6) 494 (7.0) 
Antipsychotic and Stimulant 299 (4.4) 388 (5.4) 410 (5.8) 
Antidepressant and Stimulant 157 (2.3) 140 (1.9) 153 (2.2) 
Three or More Classes    
Mood Stabilizer, Antipsychotic and Antidepressant 446 (6.5) 441 (6.1) 429 (6.1) 
Mood Stabilizer, Antipsychotic and Stimulant 352 (5.2) 391 (5.4) 332 (4.7) 
Mood Stabilizer, Antidepressant and Stimulant 155 (2.3) 162 (2.2) 148 (2.1) 
Antipsychotic, Antidepressant and Stimulant 152 (2.2) 177 (2.5) 173 (2.5) 
Mood Stabilizer, Antipsychotic, Antidepressant  
and Stimulant 180 (2.6) 158 (2.2) 141 (2.0) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
Atypical and typical antipsychotic agents were combined as typicals represented only 1.2% of this category.  
Mood stabilizers include lithium or any anticonvulsant agent. Lithium represented 24% of the mood stabilizers.  
Calculations for more than one class level fill exclude multiple fills of the same agent on the same service date.  
 
 
 
 
  
113
16Table 4.10 - Psychotropic Drug Use by Drug Prescribed 30 Days After Most Recent 
Bipolar Diagnosis: Aim 1a, 2005 - 2007 
  Year of Diagnosis 
  2005 2006 2007 
Total Medications Filled* N = 15,660 N = 16,272 N = 15,524 
Lithium 1,145 (7.3) 1,026 (6.3) 928(6.0) 
Anticonvulsants 4,130 (26.4) 4,188 (25.7) 3,926 (25.3) 
Carbamazepine  158 (3.8) 149 (3.6) 170 (4.3) 
Divalproex 1,638 (39.7) 1,574 (37.6) 1,404 (35.8) 
Gabapentin 68 (1.6) 67 (1.6) 70 (1.8) 
Lamotrigine 900 (21.8) 1,171 (28.0) 1,304 (33.2) 
Levetiracetam 12 (0.29) 15 (0.36) 16 (0.41) 
Oxcarbazepine 1,039 (25.2) 885 (21.1) 677 (17.2) 
Tiagabine 23 (0.56) 13 (0.31) 7 (0.18) 
Topiramate 294 (7.1) 315 (7.5) 279 (7.1) 
Atypical Antipsychotics 4,273 (27.3) 4,709(28.9) 4,677 (30.1) 
Aripiprazole 1,209 (28.3) 1,530 (32.5) 1,499 (32.1) 
Clozapine 2 (0.05) 10 (0.21) 10 (0.21) 
Olanzapine 281 (6.6) 254 (5.4) 211 (4.5) 
Paliperidone 0 (0.0) 0 (0.0) 92 (2.0) 
Quetiapine 1,114 (26.1) 1,271 (27.0) 1,303 (27.9) 
Risperidone 1,322 (30.9) 1,245 (26.4) 1,188 (25.4) 
Ziprasidone 343 (8.0) 398 (8.4) 376 (8.0) 
Typical Antipsychotics 47 (0.30) 47(0.29) 37 (0.24) 
Antidepressants 3,576 (22.8) 3,536 (21.7) 3,309 (21.3) 
Tricyclics N = 79 N = 111 N = 82 
Tetracyclics  N = 0 N = 0 N = 0 
Selective Serotonin Reuptake Inhibitors N = 2,133 N = 2,107 N = 1,998 
Citalopram  187 (8.8) 195 (9.2) 205 (10.3) 
Escitalopram 527 (24.7) 487 (23.1) 440 (22.0) 
Fluoxetine 597 (28.0) 580 (27.5) 562 (28.1) 
Fluvoxamine 49 (2.3) 44 (2.1) 59 (3.0) 
Paroxetine 151 (7.1) 142 (6.7) 112 (5.6) 
Sertraline 622 (29.2) 658 (31.2) 618 (30.9) 
Monoamine Oxidase Inhibitors N = 1 N = 0 N = 0 
Other Antidepressants N = 1,364 N = 1,318 N = 1,229 
Bupropion 712 (52.2) 667 (50.6) 530 (43.1) 
Duloxetine 57 (4.2) 104 (7.9) 112 (9.1) 
Mirtazapine 87 (6.4) 110 (8.3) 89 (7.2) 
Nefazodone 4 (0.29) 1 (0.08) 0 (0.0) 
Trazodone 289 (21.2) 302 (22.9) 319 (26.0) 
Venlafaxine 215 (15.8) 133 (10.1) 180 (14.6) 
Stimulants 2,536 (16.2) 2,766 (17.0) 2,657 (17.1) 
N = Total number of prescriptions obtained. Patients may have more than one prescription 
therefore the total N is not equal to the study sample size.   
*Prescription fills are standardized to a 30-day supply.  
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample. 
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 Table 4.11 provides information on medication class use by bipolar subtype and year. 
Lithium use and antidepressant use decreased over the study period for each bipolar subtype. 
Use of this agent varied by study year and bipolar subtype. For example, in 2005, patients 
with bipolar unspecified type were more likely to receive lithium than patients with bipolar I 
disorder (RR: 1.22, 95%CI: 1.07, 1.39). However, this relationship was not evident in 
subsequent years. Use of anticonvulsants, similarly, differed slightly by year and bipolar 
subtype, but differences were minor (indicating similar risks of use, regardless of bipolar 
subtype or over time).  
 When comparing antipsychotic use over time and by disorder, patients with bipolar II 
disorder or Cyclothymic disorder were less likely to receive second generation 
antipsychotics, as compared with patients with bipolar I disorder, over the study period. 
Patients with bipolar unspecified type were slightly more likely to use second generation 
antipsychotics (as compared with patients with bipolar I disorder) for the study years 2006 
and 2007, but the differences were small. Use of typical antipsychotic agents (first generation 
antipsychotics) was rare among all bipolar subtypes and years.  
 Across the three study years, antidepressant use was lower among patients with 
bipolar unspecified type (as compared with patients with bipolar I disorder). Finally, 
stimulant use appeared to be stable across bipolar subtype and year, with the exception of an 
increase in stimulant use among patients with bipolar unspecified type in 2006 (RR: 1.11, 
95% CI: 1.03, 1.20).  
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17Table 4.11 - Medication Class Use by Bipolar Subtype - Drug Prescribed 30 Days  
After Most Recent Bipolar Diagnosis: Aim 1a, 2005 - 2007 
 
  Bipolar Subtype 
  Bipolar I 
  2005 2006 2007 
Medication Class Use N = 3,983 N = 4,132 N = 4,035 
Lithium 327 (8.2) 314 (7.6) 299 (7.4) 
Anticonvulsants 1,208 (30.3) 1,282 (31.0) 1,164 (28.8) 
Atypical Antipsychotics 1,324 (33.2) 1,422 (34.4) 1,348 (33.4) 
Typical Antipsychotics 16 (0.40) 15 (0.40) 19 (0.50) 
Antidepressants 1,078 (27.1) 1,109 (26.8) 1,009 (25.0) 
Stimulants 795 (20.0) 836 (20.2) 790 (19.6) 
  Bipolar II 
  2005 2006 2007 
Medication Class Use N = 1,193 N = 1,339 N = 1,261 
Lithium 93 (7.8) 87 (6.5) 72 (5.7) 
Anticonvulsants 400 (33.5) 397 (29.6) 341 (27.0) 
Atypical Antipsychotics 334 (28.0) 359 (26.8) 359 (28.5) 
Typical Antipsychotics 4 (0.30) 4 (0.30) 4 (0.30) 
Antidepressants 319 (26.7) 328 (24.5) 283 (22.4) 
Stimulants 248 (20.8) 245 (18.3) 248 (19.7) 
  Bipolar Unspecified 
  2005 2006 2007 
Medication Class Use N = 5,106 N = 5,362 N = 5,665 
Lithium 510 (10.0) 458 (8.5) 406 (7.2) 
Anticonvulsants 1,584 (31.0) 1,567 (29.2) 1,531 (27.0) 
Atypical Antipsychotics 1,760 (34.5) 1,953 (36.4) 2,056 (36.3) 
Typical Antipsychotics 24 (0.50) 24 (0.40) 24 (0.40) 
Antidepressants 1,250 (24.5) 1,252 (23.3) 1,256 (22.2) 
Stimulants 1,005 (19.7) 1,208 (22.5) 1,155 (20.4) 
  Cyclothymic Disorder* 
  2005 2006 2007 
Medication Class Use N = 283 N = 243 N = 258 
Lithium 22 (7.8) 18 (7.4) 15 (5.8) 
Anticonvulsants 82 (29.0) 67 (27.6) 84 (32.6) 
Atypical Antipsychotics 48 (17.0) 59 (24.3) 63 (24.4) 
Typical Antipsychotics 0 (0.0) 0 (0.0) 0 (0.0) 
Antidepressants 65 (23.0) 61 (25.1) 56 (21.7) 
Stimulants 47 (16.6) 47 (19.3) 41 (15.9) 
 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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 Patient treatments received, including use of counseling or electroconvulsive therapy, 
are summarized by bipolar subtype and year in Table 4.12. There was little difference in the 
use of pharmacotherapy by year or bipolar subtype. Patients with bipolar II disorder were 
slightly more likely to receive pharmacotherapy in 2005 and slightly less likely to receive 
pharmacotherapy in 2006, as compared with patients with bipolar I disorder. These 
differences were very small, with confidence intervals very close to 1.0. Overall, a majority 
of patients received pharmacotherapy (over 63% of patients with bipolar I disorder, 60% of 
patients with bipolar II, 63% with bipolar unspecified, and 57% with Cyclothymic disorder) 
in each year.  
 A majority of patients received psychotherapy or counseling visits, across all bipolar 
subtypes, over the study period. Patients with bipolar II disorder were slightly more likely 
than patients with bipolar I disorder to receive counseling or psychotherapy over the study 
period. Over each year, patients with bipolar unspecified type were less likely to receive 
counseling or psychotherapy than patients with bipolar I disorder. In addition, patients with 
bipolar unspecified who received counseling had fewer visits as compared with patients with 
bipolar I who received counseling.  
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18Table 4.12 - Summary of Treatments Received by Bipolar Subtype: Aim 1a, 2005 - 2007 
  Bipolar Subtype 
  Bipolar I 
  2005 2006 2007 
Pharmacotherapy* N = 3,983 N = 4,132 N = 4,035 
Yes 2,538 (63.7) 2,701 (65.4) 2,553 (63.3) 
No 1,445 (36.3) 1,431 (34.6) 1,482 (36.7) 
Psychotherapy N = 3,000 N = 3,226 N = 2,960 
Any Use - n (%) 2,722 (90.7) 2,901 (89.9) 2,680 (90.5) 
Num. Visits - Median (IQR) 12.1 (13) 8 (13) 8 (13) 
Electroconvulsive Therapy*     
Any Use - n (%) 1 (0.03) 0 (0.0) 1 (0.03) 
  Bipolar II 
Pharmacotherapy* N = 1,193 N = 1,339 N = 1,261 
Yes 801 (67.1) 821 (61.3) 759 (60.2) 
No 392 (32.9) 518 (38.7) 502 (39.8) 
Psychotherapy N = 911 N = 1,065 N = 966 
Any Use - n (%) 858 (94.2) 991 (93.1) 900 (93.2) 
Num. Visits - Median (IQR) 9 (12) 9 (13) 8 (12) 
Electroconvulsive Therapy*     
Any Use - n (%) 1 (0.11) 0 (0.0) 2 (0.21) 
  Bipolar Unspecified 
Pharmacotherapy* N = 5,106 N = 5,362 N = 5,665 
Yes 3,313 (64.9) 3,549 (66.2) 3,593 (63.4) 
No 1,793 (35.1) 1,813 (33.8) 2,072 (36.6) 
Psychotherapy N = 3,708 N = 4,103 N = 4,066 
Any Use  - n (%) 3,200 (86.3) 3,515 (85.7) 3,406 (83.8) 
Num. Visits - Median (IQR) 8 (12) 8 (12) 8 (12) 
Electroconvulsive Therapy*     
Any Use - n (%) 0 (0.0) 1 (0.02) 1 (0.02) 
  Cyclothymic Disorder** 
Pharmacotherapy* N = 283 N = 243 N = 258 
Yes 162 (57.2) 153 (63.0) 160 (62.0) 
No 121 (42.8) 90 (37.0) 98 (38.0) 
Psychotherapy N = 214 N = 189 N = 192 
Any Use - n (%) 200 (93.5) 180 (95.2) 180 (93.8) 
Num. Visits - Median (IQR) 6 (9) 7 (10) 7.5 (10) 
Electroconvulsive Therapy*     
Any Use - n (%) 0 (0.0) 0 (0.0) 0 (0.0) 
 
* Sample size for Pharmacotherapy cohort = Medication Use Cohort. Sample size for psychotherapy  
and ECT use is based on patients who had mental health / substance abuse  coverage available. 
* *Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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4.1.3 Aim 1a: Repeated cross-sectional design, age related comparisons of demographic 
and treatment characteristics 
Patient demographic and treatment characteristics were next assessed for children by 
age group. Comparisons were made between patients who were under the age of 10 years at 
the time of their diagnosis (Ages 0 - 9) and those who were 10 years and older (Ages 10 - 
17). Because year-to-year changes in patient demographic characteristics were uncommon, 
only patient characteristics for 2007 are presented (Table 4.13). For children with each 
bipolar subtype, the proportion of females who received the diagnosis was higher among 
older children as compared with younger children. The risk ratios for female gender by age 
group were 1.56 (95%CI: 1.38, 1.77, for bipolar I), 2.14 (95% CI: 1.61, 2.85, for bipolar II), 
1.61 (95% CI: 1.45, 1.77, for bipolar unspecified), and 1.80 (95% CI: 1.08, 3.00, for 
Cyclothymic disorder). Younger children were similar to older children in the number of 
comorbid mental health conditions identified within each bipolar subtype. However, for 
patients with bipolar I, bipolar II or bipolar unspecified, older children were more likely to 
have a higher number of total diagnoses in the year [RD: 2.44, 95%CI: 1.79, 3.08, for bipolar 
I disorder; RD: 1.85, 95% CI: 0.52, 3.18, bipolar II disorder; RD: 2.04, 95%CI: 1.53, 2.55, 
bipolar unspecified]. Additionally, older children with bipolar I, bipolar II or bipolar 
unspecified were more likely to have inpatient mental health visits during the year [RR: 1.76, 
95%CI: 1.47, 2.10 for bipolar I disorder; 2.89, 95%CI: 1.63, 5.13 for bipolar II disorder; and 
1.52, 95%CI: 1.32, 1.74 for bipolar disorder unspecified type]. Finally, when comparing 
within bipolar subtype, there were no differences in the types of providers seen by children in 
younger versus older age groups.  
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19Table 4.13 - Patient and Physician Characteristics by Bipolar Subtype and Age Group: Aim 1a Prevalence Sample - Study Year 2007 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
  N = 617 N = 5,253 N = 142  N = 1,627 N = 1,119 N = 7,525 N = 39 N = 319 
Patient Characteristics 
  
              
Age - Mean (SD) 7.6 (1.5) 14.6 (2.1) 7.5 (1.7) 14.9 (1.9) 7.6 (1.4) 14.5 (2.1) 7.5 (1.4) 14.7 (2.1) 
Sex - N (%) Female 185 (30.0) 2,464 (46.9) 36 (25.3) 882 (54.2) 314 (28.1) 3,397 (45.1) 11 (28.2) 162 (50.8) 
Comorbid Mental Health 
Conditions 1.3 (1.2) 1.4 (1.4) 1.2 (1.1) 1.2 (1.3) 1.5 (1.3) 1.5 (1.4) 1.5 (1.0) 1.2 (1.3) 
Number of Unique 
Diagnoses  8.4 (5.7) 10.8 (7.9) 8.7 (6.1) 10.6 (7.9) 9.2 (6.4) 11.2 (8.3) 9.2 (5.2) 9.8 (6.9) 
Any Inpatient  
Mental Health Visits  106 (17.2) 1,586 (30.2) 11 (7.7) 364 (22.4) 216 (19.3) 2,338 (31.1) 8 (20.5) 74 (23.2) 
Physician Specialty         
Psychiatrist 269 (43.6) 2,147 (40.9) 53 (37.3) 593 (36.4) 370 (33.1) 2,421 (32.2) 17 (43.6) 133 (41.7) 
Other Mental Health   104 (16.9) 948 (18.0) 31 (21.8) 392 (24.1) 137 (12.2) 878 (11.7) 4 (10.3) 71 (22.3) 
Primary Care / M.D. 93 (15.1) 960 (18.3) 16 (11.3) 255 (15.7) 259 (23.1) 1,693 (22.5) 5 (12.8) 39 (12.2) 
Other Medical Specialist 8 (1.3) 98 (1.9) 5 (3.5) 23 (1.4) 34 (3.0) 217 (2.9) 0 (0.0) 4 (1.3) 
Unclassified 84 (13.6) 657 (12.5) 23 (16.2) 236 (14.5) 192 (17.2) 1,399 (18.6) 6 (15.4) 32 (10.0) 
Missing 59 (9.6) 443 (8.4) 14 (9.9) 128 (7.9) 127 (11.3) 917 (12.2) 7 (17.9) 40 (12.5) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
 
 
 
 
 
 
 
 
 
 
  
120
 
 When comparing comorbid mental health conditions by age group (Tables 4.14 - 
4.16), older patients were much less likely to have comorbid Attention Deficit Hyperactivity 
Disorder (ADHD) than younger patients among those with bipolar I, bipolar II or bipolar 
unspecified disorders. In 2007, the risk ratio for having comorbid ADHD was 0.61 (95%CI: 
0.59, 0.66, for bipolar I), 0.56 (95%CI: 0.47, 0.67, for bipolar II), and 0.62 (95%CI: 0.60, 
0.67, for bipolar unspecified). However, older patients with bipolar I, bipolar II or bipolar 
unspecified disorders were much more likely to have a comorbid diagnosis of major 
depressive disorder. The risk ratio of having comorbid diagnoses of major depressive 
disorder were 2.70 (95% CI: 2.11, 3.44, for bipolar I), 4.10 (95%CI: 2.08, 8.09, for bipolar 
II), and 2.71 (95%CI: 2.21, 3.32, for bipolar unspecified).  
 There were no differences by age group for the occurrence of oppositional defiant 
disorders among children with bipolar I disorder and bipolar II disorders; however, older 
children with bipolar unspecified type were less likely to be diagnosed with oppositional 
defiant disorder as compared with younger children (2007 RR: 0.73, 95%CI: 0.64, 0.84). 
Children with Cyclothymic disorder were equally likely to be diagnosed with oppositional 
defiant disorder, regardless of age, in 2005 and 2006. However, in 2007, it appeared that 
younger children were more likely to be diagnosed with this disorder than older children 
(2007 RR: 0.41, 95%CI: 0.23, 0.74). Similarly, conduct disorder appeared to be most 
common in younger children with bipolar unspecified type. In this group, in 2007, the risk 
ratio for conduct disorder comorbidity was 0.77 (95% CI: 0.67, 0.90). 
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20Table4.14 - Comorbid Mental Health Conditions by Bipolar Subtype and Age Group: Aim 1a - Study Year 2005 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Mental Health Diagnosis N = 544 N = 4,290 N = 139 N = 1,307 N = 916  N = 5,463 N = 32  N = 326 
Disruptive Behavior Disorders         
Attention Deficit Hyperactivity  
Disorder 246 (45.2) 1,165 (27.2) 64 (46.0) 372 (28.5) 456 (49.8) 1,681 (30.8) 10 (31.3) 90 (27.6) 
Conduct Disorder 64 (11.8) 442 (10.3) 14 (10.1) 107 (8.2) 138 (15.1) 658 (12.0) 6 (18.8) 29 (8.9) 
Oppositional Defiant Disorder 52 (9.6) 390 (9.1) 11 (7.9) 118 (9.0) 134 (14.6) 616 (11.3) 1 (3.1) 27 (8.3) 
Anxiety Disorders         
Separation Anxiety Disorder 5 (0.92) 16 (0.37) 0 (0.0) 2 (0.15) 12 (1.3) 18 (0.33) 0 (0.0) 0 (0.0) 
Post-Traumatic Stress Disorder 17 (3.1) 146 (3.4) 6 (4.3) 40 (3.1) 29 (3.2) 228 (4.2) 2 (6.3) 13 (4.0) 
Obsessive Compulsive Disorder 19 (3.5) 90 (2.1) 4 (2.9) 40 (3.1) 24 (2.6) 125 (2.3) 1 (3.1) 10 (3.1) 
Generalized Anxiety Disorder 26 (4.8) 130 (3.0) 3 (2.2) 45 (3.4) 25 (2.7) 152 (2.8) 2 (6.3) 13 (4.0) 
Social Phobia 3 (0.55) 16 (0.37) 0 (0.0) 7 (0.54) 2 (0.22) 14 (0.26) 0 (0.0) 2 (0.61) 
Panic Disorder 1 (0.18) 43 (1.0) 0 (0.0) 18 (1.4) 3 (0.33) 49 (0.90) 0 (0.0) 3 (0.92) 
Depressive Disorders         
Major Depressive Disorder 45 (8.3) 1,244 (29.0) 11 (7.9) 353 (27.0) 83 (9.1) 1,260 (23.1) 0 (0.0) 81 (24.9) 
Dysthymic Disorder 10 (1.8) 248 (5.8) 5 (3.6) 90 (6.9) 21 (2.3) 291 (5.3) 2 (6.3) 26 (8.0) 
Tic Disorders         
Tourette's Syndrome or  
Other Tic Disorder 6 (1.1) 20 (0.47) 2 (1.4) 9 (0.69) 13 (1.4) 52 (0.95) 0 (0.0) 1 (0.31) 
Other Mental Health Disorders         
Schizophrenia 5 (0.92) 134 (3.1) 1 (0.72) 22 (1.7) 7 (0.76) 130 (2.4) 0 (0.0) 3 (0.92) 
Autism or Other Pervasive 
Developmental Disorders 43 (7.9) 132 (3.1) 12 (8.6) 27 (2.1) 67 (7.3) 197 (3.6) 0 (0.0) 6 (1.5) 
Mental Retardation 1 (0.18) 18 (0.42) 0 (0.0) 5 (0.38) 7 (0.76) 36 (0.66) 0 (0.0) 2 (0.61) 
Other Mood Disorders 94 (17.3) 622 (14.5) 20 (14.4) 166 (12.7) 139 (15.2) 994 (18.2) 2 (6.3) 37 (11.4) 
Substance Abuse / Use         
Alcohol Dependence 1 (0.18) 56 (1.3) 0 (0.0) 14 (1.1) 1 (0.11) 67 (1.2) 0 (0.0) 9 (2.8) 
Drug Dependence 0 (0.0) 177 (4.1) 0 (0.0) 50 (3.8) 2 (0.22) 238 (4.4) 0 (0.0) 14 (4.3) 
Drug or Alcohol Use 3 (0.55) 396 (9.2) 0 (0.0) 119 (9.1) 1 (0.11) 522 (9.6) 0 (0.0) 25 (7.7) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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21Table4.15 - Comorbid Mental Health Conditions by Bipolar Subtype and Age Group: Aim 1a - Study Year 2006 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Mental Health Diagnosis N = 687 N = 5,507 N = 151 N = 1,758 N = 1,201 N = 7,187 N = 31 N = 299 
Disruptive Behavior Disorders         
Attention Deficit Hyperactivity 
Disorder 358 (52.1) 1,577 (28.6) 79 (52.3) 488 (27.8) 643 (53.5) 2,484 (34.6) 12 (38.7) 88 (29.4) 
Conduct Disorder 97 (14.1) 556 (10.1) 18 (11.9) 124 (7.1) 214 (17.8) 861 (12.0) 7 (22.6) 18 (6.0) 
Oppositional Defiant Disorder 86 (12.5) 592 (10.8) 19 (12.6) 146 (8.3) 194 (16.2) 876 (12.2) 5 (16.1) 32 (10.7) 
Anxiety Disorders         
Separation Anxiety Disorder 4 (0.58) 18 (0.33) 2 (1.3) 5 (0.28) 18 (1.5) 29 (0.40) 0 (0.0) 2 (0.67) 
Post-Traumatic Stress Disorder 20 (2.9) 212 (3.9) 4 (2.7) 49 (2.8) 41 (3.4) 275 (3.8) 2 (6.5) 9 (3.0) 
Obsessive Compulsive Disorder 20 (2.9) 132 (2.4) 7 (4.6) 46 (2.6) 40 (3.3) 176 (2.5) 1 (3.2) 8 (2.7) 
Generalized Anxiety Disorder 21 (3.1) 200 (3.6) 8 (5.3) 78 (4.4) 50 (4.2) 246 (3.4) 1 (3.2) 13 (4.4) 
Social Phobia 1 (0.15) 34 (0.62) 0 (0.0) 12 (0.68) 1 (0.08) 33 (0.46) 0 (0.0) 3 (1.0) 
Panic Disorder 1 (0.15) 67 (1.2) 2 (1.3) 26 (1.5) 5 (0.42) 82 (1.1) 0 (0.0) 5 (1.7) 
Depressive Disorders         
Major Depressive Disorder 57 (8.3) 1,506 (27.4) 13 (8.6) 457 (26.0) 87 (7.2) 1,562 (21.7) 1 (3.2) 64 (21.4) 
Dysthymic Disorder 15 (2.2) 280 (5.1) 1 (0.66) 110 (6.3) 18 (1.5) 314 (4.4) 0 (0.0) 19 (6.4) 
Tic Disorders         
Tourette's Syndrome or  
Other Tic Disorder 8 (1.2) 46 (0.84) 3 (2.0) 3 (0.17) 18 (1.5) 60 (0.83) 2 (6.5) 1 (0.33) 
Other Mental Health Disorders         
Schizophrenia 10 (1.5) 167 (3.0) 0 (0.0) 23 (1.3) 10 (0.83) 153 (2.1) 0 (0.0) 1 (0.33) 
Autism or Other Pervasive  
Developmental Disorders 39 (5.7) 188 (3.4) 14 (9.3) 43 (2.5) 97 (8.1) 268 (3.7) 1 (3.2) 5 (1.7) 
Mental Retardation 2 (0.29) 26 (0.47) 2 (1.3) 6 (0.34) 9 (0.75) 44 (0.61) 0 (0.0) 0 (0.0) 
Other Mood Disorders 104 (15.1) 857 (15.6) 28 (18.5) 284 (16.2) 270 (22.5) 1,395 (19.4) 3 (9.7) 35 (11.7) 
Substance Abuse / Use         
Alcohol Dependence 0 (0.0) 59 (1.1) 0 (0.0) 17 (0.97) 0 (0.0) 88 (1.2) 0 (0.0)  3 (1.0) 
Drug Dependence 1 (0.15) 223 (4.1) 0 (0.0) 59 (3.4) 0 (0.0) 307 (4.3) 0 (0.0)  8 (2.7) 
Drug or Alcohol Use 3 (0.44) 525 (9.5) 0 (0.0) 132 (7.5) 2 (0.17) 704 (9.8) 0 (0.0)  16 (5.4) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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22Table 4.16 - Comorbid Mental Health Conditions by Bipolar Subtype and Age Group: Aim 1a - Study Year 2007 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Mental Health Diagnosis N = 617 N = 5,253 N = 142 N = 1,627 N = 1,119 N = 7,525 N = 39  N = 319 
Disruptive Behavior Disorders         
Attention Deficit Hyperactivity  
Disorder 320 (51.9) 1,658 (31.6) 71 (50.0) 456 (28.0) 646 (57.7) 2,748 (36.5) 22 (56.4) 82 (25.7) 
Conduct Disorder 89 (14.4) 558 (10.6) 13 (9.1) 128 (7.9) 179 (16.0) 935 (12.4) 6 (15.4) 25 (7.8) 
Oppositional Defiant Disorder 72 (11.7) 569 (10.8) 15 (10.6) 163 (10.0) 202 (18.1) 996 (13.2) 11 (28.2) 37 (11.6) 
Anxiety Disorders         
Separation Anxiety Disorder 8 (1.3) 7 (0.13) 1 (0.70) 3 (0.18) 13 (1.2) 16 (0.21) 1 (2.6) 1 (0.31) 
Post-Traumatic Stress Disorder 24 (3.9) 190 (3.6) 6 (4.2) 69 (4.2) 46 (4.1) 351 (4.7) 2 (5.1) 13 (4.1) 
Obsessive Compulsive Disorder 16 (2.6) 140 (2.7) 6 (4.2) 53 (3.3) 30 (2.7) 216 (2.9) 0 (0.0) 17 (5.3) 
Generalized Anxiety Disorder 26 (4.2) 223 (4.3) 9 (6.3) 74 (4.6) 50 (4.5) 304 (4.0) 2 (5.1) 20 (6.3) 
Social Phobia 0 (0.0) 30 (0.57) 1 (0.70) 14 (0.86) 5 (0.45) 40 (0.53) 0 (0.0) 4 (1.3) 
Panic Disorder 2 (0.32) 71 (1.4) 1 (0.70) 19 (1.2) 6 (0.54) 108 (1.4) 0 (0.0) 3 (0.94) 
Depressive Disorders         
Major Depressive Disorder 60 (9.7) 1,378 (26.2) 8 (5.6) 376 (23.1) 89 (8.0) 1,622 (21.6) 3 (7.7) 68 (21.3) 
Dysthymic Disorder 5 (0.81) 258 (4.9) 4 (2.8) 82 (5.0) 21 (1.9) 359 (4.8) 2 (5.1) 18 (5.6) 
Tic Disorders         
Tourette's Syndrome or  
Other Tic Disorder 4 (0.65) 52 (0.99) 5 (3.5) 13 (0.80) 15 (1.3) 88 (1.2) 1 (2.6) 5 (1.6) 
Other Mental Health Disorders         
Schizophrenia 3 (0.49) 144 (2.7) 2 (1.4) 24 (1.5) 9 (0.80) 183 (2.4) 0 (0.0) 1 (0.31) 
Autism or Other Pervasive 
Developmental Disorders 46 (7.5) 210 (4.0) 10 (7.0) 47 (2.9) 121 (10.8) 365 (4.9) 3 (7.7) 6 (1.9) 
Mental Retardation 1 (0.16) 33 (0.63) 1 (0.70) 8 (0.49) 5 (0.45) 50 (0.66) 0 (0.0) 0 (0.0) 
Other Mood Disorders 101 (16.4) 935 (17.8) 22 (15.5) 262 (16.1) 252 (22.5) 1,629 (21.7) 6 (15.4) 53 (16.6) 
Substance Abuse / Use         
Alcohol Dependence 0 (0.0) 57 (1.1) 0 (0.0) 21 (1.3) 1 (0.09) 108 (1.4) 0 (0.0) 4 (1.3) 
Drug Dependence 0 (0.0) 217 (4.1) 0 (0.0) 62 (3.8) 1 (0.09) 361 (4.8) 0 (0.0) 9 (2.8) 
Drug or Alcohol Use 3 (0.49) 513 (9.8) 0 (0.0) 143 (8.8) 1 (0.09) 892 (11.9) 0 (0.0) 25 (7.8) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Prevalence Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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 As with patient characteristics in the prevalence study sample, the characteristics for 
patients in the medication use sample did not vary significantly over the study period. 
Therefore, only estimates from 2007 are provided (Table 4.17). Results between the overall 
patient characteristics and those for patients included in the medication use study were 
similar. As with the overall sample, there were smaller proportions of females in the younger 
age groups, for each diagnostic subtype. Additionally, there were lower inpatient mental 
health visits for younger age groups for all subtypes, with the exception of Cyclothymic 
disorder.  Young children with bipolar I or bipolar unspecified diagnoses had fewer 
diagnoses during the year, RD: 2.43 (95%CI: 1.67, 3.18) for bipolar I, RD: 2.12 (95%CI: 
1.54, 2.69) for bipolar unspecified. Finally, there were no differences in the type of provider 
seen by younger children and older children within each bipolar subtype.  
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23Table 4.17 - Patient and Physician Characteristics by Bipolar Subtype and Age Group: Aim 1a Medication Use Population - Study Year 2007 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
 N = 420 N = 3,615 N = 101 N = 1,160 N = 731 N = 4,934 N = 28 N = 230 
Patient Characteristics 
        
Age - Mean (SD) 7.6 (1.5) 14.6 (2.1) 7.4 (1.6) 15.0 (1.9) 7.6 (1.4) 14.5 (2.1) 7.8 (1.1) 14.5 (2.2) 
Sex - N (%) Female 124 (29.5) 1,723 (47.7) 25 (24.7) 648 (55.9) 205 (28.0) 2,255 (45.7) 7 (25.0) 112 (48.7) 
Comorbid Mental  
Health Conditions 1.2 (1.2) 1.3 (1.3) 1.2 (1.1) 1.1 (1.2) 1.4 (1.2) 1.4 (1.4) 1.5 (1.1) 1.2 (1.3) 
Number of  
Unique Diagnoses  8.1 (5.3) 10.5 (7.7) 8.4 (6.3) 10.1 (7.1) 8.6 (5.7) 10.7 (7.6) 8.9 (5.6) 9.7 (6.6) 
Any Inpatient  
Mental Health Visits  67 (15.9) 1,096 (30.3) 10 (9.9) 255 (22.0) 126 (17.2) 1,482 (30.0) 7 (25.0) 56 (24.3) 
Physician Specialty         
Psychiatrist 202 (48.1) 1,657 (45.8) 38 (37.6) 493 (42.5) 281 (38.4) 1,852 (37.5) 13 (46.4) 106 (46.1) 
Other Mental Health  84 (20.0) 729 (20.2) 30 (29.7) 316 (27.2) 105 (14.4) 681 (13.8) 4 (14.3) 58 (25.2) 
Primary Care / M.D. 61 (14.5) 551 (15.2) 6 (5.9) 124 (10.7) 150 (20.5) 1,032 (20.9) 3 (10.7) 29 (12.6) 
Other Medical Specialist 3 (0.70) 63 (1.7) 4 (4.0) 13 (1.1) 23 (3.1) 114 (2.3) 0 (0.0) 1 (0.40) 
Unclassified 63 (15.0) 526 (14.6) 22 (21.8) 189 (16.3) 146 (20.0) 1,120 (22.7) 6 (21.4) 29 (12.6) 
Missing 7 (1.7) 89 (2.5) 1 (1.0) 25 (2.2) 26 (3.6) 135 (2.7) 2 (7.1) 7 (3.0) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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 When looking at drug class use by age group (Table 4.18), there are few differences 
in the number of psychotropic medication taken in the 30 days following the child's most 
recent diagnosis. In 2006, there were slightly fewer young children who received no 
medications as compared with older children. In 2005 and 2006 there were no differences in 
the proportions of young and older children who were taking anticonvulsant monotherapy. 
However, by 2007, it appears that older children were more likely to receive anticonvulsant 
monotherapy as compared with younger children (RR: 1.41, 95% CI: 1.11, 1.80).   
 Antipsychotic use was more common among younger children over each study year, 
with nearly 20% of younger aged children receiving monotherapy antipsychotic treatment in 
each year. When looking at 2007, the risk ratio for use of antipsychotics for older children as 
compared with younger children was 0.64 (95%CI: 0.55, 0.74). Antidepressant monotherapy 
was more common among older children, as was the use of any combination regimen that 
included antidepressants. Among combination regimens, mood stabilizers and antipsychotic 
combinations were used in approximately 14% of younger aged children and 12% of older 
aged children.  
 Prescription drug fills by specific drug also show some differences in use by age 
group for agents within drug classes (Table 4.19). Among anticonvulsants, young children 
were more likely than older children to receive divalproex and oxcarbazepine, and less likely 
to receive lamotrigine. For second generation antipsychotics, young children were more 
likely to receive risperidone and less likely to receive quetiapine. Regarding antidepressant 
use, young children were less likely to receive escitalopram (among SSRIs) and venlafaxine 
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(among other antidepressants) and more likely to receive sertraline (SSRI) and trazodone 
(other antidepressant), as compared with older children. 
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24Table 4.18 - Annual Drug Class Use among Medication Users within 30 Days of Most Recent Bipolar Diagnosis by Age Group:  
Aim 1a, 2005 - 2007 
 Year of Diagnosis 
 2005 2006 2007 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9  Age 10 -17 
 
N = 1,320 N = 9,245 N = 1,327 N = 9,749 N = 1,280 N = 9,939 
Total Number of Psychotropic Medications Used  
in 30 Days Following the Last Diagnosis     
None 414 (31.4) 3,337 (36.1) 384 (28.9) 3,468 (35.6) 460 (35.9) 3,694 (37.2) 
1 382 (28.9) 2,251 (24.3) 395 (29.8) 2,475 (25.4) 351 (27.4) 2,554 (25.7) 
2 325 (24.6) 2,118 (22.9) 351 (26.5) 2,238 (23.0) 310 (24.2) 2,163 (21.8) 
3 151 (11.4) 1,101 (11.9) 145 (10.9) 1,168 (12.0) 115 (9.0) 1,152 (11.6) 
4 + 48 (3.6) 438 (4.7) 52 (3.9) 400 (4.1) 44 (3.4) 376 (3.8) 
Medication Use Among Users N = 906 N = 5,908 N = 943 N = 6,281 N = 820 N = 6,245 
Single Class Use       
Lithium 16 (1.8) 162 (2.7) 13 (1.4) 150 (2.4) 10 (1.2) 139 (2.2) 
> 1 Lithium Fill - n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Anticonvulsants 106 (11.7) 696 (11.8) 90 (9.5) 685 (10.9) 66 (8.0) 711 (11.4) 
> 1 Anticonvulsant Fill - n (%) 7 (6.6) 29 (4.2) 3 (3.3) 37 (5.4) 6 (9.1) 32 (4.5) 
Antipsychotics 173 (19.1) 587 (9.9) 176 (18.7) 738 (11.7) 170 (20.7) 827 (13.2) 
> Antipsychotic Fill - n (%) 10 (5.8) 32 (5.5) 14 (8.0) 47 (6.4) 10 (5.9) 48 (5.8) 
Antidepressants 32 (3.5) 569 (9.6) 45 (4.8) 597 (9.5) 26 (3.2) 572 (9.2) 
> 1 Antidepressant Fill - n (%) 1 (3.1) 61 (10.7) 2 (4.4) 46 (7.7) 1 (3.8) 65 (11.4) 
Stimulants 75 (8.3) 363 (6.1) 92 (9.8) 443 (7.1) 96 (11.7) 454 (7.3) 
> 1 Stimulant Fill - n (%) 2 (2.7) 4 (1.1) 2 (2.2) 8 (1.8) 0 (0.0) 4 (0.88) 
Continued       
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Table 4.18 - Annual Drug Class Use among Medication Users within 30 Days of Most Recent Bipolar Diagnosis by Age Group:  
Aim 1a, 2005 - 2007 (Continued) 
 Year of Diagnosis 
 2005 2006 2007 
 
Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9  Age 10 -17 
Medication Use Among Users N = 906 N = 5,908 N = 943 N = 6,281 N = 820 N = 6,245 
Combination Therapy       
Two Classes       
Lithium + Anticonvulsant 4 (0.40) 52 (0.90) 3 (0.30) 49 (0.80) 2 (0.20) 37 (0.60) 
Mood Stabilizer and Antipsychotic 134 (14.8) 721 (12.2) 135 (14.3) 736 (11.7) 104 (12.7) 776 (12.4) 
Mood Stabilizer and Antidepressant 22 (2.4) 555 (9.4) 15 (1.6) 537 (8.5) 13 (1.6) 455 (7.3) 
Mood Stabilizer and Stimulant 68 (7.5) 294 (5.0) 56 (5.9) 329 (5.2) 44 (5.4) 283 (4.5) 
Antipsychotic and Antidepressant 39 (4.3) 405 (6.9) 36 (3.8) 442 (7.0) 39 (4.8) 455 (7.3) 
Antipsychotic and Stimulant 80 (8.8) 219 (3.7) 117 (12.4) 271 (4.3) 118 (14.4) 292 (4.7) 
Antidepressant and Stimulant 8 (0.90) 149 (2.5) 12 (1.3) 128 (2.0) 12 (1.5) 141 (2.3) 
Three or More Classes       
Mood Stabilizer, Antipsychotic 
and Antidepressant 37 (4.1) 409 (6.9) 40 (4.2) 401 (6.4) 21 (2.6) 408 (6.5) 
Mood Stabilizer, Antipsychotic 
and Stimulant 71 (7.8) 281 (4.8) 63 (6.7) 328 (5.2) 58 (7.1) 274 (4.4) 
Mood Stabilizer, Antidepressant 
and Stimulant 8 (0.90) 147 (2.5) 10 (1.1) 152 (2.4) 12 (1.5) 136 (2.2) 
Antipsychotic, Antidepressant 
and Stimulant 17 (1.9) 135 (2.3) 21 (2.2) 156 (2.5) 17 (2.1) 156 (2.5) 
Mood Stabilizer, Antipsychotic, 
Antidepressant and Stimulant 16 (1.8) 164 (2.8) 19 (2.0) 139 (2.2) 12 (1.5) 129 (2.1) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
Calculations for more than one class level fill exclude multiple fills of the same agent on the same service date.  
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25Table 4.19 - Psychotropic Drug Use by Drug Prescribed 30 Days after Most Recent Diagnosis, by Age Group:  
Aim 1a, 2005 - 2007 
  Year of Diagnosis 
 2005 2006 2007 
  Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Total Fills N = 1,910 N = 13,794 N = 1,980 N = 14,293 N = 1,637 N = 13,884 
Lithium 110 (5.8) 1,036 (7.5) 101 (5.1) 924 (6.5) 72 (4.4) 856 (6.2) 
Anticonvulsants 506 (26.5) 3,624 (26.3) 462 (23.3) 3,726 (26.1) 352 (21.5) 3,574 (25.7) 
Carbamazepine  19 (3.8) 139 (3.8) 14 (3.0) 135 (3.6) 22 (6.3) 149 (4.2) 
Divalproex 248 (49.0) 1,390 (38.4) 229 (49.6) 1,345 (36.1) 161 (45.7) 1,242 (34.8) 
Gabapentin 4 (0.79) 64 (1.8) 4 (0.87) 63 (1.7) 6 (1.7) 64 (1.8) 
Lamotrigine 68 (13.4) 832 (23.0) 74 (16.0) 1,097 (29.4) 49 (13.9) 1,254 (35.1) 
Levetiracetam 1 (0.20) 11 (0.30) 4 (0.87) 11 (0.29) 4 (1.1) 12 (0.34) 
Oxcarbazepine 148 (29.2) 890 (24.6) 114 (24.7) 771 (20.7) 93 (26.4) 584 (16.3) 
Tiagabine 3 (0.59) 20 (0.55) 1 (0.22) 12 (0.32) 2 (0.57) 5 (0.14) 
Topiramate 15 (3.0) 279 (7.7) 23 (5.0) 292 (7.8) 15 (4.3) 264 (7.4) 
Atypical Antipsychotics 667 (34.9) 3,605 (26.1) 730 (36.9) 3,980 (27.8) 649 (39.6) 4,028 (29.0) 
Aripiprazole 179 (26.8) 1,030 (28.6) 195 (26.7) 1,335 (33.5) 217 (33.4) 1,282 (31.8) 
Clozapine 0 (0.0) 2 (0.06) 1 (0.14) 9 (0.23) 0 (0.0) 10 (0.25) 
Olanzapine 34 (5.1) 248 (6.9) 35 (4.8) 219 (5.5) 32 (4.9) 179 (4.4) 
Paliperidone 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (1.4) 83 (2.1) 
Quetiapine 127 (19.0) 987 (27.4) 151 (20.7) 1,121 (28.2) 124 (19.1) 1,180 (29.3) 
Risperidone 294 (44.1) 1,028 (28.5) 303 (41.5) 942 (23.7) 236 (36.4) 951 (23.6) 
Ziprasidone 33 (4.9) 310 (8.6) 45 (6.2) 353 (8.9) 31 (4.8) 344 (8.5) 
Typical Antipsychotics 3 (0.16) 39.5 (0.29) 6 (0.30) 41 (0.29) 6 (0.37) 32 (0.23) 
Continued 
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26Table 4.19 - Psychotropic Drug Use by Drug Prescribed 30 Days after Most Recent Diagnosis, by Age Group: 
Aim 1a, 2005 - 2007  (Continued) 
  Year of Diagnosis 
 2005 2006 2007 
  Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Total Fills N = 1,910 N = 13,794 N = 1,980 N = 14,293 N = 1,637 N = 13,884 
Antidepressants 233 (12.2) 3,344 (24.2) 246 (12.4) 3,290 (23.0) 143 (8.7) 3,152 (22.7) 
Tricyclics 18 61 13 98 13 68 
Tetracyclics 0 0 0 0 0 0 
Selective Serotonin  
Reuptake Inhibitors 144 1,989 153 1,954 91 1,906 
Citalopram  7 (4.9) 180 (9.0) 15 (9.8) 180 (9.2) 8 (8.8) 197 (10.3) 
Escitalopram 24 (16.7) 503 (25.3) 21 (13.7) 466 (23.8) 17 (18.7) 423 (22.2) 
Fluoxetine 40 (27.8) 556 (28.0) 41 (26.8) 539 (27.6) 21 (23.1) 541 (28.4) 
Fluvoxamine 6 (4.2) 43 (2.2) 2 (1.3) 42 (2.1) 4 (4.4) 56 (2.9) 
Paroxetine 9 (6.3) 142 (7.1) 13 (8.5) 129 (6.6) 5 (5.5) 108 (5.7) 
Sertraline 58 (40.3) 564 (28.4) 60 (39.2) 598 (30.6) 36 (39.6) 581 (30.5) 
MAOIs 0 1 0 0 0 0 
Other Antidepressants 71 1,293 80 1,238 38 1,178 
Bupropion 38 (53.5) 675 (52.2) 33 (41.3) 634 (51.2) 18 (47.4) 512 (43.5) 
Duloxetine 0 (0.0) 57 (4.4) 6 (7.5) 98 (7.9) 3 (7.9) 109 (9.2) 
Mirtazapine 7 (9.9) 80 (6.2) 21 (26.3) 89 (7.2) 13 (34.2) 76 (6.4) 
Nefazodone 0 (0.0) 4 (0.31) 0 (0.0) 1 (0.08) 0 (0.0) 0 (0.0) 
Trazodone 20 (28.2) 269 (20.8) 19 (23.8) 283 (22.9) 13 (34.2) 306 (26.0) 
Venlafaxine 6 (8.4) 209 (16.2) 1 (1.3) 132 (10.7) 4 (10.5) 176 (14.9) 
Stimulants 391 (20.5) 2,145 (15.6) 435 (22.0) 2,332 (16.3) 415 (25.4) 2,242 (16.1) 
N = Total prescriptions obtained. Patients may have more than one prescription therefore the total N is not equal to the  
study sample size.  Prescription fills are standardized to a 30-day supply.  
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample
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 Table 4.20 provides information on medication class use by patient age group 
separately for each bipolar subtype and year. For patients with bipolar I disorder, use of 
lithium does not differ over the study period by age group, nor does the use of anticonvulsant 
medications. Use of antipsychotics among children with bipolar I disorder is lower among 
older children in each study year (2005 RR: 0.70, 95%CI: 0.63, 0.79; 2006 RR: 0.76, 95%CI: 
0.68, 0.85; 2007 RR: 0.86, 95%CI: 0.76, 0.98). However, it appears that use of second 
generation antipsychotics has decreased somewhat in the younger age groups and has 
increased in the older age groups over the study period. Use of antidepressant agents was 
higher among older children with bipolar I disorder as compared with younger children, 
across each study year (2005 RR: 1.78, 95%CI: 1.43, 2.20; 2006 RR: 1.78, 95%CI: 1.42, 
2.22; 2007 RR: 2.10, 95%CI: 1.62, 2.71). Finally, use of stimulants was lower in the older 
aged children, as compared with younger children, throughout the study period (2005 RR: 
0.63, 95%CI: 0.54, 0.74; 2006 RR: 0.62, 95%CI: 0.53, 0.72; 2007 RR: 0.62, 95%CI: 0.53, 
0.73).  
 Among children with bipolar II disorder, treatment patterns were similar to those seen 
for patients with bipolar I disorder with a few exceptions. Children in both age groups were 
equally likely to receive lithium or anticonvulsants (except for study year 2007, when 
younger children were less likely to receive anticonvulsants). Younger children with bipolar 
II disorder were more likely to receive atypical antipsychotic medications, as compared with 
older children. Children with bipolar II disorder in both age groups were equally likely to 
receive stimulants in 2006 and 2007, but younger children were more likely to receive 
stimulants in this group in 2005. 
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 For children with bipolar disorder, unspecified type, it appeared that there was a trend 
for older aged children receiving lithium more often than younger aged children, but use in 
this category was low.  Use of the other drug classes (anticonvulsants, antipsychotics, 
antidepressants, and stimulants) mirrored that of children with bipolar I disorder (no 
differences in anticonvulsant use by age group; lower atypical antipsychotic use among older 
children; higher antidepressant use among older children; lower stimulant use among older 
children). 
 Finally, among patients with Cyclothymic disorder, there were few detectable 
differences in treatment characteristics by age group. This is likely due to the small number 
of children who were under the age of 10 years in this category. It appeared that second 
generation antipsychotic use was higher in younger aged children and that antidepressant use 
was lower in younger aged children.     
 When comparing overall treatment use by age group and bipolar subtype (Table 
4.21), in 2005 and 2006, younger patients with bipolar I or bipolar unspecified disorders 
were more likely to receive pharmacotherapy, as compared with older children. However, by 
2007, treatment rates for both age groups were similar. There were no significant difference 
by age group for the use of psychotherapy or counseling or the number of visits received 
across any of the years studied across any of the bipolar subtypes.   
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27Table 4.20 - Medication Class Use by Bipolar Subtype - Drug Prescribed 30 Days Following Most Recent  
Bipolar Diagnosis - By Age Group: Aim 1a, 2005 - 2007 
 
Bipolar Subtype 
 
Bipolar I 
 
2005 2006 2007 
 
Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Medication Class Use N = 455 N = 3,528 N = 436 N = 3,696 N = 420 N = 3,615 
Lithium 36 (7.9) 291 (8.2) 31 (7.1) 283 (7.7) 21 (5.0) 278 (7.7) 
Anticonvulsants 143 (31.4) 1065 (30.2) 128 (29.4) 1,154 (31.2) 104 (24.8) 1,060 (29.3) 
Atypical Antipsychotics 205 (45.1) 1,119 (31.7) 191 (43.8) 1,231 (33.3) 160 (38.1) 1,188 (32.9) 
Typical Antipsychotics 2 (0.40) 14 (0.40) 0 (0.0) 15 (0.40) 1 (0.20) 18 (0.50) 
Antidepressants 73 (16.0) 1,005 (28.5) 69 (15.8) 1,040 (28.1) 53 (12.6) 956 (26.4) 
Stimulants 135 (29.7) 660 (18.7) 134 (30.7) 702 (19.0) 125 (29.8) 665 (18.4) 
 Bipolar II 
 2005 2006 2007 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Medication Class Use N = 112 N = 1,081 N = 114 N = 1,225 N = 101 N = 1,160 
Lithium 7 (6.3) 86 (8.0) 9 (7.9) 78 (6.4) 5 (5.0) 67(5.8) 
Anticonvulsants 37 (33.0) 363 (33.6) 31 (27.2) 366 (29.9) 18 (17.8) 323 (27.8) 
Atypical Antipsychotics 46 (41.1) 288 (26.6) 45 (39.5) 314 (25.6) 42 (41.6) 317 (27.3) 
Typical Antipsychotics 0 (0.0) 4 (0.40) 0 (0.0) 4 (0.30) 0 (0.0) 4 (0.30) 
Antidepressants 16 (14.3) 303 (28.0) 20 (17.5) 308 (25.1) 11 (10.9) 272 (23.4) 
Stimulants 33 (29.5) 215 (19.9) 27 (23.7) 218 (17.8) 22 (21.8) 226 (19.5) 
Continued       
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28Table 4.20 - Medication Class Use by Bipolar Subtype - Drug Prescribed 30 Days Following Most Recent 
Bipolar Diagnosis - By Age Group: Aim 1a, 2005 - 2007 (Continued) 
 Bipolar Unspecified 
 2005 2006 2007 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Medication Class Use N = 727 N = 4,379 N = 755 N = 4,607 N = 731 N = 4,934 
Lithium 56 (7.7) 454 (10.4) 54 (7.2) 404 (8.8) 40 (5.5) 366 (7.4) 
Anticonvulsants 226 (31.1) 1,358 (31.0) 206 (27.3) 1,361 (29.5) 167 (22.8) 1,364 (27.6) 
Atypical Antipsychotics 300 (41.3) 1,459 (33.3) 363 (48.1) 1,590 (34.5) 322 (44.0) 1,734 (35.1) 
Typical Antipsychotics 5 (0.70) 19 (0.40) 5 (0.70) 19 (0.40) 5 (0.70) 19 (0.40) 
Antidepressants 87 (12.0) 1,163 (26.6) 106 (14.0) 1,146 (24.9) 83 (11.4) 1,173 (23.8) 
Stimulants 170 (23.4) 835 (19.1) 223 (29.5) 985 (21.4) 215 (29.4) 940 (19.1) 
 Cyclothymic Disorder* 
 2005 2006 2007 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Medication Class Use N = 26 N = 257 N = 22 N = 221 N = 28 N = 230 
Lithium 1 (3.8) 21 (8.2) 1 (4.5) 17 (7.7) 1 (3.6) 14 (6.1) 
Anticonvulsants 5 (19.2) 77 (30.0) 8 (36.4) 59 (26.7) 8 (28.6) 76 (33.0) 
Atypical Antipsychotics 12 (45.2) 36 (14.0) 7 (31.8) 52 (23.5) 11 (39.3) 52 (22.6) 
Typical Antipsychotics 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Antidepressants 3 (11.5) 62 (24.1) 3 (13.6) 58 (26.2) 5 (17.9) 51 (22.2) 
Stimulants 5 (19.2) 42 (16.3) 6 (27.3) 41 (18.6) 7 (25.0) 34 (14.8) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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29Table 4.21 Summary of Treatment Received by Bipolar Subtype and Age Group: Aim 1a, 2005 - 2007 
 Bipolar Subtype 
 Bipolar I 
 2005 2006 2007 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Pharmacotherapy* N = 455 N = 3,528 N = 436 N = 3,696 N = 420 N = 3,615 
Yes 312 (68.6) 2,226 (63.1) 308 (70.6) 2,393 (64.8) 267 (63.6) 2,286 (63.2) 
No 143 (31.4) 1,302 (36.9) 128 (29.4) 1,303 (35.3) 153 (36.4) 1,329 (36.8) 
Psychotherapy N = 338 N = 2,662 N = 327 N = 2,899 N = 300 N = 2,660 
Any Use - n (%) 313 (92.6) 2,409 (90.5) 395 (90.2) 2,606 (89.9) 269 (89.7) 2,411 (90.6) 
Visits - Median (IQR) 10.9 (10.0) 9.0 (13.0) 8.0 (11.0) 8.0 (13.0) 7.0 (11.0) 8.0 (13.0) 
ECT*      
Any Use - n (%) 0 (0.0) 1 (0.04) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.04) 
 Bipolar II 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Pharmacotherapy* N = 112 N = 1,081 N = 114 N = 1,225 N = 101 N = 1,160 
Yes 78 (69.6) 723 (66.9) 77 (67.5) 744 (60.7) 61 (60.4) 698 (60.2) 
No 34 (30.4) 358 (33.1) 37 (32.5) 481 (39.3) 40 (39.6) 462 (39.8) 
Psychotherapy N = 79 N = 832 N = 86 N = 979 N = 79 N = 887 
Any Use - n (%) 76 (96.2) 782 (94.0) 82 (95.3) 909 (92.9) 78 (98.7) 826 (93.1) 
Visits - Median (IQR) 9.5 (13.0) 9.0 (12.0) 10.5 (10.0) 9.0 (13.0) 7.5 (10.0) 8.0 (12.0) 
ECT*       
Any Use - n (%) 0 (0.0) 1 (0.12) 0 (0.0) 0 (0.0) 1 (1.3) 1 (0.11) 
Continued       
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30Table 4.21 Summary of Treatment Received by Bipolar Subtype and Age Group: Aim 1a, 2005 - 2007 
(Continued) 
 Bipolar Unspecified 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Pharmacotherapy* N = 727 N = 4,379 N = 755  N = 4,607 N = 731 N = 4,934 
Yes 498 (68.5) 2,815 (64.3) 543 (71.9) 3,006 (65.3) 472 (64.6) 3,121 (63.3) 
No 229 (31.5) 1,564 (35.7) 212 (28.1) 1,601 (34.8) 259 (35.4) 1,813 (36.8) 
Psychotherapy N = 530 N = 3,178 N = 563 N = 3,540 N = 506 N = 3,560 
Any Use - n (%) 463 (87.4) 2,732 (86.1) 493 (87.6) 3,022 (85.4) 421 (83.2) 2,985 (83.8) 
Visits - Median (IQR) 8.0 (11.0) 8.0 (12.0) 8.0 (10.0) 8.0 (12.0) 8.0 (11.0) 8.0 (12.0) 
ECT*       
Any Use - n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.03) 0 (0.0) 1 (0.03) 
 Cyclothymic Disorder* 
 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 Age 0 - 9 Age 10 - 17 
Pharmacotherapy* N = 26 N = 257 N = 22 N = 221 N = 28 N = 230 
Yes 18 (69.2) 144 (56.0) 15 (68.2) 138 (62.4) 20 (71.4) 140 (60.9) 
No 8 (30.8) 113 (44.0) 7 (31.8) 83 (37.6) 8 (28.6) 90 (39.1) 
Psychotherapy N = 21 N = 193 N = 19 N = 170 N = 20 N = 172 
Any Use - n (%) 19 (90.5) 181 (93.8) 17 (89.5) 163 (95.9) 19 (95.0) 161 (93.6) 
Visits - Median (IQR) 6.0 (10.0) 6.0 (9.0) 4.0 (8.0) 8.0 (11.0) 9.0 (8.0) 7.0 (12.0) 
ECT*       
Any Use - n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
SOURCE: Repeated Cross Sectional Analysis Using Aim 1a Medication Use Study Sample 
ECT = Electroconvulsive Therapy. 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum.
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4.2 Aim 1b: Incident Diagnosis Design 
Next, additional exclusionary criteria were applied to address Aim 1b.  In order to 
identify patients who were newly diagnosed and to accurately identify their treatments 
received over time, the initial sample was reduced by restricting the sample to patients whose 
first diagnosis occurred between July 1, 2005 and December 31, 2006. Patients also were 
required to have had continuous enrollment over the period spanning 6 months prior to their 
index diagnosis and 12 months following their index diagnosis, and no previous evidence of 
a bipolar diagnosis or treatment (antipsychotic, anticonvulsant or lithium) for 6 months prior 
to their index diagnosis.  The index diagnosis was the first recorded diagnosis date among 
patients who met these criteria.  
Patients who had a diagnosis of schizophrenia,  a pervasive developmental disorder, 
mental retardation, or a substance abuse disorder and those whose insurance plans did not 
provide information on medication use were excluded. Details of these exclusions are 
provided in Figure 4.4 and in Chapter 3.   
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 9Figure 4.4 - Inclusion and Exclusion Criteria: Aim 1b 
 
 Characteristics of children who were newly diagnosed with a bipolar spectrum 
disorder from July 1, 2005 through December 31, 2006 are provided in Table 4.22. When 
comparing patient characteristics by bipolar subtype (with patients with bipolar I disorder as 
the reference group), patients with bipolar unspecified were younger on average (RD: -0.40, 
95%CI: -0.65, -0.15) with proportionately more children in the middle age group (RR: 1.23, 
95%CI: 1.05, 1.44, ages 7 - 12) and fewer in the oldest age group (RR: 0.92, 95%CI: 0.88, 
 Exclude patients whose first bipolar 
diagnosis was before July 1, 2005 or 
after December 31, 2006. 
N=19,231 
N= 35,526  Initial Sample from Aim 1a 
N= 16,295 
N=9,176 
N= 7,119 
 Exclude patients who were not 
continuously enrolled for 6 months 
prior to and 12 months post diagnosis. 
N=1,011  Exclude patients with schizophrenia (ICD-9 
code 295.x), a pervasive developmental 
disorder (ICD-9 code 299.x), mental 
retardation (ICD-9 codes 317 - 319),  or a 
substance abuse disorder (ICD-9 codes 303 - 
304). 
N= 6,108 
 Exclude patients with use of lithium, 
anticonvulsants or antipsychotics in the 6 
months prior to index diagnosis. 
N=2,139 
N= 3,969 
 Exclude patients who were 18 years of 
age as of the initial diagnosis, and those 
who did not have prescription drug 
information reported to MarketScan. 
N=1,124 
N= 2,845 
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0.97, ages 13 - 17). Children with bipolar II disorder were more likely to be older than those 
with bipolar I disorder (RD: 0.54, 95%CI: 0.18, 0.89), with proportionately more children in 
the oldest age group (RR: 1.08, 95%CI: 1.02, 1.14).  Children with bipolar II disorder and 
Cyclothymic disorder were more likely to be female, as compared with children with bipolar 
I disorder (RR: 1.13, 95% CI: 1.02, 1.25, for bipolar II and RR: 1.26, 95%CI: 1.08, 1.47, for 
Cyclothymic disorder). 
 Across all bipolar subtypes, there were no differences in the number of comorbid 
mental health conditions or the total number of diagnoses received over the 18 month study 
period. Children with Cyclothymic disorder were slightly less likely to have inpatient mental 
health days, as compared with children with bipolar I disorder (RR: 0.71, 95%CI: 0.49, 1.03), 
although this difference was not statistically significant.  
There were several differences noted when comparing bipolar subtype distributions 
by region and insurance status. It is important to note, however, that the MarketScan data are 
not sampled in a way that provides reliable information on regional variation of disease. 
Additionally, insurance type may be correlated with region so interpretations of differences 
in insurance or regional variation by bipolar subtype should be made in light of these data 
limitations.  
 While regional distributions within each bipolar subtype largely reflected the 
sampling strategy of MarketScan (where the south is more heavily represented than other 
regions), there were some differences in region by bipolar subtype. For example, in the south, 
bipolar II disorder was diagnosed proportionately less often than bipolar I disorder (RR: 0.75, 
95%CI: 0.64, 0.88). In the west, there were proportionately higher diagnoses of bipolar NOS 
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(RR: 1.22, 95%CI: 1.03, 1.45), bipolar II (RR: 1.56, 95%CI: 1.26, 1.93), and Cyclothymic 
disorder (RR: 1.59, 95%CI: 1.11, 2.26) as compared with bipolar I disorder. 
 When comparing insurance types, patients with bipolar unspecified type were slightly 
more likely to have an insurance type categorized as "other" (as compared with patients with 
bipolar I disorder), although few patients were included in this category overall.  Regarding 
benefit generosity patients with bipolar unspecified were less likely than those with bipolar I 
disorder to have fair benefits or no benefits (RR: 0.90, 95%CI: 0.82, 0.98, for fair and RR: 
0.59, 95%CI: 0.37, 0.94 for none), and more likely to have good generosity of benefits (RR: 
1.13, 95%CI: 1.02, 1.25). Similarly, compared with patients with bipolar I disorder, patients 
with bipolar II disorder were less likely to have no benefits (RR: 0.39, 95%CI: 0.17, 0.91), 
and more likely to have good benefits (RR: 1.19, 95%CI: 1.04, 1.36)  
 Patients with bipolar unspecified type were more likely to receive their diagnosis 
from a primary care provider (RR: 1.29, 95%CI: 1.10, 1.52) or an unclassified provider (RR: 
1.23, 95%CI: 1.06, 1.44), and were less likely to receive their diagnosis from mental health 
provider (non-psychiatry) (RR: 0.59, 95%CI: 0.49, 0.71) as compared with those with bipolar 
I disorder. Patients with bipolar II and Cyclothymic disorder were more likely than patients 
with bipolar I to receive their diagnosis from a psychiatrist (RR: 1.19, 95%CI: 1.04, 1.36, for 
bipolar II and RR: 1.30, 95%CI: 1.04, 1.62 for Cyclothymic disorder). Additionally, patients 
with bipolar II disorder were less likely to receive their diagnosis from a primary care 
provider (RR: 0.60, 95%CI: 0.44, 0.82).  
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31Table 4.22 - Patient and Physician Characteristics by Bipolar Subtype: Aim 1b 
  
Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  
N = 1,036 N = 398 N = 1,314 N = 97 
Patient Characteristics         
Age - Mean (SD) 13.9 (2.9) 14.5 (2.5) 13.5 (3.3) 14.1 (2.8) 
0 - 6 Years 38 (3.7) 6 (1.5) 66 (5.0) 3 (3.1) 
7 - 12 Years 200 (19.3) 61 (15.3) 312 (23.7) 17 (17.5) 
13 - 17 Years 798 (77.0) 331 (83.2) 936 (71.2) 77 (79.4) 
Sex - N (%) Female 541 (52.2) 234 (58.8) 664 (50.5) 64 (66.0) 
Geographic Region      
Northeast 108 (10.4) 37 (9.3) 123 (9.4) 6 (6.2) 
North Central 288 (27.8) 119 (29.9) 384 (29.2) 27 (27.8) 
South 453 (43.7) 131 (32.9) 526 (40.0) 37 (38.1) 
West 175 (16.9) 105 (26.4) 271 (20.6) 26 (26.8) 
Unknown 12 (1.2) 6 (1.5) 10 (0.76) 1 (1.0) 
Insurance Type      
Comprehensive 70 (6.8) 35 (8.8) 111 (8.4) 10 (10.3) 
HMO 225 (21.7) 94 (23.6) 269 (20.5) 21 (21.7) 
POS 126 (12.2) 49 (12.3) 171 (13.0) 9 (9.3) 
PPO 558 (53.9) 200 (50.3) 664 (50.5) 53 (54.6) 
Other  30 (2.9) 12 (3.0) 65 (5.0) 4 (4.1) 
Unknown 27 (2.6) 8 (2.0) 34 (2.6) 0 (0.0) 
Generosity of Prescription 
Drug Benefits      
None / Poor 40 (4.3) 6 (1.7) 30 (2.6) 4 (4.4) 
Fair 498 (54.1) 178 (49.6) 566 (49.4) 50 (54.4) 
Good 383 (41.6) 175 (48.8) 549 (48.0) 38 (41.3) 
Disease Severity      
Comorbid Mental Health  Conditions 1.4 (1.2) 1.3 (1.1) 1.5 (1.2) 1.3 (1.3) 
Number of Unique  
Diagnoses in Year 12.8 (8.4) 12.0 (7.7) 12.9 (8.0) 12.1 (8.0) 
Any Inpatient Mental Health Visits 345 (33.3) 117 (29.4) 472 (35.9) 23 (23.7) 
Physician Specialty      
Psychiatrist 379 (37.6) 173 (44.9) 443 (34.8) 46 (50.0) 
Other Mental Health  206 (20.4) 83 (21.6) 154 (12.1) 19 (20.7) 
Primary Care / M.D. 186 (18.4) 43 (11.2) 305 (23.9) 11 (12.0) 
Other Medical Specialist 25 (2.5) 8 (2.1) 41 (3.2) 0 (0.0) 
Unclassified 212 (21.0) 78 (20.3) 332 (26.0) 16 (17.4) 
MSA Status 750 (97.7) 337 (98.0) 919 (94.9) 79 (100.0) 
SOURCE: Aim1b Incident Diagnosis Design Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
 
 
When considering the impact of comorbid mental health conditions (Table 4.23), 
there was no difference in the occurrence of ADHD, either occurring prior to bipolar 
diagnosis or occurring post bipolar diagnosis, across any bipolar spectrum disorder. ADHD 
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diagnoses occurred (either before or after bipolar diagnosis) in over 30% of children with 
bipolar I, or bipolar unspecified disorders, and in approximately 25% of children with bipolar 
II or Cyclothymic disorders. Conduct disorder was less likely to be diagnosed in children 
with bipolar II disorder (RR: 0.67, 95%CI: 0.46, 1.00), and was more likely to be diagnosed 
in children with bipolar NOS (RR: 1.39, 95%CI: 1.12, 1.73) , as compared with those with 
bipolar I disorder. 
 Anxiety disorders were rare and there were no differences in the occurrence of these 
disorders by bipolar subtype (with bipolar I as the reference group), with the exception of co-
morbid panic disorder among patients with bipolar unspecified. However, there were only a 
small number of patients in this category so the confidence interval for this estimate was 
somewhat imprecise (RR: 3.64, 95%CI: 1.16, 11.41).  
 Patients with bipolar unspecified type were less likely to have a diagnosis of major 
depressive disorder in either the pre or post diagnosis periods as compared with those with 
bipolar I disorder (RR: 0.84, 95%CI: 0.75, 0.94). Dysthymic disorder was less common than 
major depressive disorder, and was more likely to be diagnosed in children with bipolar II 
disorder prior to their index bipolar diagnosis (RR: 1.63, 95%CI: 1.02, 2.61). Children with 
bipolar unspecified type were more likely than children with bipolar I disorder to receive a 
mental health diagnosis for an "other mood disorder" (RR: 1.26, 95%CI: 1.06, 1.49). 
 Substance use (alcohol or drug use, excluding abuse) was less common prior to 
diagnosis, among all bipolar subtypes. Overall, the use of drugs or alcohol did not differ by 
bipolar subtype. However, between 7 and 8% of children were identified as substance users 
in the period following their initial bipolar diagnosis. 
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                           32Table 4.23 - Occurrence of Comorbid Mental Health Conditions by Timing of Diagnosis: Aim 1b 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
 N = 1,036 N = 398 N = 1,314 N = 97 
Mental Health Diagnosis Pre-Dx Post-Dx Pre-Dx Post-Dx Pre-Dx Post-Dx Pre-Dx Post-Dx 
Disruptive Behavior Disorders 
        
Attention Deficit  
Hyperactivity Disorder 186 (18.0) 133 (12.8) 79 (19.8) 30 (7.5) 270 (20.5) 170 (12.9) 15 (15.5) 9 (9.3) 
Conduct Disorder 48 (4.6) 64 (6.2) 9 (2.3) 20 (5.0) 74 (5.6) 124 (9.4) 3 (3.1) 7 (7.2) 
Oppositional Defiant Disorder 47 (4.5) 72 (6.9) 18 (4.5) 15 (3.8) 70 (5.3) 106 (8.1) 7 (7.2) 2 (2.1) 
Anxiety Disorders         
Separation Anxiety Disorder 2 (0.20) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.20) 2 (0.20) 0 (0.0) 1 (1.0) 
Post-Traumatic Stress Disorder 15 (1.4) 19 (1.8) 5 (1.3) 4 (1.0) 27 (2.1) 35 (2.7) 1 (1.0) 1 (1.0) 
Obsessive Compulsive Disorder 10 (1.0) 6 (0.60) 3 (0.80) 5 (1.3) 19 (1.4) 17 (1.3) 2 (2.1) 1 (1.0) 
Generalized Anxiety Disorder 19 (1.8) 39 (3.8) 12 (3.0) 6 (1.5) 34 (2.6) 29 (2.2) 2 (2.1) 5 (5.2) 
Social Phobia 5 (0.50) 4 (0.40) 1 (0.30) 3 (0.80) 2 (0.20) 2 (0.20) 0 (0.0) 2 (2.1) 
Panic Disorder 5 (0.50) 5 (0.50) 3 (0.80) 6 (1.5) 6 (0.50) 12 (0.90) 0 (0.0) 2 (2.1) 
Depressive Disorders         
Major Depressive Disorder 193 (18.6) 183 (17.7) 81 (20.4) 72 (18.1) 198 (15.1) 203 (15.4) 13 (13.4) 13 (13.4) 
Dysthymic Disorder 43 (4.2) 38 (3.7) 27 (6.8) 11 (2.8) 65 (4.9) 35 (2.7) 7 (7.2) 7 (7.2) 
Other Mental Health Disorders         
Other Mood Disorders 54 (5.2) 124 (12.0) 31 (7.8) 41 (10.3) 102 (7.8) 182 (13.9) 6 (6.2) 7 (7.2) 
Tic Disorders         
Tourette's Syndrome or  
Other Tic Disorders 
3 (0.30) 4 (0.40) 0 (0.0) 2 (0.50) 3 (0.20) 6 (0.50) 0 (0.0) 0 (0.0) 
        
Substance Use         
Drug or Alcohol Use 24 (2.3) 84 (8.1) 6 (1.5) 27 (6.8) 25 (1.9) 100 (7.6) 2 (2.1) 7 (7.2) 
SOURCE: Aim1b Incident Diagnosis Design Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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 Newly diagnosed patients were evaluated over the course of one year to determine 
how stable their bipolar diagnoses were over time. Table 4.24 details the extent to which the 
patient's initial bipolar spectrum diagnosis matched their final bipolar spectrum diagnosis 
(after one year of follow up). Approximately 80% of patients in each bipolar subtype had the 
same diagnosis at the beginning and end of the study period. Approximately 13% of patients 
who were initially diagnosed with bipolar I disorder or bipolar II disorder had a bipolar 
unspecified disorder diagnosis at their last visit. Approximately 8% of patients with a 
Cyclothymic disorder diagnosis at the initial visit had a bipolar II diagnosis at their last visit. 
Approximately 14% of patients with a bipolar unspecified type at the first visit had bipolar I 
diagnoses at the last visit.  
 
 
33Table 4.24 - Diagnostic Stability of Bipolar Spectrum Disorders Over One Year from Initial Diagnosis: 
Aim 1b 
 
SOURCE: Aim1b Incident Diagnosis Design Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
 
 
 
Overall, a majority of patients had no changes in their bipolar diagnostic subtype over 
the course of one year after their initial diagnosis (Table 4.25). Changes were most likely for 
patients who received diagnoses of bipolar II disorder, with approximately 34% of these 
patients having a diagnosis change in the year. Patients with initial diagnoses of bipolar II 
  Last Bipolar Subtype 
Initial Bipolar Subtype   
      
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
Bipolar I 861 (83.1) 34 (3.3) 140 (13.5) 1 (0.10) 
Bipolar II 34 (8.5) 310 (77.9) 53 (13.3) 1 (0.30) 
Bipolar NOS 179 (13.6) 44 (3.3) 1,085 (82.6) 6 (0.50) 
Cyclothymia 7 (7.2) 8 (8.2) 7 (7.2) 75 (77.3) 
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disorder had the most diagnostic switching over the year (with a range of 0 switches to 36 
switches). Having 4 or more diagnostic changes was also most common for patients with 
bipolar II disorders (occurring in 11% of patients).  
 
 
34Table 4.25 - Number of Bipolar Diagnostic Changes Over One Year from Initial Diagnosis: Aim 1b 
 Initial Bipolar Subtype 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
 N = 1,036 N = 398 N = 1,314 N = 97 
Number of Diagnostic Changes     
No Changes 761 (73.5) 264 (66.3) 962 (73.2) 70 (72.2) 
1 Change 117 (11.3) 48 (12.1) 136 (10.4) 16 (16.5) 
2 Changes 62 (6.0) 24 (6.0) 77 (5.9) 7 (7.2) 
3 Changes 28 (2.7) 17 (4.3) 30 (2.3) 1 (1.0) 
4+ Changes 68 (6.6) 45 (11.3) 109 (8.3) 3 (3.1) 
Range 0 - 22 0 - 36 0 - 24 0 - 21 
SOURCE: Aim1b Incident Diagnosis Design Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
 
 
 When comparing drug class use by bipolar subtype, there was no difference in the 
number of drugs received at 30 days, 90 days or one year following diagnosis (Tables 4.26 - 
4.28) for any bipolar subtype. Children with bipolar II disorder were somewhat more likely 
than children with bipolar I to receive at least one drug at each of the time points (RR: 1.07, 
95%CI: 1.01, 1.13, at one year). Use of specific drug classes was also evaluated to see if 
there were any bipolar-related treatment differences at the different time points.  
Drug use in the 30 days after a child's first bipolar diagnosis was similar among all 
bipolar subtypes, and ranged from 56.1% (bipolar NOS) to 62.6% (bipolar II) (Table 4.26). 
Of those that received medication in the first 30 days following initial diagnosis, there was no 
statistically significant difference in the use of lithium, or stimulants. Use of lithium was rare 
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across all bipolar subtypes, particularly for those with bipolar II disorder. Antidepressant use 
was lower among patients with bipolar unspecified type (RR: 0.87, 95%CI: 0.77, 0.98) and 
patients with bipolar II (RR: 0.79, 95%CI: 0.66, 0.94) as compared with patients with bipolar 
I. Anticonvulsant use was somewhat higher among patients with bipolar II disorder as 
compared with patients with bipolar I disorder (RR: 1.20, 95% CI: 1.02, 1.42). Finally, 
antipsychotic agents were less likely to be used by patients with bipolar II disorder (RR: 
0.69, 95%CI: 0.55, 0.86), and those with Cyclothymic disorder (RR: 0.50, 95%CI: 0.30, 
0.84) as compared with those with bipolar I disorder during the 30 day period.  
 
35Table 4.26 - Drug Class Use 30 Days Following Initial Diagnosis by Bipolar Subtype: Aim 1b 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 1,036 N = 398 N = 1,314 N = 97 
Total Number of Psychotropic  
Medications Used in 30 Days  
Following Initial Diagnosis 
  
      
None 449 (43.3) 149 (37.4) 577 (43.9) 38 (39.2) 
1 312 (30.1) 153 (38.4) 398 (30.3) 38 (39.2) 
2 189 (18.2) 74 (18.6) 250 (19.0) 17 (17.5) 
3 72 (6.9) 21 (5.3) 73 (5.6) 4 (4.1) 
4 + 14 (1.3) 1 (0.25) 16 (1.2) 0 (0.0) 
Medication Class Use Among 
Users** N = 587 N = 249 N = 737 N = 59 
Lithium 39 (6.6) 10 (4.0) 44 (6.0) 5 (8.5) 
Anticonvulsants 227 (38.7) 116 (46.6) 313 (42.5) 26 (44.1) 
Antipsychotics 238 (40.5) 69 (27.7) 317 (43.0) 12 (20.3) 
Antidepressants 284 (48.4) 95 (38.2) 310 (42.1) 26 (44.1) 
Stimulants 119 (20.3) 56 (22.5) 142 (19.3) 11 (18.6) 
SOURCE: Aim1b Incident Diagnosis Design Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
** Drug class use does not sum to the total medication users sample size as users could be included in multiple 
categories.  
 
 
 
When comparing medication class use over the first 90 days following initial 
diagnosis, a larger proportion of patients were receiving treatment (ranging from 
approximately 70 to 75% within each bipolar subtype) (Table 4.27).  As with the 30 day time 
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point, there were no differences in the use of lithium or stimulants by bipolar subtype. 
However, patients with bipolar II disorder and those with Cyclothymic disorder were less 
likely to receive antipsychotic medications as compared with those with bipolar I disorder 
(RR: 0.75, 95%CI: 0.62, 0.90 for bipolar II and RR: 0.65, 95%CI: 0.44, 0.95 for Cyclothymic 
disorder). Patients with bipolar II disorder were also more likely to receive anticonvulsants 
(RR: 1.31, 95%CI: 1.15, 1.50) and less likely to receive antidepressants (RR: 0.85, 95%CI: 
0.74, 0.97) than those with bipolar I disorder.  
 
 
36Table 4.27 - Drug Class Use 90 Days Following Initial Diagnosis by Bipolar Subtype: Aim 1b 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 1,036 N = 398 N = 1,314 N = 97 
Total Number of Psychotropic  
Medications Used in 90 Days 
Following Initial Diagnosis 
  
      
None 314 (30.3) 94 (23.6) 403 (30.7) 24 (24.7) 
1 290 (28.0) 137 (34.4) 380 (28.9) 36 (37.1) 
2 267 (25.8) 97 (24.4) 317 (24.1) 25 (25.8) 
3 112 (10.8) 54 (13.6) 152 (11.6) 9 (9.3) 
4 + 53 (5.1) 16 (4.0) 62 (4.7) 3 (3.1) 
Medication Class Use Among 
Users** N = 722 N = 304 N = 911 N = 73 
Lithium 52 (7.2) 17 (5.6) 60 (6.6) 6 (8.2) 
Anticonvulsants 307 (42.5) 170 (55.9) 432 (47.4) 38 (52.0) 
Antipsychotics 307 (42.5) 96 (31.6) 422 (46.3) 20 (27.4) 
Antidepressants 393 (54.4) 140 (46.0) 435 (47.8) 36 (49.3) 
Stimulants 192 (26.6) 78 (25.7) 233 (25.6) 14 (19.2) 
SOURCE: Aim1b Incident Diagnosis Design Sample. 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
** Drug class category use does not sum to the total medication users sample size as users could be included in 
multiple categories. 
 
Finally, when looking at drug class use over one year following diagnosis, a majority 
of patients received at least one psychotropic prescription over the year (Table 4.28). Over 
the course of the year, there was no difference in the proportion of children who received 
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lithium, stimulants, or antidepressants by bipolar subtype. However, anticonvulsant use was 
higher in patients with bipolar II disorder (RR: 1.26, 95%CI: 1.13, 1.41) and those with 
Cyclothymic disorder (RR: 1.25, 95%CI: 1.03, 1.51) when compared with those with bipolar 
I disorder. Antipsychotic use also differed by bipolar subtype with patients with bipolar II 
and patients with Cyclothymic disorder being less likely to receive antipsychotics (RR: 0.86, 
0.74, 0.90, for bipolar II, and RR: 0.70, 95% CI: 0. 52, 0.96, for Cyclothymic disorder) as 
compared with children with bipolar I disorder.  
 
37Table 4.28 - Drug Class Use One Year Following Initial Diagnosis by Bipolar Subtype: Aim 1b 
  Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
  N = 1,036 N = 398 N = 1,314 N = 97 
Total Number of Psychotropic  
Medications Used During the Year         
None 234 (22.6) 69 (17.3) 289 (22.0) 18 (18.6) 
1 221 (21.3) 94 (23.6) 290 (22.1) 23 (23.7) 
2 228 (22.0) 99 (24.9) 303 (23.1) 25 (25.8) 
3 177 (17.1) 67 (16.8) 203 (15.4) 15 (15.5) 
4 + 176 (17.0) 69 (17.3) 229 (17.4) 16 (16.5) 
Medication Class Use Among 
Users** N = 802 N = 329 N = 1,025 N = 79 
Lithium 78 (9.7) 23 (7.0) 89 (8.7) 8 (10.1) 
Anticonvulsants 391 (48.7) 202 (61.4) 534 (52.1) 48 (60.8) 
Antipsychotics 407 (50.7) 142 (43.2) 555 (54.1) 28 (35.4) 
Antidepressants 494 (61.6) 183 (55.6) 587 (57.3) 47 (59.5) 
Stimulants 262 (32.9) 107 (32.5) 360 (35.1) 20 (25.3) 
SOURCE: Aim1b Incident Diagnosis Design Sample 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
** Drug class category use does not sum to the total medication users sample size as users could be included in 
multiple categories. 
 
 
 Figure 4.5 shows the time in months until patients received any psychotropic 
treatment by each bipolar spectrum disorder. Rates of treatment were similar, regardless of 
bipolar subtype recorded at the patients' initial visit. For example, at 6 months, 73.6% of 
patients with bipolar I disorder, 79.6% of those with bipolar II disorder, 74.0% of those with 
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bipolar unspecified, and 78.3% of those with Cyclothymic disorder had received treatment. 
At one year, treatment rates were 77.4% for bipolar I disorder, 82.7% for bipolar II disorder, 
77.9% for bipolar unspecified, and 81.4% for Cyclothymic disorder. 
 
10Figure 4.5 - Time to Any Treatment by Bipolar Subtype:  Aim 1b 
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* Treatments included use of lithium, anticonvulsants, antipsychotics, antidepressants or stimulants. 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
 
 
 
 Prescription drug use by specific agent at each time point (30 days, 90 days and 1 
year after diagnosis) is provided in Table 4.29. Antidepressant medications were the most 
commonly filled psychotropic medications within 30 days of diagnosis, followed by 
anticonvulsants, and atypical antipsychotics. Of the anticonvulsants, divalproex was the most 
commonly filled medication after 30 days and after 90 days from diagnosis. After one year, 
lamotrigine surpassed divalproex in the number of fills. Another commonly prescribed agent 
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within the anticonvulsant class was oxcarbazepine, although use of this agent appeared to 
decline slightly over the three time points.  
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38Table 4.29 - Medication Use by Drug Prescribed: Aim 1b 
  
30 Days After 
Diagnosis 
90 Days After 
Diagnosis 
One Year After 
Diagnosis 
Total Medications Filled N = 3,173 N = 8,262 N = 27,698 
Mood Stabilizers 
   
Lithium 126 (4.0) 312 (3.8) 1,020 (3.7) 
Anticonvulsants 851 (26.8) 2,199 (26.6) 6,936 (25.0) 
Carbamazepine  21 (2.5) 48 (2.2) 140 (2.0) 
Divalproex 376 (44.2) 880 (40.0) 2,298 (33.1) 
Gabapentin 5 (0.59) 19 (0.86) 86 (1.2) 
Lamotrigine 208 (24.4) 708 (32.2) 2,730 (39.4) 
Levetiracetam 0 (0.0) 2 (0.09) 9 (0.13) 
Oxcarbazepine 201 (23.6) 447 (20.3) 1,343 (19.4) 
Tiagabine 2 (0.23) 4 (0.18) 13 (0.19) 
Topiramate 37 (4.3) 91 (4.1) 317 (4.6) 
Atypical Antipsychotics 816 (25.7) 1,970 (23.8) 6,510 (23.5) 
Aripiprazole 229 (28.1) 583 (29.6) 2,121 (32.6) 
Clozapine 0 (0.0) 0 (0.0) 9 (0.14) 
Olanzapine 58 (7.1) 117 (5.9) 273 (4.2) 
Paliperidone 0 (0.0) 0 (0.0) 9 (0.14) 
Quetiapine 238 (29.2) 582 (29.5) 1,807 (27.8) 
Risperidone 227 (27.8) 533 (27.1) 1,763 (27.1) 
Ziprasidone 64 (7.8) 155 (7.9) 528 (8.1) 
Typical Antipsychotics 3 (0.09) 7 (0.85) 9 (0.03) 
Antidepressants 973 (30.7) 2,523 (30.5) 8,418 (30.4) 
Tricyclics N = 28 N = 75 N = 246 
Tetracyclics N = 0 N = 0 N = 0 
Selective Serotonin Reuptake Inhibitors N = 626 N = 1,646 N = 5,387 
Citalopram  64 (10.2) 154 (9.4) 475 (8.8) 
Escitalopram 147 (23.5) 392 (23.8) 1,316 (24.4) 
Fluoxetine 196 (31.3) 497 (30.2) 1,569 (29.1) 
Fluvoxamine 3 (0.48) 12 (0.73) 70 (1.3) 
Paroxetine 26 (4.1) 84 (5.1) 287 (5.3) 
Sertraline 190 (30.3) 507 (30.8)  1,670 (31.0) 
Monoamine Oxidase Inhibitors N = 0 N = 0 N = 0 
Other Antidepressants N = 319 N = 801 N = 2,785 
Bupropion 129 (40.4) 364 (45.4) 1,332 (47.8) 
Duloxetine 8 (2.5) 44 (5.5) 233 (8.4) 
Mirtazapine 28 (8.8) 62 (7.7) 216 (7.8) 
Nefazodone 0 (0.0) 0 (0.0) 0 (0.0) 
Trazodone 104 (32.6) 207 (25.8) 547 (19.6) 
Venlafaxine 50 (15.7) 124 (15.5) 457 (16.4) 
Stimulants 404 (12.7) 1,258 (15.2) 4,814 (17.4) 
N = Total prescriptions obtained. Patients may have more than one prescription therefore the total N is 
 not equal to the study sample size.  Prescription fills are standardized to a 30-day supply. 
SOURCE: Aim1b Incident Diagnosis Design Sample 
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Among atypical antipsychotic agents, aripiprazole, quetiapine, and risperidone were 
the most heavily prescribed agents over each time point. Clozapine, often considered to be 
the agent of last resort, was not used in any of the newly diagnosed patients in the first 30 or 
90 days, but there were 9 fills for clozapine during the one year period. Finally, of 
antidepressant use, SSRIs were the most frequently filled antidepressants, followed by agents 
in the "other antidepressants" class. Among the SSRIs, escitalopram, fluoxetine, and 
sertraline were the most commonly filled agents. Bupropion was the most commonly filled 
drug of the other antidepressant over each time point. 
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39Table 4.30 - Annual Payments for Medical Care by Bipolar Subtype: Aim 1b 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
Total Medical Payments N = 1,036 N = 398 N = 1,314 N = 97 
Patient Payment     
Median (IQR), $ 852 (1,721) 695 (1,185) 793 (1,236) 882 (1,183) 
Mean (SD) 1,341 (1,274) 1,085 (1,151) 1,232 (1,592) 1,481 (3,097) 
Patient & Insurer Payment     
Median (IQR), $ 4,958 (8,346) 4,775 (7,186) 5,235 (8,316) 4,416 (4,738) 
Mean (SD) 8,930 (13,140) 8,202 (14,270) 9,446 (15,011) 7,333 (9,808) 
Inpatient Payments 
    
Patient Payment 
    
Median (IQR), $ 0 (42) 0 (0) 0 (104) 0 (0) 
Mean (SD) 348 (1,126) 221 (671) 292 (956) 535 (2,909) 
Patient & Insurer Payment     
Median (IQR), $ 0 (3,670) 0 (2,080) 0 (3,988) 0 (0) 
Mean (SD) 3,424 (8,784) 3,046 (11,634) 3,861 (12,239) 1,842 (5,219) 
Outpatient Payments     
Patient Payment     
Median (IQR), $ 401 (682) 339 (576) 385 (665) 426 (683) 
Mean (SD) 668 (931) 537 (574) 619 (916) 590 (573) 
Patient & Insurer Payment     
Median (IQR), $ 2,133 (3,219) 2,023 (3,256) 2,121 (3,068) 2,136 (2,477) 
Mean (SD) 3,768 (6,868) 3,213 (3,547) 3,697 (5,187) 3,538,021 (5,555) 
Medication Payments     
Patient Payment     
Median (IQR), $ 213 (422) 198 (391) 182 (410) 238 (466) 
Mean (SD) 325 (352) 328 (373) 320 (390) 356 (394) 
Patient & Insurer Payment     
Median (IQR), $ 1,057 (2,310) 1,162 (2,362) 1,015 (2,310) 1,232 (2,431) 
Mean (SD) 1,739 (2,203) 1,943 (2,151) 1,888 (3,254) 1,953 (2,415) 
SOURCE: Aim1b Incident Diagnosis Design Sample 
All dollars are inflation adjusted to 2007 dollars using the Medical Consumer Price Index. 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
 
 
Payments made for medical care over one year following the patient's index diagnosis 
are summarized in Tables 4.30 and 4.31. Patient payments represent the total that the patient 
paid in copayments, coinsurance, and deductible payments. Patient and Insurer Payments 
represent the total payments made for services after applying pricing guidelines (fee 
schedules and discounts) but before applying deductibles, copayments, and coinsurance. 
Therefore, both the patient cost and the cost to the insurer are combined in this second cost 
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measure. When considering average payments for all patients, the mean patient medical 
payments ranged from $1,085 to $1,481 over the one year period following diagnosis. The 
mean total medical payments, when considering payments made by both patients and the 
insurance providers combined, ranged from $7,333 to $9,446.   
 When considering payments made by service users only, inpatient payments were 
highest for patients with Cyclothymic disorder (mean payment was $2,470). However, for all 
patient and insurer payments combined, inpatient services appeared to be slightly higher 
among patients with bipolar II disorder ($11,225).  
 
 
40Table 4.31 - Annual Payments for Medical Care by Service Type among Users,  
by Bipolar Subtype: Aim 1b 
 Bipolar I Bipolar II Bipolar NOS Cyclothymia* 
Inpatient Payments N = 331 N = 108 N = 458 N = 21 
Patient Payment 
    
Median (IQR), $ 520 (1,354) 477 (6,252) 433 (965) 758 (1,101) 
Mean (SD) 1,088 (1,780) 807 (1,092) 839 (1,471) 2,470 (5,967) 
Patient & Insurer Payment     
Median (IQR), $ 6,505 (8,501) 5,652 (6,481) 6,277 (7,454) 5,117 (6,203) 
Mean (SD) 10,715 (12,792) 11,225 (20,238) 11,078 (18,715) 8,509 (8,436) 
Outpatient Payments N = 1,026 N = 393 N = 1,307 N = 97 
Patient Payment     
Median (IQR), $ 406 (683) 344 (574) 387 (674) 426 (683) 
Mean (SD) 674 (933) 543 (575) 622 (917) 590 (573) 
Patient & Insurer Payment     
Median (IQR), $ 2,163 (3,249) 2,076 (3,234) 2,140 (3,063) 2,136 (2,477) 
Mean (SD) 3,804 (6,891) 3,253 (3,551) 3,717 (5,194) 3,538 (5,555) 
Medication Payments N = 923 N = 360 N = 1,148 N = 92 
Patient Payment     
Median (IQR), $ 260 (428) 231 (389) 235 (411) 262 (515) 
Mean (SD) 365 (352) 362 (376) 367 (397) 376 (395) 
Patient & Insurer Payment     
Median (IQR), $ 1,316 (2,303) 1,346 (2,334) 1,278 (2,459) 1,349 (2,416) 
Mean (SD) 1,952 (2,243) 2,148 (2,163) 2,161 (3,395) 2,059 (2,436) 
SOURCE: Aim1b Incident Diagnosis Design Sample 
All dollars are inflation adjusted to 2007 dollars using the Medical Consumer Price Index. 
Sample sizes represent the number of people who received the type of medical care described. 
* Cyclothymia is considered to be the mildest disorder on the bipolar spectrum. 
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4.3 Aim 2: Receipt of Appropriate First Line Therapy 
 
In order to address Aims 2 and 3 of the research plan, the aim 1b study sample was 
restricted to patients who were initially diagnosed with bipolar I disorder, those with no 
evidence of hospitalizations 60 days prior to or 45 days post diagnosis, and children under 
the age of 6 years at the time of their diagnosis. Rationale regarding the use of these inclusion 
and exclusion criteria is provided in Chapter 3.  After all exclusions, there were 730 patients 
remaining for aim 2 and aim 3 analyses.  
 
11Figure 4.6 - Inclusion and Exclusion Criteria: Aims 2 and 3 
 
 Table 4.32 provides basic frequency information for patient and provider 
characteristics by the type of care received, and overall. Based on the unadjusted frequencies, 
it appears that patients who received guideline recommended care were more likely to be in a 
N= 1,809 
N= 2,845  Initial Sample from Aim 1b 
N= 1,036 
N= 289 
N= 747 
N= 17 
N= 730 
 Exclude patients with initial diagnoses of 
Bipolar Unspecified, Bipolar II, or 
Cyclothymic Disorder. 
 Exclude patients with hospitalizations 60 
days prior or 45 days post index diagnosis 
 Exclude patients under the age of 6 
years at the time of index diagnosis  
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younger age group (31.7% vs. 23.9%) and were less likely to be female (46.7% versus 
52.5%). They were more likely to be diagnosed with bipolar I mixed episode type (53.3% vs. 
40.2%), and less likely to be diagnosed with a generic bipolar type (8.3% versus 20.0%). 
They were also less likely to have a diagnosis for a depressive disorder (major depressive 
disorder or dysthymic disorder, 13.3% versus 22.3%) at or prior to their bipolar diagnosis. 
Patients who received guideline recommended care also appeared to have been more likely to 
have received care by a psychiatrist (61.7% versus 40.3%), and less likely to receive care by 
a non-psychiatric mental health provider (8.3% versus 25.2%). Finally, patients who received 
guideline recommended care appeared to be slightly more likely to have treatment plans that 
included psychotherapy (71.7% versus 64.4%).  
 Table 4.33 provides information about the treatments received among those with and 
without recommended care. Among those who received recommended care, 55.8% received 
antipsychotics, 32.5% received anticonvulsants, and 11.7% received lithium. There were 66 
children (10.8%) that received non-recommended anticonvulsants. These medications were 
used as monotherapy but were not recommended by the guidelines because of a lack of 
evidence for their use in children. Sensitivity analysis of an expanded guideline definition 
included these children as receiving appropriate care, but the primary analysis did not.  
 Among patients who did not receive the recommended treatments, a majority       
received no psychotropic medications (40.2%) and 25.2% received antidepressant 
monotherapy. Approximately 14% of children received combination therapy at treatment 
initiation.  
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41Table 4.32- Patient and Physician Characteristics by Type of Care Received and Overall: Aim 2 
SOURCE: Aim 2 Study Sample 
* Only patients who had mental health / substance abuse coverage information provide to MarketScan 
were included for this variable. Those without coverage were categorized as unknown. 
 
 
 
 
 
  
All Patients Guideline Concordant 
Guideline 
Discordant 
  
N = 730 N = 120 N = 610 
Patient Characteristics       
Age - Mean (SD) 13.9 (2.9) 13.5 (3.4) 13.9 (2.8) 
6 - 12 Years 184 (25.2) 38 (31.7) 146 (23.9) 
13 - 17 Years 546 (74.8) 82 (68.3) 464 (76.1) 
Sex - N (%) Female 376 (51.5) 56 (46.7) 320 (52.5) 
Bipolar I Episode Type    
Bipolar I Mania 103 (14.1) 18 (15.0) 85 (13.9) 
Bipolar I Depression 186 (25.5) 28 (23.3) 158 (25.9) 
Bipolar I Mixed Episode 309 (42.3) 64 (53.3) 245 (40.2) 
Generic Bipolar I  132 (18.1) 10 (8.3) 122 (20.0) 
Comorbid Mental Health Diagnoses at Visit    
Attention Deficit Hyperactivity Disorder 144 (19.7) 22 (18.3) 122 (20.0) 
Other Disruptive Behavioral Disorders 61 (8.4) 13 (10.8) 48 (7.9) 
Anxiety Disorders 45 (6.2) 8 (6.7) 37 (6.1) 
Depressive Disorders 152 (20.8) 16 (13.3) 136 (22.3) 
Disease Severity    
Prior Comorbid Mental Health Conditions - Mean (SD) 0.67 (0.79) 0.60 (0.71) 0.68 (0.81) 
Unique Diagnoses Prior to Bipolar Visit - Mean (SD) 4.5 (3.1) 4.5 (3.2) 4.5 (3.1) 
Inpatient Mental Health Visits in Year 64 (8.8) 13 (10.8) 51 (8.4) 
Psychosis Present at Visit 58 (7.9) 13 (10.8) 45 (7.4) 
Physician Specialty    
Psychiatrist 320 (43.8) 74 (61.7) 246 (40.3) 
Primary Care / M.D. 133 (18.2) 21 (17.5) 112 (18.4) 
Other Mental Health  164 (22.5) 10 (8.3) 154 (25.2) 
Other / Unclassified 105 (14.4) 15 (12.5) 90 (14.7) 
Treatment Plan Included Psychotherapy*    
Yes 479 (65.6) 86 (71.7) 393 (64.4) 
No  125 (17.1) 14 (11.7) 111 (18.2) 
Unknown 126 (17.3) 20 (16.7) 106 (17.4) 
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42Table 4.33 Drug Class Use by  guideline Concordance Status 
Medication Class Use - Guideline Concordant Care N = 120 
Lithium 14 (11.7) 
Anticonvulsants 39 (32.5) 
Antipsychotics 67 (55.8) 
Medication Class Use - Guideline Discordant Care N = 610 
No Medications in 90 Days 245 (40.2) 
Single Class Use  
Non-Recommended Anticonvulsant 66 (10.8) 
Non-Recommended Antipsychotic 0 (0.0) 
Antidepressant 154 (25.2) 
Stimulant 62 (10.2) 
Combination Therapy  
Lithium + Anticonvulsant 1 (0.16) 
Mood Stabilizer and Antipsychotic 16 (2.6) 
Mood Stabilizer and Antidepressant 20 (3.3) 
Mood Stabilizer and Stimulant 1 (0.16) 
Antipsychotic and Antidepressant 19 (3.1) 
Antipsychotic and Stimulant 7 (1.1) 
Antidepressant and Stimulant 10 (1.6) 
Three or More Classes  
Mood Stabilizer, Antipsychotic and Antidepressant 5 (0.82) 
Mood Stabilizer, Antipsychotic and Stimulant 2 (0.33) 
Mood Stabilizer, Antidepressant and Stimulant 2 (0.33) 
SOURCE: Aim 2 Study Sample 
Mood stabilizer category includes both lithium and anticonvulsants. 
 
 To assess the extent to which appropriate treatment was received over time, the 
assessment period was expanded to look at treatments over three timeframes: 90 days, 180 
days, and 1 year. This was done to determine to what extent delays in treatment were 
influencing our classification of appropriate or inappropriate care. Figure 4.7 presents the 
type of care received over the three time points using the primary guideline concordance 
definition (only patients who received the medications listed as acceptable were considered 
guideline concordant). Figure 4.8 uses an expanded version of the guideline (including any 
monotherapy lithium, antipsychotic or anticonvulsant as acceptable).  
 
  
160
 
 
12Figure 4.7- Treatments Received After Initial Diagnosis of Bipolar I Disorder: 
3 Months, 6 Months and One Year 
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SOURCE: Aim 2 Study Sample 
Recommended drugs include only those identified as acceptable in the 2005 or 2007 guidelines 
(Lithium, divalproex, carbamazepine, olanzapine, quetiapine, risperidone, ziprasidone or 
aripiprazole). 
 
 When considering the more restrictive definition of guideline concordant care, and 
the 90 day timeframe, only 16% of children received the recommended care (Figure 4.7). By 
expanding the timeframe to 180 days, and 1 year, we saw only a slight increase in the 
proportion of children who received recommended care (19.7% at one year). By one year, 
approximately 25% of children had no medication, and over 55% received non-
recommended treatments. 
 Even when considering the less restrictive definitions for guideline concordant care 
(where all monotherapy lithium, antipsychotic or anticonvulsant treatments were acceptable), 
a majority receive non-recommended treatments (46% at one year), with only 29.3% 
receiving approved therapies in the same timeframe (Figure 4.8).  
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13Figure 4.8 - Treatments Received After Initial Diagnosis of Bipolar I Disorder:  
3 Months, 6 Months and One Year - Sensitivity Analysis 
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SOURCE: Aim 2 Study Sample 
Recommended drugs include Lithium, any anticonvulsant monotherapy or any atypical antipsychotic 
monotherapy. 
 
 
 
 Unadjusted estimates of the risk of receiving guideline recommended care are 
provided in Table 4.34. Three definitions of guideline recommended care were considered:  
(1) explicit definition of guideline recommended care and non-recommended - only 
medications specifically recommended by guidelines, appropriate pharmacotherapy received; 
(2) expanded definition of guideline recommended care and non-recommended - any 
anticonvulsant or antipsychotic monotherapy considered appropriate; (3) guideline 
recommended and non-recommended, among only patients who received medication - 
explicit definition for recommended care, exclusion of patients who did not use medications 
(comparison of appropriate and inappropriate care among medications users). Corresponding 
risk ratios (crude and adjusted) are provided in Tables 4.35 - 4.37. 
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43Table 4.34 - Risk of Receipt of Guideline Recommended Care by Guideline Definition:  
Aim 2, Unadjusted Estimates of Risk 
  Proportion Receiving Recommended Care 
  
Guideline 
Recommended Care 
Expanded Guideline 
Definition 
Medication Users 
Only 
  
N = 120 Concordant 
N = 610 Discordant 
N = 184 Concordant 
N = 546 Discordant 
N = 120 Concordant 
N = 367 Discordant 
Categorical Variables       
Sex       
Female 0.149 0.261 0.220 
Male 0.181 0.243 0.276 
Insurance Generosity*       
Good -- -- 0.288 
Fair -- -- 0.224 
Bipolar I Episode Type       
Bipolar I Mania 0.175 0.282 0.273 
Bipolar I Depression 0.150 0.242 0.228 
Bipolar I Mixed Episode 0.207 0.317 0.296 
Generic Bipolar I  0.076 0.091 0.122 
Comorbid Mental Health Diagnoses at Visit      
Attention Deficit Hyperactivity Disorder 0.153 0.201 0.206 
Other Disruptive Behavioral Disorders 0.213 0.295 0.317 
Depressive Disorders 0.105 0.178 0.134 
Disease Severity       
Inpatient Mental Health Visits in Year 0. 203 0.312 0.271 
Psychosis Present at Visit 0.224 0.362 0.289 
Physician Specialty       
Primary Care / M.D. 0.158 0.233 0.244 
Other Mental Health  0.061 0.116 0.120 
Other / Unclassified 0.143 0.200 0.197 
Psychiatrist 0.231 0.353 0.306 
Continued    
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44Table 4.34 - Risk of Receipt of Guideline Recommended Care by Guideline Definition:  
Aim 2, Unadjusted Estimates of Risk (Continued) 
  Proportion Receiving Recommended Care 
  
Guideline 
Recommended Care 
Expanded Guideline 
Definition 
Medication Users 
Only 
  
N = 120 Concordant 
N = 610 Discordant 
N = 184 Concordant 
N = 546 Discordant 
N = 120 Concordant 
N = 367 Discordant 
Categorical Variables       
Treatment Plan Included Psychotherapy       
Yes 0.179 0.273 0.251 
Continuous Variables Estimate (β) Estimate (β) Estimate (β) 
Age -0.0057 0.0023 -0.0113 
Unique Diagnoses Prior to Bipolar Visit 0.0004 -0.0010 -0.0004 
SOURCE: Aim 2 Study Sample 
Unadjusted proportions (risks) were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables. 
*Insurance generosity is only considered in the medication use analysis.  
 
 
 
  
164
 
Primary Outcome Model Results - Aim 2 
 Crude and adjusted risk ratio estimates for the primary outcome model are provided 
in Table 4.35. This model defines guideline recommended care as the receipt of only those 
medications specifically recommended by guidelines. Patients with no medications or those 
with non-recommended medications were classified as receiving inappropriate therapy in 
this analysis. 
 When considering the unadjusted results, five variables were statistically significantly 
related to the receipt of guideline recommended care (Table 4.35). These were having a 
episode type coded as bipolar I mania, bipolar I depression, or bipolar I mixed (as compared 
with having a generic code for bipolar disorder; having a depressive disorder on or before 
the initial bipolar diagnosis, and receiving a diagnosis from a non-psychiatric mental health 
provider. In the adjusted model, each of these variables were significant at the p < 0.10 
level, and three were significant at a p < 0.05 level. These were bipolar I mixed episode type 
(RR: 2.21, 95%CI: 1.15, 4.20), having a depressive disorder on or before the initial bipolar 
diagnosis (RR: 0.60, 95%CI: 0.36, 0.98), and receiving a diagnosis from a non-psychiatric 
mental health provider (RR: 0.28, 95%CI: 0.15, 0.53).  
Sensitivity Analysis Results - Part 1, Aim 2 
 Crude and adjusted risk ratio estimates for the first sensitivity analysis of aim 2 are 
presented in Table 4.36. This model defines guideline recommended care as the receipt of 
any monotherapy mood stabilizer or antipsychotic medication. Patients with no medications 
or those with non-recommended medications were classified as receiving inappropriate 
therapy in this analysis.  
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When considering the unadjusted results (Table 4.36), eight variables were 
statistically significantly related to the receipt of guideline recommended care once the 
definition for guideline recommended care was expanded. In the unadjusted model, the 
bipolar episode type (manic, depressive, or mixed), and the presence of psychosis at the 
time of diagnosis was associated with a higher likelihood of receiving recommended 
treatment. Depressive disorders on or before the index bipolar diagnosis reduced the 
likelihood that a patient would receive recommended treatment, as did receiving a diagnosis 
from any non-psychiatric provider.  
The adjusted results remained somewhat consistent with the crude analysis results; 
however, after adjustment, psychosis was no longer a statistically significant predictor of 
receiving guideline recommended treatment, and the presence of inpatient mental health 
days became a statistically significant predictor (RR: 1.58, 95% CI: 1.11, 2.24). In the 
adjusted model, as in the crude, each of the bipolar episode types were associated with 
receiving recommended first line therapy (as compared with receiving a generic bipolar 
diagnosis type). The corresponding risk ratios were 2.83 (95%CI: 1.52, 5.26) for bipolar I 
mania, 2.28 (95%CI: 1.26, 4.12) for bipolar I depression, and 2.85 (95%CI: 1.62, 5.03) for 
bipolar I mixed episode type. Having a co-morbid diagnosis for attention deficit 
hyperactivity disorder or a depressive disorder decreased a patient's likelihood of receiving 
recommended treatment (RR: 0.65, 95% CI: 0.46, 0.92, and RR: 0.61, 95%CI: 0.42, 0.87, 
respectively). Finally, two provider types were associated with a lower likelihood of 
receiving recommended first line treatment. These were non-psychiatric mental health 
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professionals (RR: 0.35, 95%CI: 0.22, 0.54), and Other / Unclassified professionals (RR: 
0.59, 95%CI: 0.40, 0.89).  
Sensitivity Analysis Results - Part 2, Aim 2 
The final model for aim 2 utilized the same definition for guideline recommended 
first line treatment as the primary outcome measure. However, patients were categorized as 
receiving guideline non-recommended treatment only if they received a non-recommended 
drug. In this case, patients who received no medications were excluded from the analysis.  
Crude and adjusted risk ratio estimates for this model are provided in Table 4.37.  
 In the unadjusted model, there were four predictors that were related to receipt of 
recommended first line therapy. These were having a diagnosis for bipolar I mania, or 
bipolar I mixed episode type, having a depressive disorder at the time of bipolar diagnosis, 
and receiving the diagnosis from a non-psychiatric mental health provider. In the adjusted 
model, each of these factors was identified as being statistically significantly related to the 
outcome, with the exception of bipolar I manic episode type (p = 0.07).  
Summary of Aim 2 Results 
A-priori hypotheses regarding the receipt of appropriate care were that patients who 
received guideline discordant care were more likely to: 
• have a younger age of diagnosis (H02a) 
• be male (H02b) 
• have more generous insurance benefits (H02c) 
• have co-morbid mental health conditions (H02d) 
• have higher levels of disease severity (H02e) 
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• have an initial diagnosis of bipolar I depressed episode (H02f) 
• have treatment plans that exclude psychotherapy or counseling (H02g) 
• have received their diagnosis from a provider other than a psychiatrist (H02h)   
 
Across all three guideline concordance definitions, there were several variables that 
were consistently related (either positively or negatively associated) to the receipt of 
guideline recommended care (Tables 4.35 - 4.37). These were having a diagnosis code for 
bipolar I mixed type episode, having a depressive disorder diagnosis (major depressive 
disorder or dysthymic disorder) on or prior to bipolar diagnosis, and receiving care by a non-
psychiatric mental health professional. 
Patient age was not related to the receipt of guideline recommended care in any of the 
models (crude or adjusted) for any definition of the outcome. Sex was also unrelated in the 
crude and adjusted analyses. Similarly, the generosity of a patient's insurance benefits did not 
appear to be related to the receipt of guideline appropriate care, although it is important to 
note that this variable was only considered for the Medication Users sensitivity analysis 
(Table 4.37).  
The influence of comorbid mental health conditions was more complex than 
originally anticipated. Previous studies have suggested that ADHD and other disruptive 
disorders could be combined into a single category. However, we found that these disorders 
differed in their relationships to the outcome. We found that ADHD was related to a lower 
likelihood of receiving recommended care (marginally significant in the adjusted model for 
the original definition, and statistically significant in the other models at a p < 0.10).  
Surprisingly, the other disruptive disorders (oppositional defiant disorder and conduct 
  
168
 
disorder, combined) were associated with a higher likelihood of receiving recommended care 
for all comparisons (although this finding was not statistically significant).  
Of the mental health comorbidities, the presence of depressive disorders on or before 
bipolar diagnosis was related to a lower likelihood of receiving recommended care. This 
relationship was consistent across all models. Using the primary outcome definition of 
guideline recommended care (Table 4.35), the adjusted estimate for the effect of depressive 
disorder comorbidities was RR: 0.60 (95%CI: 0.36, 0.98). This indicated that patients with 
existing or comorbid diagnoses of major depressive disorder or dysthymic disorder were 40% 
less likely to receive recommended care as those without these comorbidities.    
When considering the role of disease severity, three indicators were used: number of 
unique diagnoses prior to the bipolar diagnosis, any inpatient mental health visits during the 
study period, and psychosis at initial presentation. The first of these indicators, number of 
unique diagnoses, was not significantly related to the receipt of recommended care in any 
model tested. When considering the role of inpatient mental health visits, it appeared that 
patients who had inpatient mental health visits were more likely to receive recommended 
care when considering the primary outcome definition (Table 4.35, RR: 1.53, 95%CI: 0.95, 
2.47) and the expanded definition (Table 4.36, RR: 1.58, 95%CI: 1.11, 2.24); although some 
estimates were not statistically significant. Similarly, the presence of psychosis also appeared 
to increase the likelihood of receiving guideline recommended care (Table 4.35, RR: 1.18, 
95%CI: 0.71, 1.96; primary outcome definition, adjusted model) but this result was not 
statistically significant in any model. It is important to note that there were only a small 
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number of patients who had inpatient visits or the presence of psychosis, likely one reason 
for the variability in the estimates.  
The role of the initial episode type indicated that patients with coding for specific 
bipolar I episode types were more likely to receive recommended care than those with a 
generic bipolar diagnosis (ICD-9 codes 296.0x or 296.1x). The risk ratio for receiving 
recommended care for the primary outcome definition (Table 4.35, adjusted estimates) was 
1.97 (95%CI: 0.94, 4.13) for patients with bipolar I manic type episode, 1.80 (95%CI: 0.91, 
3.56) for patients with bipolar I depressed type episode, and 2.21 (95%CI: 1.16, 4.20) for 
patients with mixed type episodes.  
Use of psychotherapy in a patients' treatment plan also appeared to be positively 
related to the use of guideline recommended care. The risk ratio for receiving recommended 
care for the primary outcome definition was 1.44 (95%CI: 1.00, 2.09), and that for the 
expanded outcome definition was 1.31 (95%CI: 1.00, 1.72). However, use of psychotherapy 
was not statistically related to the receipt of guideline recommended care when restricting to 
patients with medication use only (Table 4.37).   
Finally, when comparing the type of provider that initiated treatment, it appeared that 
receiving guideline recommended care was much more likely if a patient received treatment 
from a psychiatrist. Using psychiatry as the reference group, the risk ratio for receiving 
recommended care was lower among all other specialties as compared with psychiatry, 
although most estimates were not statistically significant. Perhaps most notably, the 
probability of receiving recommended care was lowest among non-psychiatric mental health 
professionals. This was true across all comparisons, even those that considered only 
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medication users (non-users were excluded). The risk ratio for receiving recommended care 
was 0.28 (95% CI: 0.15, 0.53, primary guideline definition, adjusted estimate) for other 
mental health providers, as compared with psychiatrists. This indicates that patients who 
received care from a non-psychiatric mental health provider were 72% less likely to receive 
guideline recommended care as those who received their treatment from a psychiatrist. When 
looking among medication users only, patients who see a non-psychiatric mental health 
provider were 53% less likely to receive recommended care (Adjusted RR: 0.47, 95%CI: 
0.25, 0.86).  
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45Table 4.35- Risk Ratio for Receipt of Guideline Recommended Care: Aim 2 Primary Guideline Definition 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Sex       
Female 0.82 (0.59, 1.14) 0.247 0.96 (0.69, 1.33) 0.794 
Male 1.00 REF  1.00 REF  
Bipolar I Episode Type       
Bipolar I Mania 2.31 (1.11, 4.78) 0.025 1.97 (0.94, 4.13) 0.072 
Bipolar I Depression 1.99 (1.00, 3.95) 0.050 1.80 (0.91, 3.56) 0.093 
Bipolar I Mixed  2.73 (1.45, 5.16) 0.002 2.21 (1.16, 4.20) 0.015 
Generic Bipolar I  1.00 REF  1.00 REF  
Comorbid Mental Health Diagnoses at Visit     
Attention Deficit  
Hyperactivity Disorder 0.91 (0.60, 1.40) 0.677 0.72 (0.47, 1.11) 0.135 
Other Disruptive  
Behavioral Disorders 1. 33 (0.79, 2.22) 0.272 1.20 (0.73, 1.97) 0.476 
Depressive Disorders 0. 58 (0.36, 0.96) 0.033 0.60 (0.36, 0.98) 0.043 
Disease Severity       
Inpatient Mental Health  
Visits in Year 1.26 (0.75, 2.12) 0.372 1.53 (0.95, 2.47) 0.079 
Psychosis Present at 
Visit 1.41 (0.85, 2.34) 0.188 1.18 (0.71, 1.96) 0.527 
Physician Specialty       
Primary Care / M.D. 0.68 (0.44, 1.06) 0.089 0.86 (0.55, 1.36) 0.526 
Other Mental Health  0.26 (0.14, 0.50) < 0.001 0.28 (0.15, 0.53) < 0.001 
Other / Unclassified 0.62 (0.37, 1.03) 0.064 0.67 (0.40, 1.12) 0.127 
Psychiatrist 1.00 REF  1.00 REF  
Continued       
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46Table 4.35- Risk Ratio for Receipt of Guideline Recommended Care: Aim 2 Primary 
Guideline Definition (Continued) 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Treatment Plan Included Psychotherapy      
Yes 1.32 (0.92, 1.91) 0.132 1.44 (1.00, 2.09) 0.050 
Continuous Variables 
Estimate (β) 95% CI Crude p-value 
Adjusted 
Estimate 
(β) 
95% CI Adjusted  p-value 
Age -0.0057 (-0.01, 0.00) 0.210 -0.040 (-0.09, 0.01) 0.132 
Diagnoses Prior to 
Bipolar Visit 0.0004 (-0.01, 0.01) 0.919 0.0123 (-0.04, 0.06) 0.639 
SOURCE: Aim 2 Study Sample 
Reference category for dichotomous variables is 0, condition not present.  
Crude risk ratios were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables.  
Adjusted risk ratios were calculated using a log binomial model, controlling for each variable listed above. 
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47Table 4.36- Risk Ratio for Receipt of Guideline Recommended Care: Aim 2 Expanded Guideline Definition 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Sex       
Female 1.07 (0.83, 1.38) 0.583 1.20 (0.94, 1.54) 0.150 
Male 1.00 REF  1.00 REF  
Bipolar I Episode Type       
Bipolar I Mania 3.10 (1.66, 5.77) <0.001 2.83 (1.52, 5.26) 0.001 
Bipolar I Depression 2.66 (1.47, 4.83) 0.001 2.28 (1.26, 4.12) 0.006 
Bipolar I Mixed 3.49 (1.98, 6.13) <0.001 2.85 (1.62, 5.03) < 0.001 
Generic Bipolar I  1.00 REF  1.00 REF  
Comorbid Mental Health Diagnoses at Visit     
Attention Deficit  
Hyperactivity Disorder 0. 76 (0.53, 1.08) 0.129 0.65 (0.46, 0.92) 0.015 
Other Disruptive  
Behavioral Disorders 1.19 (0.78, 1.79) 0.407 1.11 (0.76, 1.61) 0.586 
Depressive Disorders 0.65 (0.45, 0.94) 0.023 0.61 (0.42, 0.87) 0.006 
Disease Severity       
Inpatient Mental Health  
Visits in Year 1.27 (0.86, 1.87) 0.227 1.58 (1.11, 2.24) 0.010 
Psychosis Present at Visit 1.49 (1.03, 2.15) 0.032 1.30 (0.91, 1.86) 0.149 
Physician Specialty       
Primary Care / M.D. 0.66 (0.47, 0.93) 0.017 0.84 (0.60, 1.18) 0.308 
Other Mental Health  0.33 (0.21, 0.51) < 0.001 0. 35 (0.22, 0.54) < 0.001 
Other / Unclassified 0.57 (0.38, 0.85) 0.007 0.59 (0.40, 0.89) 0.011 
Psychiatrist 1.00 REF  1.00 REF  
Continued       
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48Table 4.36- Risk Ratio for Receipt of Guideline Recommended Care: Aim 2 Expanded Guideline 
Definition (Continued) 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Treatment Plan Included Psychotherapy      
Yes 1.29 (0.98, 1.71) 0.070 1.31 (1.00, 1.72) 0.052 
Continuous Variables 
Estimate (β) 95% CI Crude  p-value 
Adjusted 
Estimate 
(β) 
95% CI Adjusted  p-value 
Age 0.0023 (-0.01, 0.01) 0.665 0.001 (-0.04, 0.04) 0.942 
Diagnoses Prior to 
Bipolar Visit -0.0010 (-0.01, 0.01) 0.836 0.005 (-0.04, 0.05) 0.829 
SOURCE: Aim 2 Study Sample 
Reference category for dichotomous variables is 0, condition not present.  
Crude risk ratios were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables.  
Adjusted risk ratios were calculated using a log binomial model, controlling for each variable listed above. 
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49Table 4.37- Risk Ratio for Receipt of Guideline Recommended Care: Aim 2, Medication Users Only 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Sex       
Female 0. 80 (0.58, 1.09) 0.151 0.94 (0.68, 1.30) 0.726 
Male 1.00 REF   1.00 REF  
Insurance Generosity          
Good 1.29 (0.94, 1.76) 0.111 1.11 (0.81, 1.53) 0.521 
Fair 1.00 REF   1.00 REF  
Bipolar I Episode Type          
Bipolar I Mania 2.34 (1.11, 4.51) 0.025 1.95 (0.95, 3.98) 0.067 
Bipolar I Depression 1.87 (0.96, 3.63) 0.066 1.88 (0.97, 3.64) 0.063 
Bipolar I Mixed  2.43 (1.31, 4.50) 0.005 2.16 (1.15, 4.04) 0.017 
Generic Bipolar I  1.00 REF   1.00 REF  
Comorbid Mental Health Diagnoses at Visit  
    
  
Attention Deficit  
Hyperactivity Disorder 0.80 (0.53, 1.21) 0.278 0.68 (0.45, 1.03) 0.068 
Other Disruptive  
Behavioral Disorders 1.32 (0.82, 2.13) 0.253 1.21 (0.74, 1.97) 0.442 
Depressive Disorders 0.48 (0.29, 0.77) 0.003 0.50 (0.30, 0.84) 0.008 
Disease Severity          
Inpatient Mental Health  
Visits in Year 1.11 (0.68, 1.82) 0.675 1.38 (0.87, 2.20) 0.174 
Psychosis Present at Visit 1.19 (0.73, 1.94) 0.477 1.06 (0.65, 1.74) 0.812 
Physician Specialty          
Primary Care / M.D. 0.80 (0.53, 1.21) 0.291 0.97 (0.62, 1.51) 0.879 
Other Mental Health  0.39 (0.21, 0.73) 0.003 0.47 (0.25, 0.86) 0.015 
Other / Unclassified 0.64 (0.39, 1.05) 0.081 0.71 (0.43, 1.15) 0.166 
Psychiatrist 1.00 REF   1.00 REF  
Continued       
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50Table 4.37- Risk Ratio for Receipt of Guideline Recommended Care: Aim 2, Medication Users Only 
(Continued) 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Treatment Plan Included Psychotherapy 
      
  
Yes 1.06 (0.75, 1.50) 0.734 1.10 (0.70, 1.72) 0.685 
Continuous Variables Estimate (β) 95% CI 
Crude  
p-value 
Adjusted 
Estimate 
(β) 
95% CI Adjusted  p-value 
Age -0.0113 (-0.02, 0.00) 0.091 -0.043 (-0.09, 0.00) 0.064 
Diagnoses Prior to Bipolar 
Visit -0.0004 (-0.01, 0.01) 0.946 0.018 (-0.03, 0.06) 0.454 
SOURCE: Aim 2 Study Sample 
Reference category for dichotomous variables is 0, condition not present.  
Crude risk ratios were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables. 
 Adjusted risk ratios were calculated using a log binomial model, controlling for each variable listed above. 
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4.4 Aim 3: Receipt of Early Treatment Changes 
 
In order to address Aim 3 of the research plan, patients who did not receive any 
medications within 90 days of their initial bipolar diagnosis were excluded from the initial 
sample for Aims 2 and 3. After excluding patients who did not have medication use, there 
were 487 patients available for the analyses. 
Three samples were used for Aim 3 analysis. The primary analysis used a 6-week 
timeframe to assess medication therapy changes. Additionally, this definition required that 
patients only be included if they had continuous medication therapy over the 6 week 
timeframe (more than one medication fill and/or more than 42 days of medication supply, N 
= 375). A secondary analysis was conducted in which patients who discontinued therapy 
early were considered to have received non-recommended care (early treatment regimen 
changes, N = 486). Finally, the primary analysis was revised to consider early medication 
changes over the first four weeks of therapy (rather than 6 weeks), as guidelines recommend 
medication therapy to last between 4 and 6 weeks (N = 470).   
Patients who continued therapy were similar to those who discontinued therapy, with 
the exception of one predictor. Those who discontinued early were less likely to have 
antidepressants as part of their initial treatment regimen as compared with those who 
continued therapy (Crude RR: 0.63, 95%CI: 0.44, 0.90).  
Table 4.38 provides basic frequency information for patient and provider 
characteristics by the type of care received and overall for patients included in the primary 
analysis for Aim 3. Based on the unadjusted frequencies, it appeared that patients who 
discontinued early were  less likely to have a generic bipolar diagnosis. They were also more 
  
178
 
likely to have comorbid Attention Deficit Hyperactivity Disorder or Other Disruptive 
Behavioral disorders and less likely to have a depressive disorder at the time of their bipolar 
diagnosis. Overall, it appeared that disease severity measures did not differ between those 
who received the recommended time on treatment and those that did not, with the exception 
of the presence of psychosis. Patients who received early treatment regimen changes were 
more likely to have psychosis than those who did not. Finally, it appeared that having 
psychotherapy as part of the treatment plan was related to having early regimen changes. 
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51Table 4.38- Patient and Physician Characteristics by Type of Care Received and Overall: Aim 3 
  All Patients 
Guideline 
Concordant 
Guideline 
Discordant 
  N = 375 N = 222 N = 153 
Patient Characteristics       
Age - Mean (SD) 13.9 (2.9) 13.8 (2.9) 13.9 (3.0) 
6 - 11 Years 39 (10.4) 21 (9.5) 18 (11.8) 
12-14 Years 88 (23.5) 58 (26.1) 30 (19.6) 
15-17 Years 248 (66.1) 143 (64.4) 105 (68.6) 
Sex - N (%) Female 200 (53.3) 122 (54.9) 78 (51.0) 
Bipolar I Episode Type       
Bipolar I Mania 46 (12.3) 26 (11.7) 20 (13.1) 
Bipolar I Depression 99 (26.4) 56 (25.2) 43 (28.1) 
Bipolar I Mixed Episode 171 (45.6) 99 (44.6) 72 (47.1) 
Generic Bipolar I  59 (15.7) 41 (18.5) 18 (11.8) 
Comorbid Mental Health Diagnoses at Visit       
Attention Deficit Hyperactivity Disorder 89 (23.7) 44 (19.8) 45 (29.4) 
Other Disruptive Behavioral Disorders 27 (7.2) 11 (4.9) 16 (10.5) 
Anxiety Disorders 31 (8.3) 21 (9.5) 10 (6.5) 
Depressive Disorders 98 (26.1) 62 (27.9) 36 (23.5) 
Disease Severity       
Prior Comorbid Mental Health Conditions - Mean (SD) 0.79 (0.83) 0.75 (0.80) 0.86 (0.87) 
Unique Diagnoses Prior to Bipolar Visit - Mean (SD) 4.5 (2.8) 4.6 (2.9) 4.3 (2.6) 
Inpatient Mental Health Visits in Year 35 (9.3) 20 (9.0) 15 (9.8) 
Psychosis Present at Visit 32 (8.5) 14 (6.3) 18 (11.8) 
Physician Specialty       
Psychiatrist 187 (49.9) 112 (50.4) 75 (49.0) 
Primary Care Physician / M.D. 56 (14.9) 36 (16.2) 20 (13.1) 
Other Mental Health Professional 68 (18.1) 38 (17.1) 30 (19.6) 
Other / Unclassified 64 (17.1) 36 (16.2) 28 (18.3) 
Treatment Plan Included Psychotherapy       
Yes 269 (71.7) 154 (69.4) 115 (75.2) 
No  53 (14.1) 34 (15.3) 19 (12.4) 
Unknown* 48 (12.8) 31 (14.0) 17 (11.1) 
SOURCE: Aim 3 Study Sample, primary outcome definition. 
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52Table 4.39- Medication Regimen at Treatment Initiation by Type of Care Received and Overall: Aim 3 
  All Patients 
Guideline 
Concordant 
Guideline 
Discordant 
  N = 375 N = 222 N = 153 
Initially Prescribed Therapy       
Lithium in Initial Regimen 18 (4.8) 9 (4.0) 9 (5.9) 
Monotherapy Only 10 (55.5) 4 (44.4) 6 (66.7) 
Anticonvulsant in Initial Regimen 114 (30.4) 60 (27.0) 54 (35.3) 
Monotherapy Only 64 (56.1) 35 (58.3) 29 (53.7) 
Antipsychotic in Initial Regimen 103 (27.5) 58 (26.1) 45 (29.4) 
Monotherapy Only 46 (44.7) 29 (50.0) 17 (37.8) 
Antidepressant in Initial Regimen 177 (47.2) 108 (48.6) 69 (45.1) 
Monotherapy Only 104 (58.8) 67 (62.0) 37 (53.6) 
Stimulant in Initial Regimen 73 (19.5) 44 (19.8) 29 (18.9) 
Monotherapy Only 42 (57.5) 27 (61.4) 15 (51.7) 
* Among patients who had continuous therapy over the first 6 weeks, primary outcome definition.  
 
 
Table 4.39 provides a summary of initially prescribed treatment regimens for patients 
in the primary analysis. Overall, the most commonly prescribed class of psychotropic 
medications were antidepressants. Approximately 47% of all patients received an 
antidepressant in their initial therapy, and nearly 60% of those patients received monotherapy 
antidepressant treatment. Patients who had early regimen changes appeared to be more likely 
to have initial therapies that included anticonvulsants or antipsychotics, as compared with 
those who did not have early regimen changes. The patients who had early regimen changes 
were also less likely to have initially prescribed antidepressants.    
 Table 4.40 provides information on the risk of receiving an early treatment regimen 
change by the population studied. Risk of changes were highest when using the 6 week 
timeframe and when classifying those who did not have continuous therapy as receiving non-
recommended care. The risk estimates were lowest when using the 4 week discontinuation 
definition as a majority of patients had medication coverage during that time and regimen 
changes in this timeframe were less common.
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53Table 4.40 - Risk of Receipt of Early Treatment Regimen Changes by Population Selected: Aim 3,  
Unadjusted Estimates of Risk 
  Proportion Receiving Early Regimen Changes 
  
Changes in 6 Weeks, 
Continuous Users 
Changes in 6 Weeks, 
All Users 
Changes in 4 Weeks, 
Continuous Users 
  
N = 222 Concordant 
N = 153 Discordant 
N = 221 Concordant 
N = 265 Discordant 
N = 378 Concordant 
N = 92 Discordant 
Categorical Variables       
Age    
6-11 Years 0. 461 0.571 0. 255 
12-14 Years 0.341 0.468 0.165 
15-17 Years 0.423 0.567 0.197 
Sex       
Female 0.390 0.520 0.183 
Male 0.429 0.573 0.210 
Insurance Generosity    
Good 0.447 0.554 0.233 
Fair 0.387 0.537 0.178 
Bipolar I Episode Type    
Bipolar I Mania 0.435 0.606 0.254 
Bipolar I Depression 0.434 0.541 0.231 
Bipolar I Mixed  0.421 0.546 0.192 
Generic Bipolar I  0.305 0.500 0.103 
Comorbid Mental Health Diagnoses at Visit   
Attention Deficit Hyperactivity Disorder 0.506 0.589 0.272 
Other Disruptive Behavioral Disorders 0.593 0.732 0.263 
Depressive Disorders 0.367 0.483 0.179 
Disease Severity    
Inpatient Mental Health Visits in Year 0.429 0.583 0.217 
Psychosis Present at Visit 0.562 0.689 0.238 
Continued    
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54Table 4.40 - Risk of Receipt of Early Treatment Regimen Changes by Population Selected: Aim 3,  
Unadjusted Estimates of Risk (Continued) 
 Proportion Receiving Early Regimen Changes 
  
Changes in 6 Weeks, 
Continuous Users 
Changes in 6 Weeks, 
All Users 
Changes in 4 Weeks, 
Continuous Users 
  
N = 222 Concordant 
N = 153 Discordant 
N = 221 Concordant 
N = 265 Discordant 
N = 378 Concordant 
N = 92 Discordant 
Non-Mental Health Professional 0. 400 0.553 0.192 
Mental Health Professional 0.412 0.541 0.197 
Treatment Plan Included Psychotherapy       
Yes 0.427 0.554 0.210 
Initial Treatment Characteristics    
Antidepressant at Initial Treatment 0.390 0.498 0.181 
Combination Therapy at Initial Treatment 0.453 0.453 0.221 
Continuous Variables Estimate (β) Estimate (β) Estimate (β) 
Unique Diagnoses Prior to Bipolar Visit -0.0192 0.0073 -0.0126 
Unadjusted proportions (risks) were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables. 
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Primary Outcome Model Results - Aim 3 
 Crude and adjusted risk ratio estimates for the primary outcome model are provided 
in Table 4.41. This model defines guideline recommended care as having no medication 
switching or augmenting within the first 6 weeks following initial bipolar I treatment. 
Patients who did not have continuous medication use over the 6 week period were excluded 
from this analysis. 
 When considering the unadjusted results, three variables were statistically 
significantly related to the receipt of guideline recommended care (Table 4.41). These were 
having comorbid attention deficit hyperactivity disorder (RR: 1.34, 95%CI: 1.04, 1.72), 
having other disruptive behavioral disorders (RR: 1.50, 95%CI: 1.07, 2.11), and having 
psychosis at the initial bipolar visit (RR: 1.43, 95%CI: 1.02, 1.99). After adjustment, 
however, only one factor remained statistically significantly related to the outcome at the p 
= 0.05 level (comorbid ADHD).  
Sensitivity Analysis Results - Part 1, Aim 3 
 Crude and adjusted risk ratio estimates for the first sensitivity analysis of aim 3 are 
presented in Table 4.42. Similar to the primary outcome model, this model defines guideline 
recommended care as having no medication switching or augmenting within the first 6 
weeks following initial bipolar I treatment. However, patients who did not have continuous 
medication use over the 6 week period were included in this model as having received 
guideline discordant care. 
When considering the unadjusted results (Table 4.42), only other behavioral disorders 
and psychosis were related to the likelihood of having early treatment regimen changes 
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(RR: 1.39, 95%CI: 1.13, 1.70, and RR: 1.30, 95%CI: 1.05, 1.61, respectively). In the 
adjusted model, only the presence of comorbid disruptive behavior disorders remained 
statistically significantly related to the outcome (RR: 1.30, 95%CI: 1.04, 1.63). 
Sensitivity Analysis Results - Part 2, Aim 3 
The final model for aim 3 utilized the same definition for guideline recommended 
first line treatment as the primary outcome measure, however treatment changes were 
evaluated within the first 4 weeks (rather than 6 weeks) for this analysis.  
 In the unadjusted model, there were three predictors that were related to receipt of 
recommended first line therapy. These were having a diagnosis for bipolar I mania, or 
bipolar I depressive episode type, and having a comorbid diagnosis for ADHD. In the 
adjusted model, two of these factors was identified as being statistically significantly related 
to the outcome (at p = 0.05). These were having an initial episode type coded as bipolar I 
mania (RR: 2.50, 95%CI: 1.12, 5.59), and having an initial episode type coded as bipolar I 
depression (RR: 2.37, 95%CI: 1.12, 5.02).   
Summary of Aim 3 Results 
A-priori hypotheses regarding the receipt of appropriate care were that patients who 
received guideline discordant care were more likely to: 
• have a younger age of diagnosis (H03a) 
• be male (H03b) 
• have less generous insurance benefits (H03c) 
• have co-morbid mental health conditions (H03d) 
• have higher levels of disease severity (H03e) 
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• have an initial diagnosis of bipolar I depressed episode (H02f) 
• have treatment plans that exclude psychotherapy or counseling (H02g) 
• have received their diagnosis from a non-mental health provider (H03h) 
• be initially prescribed an antidepressant (H03j)  
• use combination treatments(H03j) 
 
 
Across all models (6 week, continuous users only; 6 week, all users; 4 week, 
continuous users) patient age and sex were unrelated to the risk of early treatment regimen 
changes.  This was true for both the crude estimates and the adjusted estimates (Tables 4.41 - 
4.43).  Similarly insurance generosity, the type of provider, or having treatment plans that 
included psychotherapy, having an antidepressant in the initial medication regimen, or using 
combination therapy from initiation were not related to an increased risk of receiving early 
treatment changes.  
Regarding disease severity, having psychosis appeared to increase the risk of 
receiving early regimen changes in two of the crude models, but this result was inconsistent 
and not seen in the adjusted model. Initial bipolar subtype appeared to be unrelated to the 
receipt of early regimen changes, with the exception of the model that utilized a 4 week 
assessment period (Table 4.43). In this model, bipolar I depressive episode type and bipolar I 
manic episode type appeared to increase the risk of early treatment changes.  
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55Table 4.41- Risk Ratio for Receipt of Early Treatment Regimen Changes within the First 6 Weeks of Treatment -  
Medication Continuers Only: Aim 3 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Sex       
Female 0.91 (0.71, 1.16) 0.448 0.94 (0.73, 1.22) 0.660 
Male 1.00 REF  1.00 REF  
Insurance Generosity       
Good 1.15 (0.90, 1.47) 0.251 1.11 (0.86, 1.42) 0.426 
Fair 1.00 REF  1.00 REF  
Bipolar I Episode Type       
Bipolar I Mania 1.42 (0.86, 2.37) 0.171 1.23 (0.71, 2.14) 0.460 
Bipolar I Depression 1.42 (0.91, 2.22) 0.120 1.40 (0.89, 2.22) 0.146 
Bipolar I Mixed 
Episode 1.38 (0.90, 2.11) 0.136 1.30 (0.84, 2.02) 0.235 
Generic Bipolar I  1.00 REF  1.00 REF  
Comorbid Mental Health Diagnoses at Visit     
Attention Deficit  
Hyperactivity Disorder 1.34 (1.04, 1.72) 0.024 1.33 (1.01, 1.74) 0.040 
Other Disruptive  
Behavioral Disorders 1.50 (1.07, 2.11) 0.018 1.45 (0.98, 2.14) 0.062 
Depressive Disorders 0. 87 (0.65, 1.17) 0.352 0.95 (0.69, 1.31) 0.755 
Disease Severity       
Inpatient Mental Health  
Visits in Year 1.06 (0.70, 1.58) 0.797 1.12 (0.74, 1.70) 0.581 
Psychosis  1.43 (1.02, 1.99) 0.035 1.23 (0.85, 1.78) 0.273 
Continued       
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56Table 4.41- Risk Ratio for Receipt of Early Treatment Regimen Changes within the First 6 Weeks of 
Treatment - Medication Continuers Only: Aim 3 (Continued) 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Physician Specialty       
Non-Mental Health 
Professional 0.97 (0.75, 1.26) 0.829 1.06 (0.80, 1.40) 0.680 
Mental Health 
Professional 1.00 REF  1.00 REF  
Treatment Plan Included 
Psychotherapy      
Yes 1.19 ( 0.89, 1.59) 0.234 1.12 (0.83, 1.51) 0.440 
Initial Treatment 
Characteristics       
Antidepressant at Initial 
Treatment 0.92 (0.72, 1.17) 0.500 0.99 (0.74, 1.32) 0.930 
Combination Therapy at 
Initial Treatment 1.15 (0.88, 1.50) 0.829 1.02 (0.76, 1.38) 0.869 
Continuous Variables 
Estimate (β) 95% CI Adjusted  p-value 
Adjusted 
Estimate 
(β) 
95% CI Adjusted  p-value 
Age 0.013 (-0.01, 0.02) 0.985 -0.0121 (-0.05, 0.02) 0.514 
Crude risk ratios were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables.  
Adjusted risk ratios were calculated using a log binomial model, controlling for each variable listed above. 
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57Table 4.42- Risk Ratio for Receipt of Early Treatment Regimen Changes within the First 6 Weeks of Treatment -  
Full Study Population: Discontinuers Classified as Early Regimen Changes: Aim 3 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Sex       
Female 0.91 (0.77, 1.07) 0.236 0.95 (0.82, 1.09) 0.455 
Male 1.00 REF  1.00 REF  
Insurance Generosity       
Good 1.03 (0.87, 1.22) 0.716 1.01 (0.86, 1.17) 0.942 
Fair 1.00 REF  1.00 REF  
Bipolar I Episode Type       
Bipolar I Mania 1.21 (0.91, 1.62) 0.195 1.09 (0.81, 1.46) 0.566 
Bipolar I Depression 1.08 (0.82, 1.42) 0.569 1.07 (0.83, 1.39) 0.578 
Bipolar I Mixed  1.09 (0.85, 1.40) 0.484 1.03 (0.82, 1.31) 0.778 
Generic Bipolar I  1.00 REF  1.00 REF  
Comorbid Mental Health Diagnoses at Visit     
Attention Deficit  
Hyperactivity Disorder 1.10 (0.92, 1.33) 0.289 1.10 (0.92, 1.30) 0.300 
Other Disruptive  
Behavioral Disorders 1.39 (1.13, 1.70) 0.002 1.30 (1.04, 1.63) 0.021 
Depressive Disorders 0.85 (0.69, 1.05) 0.137 0.91 (0.75, 1.11) 0.356 
Disease Severity       
Inpatient Mental Health  
Visits in Year 1.08 (0.84, 1.39) 0.562 1.07 (0.84, 1.37) 0.587 
Psychosis  1.30 (1.05, 1.61) 0.017 1.17 (0.94, 1.45) 0.151 
Continued       
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58Table 4.42- Risk Ratio for Receipt of Early Treatment Regimen Changes within the First 6 Weeks of 
Treatment - Full Study Population: Discontinuers Classified as Early Regimen Changes: Aim 3 
(Continued) 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Physician Specialty       
Non-Mental Health 
Professional 1.02 (0.86, 1.21) 0.814 1.03 (0.88, 1.22) 0.689 
Mental Health 
Professional 1.00 REF  1.00 REF  
Treatment Plan Included Psychotherapy      
Yes 1.06 (0.88, 1.27) 0.558 1.03 (0.87, 1.22) 0.719 
Initial Treatment 
Characteristics       
Antidepressant at Initial 
Treatment 0.85 (0.72, 1.01) 0.067 0.95 (0.80, 1.14) 0.605 
Combination Therapy at 
Initial Treatment 0.80 (0.63, 1.01) 0.061 0.84 (0.68, 1.03) 0.096 
Continuous Variables 
Estimate (β) 95% CI Adjusted  p-value 
Adjusted 
Estimate 
(β) 
95% CI Adjusted  p-value 
Age 0.0073 (-0.01, 0.02) 0.356 0.024 (-0.00, 0.05) 0.101 
Crude risk ratios were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables.  
Adjusted risk ratios were calculated using a log binomial model, controlling for each variable listed above. 
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59Table 4.43- Risk Ratio for Receipt of Early Treatment Regimen Changes within the First 4 Weeks of Treatment -  
Medication Continuers Only: Aim 3 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Sex       
Female 0.87 (0.60, 1.26) 0.267 0.97 (0.66, 1.42) 0.876 
Male 1.00 REF  1.00 REF  
Insurance Generosity       
Good 1.31 (0.91, 1.88) 0.152 1.20 (0.82, 1.76) 0.341 
Fair 1.00 REF  1.00 REF  
Bipolar I Episode Type       
Bipolar I Mania 2.47 (1.13, 5.41) 0.023 2.50 (1.12, 5.59) 0.025 
Bipolar I Depression 2.26 (1.08, 4.69) 0.029 2.37 (1.12, 5.02) 0.024 
Bipolar I Mixed Episode 1.87 (0.92, 3.82) 0.084 1.98 (0.95, 4.11) 0.067 
Generic Bipolar I  1.00 REF  1.00 REF  
Comorbid Mental Health Diagnoses at Visit     
Attention Deficit  
Hyperactivity Disorder 1.56 (1.06, 2.29) 0.024 1.49 (0.99, 2.24) 0.058 
Other Disruptive  
Behavioral Disorders 1.39 (0.79, 2.44) 0.258 1.25 (0.69, 2.26) 0.460 
Depressive Disorders 0.89 (0.57, 1.38) 0.612 1.02 (0.64, 1.61) 0.944 
Disease Severity       
Inpatient Mental Health  
Visits in Year 1.12 (0.63, 2.01) 0.693 1.33 (0.74, 2.39) 0.341 
Psychosis  1.24 (0.70, 2.21) 0.459 1.11 (0.62, 1.98) 0.732 
Continued       
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60Table 4.43- Risk Ratio for Receipt of Early Treatment Regimen Changes within the First 4 Weeks of 
Treatment - Medication Continuers Only: Aim 3 (Continued) 
 
Crude Risk  
Ratio 95% CI 
Crude  
p-value 
Adjusted 
Risk 
Ratio 95% CI 
Adjusted 
 p-value 
Categorical Variables       
Physician Specialty       
Non-Mental Health 
Professional 0.97 (0.66, 1.44) 0.895 1.17 (0.79, 1.74) 0.438 
Mental Health Professional 1.00 REF  1.00 REF  
Treatment Plan Included Psychotherapy      
Yes 1.31 (0.85, 2.02) 0.226 1.26 (0.81, 1.97) 0.301 
Initial Treatment 
Characteristics       
Antidepressant at Initial 
Treatment 0.87 (0.60, 1.26) 0.258 1.00 (0.66, 1.51) 0.992 
Combination Therapy at 
Initial Treatment 1.17 (0.76, 1.80) 0.482 1.06 (0.66, 1.70) 0.798 
Continuous Variables 
Estimate (β) 95% CI Adjusted  p-value 
Adjusted 
Estimate 
(β) 
95% CI Adjusted  p-value 
Age -0.0058 (-0.02, 0.01) 0.380 -0.0032 (-0.07, 0.07) 0.922 
Crude risk ratios were generated using SAS PROC GENMOD with a binomial distribution.  
A log link was used for categorical variables and an identity link was used for continuous variables.  
Adjusted risk ratios were calculated using a log binomial model, controlling for each variable listed above. 
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The role of drug class initially prescribed on the receipt of early treatment regimen 
changes was considered next. None of the drug classes prescribed was statistically 
significantly related to the likelihood of receiving early treatment regimen changes (lithium, 
stimulants, antidepressants, antipsychotics, or anticonvulsants. However, there was a 
marginally significant effect for anticonvulsants (RR: 1.25, 95%CI: 0.97, 1.65) indicating 
that patients with anticonvulsants in the initial treatment regimen were more likely to receive 
early regimen changes.. Finally, when considering the impact of a patient receiving initial 
treatments recommended by guidelines, it appeared that those patients were more likely to 
have early regimen changes (RR: 1.28, 95%CI: 0.86, 1.48) as compared with patients who 
did not receive initially recommended treatments (although the result was not statistically 
significant, p = 0.39). 
CHAPTER FIVE: DISCUSSION 
 
5.1 Aim 1a - Prevalence Study 
 Estimates of the annual diagnostic prevalence of bipolar spectrum disorders were 
lower than anticipated based on the literature to date, with annual prevalence rates of 0.24% 
to 0.26% over the three study years. This may be due to the population studied, privately 
insured children versus clinic population or children on public insurance, and due to the way 
that bipolar disorders were counted in the population. Even within community samples, 
prevalence estimates have ranged from 0.10% in the Great Smoky Mountain Study 40 to 6.6% 
in the National Comorbidity Survey Replication-Adolescent study.262 Most of these 
differences are attributed to the populations studied and the timeframes selected for 
assessment.  
In this study, patients were only included as having bipolar spectrum disorders if they 
had two outpatient or one inpatient claim for the disorder. Patients who had only one 
outpatient claim were not included as it is unclear in that case if the physician was using the 
bipolar diagnostic code to "rule-out" bipolar disorder, or if the patient was a true case. If 
patients in this category were included, the initial sample would have increased from 35,526 
to 46,317 (approximately 30% more patients). While the method selected may have led to an 
underestimate of the disorder, it was the most conservative way to identify cases without 
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risking overestimating the true prevalence. Methodologists with expertise in claims-based 
analyses have determined that such methods of patient selection improve the specificity, 
which can lead to unbiased risk estimates.263 Moreover, this method has been employed 
commonly in other claims-based studies of bipolar disorder, which allows for better 
comparisons across studies.235, 237, 245, 246  
In addition to finding a lower than anticipated diagnostic prevalence, the rate of 
bipolar diagnosis did not increase as dramatically as has been previously noted in the 
literature. For example, Moreno's widely cited study showed a 40-fold increase in visits for 
bipolar disorder from 1994-1995 to 2002-2003.1 This study found an 8% increase in bipolar 
diagnoses from 2005 to 2006 and no increase from 2006 to 2007. It is possible that increased 
media and academic attention to bipolar disorder in children over the past five years has led 
to more sensitivity in diagnosing the disorder.264 This would lead to lower diagnosis rates 
(slower rate of growth) over time. Also, we do not have estimates of the prevalence of 
bipolar spectrum disorders in children who were in the MarketScan database in years prior to 
2005. It is possible that the current estimates of the prevalence are higher than estimates 
would have been in the mid 1990s (as found by Moreno and colleagues) and that the rate of 
increase had leveled off as of 2006.   
Another reason that our results may have differed from others was likely due to the 
study design. The study design that was used for this evaluation is not ideal for evaluating 
longitudinal trends. The cross-sectional design employed included all children within each 
year who met our inclusion criteria, thus samples were not independent from year to year, 
nor were there repeated measures on all subjects. Because the purpose of this project was to 
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identify aggregate patterns in use and not longitudinal trends specifically, the design selected 
met our initial study goals but did not allow for true longitudinal comparisons.   
 When considering the prevalence of each bipolar subtype, bipolar unspecified type 
was the most common diagnosis in our sample. Most studies conducted using patients with 
bipolar disorder have focused on only one subtype (bipolar I). One notable study that 
provided information on multiple disorders on the bipolar spectrum showed bipolar I to be 
the most prevalent bipolar subtype.250 However, epidemiologic surveys have shown higher 
rates of sub-threshold bipolar disorders, than bipolar I or bipolar II disorders.41 The higher 
rate in bipolar unspecified disorder in our sample (than in clinic samples) may be due to 
several potential factors.  
First, there may be less accurate assessment of the disorder in privately insured 
patients. This could be due to intentional vagueness in coding of diagnosis (such as clinicians 
not wanting to label children with a serious mental illness like bipolar I disorder), or that 
most clinicians are unable to determine the appropriate bipolar subtype. For example, non-
identification of the appropriate bipolar subtype could occur if diagnostic assessment tools 
are not used, or if the history of the child's bipolar symptoms are inadequately collected or 
reported. We also identified a larger proportion of children with Bipolar NOS were 
diagnosed by primary care physicians or by an unclassified physician type (as compared with 
children with any other bipolar subtype).  
The unclassified physician type was made up of primarily acute care center 
affiliations. This finding suggests that diagnoses made in primary care providers or in acute 
care settings are associated with receiving less specific bipolar diagnosis coding. However, 
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the causal relationship is unclear. For example, patients who do not meet the symptom 
criteria for bipolar I or bipolar II disorder could be more likely to visit an acute care center or 
a primary care physician for their care. Conversely, these providers could be hesitant to 
diagnose children with a more specific disorder due to having less expertise in the area of 
severe childhood mental illness than a mental health professional.   
Alternatively, our results related to the elevated diagnosis of bipolar unspecified type 
could be due to the privately insured population more closely resembling patients from 
community-based samples than clinic samples. In such cases, milder forms of the disorder 
would be seen more commonly in our sample than reported in children who were referred to 
specialty psychiatric clinics (the source population for most of the evidence to date).  
When looking at patient characteristics by bipolar subtype, our results were similar to 
those reported in the Course and Outcome for Bipolar Youth (COBY) study.250 For example, 
children with bipolar unspecified type where slightly younger, and patients with bipolar II 
were slightly older than those with bipolar I disorder. Our gender distribution also was 
similar across disorders, with the exception of bipolar II disorder (our sample showed nearly 
equal percentages of males and females had bipolar II disorder, while the COBY study 
showed higher percentages [60%] of females with bipolar II).  
 Similar to other studies, attention deficit hyperactivity disorder was the most common 
comorbid condition in our overall sample. Comorbid major depressive disorder, oppositional 
defiant disorders, conduct disorder, and anxiety disorders were also somewhat common. It is 
important to note, for this particular evaluation, the occurrence of comorbid mental health 
disorders capture the recording of diagnoses during the year in which the patient had a 
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bipolar diagnosis. The COBY study and other clinic samples generally assess lifetime history 
of comorbid mental health conditions. While estimates provided in the COBY study are 
higher than those seen here, this is expected due to the nature of the data collected. A 
recently published study that used MarketScan claims from April 2004 to March 2005 to 
study bipolar disorder in children provides nearly identical estimates of the prevalence of 
comorbid mental health conditions (although the definition of the initial cohort was less 
reliable as they included patients with one or more diagnoses for bipolar spectrum 
disorders).265  
 The comorbidity of major depressive disorder diagnosis (which occurred in 
approximately 25% of children) is of serious concern, as it is clinically inaccurate to 
diagnose a patient as having both a bipolar spectrum disorder, and a major depressive 
disorder. As mentioned above, comorbid mental health diagnoses were collected as any 
diagnosis that occurred during the year that the bipolar diagnosis occurred. It is unclear from 
the prevalence study how many patients were diagnosed with major depressive disorder prior 
to their bipolar diagnosis (potential misdiagnosis of major depressive disorder, later 
clarified), or how many patients received a new diagnosis of major depressive disorder 
following the bipolar diagnosis (potential misdiagnosis of bipolar disorder, later clarified).  
5.2 Aim 1a - Medication Use Study 
When considering prevalent medication use, there appeared to be little variation in 
the likelihood of receiving pharmacotherapy when comparing patients by coded bipolar 
subtype. Additionally, medication use was similar across all bipolar subtypes when 
considering class-level use. Use of anticonvulsants, lithium, and antidepressants differed only 
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slightly over time or by bipolar subtype.  This finding was surprising, as the primary 
spectrum disorders (bipolar I, bipolar II, and bipolar NOS) differ widely in symptom 
presentation.  
Perhaps most concerning was the similarity in treatment characteristics for children 
with diagnoses of Cyclothymic disorder (considered to be the mildest disorder on the bipolar 
spectrum) to those with bipolar I mania. It is possible that the similarities in treatment across 
spectrum disorders may be due to the lack of evidence-based recommendations for effective 
treatments in this area. Even recent guidelines emphasize that evidence does not exist for 
treatment recommendations outside of those made for bipolar I disorder. Treatments for each 
of the other spectrum disorders remain largely untested, particularly in children. It is possible 
that clinicians are merely treating each spectrum disorder similarly, since there are few 
alternatives for additional guidance on treatment selections.   
 While lithium has traditionally had the most evidence for use in children, it was rarely 
used in this population. In fact, of each of the drug classes studied (with the exception of 
typical antipsychotics), lithium was used the least frequently. One potential reason for this is 
that there are potential safety concerns regarding lithium overdose or severe adverse drug 
reactions. While these concerns are important, lithium has also been shown to reduce the risk 
of suicide as compared with divalproex.249 This is a critically important consideration 
considering the high risk of suicide attempts and completed suicide among patients who have 
bipolar disorders.  
Another reason for the lower-than-expected use of lithium may be that it is no longer 
actively marketed, as opposed to many of the anticonvulsant and atypical antipsychotic 
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agents which are heavily marketed to physicians. For example, one study indicated that 
divalproex generated at least 10 times more sales revenue than lithium, resulting in far more 
industry-sponsored education regarding divalproex.249 It is also possible that clinicians would 
adopt prescribing practices that heavily favored some of the newer medications, as initial 
monotherapy response rates for patients taking lithium have been low (less than 40%).142 
This could lead clinicians to rely on newer agents, even if those agents have less safety or 
effectiveness data available.  
 Anticonvulsant medications were used commonly, with divalproex being the most 
heavily prescribed among all anticonvulsants. During the study period, divalproex and 
carbamazepine had the most evidence for use in this population and these agents were the 
only anticonvulsants supported by the prescribing guidelines as of 2005.17 However, this 
study found a very low rate of prescribing of carbamazepine (approximately 4% of 
anticonvulsants prescribed), and a very high rate of prescribing for lamotrigine 
(approximately 32% of anticonvulsants prescribed). Although lamotrigine had some initial 
evidence for use in maintenance treatment for bipolar disorder, there was little to no evidence 
for its use in children during this timeframe. It is possible that initial evidence regarding its 
effectiveness for bipolar depression may have led to the high levels of use during the study 
period. Lamotrigine is often used for seizure disorders in children, which may increase a 
clinician's comfort with prescribing this agent in the face of less evidence. Similarly, the 
broad use of this agent could also be related to the favorable side-effect profile seen for this 
anticonvulsant agent, as compared with similar agents in the drug class. For example, weight 
gain is a common side effect of most of the mood stabilizing agents, but is not a prominent 
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side effect of lamotrigine. Given the concerns of clinicians and parents in the long term 
impact of weight gain on the child's physical and mental health, avoiding this side effect may 
be sufficient motivation for prescribing this product. 
 As anticipated, two of the most commonly prescribed atypical antipsychotics were 
risperidone and aripiprazole, both of which were approved for use in children (ages 10 to 17) 
as of 2007. Quetiapine was also heavily prescribed during the timeframe, although it was not 
recommended specifically by the guidelines at that time. Quetiapine prescribing was 
somewhat concerning due to the increased risk of tachycardia with this agent. However, it 
may have been popular due to a lower risk of weight gain.   
Antidepressant use was common, with or without mood stabilizers. SSRIs were the 
most commonly used subclass of antidepressants, representing approximately 60% of the 
antidepressants used. This finding is particularly concerning as (1) there is concern in the 
literature regarding possible manic switching due to antidepressant treatment,203 and (2) 
SSRIs have been associated with increased suicide risk in children with depressive disorders, 
although it is unclear at this time if the risk for suicide completion is elevated.266 
Nevertheless, due to the already elevated risk of suicide in children with bipolar disorder, 
prescribing medications that are known to increase the risk of suicide is risky. The practice of 
prescribing antidepressants for children with bipolar disorder is unacceptable based on 
current practice standards for adults, let alone children.52 
Similar to other reports,1, 267 polypharmacy was common in our study population, with 
nearly 40% of the population receiving at least 2 medications in a 30 day period following 
their diagnosis. However, in this evaluation, a large portion of children received no 
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medications (35%). This is consistent with one previous study that used MarketScan data in a 
similar population,265 but is somewhat lower than estimates from the study by Moreno and 
colleagues (where 90% of office visits resulted in a prescription of one or more psychotropic 
medications). In a separate study of 111 children and adolescents with bipolar disorder, 
researchers found the mean number of current psychotropic agents among the sample was 3.4 
agents. Approximately 18% of the children were taking five or more medications and only 
30% were taking 2 or fewer medications.207 The use of multiple drugs was somewhat lower 
in our study, but this is likely due to the previous study population being treated in 
psychiatric clinics (i.e., they may have more severe, or closely managed illness).  
Finally, when considering the use of psychotherapy or counseling, use in the prevalence 
study population was higher than anticipated based on a review of the literature. For 
example, Moreno's study found that psychotherapy occurred in approximately 42% of the 
sample 1. Rates of psychotherapy use were nearly 90% among all bipolar subtypes and each 
year. Part of this may be due to the inclusion of only a subset of patients in this evaluation. 
Specifically, patients whose mental health / substance abuse data were not available were 
excluded as it would be impossible to determine if they did or did not receive services. This 
may have biased our results towards overestimating counseling or psychotherapy among the 
population.  
5.3 Aim 1a - Age Related Treatment Differences 
 Age related differences in demographic and treatment characteristics of children with 
bipolar disorder have important implications for clinical trials testing and treatment. When 
comparing young children (ages 0-9) to older children (ages 10-17) several interesting 
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findings emerge. Literature in this area has previously identified early-onset cases (prior to 
age 13) are more frequently male, 19 and gender differences are found in the presentation of 
co-morbid conditions, the age at first treatment, and in rates of symptomatic recovery. 59, 62 
As expected, younger girls were much less likely to receive diagnoses of bipolar spectrum 
disorders, as compared with younger boys. This could be due to symptom presentation, 
where boys are more likely to display aggressive features which would make parents more 
likely to seek treatment earlier. Also consistent with what is known regarding comorbidity 
with bipolar disorder, younger children were more likely to have comorbid Attention Deficit 
Hyperactivity Disorder and less likely to have depressive disorders.  
Reasons for the sex differences in childhood-onset bipolar diagnoses and adolescent-
onset bipolar diagnoses are largely unknown. There are several plausible explanations that 
could be leading to the differences found in this study. For example, young boys with bipolar 
disorder diagnoses are more likely to be diagnosed with attention deficit hyperactivity 
disorder (ADHD), as compared with young girls.61 Additionally, some studies have identified 
possible links between treatment emergent mania and stimulant use in children who are 
subsequently diagnosed with bipolar disorder.226 It is also possible that young boys are more 
often referred for treatment for ADHD, as compared with young girls, and subsequently they 
are determined to have bipolar disorder. If this were true, it would suggest that young boys 
are more likely to be seen by a health care provider, and thus are more likely to receive an 
earlier diagnosis or treatment for bipolar disorder.    Surprisingly, there were no differences 
in the number of medications used by younger and older children. When looking at the 30 
days following a child's most recent diagnosis, approximately 30% of children in each age 
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group had 2 or more psychotropic medications. Treatment characteristics, however, showed 
some surprising differences in class-level medication use. The probability of receiving any 
medication was similar among both age groups, but young children were much more likely to 
receive antipsychotic medications over each study year, as compared with older children. 
These findings may be related to a general increase in the use of antipsychotics among very 
young children. Several recent studies have shown significant increases in the use of 
antipsychotic agents among very young children (ages 2 through 5 years), both in public268 
and private269 insurance plans. This finding is particularly troublesome as there is little 
evidence of the effectiveness and safety of antipsychotics in children younger than 10 years 
of age.269  
 Other important, but anticipated, class level differences in medication use were that 
young patients were more likely to receive stimulants and older patients were more likely to 
receive antidepressants. These treatments coincide with the elevated rates of ADHD in young 
children and major depressive disorder in older children.  
5.4 Aim 1b - Incident Bipolar Diagnoses 
In addition to prevalent drug use information, an incident diagnosis study design was 
employed to assess new diagnoses and treatments for bipolar disorder. Using this study 
design allowed us to capture information in a way that provides a better understanding of the 
chronology of the disease and treatment.263  
When considering the characteristics of newly diagnosed patients to those observed in 
the prevalence study, most characteristics were similar across the samples. However, there 
was one notable difference. This was related to the distribution of females within the bipolar 
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subtypes. When considering the newly diagnosed patients, girls made up a higher proportion 
of each of the bipolar spectrum disorders. This is in contrast to the prevalence study, where 
boys were either slightly more likely or equally likely to be diagnosed with bipolar I, bipolar 
unspecified, or bipolar II disorder. Most of the increase that is seen for girls, however, can be 
explained by the exclusion of children with previous use of lithium, anticonvulsants, or 
antipsychotics. In fact, 58% of the 2,139 children excluded for previous medication use were 
male. This provides further evidence that bipolar diagnosis in girls and boys is stable after 
puberty.62,19  
As mentioned above, a major advantage of using this design was that information on 
comorbid mental health conditions could be captured as those existing prior to the bipolar 
diagnosis, versus those that were diagnosed after the bipolar diagnosis. There were several 
interesting patterns that emerged when evaluating comorbidities in this manner. First, a 
majority of patients with ADHD comorbidity received their diagnosis prior to their initial 
bipolar diagnosis. However, the occurrence of new ADHD diagnoses after bipolar diagnosis 
was fairly high, with between 7 and 13% of patients receiving an ADHD diagnosis in the 
year after bipolar diagnosis. The occurrence of conduct disorder and oppositional defiant 
disorder also seemed to occur more commonly after a diagnosis of bipolar disorder had been 
established.  
 There were high rates of Major Depressive Disorder diagnosed prior to bipolar 
diagnoses. This is not completely surprising, as children often present with depressive 
symptoms, thus misdiagnosis with Major Depressive Disorder is a major concern. However, 
between 11 and 17% of children received a diagnosis of Major Depressive Disorder after 
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their initial bipolar diagnosis. This was not anticipated as major depressive episodes are 
considered to be symptoms of bipolar disorder, thus an additional diagnosis of comorbid 
Major Depressive Disorder is not clinically meaningful. It is unclear to what extent these 
patients are receiving clarifying diagnoses (bipolar diagnosis was inaccurate and the clinician 
is clarifying the diagnosis as major depression).   
It is important to note, that this evaluation assessed pre-diagnosis conditions as those 
that were present within the 6 month pre-period, and post-diagnosis conditions as those 
occurring in the year following diagnosis. The differences in the timeframe may have led to a 
higher proportion with post-diagnosis conditions (since they had twice the follow up time for 
diagnoses to be present). Because the focus of this evaluation is on describing the timing of 
patients' diagnoses of comorbidities, and not on directly comparing differences in the rate of 
comorbid diagnoses before and after bipolar diagnosis, we felt that it was more appropriate to 
use all of the available information than to create similar assessment times.   
 Next, we tested the extent to which patients' bipolar diagnostic classification changed 
over the one year study period. This was done because there has been concern about 
diagnostic switching within children with bipolar disorder. We found that a majority of 
patients had the same bipolar diagnostic subtype at both their first and last visits during the 
study year. Approximately 20% of children in each category switched diagnostic subtypes. 
Switching diagnoses was most common among patients with bipolar II disorder (with only 
66% with no diagnostic switches over one year). It is possible that this lower rate of 
diagnostic stability is related more to the billing codes, rather than to true diagnostic 
confusion among bipolar subtypes. Bipolar II is defined by the DSM-IV by the diagnostic 
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code "296.89." However, the corresponding ICD-9 description for code "296.89" is "other" 
bipolar disorder. It is possible that this incongruence between the diagnostic manual and the 
major coding classification leads to less stability for assessing this bipolar subtype in billing 
claims data.   
Theoretically, diagnostic switching would have implications for treatment; however, 
this study found no major differences in the types of treatment received by bipolar subtype 
diagnosed. Results for medication use in the 30 or 90 days following initial bipolar diagnosis 
indicated that there was no difference in medication class use by bipolar subtype, with the 
exception of antipsychotics (used less frequently in those with bipolar II or Cyclothymic 
disorder). This indicates that the coded diagnosis may have little to do with the actual 
treatment received. This is not surprising, however, as clinicians have little guidance for 
treating patients with bipolar disorders other than bipolar I.  
5.5 Quality of Care in Children with Bipolar Disorder 
 While guidance does not exist for the treatment of most of the bipolar spectrum 
disorders, experts consensus guidelines exist for the treatment of children with bipolar I 
disorder. When considering patients with new diagnoses of bipolar I, we found that a 
majority of patients did not receive recommended first line therapy. Our primary analysis 
found only 16% of patients received appropriate first-line therapy within 90 days of their first 
bipolar diagnosis. Even after one year, less than 20% of these children received 
recommended pharmacotherapy. Considering the least restrictive definition for appropriate 
care, there were still over 70% of patients receiving inappropriate initial treatment for bipolar 
I disorder after one year. Surprisingly, the most commonly used medication class among all 
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children was antidepressants. These agents were used as first line treatment, without other 
mood stabilizing agents, in 25% of children. Additionally, approximately 40% of patients 
received no medication after initial diagnosis with bipolar I disorder.  
 When considering the factors that were associated with the receipt of recommended 
care, the type of episode at treatment initiation appeared to be strongly related to the receipt 
of recommended care. For example, patients with bipolar I depressive episodes and mixed 
episode types were more likely to receive recommended first line therapy, as compared with 
patients with generic bipolar episode types. It is possible that patients who receive generic 
bipolar diagnoses (ICD-9 codes 296.0x or 296.1x) have less clear illness presentation, 
limiting the clinician's confidence in the diagnosis and treatment strategy. When more 
defined episode types are selected (such as bipolar I mixed episode type) it may be an 
indicator of more clinical certainty in the diagnosis.  
 Additionally, having certain comorbid mental health conditions was related to receipt 
of guideline recommended care. In particular, patients with comorbid Major Depressive 
Disorder were less likely to receive guideline recommended care. The high level of 
antidepressant use at treatment initiation may be related to continued treatment of Major 
Depressive Disorder after diagnosis of bipolar disorder. It is important to note, however, that 
guidelines specifically address the importance of discontinuing ongoing therapies upon 
diagnosis of bipolar I disorder. This is because patients often receive multiple diagnoses (and 
often multiple treatments) prior to establishing the bipolar I diagnosis. Once bipolar disorder 
is recognized and treatment has been initiated, comorbidities should be re-assessed to 
determine if they exist once a patients' bipolar disorder is stabilized. 
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 Receiving recommended treatment was also consistently related to receiving care 
from a psychiatrist. This could be due to psychiatrists' being more aware of guideline 
recommendations, their having better methods to assess bipolar disorder, or perhaps due to 
differences in patient characteristics that could not be measured in this evaluation. Children 
who were seen by non-psychiatric mental health professionals were the least likely to receive 
recommended treatment (as compared with psychiatrists). This is likely due to the guidelines 
recommending pharmacotherapy as initial treatment (and many non-psychiatric mental 
health professionals do not have prescribing privileges).  
 Early treatment regimen changes were also common among children with newly 
diagnosed bipolar I disorder. Over 40% of children experienced treatment regimen changes 
within the first 6 weeks of initiating treatment. When considering the factors associated with 
early treatment regimen changes, few of the variables that were included in the final adjusted 
model were related to treatment changes, and results were inconsistent across models. 
However, there did appear to be a consistent relationship between the receipt of a bipolar I 
depressive or manic episode type and the occurrence of early regimen changes.   The findings 
here were not completely surprising, as regimen changes could likely be more closely related 
to a patient's tolerance for the medication, and their complete clinical picture, rather than 
indicators that are present at the time of medication initiation. Many un-measureable factors 
could be involved in this relationship, such as parent demand for medications, adverse 
reactions to medications, or partial improvement in symptoms. None of these factors could 
be identified with the current database, but they may be more relevant for such an analysis.  
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 Notably, there was a marginally significant effect for the type of medication at 
initiation and the length of time on the medication. Patients with anticonvulsants at treatment 
initiation were more likely to have regimen changes, as were those who received 
recommended first-line therapy (from aim 2). These findings may indicate that treatment 
changes are more likely for patients who receive close disease management (or conversely, 
the more severely ill the patient, the more likely they are to receive medication changes).  
 The findings related to the use of published guidelines are not altogether surprising. 
Studies of physician' adherence to published guidelines routinely find that there are often 
large gaps in what is recommended in guidelines and what occurs in clinical practice. The 
reasons for this vary by condition and by physician type but often include lack of awareness 
or familiarity, disagreement, discomfort, low outcome expectancy or low self efficacy and 
practice inertia related to guidelines.231  Non-use of guidelines is common, but unacceptable, 
as guidelines signal increasing consensus in the medical literature, and they promote 
awareness of this consensus.237 In disorders that are as complex as pediatric bipolar disorder, 
reliance on expert consensus guidelines (based on current evidence) should be considered 
best practice.  
For the purposes of this study, we utilized a conceptual framework based on the 
Andersen model and Donabedian's structure process and outcome model (Chapter 2, Figure 
2.2). Based on this framework, we expected both patient characteristics and physician 
characteristics would be associated with receipt of guideline recommended care. We also 
assumed that receipt of guideline recommended care would be associated with improved 
health and economic outcomes for patients. While the latter assumption was not evaluated in 
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this study, there have been several studies that have tied guideline adherence back to patient 
outcomes in the area of bipolar disorder. The Texas Medication Algorithm Projects, for 
example, utilized prescribing algorithms for severe mental illness (including bipolar disorder) 
and assessed the extent to which adherence to these algorithms impacted patient health and 
economic outcomes.27 Additionally, a recent study of inpatients with acute mania was 
conducted to determine how well current prescribing patterns reflected the published clinical 
guidelines and the overall impact of short-term clinical outcomes. The researchers found 
generally good concordance with treatment guidelines and a statistically significant 
relationship between early medication initiation and reduced time to hospital discharge.230 
Although these study samples were restricted to adults with bipolar disorder, they provide 
some evidence that treatment patterns are useful tools for assessing the quality of care and 
patient outcomes in bipolar disorder. They also provide initial evidence that guideline 
recommended prescribing is associated with improved health outcomes. 
Interestingly, we found that none of the patient's predisposing characteristics (age, 
sex, or geographic region) were associated with either of the guideline-related measures of 
quality of care. This was also the case for patient enabling resources (insurance type, or 
generosity of benefits). However, enabling resources may still provide relevant information 
regarding the access to health care. This study utilized a sample of privately insured children, 
and specific plan information (such as details of the drug benefits) was unavailable. It is 
likely that no differences were found due to a floor effect (where everyone had some level of 
coverage). Patients who are uninsured, those with public insurance, or those with highly 
restrictive or expensive benefit structures may differ from the patients observed in this study.  
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Several need characteristics, as well as physician type (structural variable) appeared 
to be influential in the relationship with guideline recommended care. For example, having 
depressive disorders was associated with receiving non-recommended first-line therapy. 
Having a more specific diagnostic classification was associated with receiving recommended 
first line therapy, as was having a diagnosis provided by a psychiatrist. 
Most of the other disease severity indicators were not statistically significantly related 
to the likelihood of receiving recommended first line treatment, or to the likelihood of having 
early treatment regimen changes. This finding was likely due to difficulties in accurately 
identifying disease severity in the claims database, and may not represent the true 
relationship between diseases severity / patient need and the likelihood of receiving 
recommended care. Perhaps more detailed information about the patient's true clinical picture 
would lend itself to be a better predictor of the type of care received. 
5.6 Limitations 
There are several limitations to the proposed project. First, this project utilized 
Marketscan Commercial Claims data, which limits the generalizability of the results to the 
privately insured U.S. population. This study does not represent children who are covered by 
public insurance (such as Medicaid or SCHIP), and there may be important differences in the 
prevalence of bipolar disorder and the treatments received in these other populations. The 
benefits of using this source were the large size (millions of covered lives available) which 
resulted in a reasonably large sample size for the desired cohort.  
 Next, the process-related outcome variables were based on guidelines for treatment 
that were published in 2005 and 2007, respectively. Clinicians might have used other 
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evidence for treatment decisions during that time, and the 2005-2007 recommendations may 
no longer reflect current practice. However, the quality indicators that were selected for 
inclusion were both considered to be "minimal standards of care" per the guidelines. 
According to the guidelines, recommendations within this category are based on rigorous 
empirical evidence and/or overwhelming clinical consensus and the minimal standards are 
expected to apply over 95% of the time (or in nearly all cases).19 In addition to this, we are 
not able to determine the extent to which these guidelines were promoted for use in practice 
or how quickly they were adopted by clinicians. 
Another important factor is related to the use of secondary databases. Secondary 
datasets, such as prescription drug claims and encounters data, rely on diagnosis codes, rather 
than structured evaluations, to identify patients. Researchers then infer, based on the presence 
of diagnostic codes, that a patient has the disease of interest if the codes are recorded. This 
method of identification may lead to misclassification bias, where patients who received a 
diagnosis may not actually have the disease in question. For example, clinicians may hesitate 
to diagnose a child with a major mental illness (perhaps due to concerns regarding labeling 
children with major disorders, or due to stigma regarding the condition). Conversely, 
diagnoses could be used to "rule-out" conditions and may not actually reflect true disease 
presence. This misclassification bias can be minimized to some degree by including only 
those who had evidence of more than one bipolar diagnosis (two unique service dates).263   
Additionally, because data are collected for non-research purposes (i.e., billing), it is 
possible that clinicians could "up-code" diagnoses to ensure that payment is received. For 
example, clinicians may "up-code" severe behavioral disturbances to major mood disorder 
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that represent more pernicious illness.29 This would bias our results by including patients 
who had less severe behavioral diagnoses as cases of bipolar disorder. Similarly, they may 
code for diagnoses for which they are more certain that payment would be received, or for 
which reimbursements are higher. This would cause us to underestimate the true prevalence 
of the disorder.  
  While we do not know the extent to which "rule-outs" and "up-coding" impact our 
sample, a previous validation effort in the area of bipolar disorder provides some evidence 
that the impact is likely small. This validation study compared diagnoses in an administrative 
database (Group Health Cooperative of Puget Sound, a staff model HMO) with medical 
records and found a false positive rate of less than 10% for (1) patients with any inpatient 
diagnoses of bipolar disorder, (2) patients with any outpatient diagnoses of bipolar disorder 
who were seen by a mental health professional, and (3) patients with any diagnoses of bipolar 
disorder and accompanying mood stabilizers from a non-mental health provider.270 Our 
definition for inclusion of patients was somewhat less restrictive regarding the type of 
provider who was seen, but required at least two diagnostic codes (on unique service dates) 
for patients who were seen in an outpatient setting.  
Additionally, we were unable to detect medication use outside of the insurance claims 
data or prior treatment for bipolar disorder (in advance of the 6 month wash-out period). This 
is particularly important when evaluating physician adherence to guidelines for initial 
therapy.  It also was possible for patients to obtain medications outside of their insurance but 
the high costs associated with commonly used medications for bipolar disorder (particularly 
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newer antipsychotic agents) would have made it more likely that a patient would make these 
purchases through their insurer.  
Similarly, patients may receive medication samples from their physician, which 
would cause us to underestimate medication use in the population. A recent study of the 2004 
Medical Expenditure Panel Survey (MEPS) indicated that samples are used in approximately 
4.9% of all children, and approximately 10% of children who received prescription 
medications.271 In this study, several of the agents of interest were identified as being used as 
samples, including amphetamine / dextroamphetamines (Adderall), escitalopram (Lexapro), 
paroxetine (Paxil), and methylphenidate (Ritalin). Among these agents, Adderall was among 
the top 15 most sampled products.271 Medication non-use is also undetectable in insurance 
claims data. If a provider wrote a prescription that was not filled by the patient, this would 
not be detected within the database. Only filled prescriptions are recorded.  
 Another limitation of claims based analysis is the relationship between the provider 
type and the medication prescribed. In these data, as with most prescription claims data 
sources, providers are associated with services, and not specifically with medication 
dispensing. This requires that temporal associations be created to identify the most likely 
provider. For example, analyses of initial regimen prescribed considered the provider type to 
be the provider seen at the closest date to the date of medication dispensing. It is possible that 
a patient may have seen multiple providers, or could have been delayed in obtaining their 
prescription medication. This leads to less certainty regarding the relationships established 
between the type of the provider and the appropriateness of therapy.   
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 Finally, this project does not address the extent to which treatment, diagnosis or the 
available guidelines are appropriate for use in the pediatric population. Nor does it address 
the adequacy of detecting bipolar disorder in children. Due to the nature of our data 
(secondary analysis) and the lack of clinical focus of this project, we assessed only the extent 
to which guidelines were followed and the variables that were associated with receiving 
guideline recommended care or not.  
5.7 Summary and Future Research  
This project adds to current epidemiologic information on the potential risk factors 
for bipolar disorder, including current estimates of the diagnostic prevalence of bipolar 
spectrum disorders in a cohort of privately insured children. Most of the previous studies in 
this area have been limited to clinic samples (generally from specialty clinics or psychiatry 
practices). These studies are generally restricted to the most severely ill patients (those who 
would seek specialized care), and their limited size make it difficult to detect diagnostic and 
treatment patterns that may exist in the population.26 Because of the size of the study 
population utilized, we were able to identify aggregate treatment patterns for some of the less 
common bipolar spectrum disorders (such as bipolar II disorder and Cyclothynic disorder). 
Perhaps more importantly, this study provided some insight into the current 
pharmacologic treatment of bipolar spectrum disorders in privately insured patients. No 
studies to date have identified differences in treatments received by children with bipolar 
subtypes other than bipolar I disorder. Focus of research efforts and guideline development 
have almost exclusively targeted bipolar I disorder, as this is perceived to be the most severe 
of the bipolar spectrum disorders. Treatment of each of the other subtypes has been largely 
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ignored in the literature. It is interesting to note that we found treatment rates were similarly 
high across each bipolar subtype (the proportion of children receiving psychotropic 
medications was similar), and the medication classes used varied only slightly.  
We found significant areas of concern regarding the medication prescribing practices 
for children with bipolar spectrum disorders. For example, we identified significant 
differences in the rates of use of atypical antipsychotic agents among young children (under 
the age of 10 years) as compared with older children. We also found similarly high rates of 
treatment, including combination therapy, in young children (as compared with older 
children). This age group is particularly important because current recommendations are to 
conduct medication trials of only 10 to 17 year old children.20  Routine exclusion of young 
children from clinical trials testing should be carefully considered, particularly for testing of 
atypical antipsychotic agents. While this is certainly a complex issue (inclusion of young 
children in clinical trials), excluding them from trials forces physicians to make treatment 
decisions without good evidence. Given concerns about the impact of psychotropic 
medications on childhood developmental processes, studying medication use in a rigorous 
manner (a controlled trial) versus collecting case reports of complications seems to be a more 
prudent response.  
Next, we were able to identify the extent to which initial first line therapies matched 
those that were suggested by recent expert consensus guidelines. We found that very few 
children received treatments that were recommended by the guidelines. Instead, we found 
that a majority of children received either no treatment, or antidepressant monotherapy. 
These findings are of significant concern as patients with bipolar I disorder should receive 
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pharmacotherapy (per the guideline, pharmacotherapy is indicated in over 95% of cases), and 
antidepressant use is still considered to be questionable in this population. Similarly, we were 
able to assess the extent to which medication changes occurred early for patients with newly 
treated bipolar I disorder. Again, a large proportion of children received early treatment 
regimen changes (shorter medication trials than recommended by guidelines).  
Both of these assessments were structured to identify factors that were associated 
with non-adherence to guidelines. The rationale for this was to try to identify targets for 
quality improvement efforts in the pediatric bipolar population. Unfortunately, the evaluation 
related to early regimen changes added little information about the factors that drive these 
medication changes. However, the analysis of initial first line therapy provided some useful 
information for quality improvement.  
First, we found a significant disconnect between the actual medication prescribing in 
the population and what the guidelines recommend. This finding could be due to several 
potential causes. First, physicians may be either unfamiliar with the guidelines, or they may 
disagree with the guidelines on the appropriate management of patients with this disorder. In 
such cases physicians may use their clinical judgment or previous experience to guide their 
prescribing behavior, rather than the expert consensus guidelines. Understanding the extent 
to which physicians are aware of and agree with the guidelines would be important for 
determining the appropriate strategy for improving their adoption among clinicians.  
Second, there may be some detection problems within the data source used that would 
impact our findings. For example, there could also be problems with misclassification bias, 
as patients could be inaccurately diagnosed as having bipolar I disorder (coding error, 
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upcoding for higher reimbursments, or misdiagnosis). However, we tried to improve the 
specificity of our detection of bipolar diagnoses by requiring that patients have at least one 
inpatient or two outpatient diagnoses. While this may impact our results to some extent, the 
overwhelming majority of children received inappropriate treatment. This would suggest that 
a majority of the patients in this study would have to be misclassified to change our 
conclusions substantially.   
Third, there may be other factors that promote the use of non-recommended drugs, or 
the non-use of drugs, such as pharmaceutical company drug promotion, patient or parent 
demand for particular medications, or patient or parent hesitation in using prescribed 
medications.  Regarding parent hesitation in using prescribed medications, parents may not 
want to give their children powerful psychotropic medications due to concerns regarding side 
effects, potential impact on childhood development, or stigma related to having or treating a 
severe mental illness. Alternatively, parents may demand medications that they believe 
would help their child to function better. For example, if a child had severe depressive 
episodes in the course of their bipolar disorder, a parent may request that an antidepressant be 
given to the child to help with the depressive phase of the bipolar illness. These behaviors 
could influence both the prescribing clinician's decisions regarding initially prescribed 
therapies (which medications, if any, to choose), and their use of an adequate treatment trial.    
Based on this research, it appears that the quality of medication prescribing and use in 
children with bipolar disorder is poor. It is critical to determine why there is a disconnect 
between the expert-consensus recommendations and medication prescribing patterns in the 
community. There are several things that should be done to identify the extent to which the 
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currently available guidelines are suitable for the pediatric bipolar population. Perhaps the 
single most important first step to improving the quality of care received would be to 
determine the extent to which antidepressant monotherapy at treatment initiation is causing 
harm (or benefit) in the pediatric bipolar population. This was the single most used drug 
category and is specifically noted in the guidelines as not recommended for children with 
bipolar disorder. If experts believe that this is a truly inappropriate treatment for these 
patients, emphasis should be placed on changing this common prescribing behavior.  
Next, if pharmacotherapy is the primary treatment mechanism (as is noted in the 
guideline), the mental health community should further emphasize the importance of referral 
of these patients to a provider trained in the area of mental health (psychiatrist) so that 
appropriate pharmacotherapy can be selected. Although it is currently unclear to what extent 
guideline discordant treatment impacts a patient's health outcomes, it is important to ensure 
that all children are receiving what is currently believed to be the most appropriate treatment 
course.  
In addition to the above recommendations, it will be critical for future studies in this 
area to (1) determine the extent to which use of medication treatment guidelines is related to 
patient health outcomes;  (2) confirm that medication use patterns identified within this 
evaluation are consistent across other samples; (3) better measure factors associated with 
disease severity to understand their true relationship with how care is delivered; and (4) 
identify gaps in clinician training that could be addressed to improve the adoption of 
guidelines for mental health treatment.  
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Regarding the first goal, to identify the extent to which use (or non-use) of guidelines 
impacts patient health outcomes, claims based analyses may be a starting point for this type 
of evaluation. This study provided evidence that guidelines for medication management in 
children with bipolar disorder are not followed in most cases, and we identified potential 
factors that are related to receiving recommended care. However, we need to establish how 
receipt of recommended care is related to improvements in the patient's outcomes. If 
guideline concordance is found to be related to improvements in patient outcomes, then it 
will be critical that interventions be developed, or training programs be implemented to 
improve clinician awareness and/or adoption of these guidelines. Establishing this link will 
help to quantify the need for quality improvement in this area by providing evidence for the 
importance of using guidelines in this vulnerable population.  
To address the second goal (confirming that medication use patterns are consistent 
across other samples), claims based analyses could be used as a starting point. It is important 
to understand if these prescribing patterns are consistent across other privately insured 
populations, but also to understand if our findings could be generalized to publicly insured 
children. To establish this, we would need to evaluate medication use patterns within other 
privately insured plans (e.g., Blue Cross and Blue Shield, State Employees Health Plan), and 
for children in public insurance programs (i.e., Medicaid).   
The next goal - to better measure factors associated with disease severity and to 
understand the true relationship of disease severity and receipt of appropriate care - is 
somewhat more complex. Given the difficulty in diagnosing and treating bipolar disorder in 
children, and the controversy within the field of child psychiatry regarding the existence of 
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true bipolar disorder in children, a claims-based analysis is unlikely to provide enough details 
regarding the patients' true clinical picture to allow for a thorough investigation of outcomes. 
This is because claims data are collected for billing purposes, so many variables related to a 
patient's true diagnostic or treatment picture are either unmeasured or are crude estimators. It 
is important to identify the extent to which the patient's true disease severity is associated 
with the use of treatment guidelines, as this may help to clarify why guidelines are so 
infrequently used (or what group of patients does not receive recommended treatment).  
One potential way to address this would be for future studies to utilize detailed 
medical records to determine if there are differences in treatment strategies for patients with 
different clinical presentations of bipolar I disorder. Utilizing patient medical records would 
also potentially allow for an investigation of how adherence to medication treatment 
guidelines leads to improvements in patient health outcomes. This level of clinical detail 
would be necessary for thorough outcomes evaluations, as "improvement" in outcomes 
would need to consider changes in manic or depressive symptoms, and not just crude 
measures such as hospitalizations.  
Finally, improving the connection between guideline development and clinical 
practice will be necessary for improving the quality of care received by children with bipolar 
disorder. Guidelines should be developed and disseminated in a way that actively encourages 
physician adoption (by eliciting physician feedback, or by identifying trends in practice that 
need to be reversed). Prior to developing new or revised guidelines, experts should seek to 
identify the barriers that physicians face when prescribing medication to children with 
bipolar disorder. This may help to create guidelines that are more useful for practicing 
  
222
 
clinicians, or to address concerns that would prohibit a clinician from adopting the guideline 
recommendations. Finally, incorporating guideline recommended treatment algorithms into 
electronic order-entry systems may be one way to improve physicians' knowledge about 
guidelines, or their awareness of current recommendations. As the area of electronic health 
records develops over the coming years, integration of guideline recommendation-based 
prompts may be one way to help to decrease the gap between expert recommendations and 
clinical practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
223
 
WORKS CITED 
 
 
1. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the 
outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 
2007;64(9):1032-1039. 
 
2. Goldstein TR, Birmaher B, Axelson D, et al. Psychosocial functioning among bipolar 
youth. J Affect Disord. 2008;18:18. 
 
3. Dickstein DP, Rich BA, Binstock AB, et al. Comorbid anxiety in phenotypes of 
pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15(4):534-548. 
 
4. Wilens TE, Biederman J, Forkner P, et al. Patterns of comorbidity and dysfunction in 
clinically referred preschool and school-age children with bipolar disorder. J Child 
Adolesc Psychopharmacol. 2003;13(4):495-505. 
 
5. Jolin EM, Weller EB, Weller RA. The public health aspects of bipolar disorder in 
children and adolescents. Curr Psychiatry Rep. 2007;9(2):106-113. 
 
6. Pavuluri MN, Birmaher B, Naylor MW. Pediatric bipolar disorder: a review of the 
past 10 years. J Am Acad Child Adolesc Psychiatry. 2005;44(9):846-871. 
 
7. Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. 
J Am Acad Child Adolesc Psychiatry. 1997;36(9):1168-1176. 
 
8. Akiskal HS, Downs J, Jordan P, Watson S, Daugherty D, Pruitt DB. Affective 
disorders in referred children and younger siblings of manic-depressives. Mode of 
onset and prospective course. Arch Gen Psychiatry. 1985;42(10):996-1003. 
 
9. Carlson GA, Meyer SE. Phenomenology and diagnosis of bipolar disorder in 
children, adolescents, and adults: complexities and developmental issues. Dev 
Psychopathol. 2006;18(4):939-969. 
 
10. Nandagopal JJ, DelBello MP, Kowatch R. Pharmacologic treatment of pediatric 
bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2009;18(2):455-469. 
 
11. Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and 
juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 
1996;35(8):997-1008. 
 
12. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity 
disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 
1991;148(5):564-577. 
  
224
 
13. Wozniak J, Biederman J, Kiely K, et al. Mania-like symptoms suggestive of 
childhood-onset bipolar disorder in clinically referred children. J Am Acad Child 
Adolesc Psychiatry. 1995;34(7):867-876. 
 
14. Strober M, Schmidt-Lackner S, Freeman R, Bower S, Lampert C, DeAntonio M. 
Recovery and relapse in adolescents with bipolar affective illness: a five-year 
naturalistic, prospective follow-up. J Am Acad Child Adolesc Psychiatry. 
1995;34(6):724-731. 
 
15. Pavuluri MN, Henry DB, Carbray JA, Naylor MW, Janicak PG. Divalproex sodium 
for pediatric mixed mania: a 6-month prospective trial. Bipolar Disord. 
2005;7(3):266-273. 
 
16. Rizzo CJ, Esposito-Smythers C, Swenson L, et al. Factors associated with mental 
health service utilization among bipolar youth. Bipolar Disord. 2007;9(8):839-850. 
 
17. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. 
Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad 
Child Adolesc Psychiatry. 2005;44(3):213-235. 
 
18. Pavuluri MN, Henry DB, Devineni B, Carbray JA, Naylor MW, Janicak PG. A 
pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar 
disorder. J Am Acad Child Adolesc Psychiatry. 2004;43(7):859-867. 
 
19. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and 
treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc 
Psychiatry. 2007;46(1):107-125. 
 
20. Carlson GA, Jensen PS, Findling RL, et al. Methodological issues and controversies 
in clinical trials with child and adolescent patients with bipolar disorder: report of a 
consensus conference. J Child Adolesc Psychopharmacol. 2003;13(1):13-27. 
 
21. Cummings CM, Fristad MA. Pediatric bipolar disorder: recognition in primary care. 
Curr Opin Pediatr. 2008;20(5):560-565. 
 
22. Carlson GA, Findling RL, Post RM, et al. AACAP 2006 Research Forum--Advancing 
research in early-onset bipolar disorder: barriers and suggestions. J Child Adolesc 
Psychopharmacol. 2009;19(1):3-12. 
 
23. Cahill C, Hanstock T, Jairam R, Hazell P, Walter G, Malhi GS. Comparison of 
diagnostic guidelines for juvenile bipolar disorder. Aust N Z J Psychiatry. 
2007;41(6):479-484. 
 
  
225
 
24. Dawson R, Lavori PW, Luby JL, Ryan ND, Geller B. Adaptive strategies for treating 
childhood mania. Biol Psychiatry. 2007;61(6):758-764. Epub 2006 Dec 2012. 
 
25. Costello EJ, Egger H, Angold A. 10-year research update review: the epidemiology 
of child and adolescent psychiatric disorders: I. Methods and public health burden. J 
Am Acad Child Adolesc Psychiatry. 2005;44(10):972-986. 
 
26. Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of 
older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad 
Child Adolesc Psychiatry. 1995;34(4):454-463. 
 
27. Dennehy EB, Suppes T, Rush AJ, et al. Does provider adherence to a treatment 
guideline change clinical outcomes for patients with bipolar disorder? Results from 
the Texas Medication Algorithm Project. Psychol Med. 2005;35(12):1695-1706. 
Epub 2005 Sep 1629. 
 
28. Hamrin V, Pachler M. Pediatric bipolar disorder: evidence-based 
psychopharmacological treatments. J Child Adolesc Psychiatr Nurs. 2007;20(1):40-
58. 
 
29. Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among U.S. 
child, adolescent, and adult inpatients, 1996-2004. Biol Psychiatry. 2007;62(2):107-
114. Epub 2007 Feb 2016. 
 
30. Youngstrom E, Youngstrom JK, Starr M. Bipolar diagnoses in community mental 
health: Achenbach Child Behavior Checklist profiles and patterns of comorbidity. 
Biol Psychiatry. 2005;58(7):569-575. Epub 2005 Jun 2013. 
 
31. Case BG, Olfson M, Marcus SC, Siegel C. Trends in the inpatient mental health 
treatment of children and adolescents in US community hospitals between 1990 and 
2000. Arch Gen Psychiatry. 2007;64(1):89-96. 
 
32. Martin A, Leslie D. Psychiatric inpatient, outpatient, and medication utilization and 
costs among privately insured youths, 1997-2000. Am J Psychiatry. 2003;160(4):757-
764. 
 
33. Carlson GA, Kashani JH. Manic symptoms in a non-referred adolescent population. J 
Affect Disord. 1988;15(3):219-226. 
 
34. Geller B, Williams M, Zimerman B, Frazier J, Beringer L, Warner KL. Prepubertal 
and early adolescent bipolarity differentiate from ADHD by manic symptoms, 
grandiose delusions, ultra-rapid or ultradian cycling. J Affect Disord. 1998;51(2):81-
91. 
  
226
 
35. Katzow JJ, Hsu DJ, Nassir Ghaemi S. The bipolar spectrum: a clinical perspective. 
Bipolar Disord. 2003;5(6):436-442. 
 
36. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in 
the US population: re-analysis of the ECA database taking into account subthreshold 
cases. J Affect Disord. 2003;73(1-2):123-131. 
 
37. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of 
bipolar I disorder and axis I and II disorders: results from the National Epidemiologic 
Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(10):1205-
1215. 
 
38. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S. The epidemiology of 
DSM-III-R bipolar I disorder in a general population survey. Psychol Med. 
1997;27(5):1079-1089. 
 
39. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental 
disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515-2523. 
 
40. Costello EJ, Angold A, Burns BJ, et al. The Great Smoky Mountains Study of Youth. 
Goals, design, methods, and the prevalence of DSM-III-R disorders. Arch Gen 
Psychiatry. 1996;53(12):1129-1136. 
 
41. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of 
bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen 
Psychiatry. 2007;64(5):543-552. 
 
42. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect 
Disord. 1998;50(2-3):143-151. 
 
43. Szadoczky E, Papp Z, Vitrai J, Rihmer Z, Furedi J. The prevalence of major 
depressive and bipolar disorders in Hungary. Results from a national epidemiologic 
survey. J Affect Disord. 1998;50(2-3):153-162. 
 
44. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major 
depression and bipolar disorder. Jama. 1996;276(4):293-299. 
 
45. Danielyan A, Kowatch RA. Management options for bipolar disorder in children and 
adolescents. Paediatr Drugs. 2005;7(5):277-294. 
 
46. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National 
Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J 
Affect Disord. 1994;31(4):281-294. 
  
227
 
47. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in 
the community. J Clin Psychiatry. 2003;64(1):53-59. 
 
48. Egeland JA, Hostetter AM, Pauls DL, Sussex JN. Prodromal symptoms before onset 
of manic-depressive disorder suggested by first hospital admission histories. J Am 
Acad Child Adolesc Psychiatry. 2000;39(10):1245-1252. 
 
49. Joyce PR. Age of onset in bipolar affective disorder and misdiagnosis as 
schizophrenia. Psychol Med. 1984;14(1):145-149. 
 
50. Loranger AW, Levine PM. Age at onset of bipolar affective illness. Arch Gen 
Psychiatry. 1978;35(11):1345-1348. 
 
51. Costello EJ, Pine DS, Hammen C, et al. Development and natural history of mood 
disorders. Biol Psychiatry. 2002;52(6):529-542. 
 
52. Blader JC. Increase in out-based physician diagnoses of bipolar disorder in youth in 
the USA. Evid Based Ment Health. 2008;11(2):60. 
 
53. Harpaz-Rotem I, Leslie DL, Martin A, Rosenheck RA. Changes in child and 
adolescent inpatient psychiatric admission diagnoses between 1995 and 2000. Soc 
Psychiatry Psychiatr Epidemiol. 2005;40(8):642-647. Epub 2005 Aug 2018. 
 
54. Harpaz-Rotem I, Rosenheck RA. Changes in outpatient psychiatric diagnosis in 
privately insured children and adolescents from 1995 to 2000. Child Psychiatry Hum 
Dev. 2004;34(4):329-340. 
 
55. Carlson GA. Identifying prepubertal mania. J Am Acad Child Adolesc Psychiatry. 
1995;34(6):750-753. 
 
56. Apps J, Winkler J, Jandrisevits MD. Bipolar disorders: symptoms and treatment in 
children and adolescents. Pediatr Nurs. 2008;34(1):84-88. 
57. Argelinda Baroni. Practitioner Review: The assessment of bipolar disorder in children 
and adolescents. Journal of Child Psychology and Psychiatry. 2008;9999(9999). 
 
58. APA. Diagnostic and statistical manual of mental disorders (4th ed., text revision). 
Washington, DC: American Psychiatric Association; 2000. 
 
59. Biederman J, Kwon A, Wozniak J, et al. Absence of gender differences in pediatric 
bipolar disorder: findings from a large sample of referred youth. J Affect Disord. 
2004;83(2-3):207-214. 
 
60. Duax JM, Youngstrom EA, Calabrese JR, Findling RL. Sex differences in pediatric 
bipolar disorder. J Clin Psychiatry. 2007;68(10):1565-1573. 
  
228
 
61. Geller B, Zimerman B, Williams M, et al. Diagnostic characteristics of 93 cases of a 
prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and 
comorbid attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 
2000;10(3):157-164. 
 
62. Birmaher B, Axelson D. Course and outcome of bipolar spectrum disorder in children 
and adolescents: a review of the existing literature. Dev Psychopathol. 
2006;18(4):1023-1035. 
 
63. Biederman J, Faraone SV, Wozniak J, Mick E, Kwon A, Aleardi M. Further evidence 
of unique developmental phenotypic correlates of pediatric bipolar disorder: findings 
from a large sample of clinically referred preadolescent children assessed over the last 
7 years. J Affect Disord. 2004;82(Suppl 1):S45-58. 
 
64. Weller RA, Weller EB, Tucker SG, Fristad MA. Mania in prepubertal children: has it 
been underdiagnosed? J Affect Disord. 1986;11(2):151-154. 
 
65. Carlson GA, Bromet EJ, Driessens C, Mojtabai R, Schwartz JE. Age at onset, 
childhood psychopathology, and 2-year outcome in psychotic bipolar disorder. Am J 
Psychiatry. 2002;159(2):307-309. 
 
66. Findling RL, Gracious BL, McNamara NK, et al. Rapid, continuous cycling and 
psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord. 
2001;3(4):202-210. 
 
67. Geller B, Bolhofner K, Craney JL, Williams M, DelBello MP, Gundersen K. 
Psychosocial functioning in a prepubertal and early adolescent bipolar disorder 
phenotype. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1543-1548. 
 
68. Geller B, Tillman R, Craney JL, Bolhofner K. Four-year prospective outcome and 
natural history of mania in children with a prepubertal and early adolescent bipolar 
disorder phenotype. Arch Gen Psychiatry. 2004;61(5):459-467. 
 
69. Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorder during adolescence and young 
adulthood in a community sample. Bipolar Disord. 2000;2(3 Pt 2):281-293. 
 
70. WHO. The global burden of disease: 2004 update, Part 3: Disease incidence, 
prevalence and disability. Geneva, Switzerland: World Health Organization; 2008. 
 
71. WHO. The global burden of disease: 2004 update, Part 4: Burden of disease: DALYs. 
Geneva, Switzerland: World Health Organization; 2008. 
 
  
229
 
72. Geller B, Craney JL, Bolhofner K, DelBello MP, Williams M, Zimerman B. One-year 
recovery and relapse rates of children with a prepubertal and early adolescent bipolar 
disorder phenotype. Am J Psychiatry. 2001;158(2):303-305. 
 
73. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a 
review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 
1996;35(11):1427-1439. 
 
74. Garfinkel BD, Froese A, Hood J. Suicide attempts in children and adolescents. Am J 
Psychiatry. 1982;139(10):1257-1261. 
 
75. Brent DA. Correlates of the medical lethality of suicide attempts in children and 
adolescents. J Am Acad Child Adolesc Psychiatry. 1987;26(1):87-91. 
 
76. Geller B, Craney JL, Bolhofner K, Nickelsburg MJ, Williams M, Zimerman B. Two-
year prospective follow-up of children with a prepubertal and early adolescent bipolar 
disorder phenotype. Am J Psychiatry. 2002;159(6):927-933. 
 
77. Goldstein TR, Miklowitz DJ, Mullen KL. Social skills knowledge and performance 
among adolescents with bipolar disorder. Bipolar Disord. 2006;8(4):350-361. 
 
78. Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for 
poor outcome of bipolar disorder. J Psychiatr Res. 2003;37(4):297-303. 
 
79. Slama F, Bellivier F, Henry C, et al. Bipolar patients with suicidal behavior: toward 
the identification of a clinical subgroup. J Clin Psychiatry. 2004;65(8):1035-1039. 
 
80. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance 
treatment. J Clin Psychiatry. 2000;61(Suppl 9):97-104. 
 
81. Sanchez LE, Le LT. Suicide in mood disorders. Depress Anxiety. 2001;14(3):177-
182. 
 
82. Baldessarini RJ, Jamison KR. Effects of medical interventions on suicidal behavior. 
Summary and conclusions. J Clin Psychiatry. 1999;60(Suppl 2):117-122. 
 
83. Goodwin FK. From the Alcohol, Drug Abuse, and Mental Health Administration. 
Jama. 1990;264(19):2495. 
 
84. Feinberg DT. The real cost of pediatric bipolar disorder. J Child Adolesc 
Psychopharmacol. 2003;13(4):431-433. 
 
85. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and 
parity implications. Am J Psychiatry. 2003;160(7):1286-1290. 
  
230
 
86. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: 
primary outcomes from the Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217-224. 
 
87. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness--1991. Soc 
Psychiatry Psychiatr Epidemiol. 1995;30(5):213-219. 
 
88. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the 
US: an estimate for new cases in 1998. Pharmacoeconomics. 2001;19(5 Pt 1):483-
495. 
 
89. Guo JJ, Keck PE, Jr., Li H, Jang R, Kelton CM. Treatment costs and health care 
utilization for patients with bipolar disorder in a large managed care population. 
Value Health. 2008;11(3):416-423. Epub 2007 Dec 2017. 
 
90. Carlson GA, Meyer SE. Bipolar disorder in youth. Curr Psychiatry Rep. 
2000;2(2):90-94. 
 
91. Leverich GS, Post RM, Keck PE, Jr., et al. The poor prognosis of childhood-onset 
bipolar disorder. J Pediatr. 2007;150(5):485-490. 
 
92. Birmaher B, Kennah A, Brent D, Ehmann M, Bridge J, Axelson D. Is bipolar disorder 
specifically associated with panic disorder in youths? J Clin Psychiatry. 
2002;63(5):414-419. 
 
93. McClellan J, McCurry C. Early onset psychotic disorders: diagnostic stability and 
clinical characteristics. Eur Child Adolesc Psychiatry. 1999;8(Suppl 1):I13-19. 
 
94. Feinstein SC, Wolpert EA. Juvenile manic-depressive illness. Clinical and therapeutic 
considerations. J Am Acad Child Psychiatry. 1973;12(1):123-136. 
 
95. McGlashan TH. Adolescent versus adult onset of mania. Am J Psychiatry. 
1988;145(2):221-223. 
 
96. Carlson GA, Bromet EJ, Sievers S. Phenomenology and outcome of subjects with 
early- and adult-onset psychotic mania. Am J Psychiatry. 2000;157(2):213-219. 
 
97. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly 
symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537. 
 
98. Biederman J. Resolved: mania is mistaken for ADHD in prepubertal children. J Am 
Acad Child Adolesc Psychiatry. 1998;37(10):1091-1096; discussion 1096-1099. 
 
  
231
 
99. Biederman J, Mick E, Faraone SV, Spencer T, Wilens TE, Wozniak J. Pediatric 
mania: a developmental subtype of bipolar disorder? Biol Psychiatry. 
2000;48(6):458-466. 
 
100. Faraone SV, Biederman J, Wozniak J, Mundy E, Mennin D, O'Donnell D. Is 
comorbidity with ADHD a marker for juvenile-onset mania? J Am Acad Child 
Adolesc Psychiatry. 1997;36(8):1046-1055. 
 
101. Schurhoff F, Bellivier F, Jouvent R, et al. Early and late onset bipolar disorders: two 
different forms of manic-depressive illness? J Affect Disord. 2000;58(3):215-221. 
 
102. Pavuluri MN, Herbener ES, Sweeney JA. Psychotic symptoms in pediatric bipolar 
disorder. J Affect Disord. 2004;80(1):19-28. 
 
103. Geller B, Tillman R, Bolhofner K, Zimerman B. Child bipolar I disorder: prospective 
continuity with adult bipolar I disorder; characteristics of second and third episodes; 
predictors of 8-year outcome. Arch Gen Psychiatry. 2008;65(10):1125-1133. 
 
104. Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents 
with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63(2):175-183. 
 
105. Geller B, Zimerman B, Williams M, et al. DSM-IV mania symptoms in a prepubertal 
and early adolescent bipolar disorder phenotype compared to attention-deficit 
hyperactive and normal controls. J Child Adolesc Psychopharmacol. 2002;12(1):11-
25. 
 
106. Geller B, Sun K, Zimerman B, Luby J, Frazier J, Williams M. Complex and rapid-
cycling in bipolar children and adolescents: a preliminary study. J Affect Disord. 
1995;34(4):259-268. 
 
107. Leibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defining clinical 
phenotypes of juvenile mania. Am J Psychiatry. 2003;160(3):430-437. 
 
108. Mick E, Spencer T, Wozniak J, Biederman J. Heterogeneity of irritability in attention-
deficit/hyperactivity disorder subjects with and without mood disorders. Biol 
Psychiatry. 2005;58(7):576-582. Epub 2005 Aug 2008. 
 
109. Wozniak J, Biederman J, Kwon A, et al. How cardinal are cardinal symptoms in 
pediatric bipolar disorder? An examination of clinical correlates. Biol Psychiatry. 
2005;58(7):583-588. Epub 2005 Sep 2028. 
 
110. Chang K. Adult bipolar disorder is continuous with pediatric bipolar disorder. Can J 
Psychiatry. 2007;52(7):418-425. 
  
232
 
111. Bhargava Raman RP, Sheshadri SP, Janardhan Reddy YC, Girimaji SC, Srinath S, 
Raghunandan VN. Is bipolar II disorder misdiagnosed as major depressive disorder in 
children? J Affect Disord. 2007;98(3):263-266. Epub 2006 Sep 2001. 
 
112. Kim EY, Miklowitz DJ. Childhood mania, attention deficit hyperactivity disorder and 
conduct disorder: a critical review of diagnostic dilemmas. Bipolar Disord. 
2002;4(4):215-225. 
 
113. Weckerly J. Pediatric bipolar mood disorder. J Dev Behav Pediatr. 2002;23(1):42-56. 
 
114. Kowatch RA, Youngstrom EA, Danielyan A, Findling RL. Review and meta-analysis 
of the phenomenology and clinical characteristics of mania in children and 
adolescents. Bipolar Disord. 2005;7(6):483-496. 
 
115. Birmaher B. Longitudinal course of pediatric bipolar disorder. Am J Psychiatry. 
2007;164(4):537-539. 
 
116. Angold A, Costello EJ. Depressive comorbidity in children and adolescents: 
empirical, theoretical, and methodological issues. Am J Psychiatry. 
1993;150(12):1779-1791. 
 
117. Caron C, Rutter M. Comorbidity in child psychopathology: concepts, issues and 
research strategies. J Child Psychol Psychiatry. 1991;32(7):1063-1080. 
 
118. Tillman R, Geller B, Bolhofner K, Craney JL, Williams M, Zimerman B. Ages of 
onset and rates of syndromal and subsyndromal comorbid DSM-IV diagnoses in a 
prepubertal and early adolescent bipolar disorder phenotype. J Am Acad Child 
Adolesc Psychiatry. 2003;42(12):1486-1493. 
 
119. Frank E, Cyranowski JM, Rucci P, et al. Clinical significance of lifetime panic 
spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen 
Psychiatry. 2002;59(10):905-911. 
 
120. Birmaher B, Axelson D, Strober M, et al. Comparison of manic and depressive 
symptoms between children and adolescents with bipolar spectrum disorders. Bipolar 
Disord. 2009;11(1):52-62. 
 
121. West SA, Strakowski SM, Sax KW, Minnery KL, McElroy SL, Keck PE, Jr. The 
comorbidity of attention-deficit hyperactivity disorder in adolescent mania: potential 
diagnostic and treatment implications. Psychopharmacol Bull. 1995;31(2):347-351. 
 
122. Kafantaris V, Coletti DJ, Dicker R, Padula G, Pollack S. Are childhood psychiatric 
histories of bipolar adolescents associated with family history, psychosis, and 
response to lithium treatment? J Affect Disord. 1998;51(2):153-164. 
  
233
 
123. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Pediatric bipolar disorder: 
phenomenology and course of illness. Bipolar Disord. 2004;6(4):305-313. 
 
124. Singh MK, DelBello MP, Kowatch RA, Strakowski SM. Co-occurrence of bipolar 
and attention-deficit hyperactivity disorders in children. Bipolar Disord. 
2006;8(6):710-720. 
 
125. Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in 
bipolar disorder: data from the first 1000 participants in the systematic treatment 
enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 
2004;55(9):875-881. 
 
126. Mick E, Biederman J, Faraone SV, Murray K, Wozniak J. Defining a developmental 
subtype of bipolar disorder in a sample of nonreferred adults by age at onset. J Child 
Adolesc Psychopharmacol. 2003;13(4):453-462. 
 
127. Masi G, Perugi G, Millepiedi S, et al. Developmental differences according to age at 
onset in juvenile bipolar disorder. J Child Adolesc Psychopharmacol. 
2006;16(6):679-685. 
 
128. Kovacs M, Pollock M. Bipolar disorder and comorbid conduct disorder in childhood 
and adolescence. J Am Acad Child Adolesc Psychiatry. 1995;34(6):715-723. 
 
129. Wozniak J, Biederman J, Faraone SV, et al. Mania in children with pervasive 
developmental disorder revisited. J Am Acad Child Adolesc Psychiatry. 
1997;36(11):1552-1559; discussion 1559-1560. 
 
130. Baldessarini RJ, Tondo L. Long-term lithium for bipolar disorder. Am J Psychiatry. 
2001;158(10):1740. 
 
131. Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. 
CNS Drugs. 2002;16(11):721-729. 
 
132. Kuehn BM. FDA Panel OKs 3 Antipsychotic Drugs for Pediatric Use, Cautions 
Against Overuse. JAMA. August 26, 2009 2009;302(8):833-834. 
 
133. Leibenluft E. Pediatric bipolar disorder comes of age. Arch Gen Psychiatry. 
2008;65(10):1122-1124. 
 
134. Craney JL, Geller B. A prepubertal and early adolescent bipolar disorder-I phenotype: 
review of phenomenology and longitudinal course. Bipolar Disord. 2003;5(4):243-
256. 
  
234
 
135. Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Lithium treatment of acute 
mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry. 
2003;42(9):1038-1045. 
 
136. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of 
lithium for adolescent bipolar disorders with secondary substance dependency. J Am 
Acad Child Adolesc Psychiatry. 1998;37(2):171-178. 
 
137. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J 
Psychopharmacol. 2006;20(3):347-355. Epub 2005 Sep 2020. 
 
138. Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and 
management. Am J Clin Dermatol. 2004;5(1):3-8. 
 
139. Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, Calabrese JR. 
Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex 
sodium. J Am Acad Child Adolesc Psychiatry. 2004;43(2):215-220. 
 
140. Gitlin M. Lithium and the kidney: an updated review. Drug Saf. 1999;20(3):231-243. 
 
141. Heaton PC, Garlick CM, Tran D. Evaluating drug safety in children and adolescents 
with bipolar disorder. Curr Drug Saf. 2006;1(3):307-318. 
 
142. Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, 
and carbamazepine in children and adolescents with bipolar disorder. J Am Acad 
Child Adolesc Psychiatry. 2000;39(6):713-720. 
 
143. Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA. Combination 
pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 
2003;53(11):978-984. 
 
144. Findling RL, McNamara NK, Gracious BL, et al. Combination lithium and 
divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry. 
2003;42(8):895-901. 
 
145. Lopez-Larson M, Frazier JA. Empirical evidence for the use of lithium and 
anticonvulsants in children with psychiatric disorders. Harv Rev Psychiatry. 
2006;14(6):285-304. 
 
146. West SA, Keck PE, McElroy SL, et al. Open Trial of Valproate in the Treatment of 
Adolescent Mania. Journal of Child and Adolescent Psychopharmacology. Win 
1994;4(4):263-267. 
  
235
 
147. Papatheodorou G, Kutcher SP, Katic M, Szalai JP. The efficacy and safety of 
divalproex sodium in the treatment of acute mania in adolescents and young adults: 
an open clinical trial. J Clin Psychopharmacol. 1995;15(2):110-116. 
 
148. Deltito JA, Levitan J, Damore J, Hajal F, Zambenedetti M. Naturalistic experience 
with the use of divalproex sodium on an in-patient unit for adolescent psychiatric 
patients. Acta Psychiatr Scand. 1998;97(3):236-240. 
 
149. Wagner KD, Weller EB, Carlson GA, et al. An open-label trial of divalproex in 
children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 
2002;41(10):1224-1230. 
 
150. Chang KD, Dienes K, Blasey C, Adleman N, Ketter T, Steiner H. Divalproex 
monotherapy in the treatment of bipolar offspring with mood and behavioral 
disorders and at least mild affective symptoms. J Clin Psychiatry. 2003;64(8):936-
942. 
 
151. Wagner KD, Redden L, Kowatch RA, et al. A Double-Blind, Randomized, Placebo-
Controlled Trial of Divalproex Extended-Release in the Treatment of Bipolar 
Disorder in Children and Adolescents. J Am Acad Child Adolesc Psychiatry. 
2009;24:24. 
 
152. DelBello MP, Kowatch RA, Warner J, et al. Adjunctive topiramate treatment for 
pediatric bipolar disorder: a retrospective chart review. J Child Adolesc 
Psychopharmacol. 2002;12(4):323-330. 
 
153. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third 
generation anticonvulsants in bipolar disorder: a review of efficacy and summary of 
clinical recommendations. J Clin Psychiatry. 2002;63(4):275-283. 
 
154. Delbello MP, Findling RL, Kushner S, et al. A pilot controlled trial of topiramate for 
mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc 
Psychiatry. 2005;44(6):539-547. 
 
155. Davanzo P, Nikore V, Yehya N, Stevenson L. Oxcarbazepine treatment of juvenile-
onset bipolar disorder. Journal of Child and Adolescent Psychopharmacology. Fal 
2004;14(3):344-345. 
 
156. Teitelbaum M. Oxcarbazepine in bipolar disorder. Journal of the American Academy 
of Child and Adolescent Psychiatry. Sep 2001;40(9):993-994. 
 
157. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-
controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and 
adolescents. Am J Psychiatry. 2006;163(7):1179-1186. 
  
236
 
158. Hamrin V, Bailey K. Gabapentin and methylphenidate treatment of a preadolescent 
with attention deficit hyperactivity disorder and bipolar disorder. J Child Adolesc 
Psychopharmacol. 2001;11(3):301-309. 
 
159. Soutullo CA, Casuto LS, Keck PE, Jr. Gabapentin in the treatment of adolescent 
mania: a case report. J Child Adolesc Psychopharmacol. 1998;8(1):81-85. 
 
160. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine 
and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 
2000;20(6):607-614. 
 
161. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar 
disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar 
Disorder Study Group. Bipolar Disord. 2000;2(3 Pt 2):249-255. 
 
162. Kovacs G. Polycystic Ovary Syndrome. Cambridge: Cambridge University Press; 
2000. 
 
163. Sillanpaa M. Carbamazepine. Pharmacology and clinical uses. Acta Neurol Scand 
Suppl. 1981;88:1-202. 
 
164. Wang PW, Ketter TA. Clinical use of carbamazepine for bipolar disorders. Expert 
Opin Pharmacother. 2005;6(16):2887-2902. 
 
165. Novak PH, Ekins-Daukes S, Simpson CR, Milne RM, Helms P, McLay JS. Acute 
drug prescribing to children on chronic antiepilepsy therapy and the potential for 
adverse drug interactions in primary care. Br J Clin Pharmacol. 2005;59(6):712-717. 
 
166. Pandina GJ, Bilder R, Harvey PD, Keefe RS, Aman MG, Gharabawi G. Risperidone 
and cognitive function in children with disruptive behavior disorders. Biol Psychiatry. 
2007;62(3):226-234. Epub 2007 Jan 2008. 
 
167. Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-
label prospective trial of risperidone in combination with lithium or divalproex 
sodium in pediatric mania. J Affect Disord. 2004;82(Suppl 1):S103-111. 
 
168. Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG. A one-
year open-label trial of risperidone augmentation in lithium nonresponder youth with 
preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol. 2006;16(3):336-
350. 
 
169. Chang KD NM, Aurang C, Johnson B, Jin N, Marcus R, Forbes RA, Carson WH, 
Kahn A, Findling RL. Efficacy of aripiprazole in children (10-17 years old) with 
  
237
 
mania. Paper presented at: 54th Annual Meeting of the American Academy of Child 
and Adolescent Psychiatry, 2007; Boston, MA. 
 
170. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of 
pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10(2):141-
148. 
 
171. Biederman J, Mick E, Spencer T, et al. An open-label trial of aripiprazole 
monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 
2007;12(9):683-689. 
 
172. Barzman DH, DelBello MP, Kowatch RA, et al. The effectiveness and tolerability of 
aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child 
Adolesc Psychopharmacol. 2004;14(4):593-600. 
 
173. DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study 
comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc 
Psychiatry. 2006;45(3):305-313. 
 
174. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, 
randomized, placebo-controlled study of quetiapine as adjunctive treatment for 
adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216-1223. 
 
175. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for 
pediatric bipolar disorder: a retrospective chart review. J Child Adolesc 
Psychopharmacol. 2004;14(3):405-411. 
 
176. Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of 
olanzapine monotherapy in children and adolescents with bipolar disorder. J Child 
Adolesc Psychopharmacol. 2001;11(3):239-250. 
 
177. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the 
treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164(10):1547-
1556. 
 
178. Barnett MS. Ziprasidone monotherapy in pediatric bipolar disorder. J Child Adolesc 
Psychopharmacol. 2004;14(3):471-477. 
 
179. Biederman J, Mick E, Spencer T, Dougherty M, Aleardi M, Wozniak J. A prospective 
open-label treatment trial of ziprasidone monotherapy in children and adolescents 
with bipolar disorder. Bipolar Disord. 2007;9(8):888-894. 
 
180. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. 
J Child Adolesc Psychopharmacol. 2002;12(2):93-99. 
  
238
 
181. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine 
and risperidone in adolescent patients: a comparative prospective study. J Am Acad 
Child Adolesc Psychiatry. 2002;41(3):337-343. 
 
182. Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G. Hyperglycemia 
from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol. 
2003;13(1):97-102. 
 
183. Saito E, Kafantaris V. Can diabetes mellitus be induced by medication? J Child 
Adolesc Psychopharmacol. 2002;12(3):231-236. 
 
184. Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical 
antipsychotics in the treatment of schizophrenia and comorbid disorders in children 
and adolescents. Drug Saf. 2004;27(14):1135-1156. 
 
185. Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with 
atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, 
and management. Paediatr Drugs. 2004;6(1):33-44. 
 
186. Blanz B, Schmidt MH. Clozapine for schizophrenia. J Am Acad Child Adolesc 
Psychiatry. 1993;32(1):223-224. 
 
187. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An open trial 
of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child 
Adolesc Psychiatry. 1994;33(5):658-663. 
 
188. Masi G. Pharmacotherapy of pervasive developmental disorders in children and 
adolescents. CNS Drugs. 2004;18(14):1031-1052. 
 
189. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-
blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090-
1097. 
 
190. Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with 
typical and atypical antipsychotics. Am J Psychiatry. 2002;159(1):109-115. 
 
191. Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the treatment of 
adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 
2006;45(3):289-297. 
 
192. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar 
depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant 
augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 
2006;163(2):210-216. 
  
239
 
193. Carandang CG, Maxwell DJ, Robbins DR, Oesterheld JR. Lamotrigine in adolescent 
mood disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(7):750-751. 
 
194. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or 
monotherapy for the treatment of adolescents with bipolar depression. J Am Acad 
Child Adolesc Psychiatry. 2006;45(3):298-304. 
 
195. Pavuluri MN, Henry DB, Moss M, Mohammed T, Carbray JA, Sweeney JA. 
Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar 
disorder. J Child Adolesc Psychopharmacol. 2009;19(1):75-82. 
 
196. Kafantaris V, Coletti DJ, Dicker R, Padula G, Pleak RR, Alvir JM. Lithium treatment 
of acute mania in adolescents: a placebo-controlled discontinuation study. J Am Acad 
Child Adolesc Psychiatry. 2004;43(8):984-993. 
 
197. Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of 
lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am 
Acad Child Adolesc Psychiatry. 2005;44(5):409-417. 
 
198. Baumer FM, Howe M, Gallelli K, Simeonova DI, Hallmayer J, Chang KD. A pilot 
study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, 
risk factors, and the serotonin transporter gene. Biol Psychiatry. 2006;60(9):1005-
1012. Epub 2006 Aug 1030. 
 
199. Biederman J, Mick E, Prince J, et al. Systematic chart review of the pharmacologic 
treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar 
disorder. J Child Adolesc Psychopharmacol. 1999;9(4):247-256. 
 
200. Carlson GA, Loney J, Salisbury H, Kramer JR, Arthur C. Stimulant treatment in 
young boys with symptoms suggesting childhood mania: a report from a longitudinal 
study. J Child Adolesc Psychopharmacol. 2000;10(3):175-184. 
 
201. Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled 
trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric 
bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 
2005;162(1):58-64. 
 
202. DelBello MP, Soutullo CA, Hendricks W, Niemeier RT, McElroy SL, Strakowski 
SM. Prior stimulant treatment in adolescents with bipolar disorder: association with 
age at onset. Bipolar Disord. 2001;3(2):53-57. 
 
203. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current 
controversies. Bipolar Disord. 2003;5(6):407-420. 
  
240
 
204. Pagano ME, Demeter CA, Faber JE, Calabrese JR, Findling RL. Initiation of 
stimulant and antidepressant medication and clinical presentation in juvenile bipolar I 
disorder. Bipolar Disord. 2008;10(2):334-341. 
 
205. Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in 
children and adolescents, 2003-2004. Curr Med Res Opin. 2007;23(1):49-56. 
 
206. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of 
bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002;159(6):1005-1010. 
 
207. Bhangoo RK, Lowe CH, Myers FS, et al. Medication use in children and adolescents 
treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol. 
2003;13(4):515-522. 
 
208. Committee on Quality of Health Care in America IoM, ed. To Err Is Human: 
Building a Safer Health System: The National Academies Press; 2000. Linda T. Kohn 
JMC, and Molla S. Donaldson, ed. 
 
209. Lohr KN, Schroeder SA. A strategy for quality assurance in Medicare. N Engl J Med. 
1990;322(10):707-712. 
 
210. Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory 
care delivered to children in the United States. N Engl J Med. 2007;357(15):1515-
1523. 
 
211. Dougherty D, Meikle SF, Owens P, Kelley E, Moy E. Children's Health Care in the 
First National Healthcare Quality Report and National Healthcare Disparities Report. 
Med Care. 2005;43(3 Suppl):I58-63. 
 
212. Forrest CB, Simpson L, Clancy C. Child health services research. Challenges and 
opportunities. Jama. 1997;277(22):1787-1793. 
 
213. Manderscheid RW, Henderson MJ, Witkin MJ, Atay JE. The U.S. mental health 
system of the 1990s. The challenges of managed care. Int J Law Psychiatry. 
2000;23(3-4):245-259. 
 
214. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends 
in the outpatient treatment of depression. Jama. 2002;287(2):203-209. 
 
215. Mechanic D. Closing gaps in mental health care for persons with serious mental 
illness. Health Serv Res. 2001;36(6 Pt 1):1009-1017. 
 
  
241
 
216. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol 
and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. 
Jama. 1990;264(19):2511-2518. 
 
217. Briggs-Gowan MJ, Horwitz SM, Schwab-Stone ME, Leventhal JM, Leaf PJ. Mental 
health in pediatric settings: distribution of disorders and factors related to service use. 
J Am Acad Child Adolesc Psychiatry. 2000;39(7):841-849. 
 
218. Costello EJ, Costello AJ, Edelbrock C, et al. Psychiatric disorders in pediatric 
primary care. Prevalence and risk factors. Arch Gen Psychiatry. 1988;45(12):1107-
1116. 
 
219. Horwitz SM, Leaf PJ, Leventhal JM. Identification of psychosocial problems in 
pediatric primary care: do family attitudes make a difference? Arch Pediatr Adolesc 
Med. 1998;152(4):367-371. 
 
220. Wu P, Hoven CW, Bird HR, et al. Depressive and disruptive disorders and mental 
health service utilization in children and adolescents. J Am Acad Child Adolesc 
Psychiatry. 1999;38(9):1081-1090; discussion 1090-1082. 
 
221. Edelsohn GA, Braitman LE, Rabinovich H, Sheves P, Melendez A. Predictors of 
urgency in a pediatric psychiatric emergency service. J Am Acad Child Adolesc 
Psychiatry. 2003;42(10):1197-1202. 
 
222. Briggs-Gowan MJ, Carter AS, Skuban EM, Horwitz SM. Prevalence of social-
emotional and behavioral problems in a community sample of 1- and 2-year-old 
children. J Am Acad Child Adolesc Psychiatry. 2001;40(7):811-819. 
 
223. Cassidy LJ, Jellinek MS. Approaches to recognition and management of childhood 
psychiatric disorders in pediatric primary care. Pediatr Clin North Am. 
1998;45(5):1037-1052. 
 
224. Kelleher KJ, McInerny TK, Gardner WP, Childs GE, Wasserman RC. Increasing 
identification of psychosocial problems: 1979-1996. Pediatrics. 2000;105(6):1313-
1321. 
 
225. Williams J, Klinepeter K, Palmes G, Pulley A, Foy JM. Diagnosis and treatment of 
behavioral health disorders in pediatric practice. Pediatrics. 2004;114(3):601-606. 
 
226. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in 
pediatric bipolar disorder: a retrospective case review. J Affect Disord. 
2004;82(1):149-158. 
 
  
242
 
227. Das AK, Olfson M, Gameroff MJ, et al. Screening for bipolar disorder in a primary 
care practice. Jama. 2005;293(8):956-963. 
 
228. Costello EJ, Burns BJ, Angold A, Leaf PJ. Epidemiology and health care reform. J 
Am Acad Child Adolesc Psychiatry. 1994;33(7):1058-1059. 
 
229. Thomas CR, Holzer CE, 3rd. National distribution of child and adolescent 
psychiatrists. J Am Acad Child Adolesc Psychiatry. 1999;38(1):9-15; discussion 15-
16. 
 
230. Streeruwitz A, Barnes TR, Fehler J, Ohlsen R, Curtis VA. Pharmacological 
management of acute mania: does current prescribing practice reflect treatment 
guidelines? J Psychopharmacol. 2007;21(2):206-209. 
 
231. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice 
guidelines? A framework for improvement. Jama. 1999;282(15):1458-1465. 
 
232. Trivedi MH, Claassen CA, Grannemann BD, et al. Assessing physicians' use of 
treatment algorithms: Project IMPACTS study design and rationale. Contemp Clin 
Trials. 2007;28(2):192-212. Epub 2006 Aug 2016. 
 
233. Rushton JL, Fant KE, Clark SJ. Use of practice guidelines in the primary care of 
children with attention-deficit/hyperactivity disorder. Pediatrics. 2004;114(1):e23-28. 
 
234. Perlis RH. Use of treatment guidelines in clinical decision making in bipolar disorder: 
a pilot survey of clinicians. Curr Med Res Opin. 2007;23(3):467-475. 
 
235. Busch AB, Huskamp HA, Landrum MB. Quality of care in a Medicaid population 
with bipolar I disorder. Psychiatr Serv. 2007;58(6):848-854. 
 
236. Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M. Medication prescribing patterns 
for patients with bipolar I disorder in hospital settings: adherence to published 
practice guidelines. Bipolar Disord. 2001;3(4):165-173. 
 
237. Busch AB, Ling D, Frank RG, Greenfield SF. Changes in the quality of care for 
bipolar I disorder during the 1990s. Psychiatr Serv. 2007;58(1):27-33. 
 
238. Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q. 
2005;83(4):691-729. 
 
239. Andersen RM. Revisiting the behavioral model and access to medical care: does it 
matter? J Health Soc Behav. 1995;36(1):1-10. 
 
240. Donabedian A. The quality of medical care. Science. 1978;200(4344):856-864. 
  
243
 
241. Brook RH, McGlynn EA, Cleary PD. Quality of health care. Part 2: measuring 
quality of care. N Engl J Med. 1996;335(13):966-970. 
 
242. Hulka BS, Wheat JR. Patterns of utilization. The patient perspective. Med Care. 
1985;23(5):438-460. 
 
243. Artz MB, Hadsall RS, Schondelmeyer SW. Impact of generosity level of outpatient 
prescription drug coverage on prescription drug events and expenditure among older 
persons. Am J Public Health. 2002;92(8):1257-1263. 
 
244. Golden WE, Hermann RC, Jewell M, Brewster C. Development of evidence-based 
performance measures for bipolar disorder: overview of methodology. J Psychiatr 
Pract. 2008;14(Suppl 2):18-30. 
 
245. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of 
psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. 
Psychiatr Serv. Jan 2007;58(1):85-91. 
 
246. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for 
patients with bipolar disorder in the United States: polytherapy and adherence. 
Psychiatr Serv. Oct 2008;59(10):1175-1183. 
 
247. Maniscalco ER, Hamrin V. Assessment and diagnostic issues in pediatric bipolar 
disorder. Arch Psychiatr Nurs. 2008;22(6):344-355. Epub 2008 Oct 2014. 
 
248. Ohsfeldt RL, Lage MJ, Rajagopalan K. Medication use, service utilization, and 
medical costs associated with new episodes of bipolar disorder: evidence from a 
retrospective claims database. Prim Care Companion J Clin Psychiatry. 
2007;9(4):280-286. 
 
249. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in 
bipolar disorder during treatment with lithium and divalproex. Jama. 
2003;290(11):1467-1473. 
 
250. Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents 
with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63(10):1139-1148. 
 
251. Yoon EY, Dombkowski KJ, Rocchini A, Lin JJ, Davis MM. Off-label utilization of 
antihypertensive medications in children. Ambul Pediatr. 2007;7(4):299-303. 
 
252. Cohen J. A Power Primer. Psychological Bulletin. Jul 1992;112(1):155-159. 
 
  
244
 
253. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its 
relationship to historical illness variables in 288 patients with bipolar disorder. Am J 
Psychiatry. 2001;158(3):420-426. 
 
254. Faraone SV, Glatt SJ, Tsuang MT. The genetics of pediatric-onset bipolar disorder. 
Biol Psychiatry. 2003;53(11):970-977. 
 
255. Danielyan A, Pathak S, Kowatch RA, Arszman SP, Johns ES. Clinical characteristics 
of bipolar disorder in very young children. J Affect Disord. 2007;97(1-3):51-59. Epub 
2006 Jul 2005. 
 
256. Unutzer J, Simon G, Pabiniak C, Bond K, Katon W. The treated prevalence of bipolar 
disorder in a large staff-model HMO. Psychiatr Serv. 1998;49(8):1072-1078. 
 
257. DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM. Twelve-month 
outcome of adolescents with bipolar disorder following first hospitalization for a 
manic or mixed episode. Am J Psychiatry. 2007;164(4):582-590. 
 
258. Fortney J, Rost K, Zhang M, Warren J. The impact of geographic accessibility on the 
intensity and quality of depression treatment. Med Care. 1999;37(9):884-893. 
 
259. Duhoux A, Fournier L, Nguyen CT, Roberge P, Beveridge R. Guideline concordance 
of treatment for depressive disorders in Canada. Soc Psychiatry Psychiatr Epidemiol. 
2009;44(5):385-392. Epub 2008 Oct 2022. 
 
260. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and 
differences. Am J Epidemiol. 2005;162(3):199-200. Epub 2005 Jun 2029. 
 
261. Petersen MR, Deddens JA. Re: "Easy SAS calculations for risk or prevalence ratios 
and differences". Am J Epidemiol. 2006;163(12):1158-1159; author reply 1159-1161. 
 
262. Kessler RC, Avenevoli S, Green J, et al. National comorbidity survey replication 
adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with 
clinical reassessments. J Am Acad Child Adolesc Psychiatry. 2009;48(4):386-399. 
 
263. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for 
epidemiologic research on therapeutics. Journal of Clinical Epidemiology. 
2005;58(4):323-337. 
 
264. Danner S, Fristad MA, Arnold LE, et al. Early-onset bipolar spectrum disorders: 
diagnostic issues. Clin Child Fam Psychol Rev. 2009;12(3):271-293. 
 
  
245
 
265. Olfson M, Crystal S, Gerhard T, Huang CS, Carlson GA. Mental health treatment 
received by youths in the year before and after a new diagnosis of bipolar disorder. 
Psychiatr Serv. 2009;60(8):1098-1106. 
 
266. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake 
inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane 
Database Syst Rev. 2007(3):CD004851. 
 
267. Kowatch RA, DelBello MP. The use of mood stabilizers and atypical antipsychotics 
in children and adolescents with bipolar disorders. CNS Spectr. 2003;8(4):273-280. 
 
268. Zito JM, Safer DJ, Valluri S, Gardner JF, Korelitz JJ, Mattison DR. 
Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child 
Adolesc Psychopharmacol. 2007;17(2):195-203. 
 
269. Olfson M, Crystal S, Huang C, Gerhard T. Trends in Antipsychotic Drug Use by 
Very Young, Privately Insured Children. Journal of the American Academy of Child 
& Adolescent Psychiatry.49(1):13-23. 
 
270. Unutzer J, Simon G, Pabiniak C, Bond K, Katon W. The use of administrative data to 
assess quality of care for bipolar disorder in a large staff model HMO. Gen Hosp 
Psychiatry. 2000;22(1):1-10. 
 
271. Cutrona SL, Woolhandler S, Lasser KE, et al. Free drug samples in the United States: 
characteristics of pediatric recipients and safety concerns. Pediatrics. 
2008;122(4):736-742. 
 
 
